EHTH.6.30.15.10Q

0001333493-15-000060.txt : 20150807 0001333493-15-000060.hdr.sgml : 20150807 20150807161853 ACCESSION NUMBER: 0001333493-15-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150807 DATE AS OF CHANGE: 20150807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eHealth, Inc. CENTRAL INDEX KEY: 0001333493 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 770470789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33071 FILM NUMBER: 151037757 BUSINESS ADDRESS: STREET 1: 440 EAST MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-584-2700 MAIL ADDRESS: STREET 1: 440 EAST MIDDLEFIELD ROAD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 10-Q 1 ehth6301510q.htm 10-Q EHTH.6.30.15.10Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

001-33071

(Commission File Number)

_____________________________________________

EHEALTH, INC.

(Exact name of registrant as specified in its charter)

_____________________________________________



Delaware (State or other jurisdiction of incorporation or organization)		56-2357876 (I.R.S Employer Identification No)

440 EAST MIDDLEFIELD ROAD

MOUNTAIN VIEW, CALIFORNIA 94043

(Address of principal executive offices)

(650) 584-2700

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

____________________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer ☐		Accelerated filer ☒
Non-accelerated filer ☐		Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The number of shares of the registrant’s common stock, par value $0.001 per share, outstanding as of July 31, 2015 was 18,080,207 shares.

Table of Contents

EHEALTH, INC. FORM 10-Q

TABLE OF CONTENTS



	PART I FINANCIAL INFORMATION	PAGE
Item 1.	Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets at December 31, 2014 and June 30, 2015	1
	Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2014 and 2015	2
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2015	3
	Notes to Condensed Consolidated Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	36
	PART II OTHER INFORMATION
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	38
Item 5.	Other Item	67
Item 6.	Exhibits	67
	Signatures	68

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

EHEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)



	December 31, 2014			June 30, 2015
Assets	(Note 1)			(unaudited)
Current assets:
Cash and cash equivalents	$	51,415		$	51,812
Accounts receivable	8,200			10,169
Deferred income taxes	386			386
Prepaid expenses and other current assets	6,474			6,392
Total current assets	66,475			68,759
Property and equipment, net	9,640			8,510
Other assets	5,679			4,122
Intangible assets, net	10,774			10,140
Goodwill	14,096			14,096
Total assets	$	106,664		$	105,627

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	5,961		$	2,066
Accrued compensation and benefits	8,204			8,365
Accrued marketing expenses	8,707			1,711
Deferred revenue	869			602
Accrued restructuring charges	—			289
Other current liabilities	2,996			4,647
Total current liabilities	26,737			17,680
Non-current liabilities	6,449			6,608
Stockholders’ equity:
Common stock	29			29
Additional paid-in capital	259,007			263,195
Treasury stock, at cost	(199,998		)	(199,998		)
Retained earnings	14,261			17,929
Accumulated other comprehensive income	179			184
Total stockholders’ equity	73,478			81,339
Total liabilities and stockholders’ equity	$	106,664		$	105,627

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

EHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share amounts, unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2015			2014			2015
Revenue
Commission	$	38,526		$	37,396		$	84,103		$	95,215
Other	4,068			2,498			9,431			5,967
Total revenue	42,594			39,894			93,534			101,182
Operating costs and expenses:
Cost of revenue	892			670			3,005			3,084
Marketing and advertising	9,609			9,285			32,718			34,736
Customer care and enrollment	8,984			7,658			18,697			19,519
Technology and content	9,550			8,591			20,017			19,364
General and administrative	6,857			7,516			15,151			15,489
Restructuring charges	—			58			—			4,541
Amortization of intangible assets	354			288			708			633
Total operating costs and expenses	36,246			34,066			90,296			97,366
Income from operations	6,348			5,828			3,238			3,816
Other expense, net	(29		)	(9		)	(68		)	(23		)
Income before provision for income taxes	6,319			5,819			3,170			3,793
Provision for income taxes	3,296			69			1,700			125
Net income	$	3,023		$	5,750		$	1,470		$	3,668

Net income per share:
Basic	$	0.16		$	0.32		$	0.08		$	0.20
Diluted	$	0.15		$	0.32		$	0.07		$	0.20

Weighted-average number of shares used in per share amounts:
Basic	18,978			17,967			18,914			17,906
Diluted	19,775			18,035			19,821			17,998

Comprehensive income:
Net income	$	3,023		$	5,750		$	1,470		$	3,668
Foreign currency translation adjustment	1			4			17			5
Comprehensive income	$	3,024		$	5,754		$	1,487		$	3,673

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

EHEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)



	Six Months Ended June 30,
	2014			2015
Operating activities
Net income	$	1,470		$	3,668
Adjustments to reconcile net income to net cash used in operating activities:
Deferred income taxes	(2,035		)	—
Depreciation and amortization	2,061			2,108
Amortization of internally-developed software	209			318
Amortization of book-of-business consideration	1,805			1,991
Amortization of intangible assets	708			633
Stock-based compensation expense	4,295			3,858
Deferred rent	34			28
Changes in operating assets and liabilities:
Accounts receivable	(2,277		)	(1,955		)
Prepaid expenses and other assets	(1,282		)	(243		)
Accounts payable	(227		)	(3,895		)
Accrued compensation and benefits	(3,051		)	159
Accrued marketing expenses	(6,086		)	(6,996		)
Deferred revenue	(603		)	(432		)
Accrued restructuring charges	—			569
Other liabilities	(123		)	1,736
Net cash provided by (used in) operating activities	(5,102		)	1,547
Investing activities
Purchases of property and equipment and other assets	(2,340		)	(1,432		)
Purchase of intangible assets	(4,500		)	—
Net cash used in investing activities	(6,840		)	(1,432		)
Financing activities
Net proceeds from exercise of common stock options	3,244			1,049
Cash used to net-share settle equity awards	(3,355		)	(736		)
Excess tax benefits from stock-based compensation	3,663			—
Repurchase of common stock	(28,256		)	—
Principal payments in connection with capital leases	(40		)	(40		)
Net cash provided by (used in) financing activities	(24,744		)	273

Effect of exchange rate changes on cash and cash equivalents	13			9

Net increase (decrease) in cash and cash equivalents	(36,673		)	397
Cash and cash equivalents at beginning of period	107,055			51,415
Cash and cash equivalents at end of period	$	70,382		$	51,812

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1 - Summary of Business and Significant Accounting Policies

Description of Business—eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is the leading private online source of health insurance for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process. We are licensed to market and sell health insurance in all 50 states and the District of Columbia.

Basis of Presentation—The accompanying condensed consolidated balance sheet as of June 30, 2015, the condensed consolidated statements of comprehensive income for the three and six months ended June 30, 2014 and 2015 and the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2015, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2014 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and include all adjustments necessary for the fair presentation of eHealth’s financial position as of June 30, 2015, its results of operations for the three and six months ended June 30, 2014 and 2015 and its cash flows for the six months ended June 30, 2014 and 2015. All adjustments are of a normal recurring nature. The results for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2015.

Seasonality—The majority of our individual and family plans are sold in the open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. For example, in the second quarter of 2015, the number of individual and family applications submitted on our website decreased compared to periods inside the second open enrollment period that began on November 15, 2014 and ended on February 15, 2015.

Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of

payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. As a result of the second open enrollment period for individual and family health insurance that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in individual and family submitted applications, compared to periods outside the open enrollment period. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. In addition, due to the initial open enrollment period for individual and family health insurance that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications.

In the second quarter of 2015, we recorded net income in part due to significantly lower marketing and advertising expenses associated with the decrease in the number of individual and family health insurance applications submitted outside of the open enrollment period and lower customer care and enrollment expenses associated with fewer sales and enrollment personnel required to handle the lower volume of submitted applications outside of the open enrollment period. In the second quarter of 2015, net income also benefitted from increased revenue resulting from members who submitted applications during the second open enrollment period, which ended on February 15, 2015. In addition, our customer care and enrollment and technology and content expenses decreased in the second quarter of 2015, as a result of an organizational restructuring and cost reduction plan we implemented in the first quarter of 2015, which also contributed to net income during the second quarter of 2015. Conversely, in the first quarter of 2015 and the first and fourth quarters of 2014, we incurred a net loss due in part to our higher marketing and advertising expenses associated with the individual and family health insurance applications submitted during the open enrollment periods for individual and family health insurance and Medicare-related health insurance applications submitted during the Medicare annual enrollment periods without a commensurate level of additional revenue resulting from those applicants during the enrollment periods.

Recent Accounting Pronouncements—In February 2015, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-05 , "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement." ASU 2015-05 provides guidance to clarify the customer’s accounting for fees paid in a cloud computing arrangement. It is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-05 on our consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. On July 9, 2015, the FASB agreed to delay the effective date by one year. In accordance with the agreed upon delay, the new standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period and can be adopted using either a full retrospective or modified retrospective approach. Early adoption is not permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-09 on our consolidated financial statements.

Note 2 – Balance Sheet Accounts

Cash and Cash Equivalents—As of December 31, 2014 and June 30, 2015, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At December 31, 2014 and June 30, 2015, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the three and six months ended June 30, 2014 and 2015.

As of December 31, 2014 and June 30, 2015, our cash and cash equivalent balances were invested as follows (in thousands):

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)



	December 31, 2014		June 30, 2015
Cash	$	15,793	$	17,189
Money market funds	35,622		34,623
Total cash and cash equivalents	$	51,415	$	51,812

Our money market funds reflect unadjusted quoted prices in active markets for identical assets and are classified as Level 1 as of December 31, 2014 and June 30, 2015.

Accounts Receivable—As of December 31, 2014 and June 30, 2015, our accounts receivable consisted of the following (in thousands):



	December 31, 2014		June 30, 2015
Medicare renewal commission receivable	$	355	$	8,566
Accounts receivable - from other revenues	2,462		1,304
Other commissions receivable	5,383		299
Total accounts receivable	$	8,200	$	10,169

Note 3 – Stockholders’ Equity

Stock Plans—The following table summarizes activity under our 2014 Equity Incentive Plan, 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands):



	Shares Available for Grant
Shares available for grant December 31, 2014	4,164
Restricted stock units granted	(692	)
Options granted	(34	)
Restricted stock units cancelled (1)	85
Options cancelled (2)	13
Shares available for grant June 30, 2015	3,536


(1)	Restricted stock units cancelled does not include 62,000 restricted stock units cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.


(2)	Options cancelled does not include 211,000 stock options cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.

We maintain our 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan, under which we previously granted options to purchase shares of our common stock and restricted stock units. The 2006 Equity Incentive Plan was terminated with respect to the grant of additional awards on June 12, 2014, upon adoption of our 2014 Equity Incentive Plan. The 2005 Stock Plan and 1998 Stock Plan were terminated with respect to the grant of additional awards upon the effectiveness of the 2006 Equity Incentive Plan. We will continue to issue new shares of common stock upon vesting of restricted stock units and the exercise of stock options previously granted under the 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan.

The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)



	Number of Stock Options		Weighted Average Exercise Price		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (1)
Balance outstanding at December 31, 2014	1,724		$	18.50	3.31	$	12,884
Granted	34		$	11.37
Exercised	(114	)	$	9.20		$	382
Cancelled	(224	)	$	21.79
Balance outstanding at June 30, 2015	1,420		$	18.56	3.06	$	222
Vested and expected to vest at June 30, 2015	1,397		$	18.51	3.03	$	217
Exercisable at June 30, 2015	1,108		$	17.86	2.63	$	179


(1)	The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 and the exercise price of in-the-money options as of those dates.

The total fair value of stock options vested during the three and six months ended June 30, 2014 was $0.5 million and $1.2 million, respectively. The total fair value of stock options vested during the three and six months ended June 30, 2015 was $0.4 million and $0.9 million, respectively.

The following table summarizes restricted stock unit activity, including performance-based and market-based restricted stock unit activity, under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):



	Number of Restricted Stock Units (1)		Weighted-Average Grant Date Fair Value		Weighted-Average Remaining Contractual Life (years)	Aggregate Intrinsic Value (2)
Balance outstanding as of December 31, 2014	873		$	30.86	2.52	$	21,753
Granted	692		$	10.59
Vested	(195	)	$	24.02
Cancelled	(147	)	$	26.53
Balance outstanding as of June 30, 2015	1,223		$	21.00	2.92	$	15,522


(1)	Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.


(2)	The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 multiplied by the number of restricted stock units outstanding as of December 31, 2014 and June 30, 2015, respectively.

The fair value of the restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on a straight-line basis over the vesting period. The fair value of performance-based restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on an accelerated basis over the vesting period. The amount of expense recorded for performance-based restricted stock units is based on expected attainment of performance criteria. The total fair value of restricted stock units vested during the three and six months ended June 30, 2014 was $1.4 million and $9.8 million, respectively. The total fair value of restricted stock units vested during the three and six months ended June 30, 2015 was $0.9 million and $2.1 million, respectively.

Stock Repurchase Programs—We had no stock repurchase activity during the three and six months ended June 30, 2015. In addition to the shares repurchased under our past repurchase programs as of June 30, 2015, we have in treasury 348,475 shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

units. As of December 31, 2014 and June 30, 2015, we had a total of 10,945,607 shares and 11,012,363 shares, respectively, held in treasury.

Stock-Based Compensation—The fair value of stock options granted to employees for the three and six months ended June 30, 2014 and 2015 was estimated using the following weighted average assumptions:



	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2015			2014			2015
Expected term	4.2 years			4.3 years			4.2 years			4.3 years
Expected volatility	45.9		%	63.6		%	45.9		%	63.6		%
Expected dividend yield	—		%	—		%	—		%	—		%
Risk-free interest rate	1.42		%	1.15		%	1.42		%	1.15		%
Weighted-average fair value	$	17.01		$	5.70		$	17.01		$	5.70

In March 2015, we granted market-based stock unit awards to certain members of senior management. Each market-based stock unit award represents a contingent right to receive certain shares of the Company’s common stock upon the attainment of certain stock prices over a four-year performance period. Once a stock price threshold is achieved, the portion of the award related to that threshold will vest on the one-year anniversary of the date of achievement, subject to the employee's continued service through each vesting date. Compensation expense related to these awards is recognized on an accelerated basis over the requisite service period. The weighted-average fair value of the market-based stock unit awards was determined using the Monte Carlo simulation model incorporating the following weighted average assumptions:



Expected term	2.59
Expected volatility	64.7		%
Expected dividend yield	—		%
Risk-free interest rate	1.13		%
Weighted-average fair value	$	6.69

There were no market-based stock unit awards granted during the three months ended June 30, 2015 and the three and six months ended June 30, 2014.

The following table summarizes stock-based compensation expense recorded during the three and six months ended June 30, 2014 and 2015 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Stock options	$	564	$	371	$	1,206	$	833
Restricted stock units	1,286		1,456		3,089		3,025
Total stock-based compensation expense	$	1,850	$	1,827	$	4,295	$	3,858

The following table summarizes stock-based compensation expense by operating function for the three and six months ended June 30, 2014 and 2015 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Marketing and advertising	$	579	$	446	$	1,236	$	1,037
Customer care and enrollment	71		139		167		256
Technology and content	429		511		991		946
General and administrative	771		731		1,901		1,506
Restructuring charges	—		—		—		113
Total stock-based compensation expense	$	1,850	$	1,827	$	4,295	$	3,858

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 4 – Income Taxes

The following table summarizes our provision for income taxes and our effective tax rates for the three and six months ended June 30, 2014 and 2015 (in thousands, except effective tax rate):



	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2015			2014			2015
Income before provision for income taxes	$	6,319		$	5,819		$	3,170		$	3,793
Provision for income taxes	$	3,296		$	69		$	1,700		$	125
Effective tax rate	52.2		%	1.2		%	53.6		%	3.3		%

Our effective tax rate in the three and six months ended June 30, 2014 was higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses. Our effective tax rate in the three and six months ended June 30, 2015 was lower than statutory federal and state tax rates due primarily to the change in valuation allowance, partially offset by certain discrete items.

During the three and six months ended June 30, 2014, excess federal and state tax benefits related to share-based payments resulted in increases of $0.4 million and $3.7 million, respectively, in Additional Paid-In Capital in the condensed consolidated balance sheets. These amounts are also classified in the condensed consolidated statements of cash flows as both a reduction to operating cash flows and as a financing cash inflow. During the three and six months ended June 30, 2015, no excess federal and state tax benefits related to share-based payments were recognized.

Note 5 – Net Income Per Share

Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net income per share by application of the treasury stock method.

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Basic:
Numerator:
Net income allocated to common stock	$	3,023	$	5,750	$	1,470	$	3,668
Denominator:
Weighted average number of common stock shares outstanding	18,978		17,967		18,914		17,906
Net income per share—basic:	$	0.16	$	0.32	$	0.08	$	0.20
Diluted:
Numerator:
Net income allocated to common stock	$	3,023	$	5,750	$	1,470	$	3,668
Denominator:
Weighted average number of common stock shares outstanding	18,978		17,967		18,914		17,906
Weighted average number of options	623		20		702		22
Weighted average number of restricted stock units	174		48		205		70
Total common stock shares used in diluted per share calculation (1)	19,775		18,035		19,821		17,998
Net income per share—diluted:	$	0.15	$	0.32	$	0.07	$	0.20


(1)	Total common stock shares used in diluted per share calculation excludes market-based stock unit awards for which the related contingency had not been met as of June 30, 2015.

For each of the three- and six-month periods ended June 30, 2014 and 2015, we had securities outstanding that could potentially dilute net income per share, but the shares from the assumed exercise of these securities were excluded in the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented. The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income per share consisted of the following (in thousands):



	Three Months Ended June 30,		Six Months Ended June 30,
	2014	2015	2014	2015
Common stock options	130	1,450	27	1,507
Restricted stock units	65	492	—	447
Total	195	1,942	27	1,954

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 6 – Geographic Information and Significant Customers

Geographic Information—As of December 31, 2014 and June 30, 2015, our long-lived assets consisted primarily of property and equipment, goodwill and other indefinite-lived intangible assets and finite-lived intangible assets. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area were as follows (in thousands):



	As of		As of
	December 31, 2014		June 30, 2015
United States	$	39,752	$	36,446
China	437		422
Total	$	40,189	$	36,868

Significant Customers—Substantially all revenue for the three and six months ended June 30, 2014 and 2015 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three and six months ended June 30, 2014 and 2015 are presented in the table below:



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Humana	21	%	13	%	24	%	26	%
Anthem (1)	11	%	11	%	11	%	9	%
UnitedHealthcare (2)	9	%	11	%	10	%	10	%
Aetna (3)	10	%	8	%	10	%	9	%

(1)Anthem also includes other carriers owned by Anthem.

(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.

(3)Aetna also includes other carriers owned by Aetna.

Commission revenue attributable to major medical individual and family health insurance plans was approximately 68% and 64% of our commission revenue in the three and six months ended June 30, 2014, respectively. Commission revenue attributable to major medical individual and family health insurance plans was approximately 65% and 49% of our commission revenue in the three and six months ended June 30, 2015, respectively. We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include small business, Medicare-related health insurance plan offerings and other ancillary products such as short-term, stand-alone dental, life, vision, and accident insurance plan offerings.

As of December 31, 2014, three customers represented 30%, 17% and 14%, respectively, of our $8.2 million outstanding accounts receivable balance. As of June 30, 2015, one customer represented 58% of our $10.2 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2014 and June 30, 2015. We believe the potential for collection issues with any of our customers is minimal as of June 30, 2015. Accordingly, our estimate for uncollectible amounts at June 30, 2015 was not material.

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 7 – Restructuring Charges

In March 2015, we implemented an organizational restructuring and cost reduction plan designed to rebalance our resources and help reduce our cost structure as a result of lower than expected individual and family health insurance plan membership and revenue. As part of the plan, we eliminated approximately 160 full-time positions in the United States, representing approximately 15% of our workforce primarily in our technology and content and customer care and enrollment groups, and to a lesser extent, in our marketing and advertising and general and administrative groups. We incurred pre-tax restructuring charges of approximately $3.9 million for employee termination benefits and related costs as well as $0.6 million in other pre-tax restructuring charges, primarily consisting of facility exit costs. The majority of the restructuring charges were recorded in the first quarter of 2015, when the activities comprising the plan were approved and substantially completed. In March 2015, as part of our restructuring activities, we also eliminated certain positions in our China operation.

The following table summarizes the total cash and non-cash restructuring charges recorded during the three and six months ended June 30, 2015 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015

Employee termination costs	$	—	$	57	$	—	$	3,791
Non-cash employee termination costs - stock-based compensation	—		—		—		113
Facility and other termination costs	—		1		—		637
Total restructuring charges	$	—	$	58	$	—	$	4,541

The following table summarizes the cash-based restructuring charges liability activity during the six months ended June 30, 2015 (in thousands):



	Six Months Ended June 30, 2015
	Beginning balance		Charges		Payments			Ending balance

Employee termination costs	$	—	$	3,791	$	(3,754	)	$	37
Facility and other termination costs	—		637		(105		)	532
Total restructuring liability	$	—	$	4,428	$	(3,859	)	$	569
Less: non-current restructuring charges associated with facilities								(280		)
Restructuring charges liability - current								$	289

Note 8 - Commitments and Contingencies

Legal Proceedings—On January 26 and March 10, 2015, two purported class action lawsuits were filed against us, our chairman and chief executive officer, Gary L. Lauer (“Mr. Lauer”), and our senior vice president and chief financial officer, Stuart M. Huizinga (“Mr. Huizinga”), in the United States District Court for the Northern District of California. On May 6, 2015, the Court consolidated the two cases. On June 10, 2015, a consolidated complaint was filed. The consolidated complaint alleges that the defendants made false and misleading statements regarding the Company’s financial performance, guidance and operations during an alleged class period of May 1, 2014 to January 14, 2015. The consolidated complaint alleges that we and Messrs. Lauer and Huizinga violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The consolidated complaint seeks compensatory damages, attorneys’ fees and costs, rescission or a rescissory measure of damages, equitable/injunctive relief and such other relief as the court deems proper. On July 15, 2015, defendants moved to dismiss the consolidated complaint.

Table of Contents

EHEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. At December 31, 2014 and June 30, 2015 we had no material liabilities included in our consolidated balance sheet for outstanding legal claims.


ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, among other things, statements regarding our expectations relating to submitted applications and our membership; our expectations relating to revenue (including commission revenue, advertising revenue and other revenue), sources of revenue, cost of revenue, the collectability of our accounts receivable, operating expenses, marketing and advertising expenses, customer care and enrollment employees and expenses, technology and content expenses, general and administrative expenses and profitability; expectations regarding the potential costs and impact of our cost reduction measures and reduction in headcount; our expectations regarding the impact of healthcare reform on our business; our ability to enroll and plans relating to the enrollment of individuals and families into qualified health plans through government health insurance exchanges; our ability to enter into agreements with and meet requirements to offer qualified health plans through state and federal health insurance exchanges; our expectations relating to the commission rates that health insurance carriers will pay; our expectations relating to the seasonality of our business; our expectations relating to the renewal of Medicare-related health insurance plans and the timing of our generation of renewal commission revenue on those plans; the timing of our receipt of commission payments; our expectations relating to seasonal trends in our business relating to the sale of Medicare-related health insurance; estimations of our membership and related assumptions that we make in our membership estimations; our expectations relating to membership attrition and retention rates; the shift between marketing partner and direct marketing channels as sources of submitted individual and family plan applications during 2015; our critical accounting policies and related estimates; our expectation that we will experience an increase in submitted applications during open enrollment periods; our belief that cash generated from operations and our current cash and cash equivalents will be sufficient to fund operations for the next twelve months; our beliefs relating to the potential for collection of our accounts receivable; expected competition from government-run health insurance exchanges and other sources; our ability to adjust headcount to respond to changes in demand due to annual open enrollment periods; our ability to convert subsidy-eligible individuals and families into members; the timing of open enrollment periods including restrictions on changes outside of such periods and our readiness therefore; the timing and source of our Medicare-related revenue; the impact of the healthcare reform laws on the healthcare industry in future periods; the potential impact of lawsuits challenging certain aspects of the Affordable Care Act; the merits of any lawsuits filed against us; future capital requirements; our need for additional regulatory licenses and approvals; as well as other statements regarding our future operations, financial condition, prospects and business strategies. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those risks associated with the impact of healthcare reform and court decisions relating to healthcare reform; our ability to retain existing members and enroll a large number of individuals and families during the annual healthcare reform open enrollment period; our ability to align our expenses with our revenue; the impact of annual enrollment period for the purchase of individual and family health insurance and its timing on our recognition of revenue; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy eligible individuals through government-run health insurance exchanges; competition, including competition from government-run health insurance exchanges; political, legislative and legal challenges to the Affordable Care Act; seasonality of our business and the fluctuation of our operating results; our ability to retain existing members and limit member turnover; changes in consumer behaviors and their selection of individual and family health insurance products, including the selection of products for which we receive lower commissions; product offerings among carriers and the resulting impact on our commission revenue; the impact of healthcare reform on the cost of health insurance; the cost of health insurance in the upcoming open enrollment period;

the impact of increased health insurance costs on demand; our ability to timely receive and accurately predict the amount of commission payments from health insurance carriers; variability in timing of commission payments from health insurance carriers; medical loss ratio requirements; delays in our receipt of items required to recognize Medicare revenue; changes in member conversion rates; our ability to accurately estimate membership; the evolving nature of Affordable Care Act implementation; our relationships with health insurance carriers; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to hire, train and retain licensed health insurance agents and other employees; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; our ability to successfully market and sell Medicare-related health insurance plans; the operations of our customer care center; costs of acquiring new members; scalability of the Medicare business; lack of membership growth and retention rates; consumers' satisfaction with our service; changes in the competitive landscape; our ability to attract new members and

Table of Contents

to convert online visitors into paying members; changes in products offered on our ecommerce platform; changes in commission rates; maintaining and enhancing our brand identity; our ability to derive desired benefits from investments in our business, including membership growth initiatives; system failures, capacity constraints, data loss or online commerce security risks; dependence on acceptance of the Internet as a marketplace for the purchase and sale of health insurance; our ability to develop an effective process for purchasing of health insurance over the Internet on smartphones, tablets and devices other than desktop or laptop computers; dependence upon Internet search engines; reliance on marketing partners; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; general economic factors; dependence on our operations in China; success of our sponsorship and advertising business; protection of our intellectual property and defense against intellectual property rights claims; legal liability and regulatory penalties; changes in our management and key employees; maintenance of relationships with business development partners; difficulties, delays, unexpected costs and an inability to achieve anticipated cost savings from our recently implemented organizational restructuring and cost reduction program; potential acquisitions; potential consolidation in the health insurance industry; maintenance of proper and effective internal controls; potential changes to accounting standards and interpretations; impact of provisions for income taxes; changes in laws and regulations, including in connection with health care reform and/or with respect to the marketing and sale of Medicare-related plans; compliance with insurance and other laws and regulations; exposure to security risks; and the performance, reliability and availability of our ecommerce platform and underlying network infrastructure. Other risks include the risks discussed under the heading “Risk Factors” of this report and those discussed in our other Securities and Exchange Commission filings. The following discussion should be read in conjunction with our Annual Report on Form 10-K as filed with the Securities and Exchange Commission in March 2015, and the audited consolidated financial statements and related notes contained therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.

Overview

We are the leading private online source of health insurance for individuals, families and small businesses. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, apply for and purchase individual and family, Medicare-related, ancillary and small business health insurance plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process.

We have invested heavily in technology and content related to our ecommerce platform. We have also invested significant time and resources in obtaining licenses to sell health insurance in all 50 states and the District of Columbia, developing member acquisition programs, obtaining necessary regulatory approvals of our websites and establishing relationships and appointments with leading health insurance carriers, enabling us to offer thousands of health insurance plans online. Our ecommerce platforms can be accessed directly through our website as well as through our network of marketing partners.

We generate revenue primarily from commissions we receive from health insurance carriers whose health insurance policies are purchased through our ecommerce platform. Commission revenue represented 90% of total revenue in the three and six months ended June 30, 2014 and represented 94% of total revenue in the three and six months ended June 30, 2015.

The commission payments we receive on individual and family, ancillary and small business health insurance plans we sell primarily consist of either a flat amount per member per month or a percentage of the premium on the policy, and to a much lesser extent, commission override payments that insurance carriers pay us for achieving sales volume thresholds or other objectives. The commission payments that we receive for individual and family, ancillary and small business health insurance plans are typically made to us on a monthly basis for as long as the plans remain active with us.

In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have changed and will continue to change the health insurance industry in substantial ways. We have described various aspects of health care reform in Part II, Item 1A. Risk Factors - Risks Related to Our Business. While aspects of health care reform may positively impact our business, the aggregate future impact of the implementation of health care reform on our business and financial results is uncertain. Our ability to continue to act as a health insurance agent for our members who switch to a new health insurance product and for new members will depend upon a number of factors, including health insurance company practices, individual financial circumstances and their eligibility for health care reform subsidies, our members’ existing health insurance plans, the price of health insurance and our ability to offer and sell subsidy-eligible health insurance plans efficiently in an online process. Moreover, we are facing new competition in the form of government run health insurance exchanges. Our

Table of Contents

ability to act as a health insurance agent to health care reform subsidy-eligible individuals depends upon government-run health insurance exchanges developing and maintaining an efficient, scalable and online enrollment process, and our ability to successfully enter into and maintain agreements and integrate with those government-run exchanges. In order to enroll individuals in subsidy-eligible plans over the Internet, we also need to meet a number of requirements relating to the display of information on our websites as well as new and comprehensive privacy and security requirements. Our ability to maintain compliance with these and other requirements could present significant challenges for us. In addition, the implementation of an open enrollment period for the purchase of individual health insurance also presents challenges to our ability to enroll a significant number of individuals into health insurance over a limited period of time and inhibits our ability to obtain new health insurance members outside of the open enrollment period. The impact of health care reform on our health insurance carrier partners and their reaction is also unclear. For instance, health insurance carriers have the ability to unilaterally change their relationship with us, including the commission rates we receive for acting as a health insurance agent and may reduce the amount they pay us, alter the manner and geographic areas in which they permit us to sell their products and change our relationship with them in any number of ways. In light of these and other considerations, health care reform has negatively impacted our business and results of operations and could in the aggregate have a material adverse effect on our business and results of operations in the future.

We actively market the availability of Medicare-related health insurance plans through our online Medicare plan platforms www.eHealthMedicare.com, www.Medicare.com and www.PlanPrescriber.com. Our Medicare plan platforms and telephonic enrollment capabilities enable consumers to research, compare and purchase Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. To the extent that we assist in the sale of Medicare-related insurance plans as a health insurance agent, through either online applications or telephonically, we generate revenue from commissions we receive from health insurance carriers. Commission payments we receive for Medicare Advantage and Medicare Part D prescription drug policies sold by us are typically fixed and are earned over a period of six years, or longer depending on the carrier arrangement, and are paid to us either monthly or annually. Commission payments we receive for Medicare Supplement policies sold by us typically are a percentage of the premium on the policy and paid to us until either the health insurance policy is cancelled or we otherwise do not remain the agent on the policy.

As a result of our commission structure, much of our revenue for a given financial reporting period relates to health insurance plans that we sold prior to the beginning of the period and is recurring in nature. Additionally, health insurance pricing, which is set by the health insurance carrier and approved by regulators, is not subject to negotiation or discounting by health insurance carriers or our competitors.

In addition to the commission revenue we derive from the sale of health insurance plans, we derive other revenue from our online sponsorship and advertising program and from licensing the use of our ecommerce technology. We offer advertising services for our Medicare plan carriers to purchase advertising on separate websites developed, hosted and maintained by us for a pre-determined amount of time. In addition, our online sponsorship program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. The technology platform we license enables health insurance carriers and agents to market and distribute health insurance plans online.

Restructuring

On March 10, 2015, we implemented an organizational restructuring and cost reduction plan. As part of the plan, we eliminated approximately 160 full-time positions, representing approximately 15% of our workforce primarily in our technology and content and customer care and enrollment groups, and to a lesser extent, in our marketing and advertising and general and administrative groups. We incurred pre-tax restructuring charges of approximately $3.9 million for employee termination benefits and related costs as well as $0.6 million in other pre-tax restructuring charges, primarily consisting of facility exit costs. The majority of the restructuring charges were recorded in the first quarter of 2015, when the activities comprising the plan were substantially completed. In March 2015, as part of our restructuring activities, we also eliminated certain positions in our China operation.

Sources of Revenue

Table of Contents

Commission Revenue

Commission revenue attributable to major medical individual and family health insurance plans was approximately 68% and 64% of our commission revenue in the three and six months ended June 30, 2014, respectively. Commission revenue attributable to major medical individual and family health insurance plans was approximately 65% and 49% of our commission revenue in the three and six months ended June 30, 2015, respectively. The decline in the percentage of commission revenue attributable to major medical individual and family health insurance plans in the three and six months ended June 30, 2015 compared to the three and six months ended June 30, 2014 was due primarily to increases in commission revenue attributable to Medicare-related health insurance plans while individual and family plan commissions declined year over year.

We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In addition, health insurance carriers often have the ability to terminate or amend our agreements unilaterally on short notice, including provisions in our agreements relating to our commission rates. The amendment or termination of an agreement we have with a health insurance carrier may adversely impact the commissions we are paid on health insurance plans that we have already sold through the carrier.

Individual and Family Plans. Commission rates for individual and family health insurance plans may vary by carrier, by geography and by the type of plan purchased by a member. Additionally, commission rates commonly vary based upon the amount of time that the policy has been active, with commission rates typically being higher in the first twelve months of the policy. After the first twelve months, commission rates generally decline significantly. As a result, if we do not add a sufficient number of members on new policies, our revenue growth will be negatively impacted, as we experienced in 2014. Individuals and families purchasing health insurance through us typically pay their premiums on a monthly basis. Insurance carriers typically pay commissions to us on these policies monthly, after they receive the premium payment from the member. We generally continue to receive the commission payment from the relevant insurance carrier until the health insurance policy is cancelled or we otherwise do not remain the agent on the policy. As a result, the majority of our individual and family plan commission revenue is recurring in nature. See Critical Accounting Policies and Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 for details regarding our recognition of individual and family health insurance plan commission revenue.

The implementation of health care reform has had a significant impact on our individual and family health insurance membership and commission revenue. For example, health care reform established open enrollment periods for the purchase of individual and family insurance. The first open enrollment period ran from October 1, 2013 through March 31, 2014 for coverage effective in 2014, and the second ran from November 15, 2014 through February 15, 2015 for coverage effective in 2015. The next annual open enrollment period for individual and family health insurance is scheduled to run from November 1, 2015 through January 31, 2016 for coverage effective in 2016. Individuals and families generally are not able to purchase individual and family health insurance outside of open enrollment periods, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance, moving to another state or becoming eligible or ineligible for a government subsidy for their health insurance. Open enrollment periods have changed the seasonality of our individual and family health insurance business.

Our individual and family health insurance commission revenue is influenced by a number of factors, including:


•	the number of applications for individual and family health insurance we submit to health insurance carriers;


•	the number of individuals applying for health insurance on submitted applications;


•	the rate at which the individuals and families on those applications turn into paying members;


•	the commission rates we receive for the plans that we sell; and


•	our membership retention.

Submitted Applications. In connection with the initial health care reform open enrollment period, that began on October 1, 2013 and ended on March 31, 2014, we experienced a significant increase, relative to historical levels, in the number of submitted applications for individual and family health insurance during the fourth quarter of 2013 and the first quarter of 2014. Following the conclusion of the initial open enrollment period, our individual and family health insurance submitted applications decreased significantly during the second and third quarters of 2014 relative to historical levels and to the first quarter of 2014. The second open enrollment period began on November 15, 2014 and ended on February 15, 2015. While we experienced a significant increase in the number of submitted applications for individual and family health insurance

Table of Contents

during the fourth quarter of 2014 compared to the second and third quarters of 2014, they were 41% below the number of submitted application during the fourth quarter of 2013. The number of individual and family health insurance submitted applications during the first quarter of 2015 was higher than the number of applications submitted during the fourth quarter of 2014, but 17% below the number of applications submitted during the first quarter of 2014. Outside the second open enrollment period, the number of individual and family health insurance submitted applications during the second quarter of 2015 decreased significantly compared to the first quarter of 2015 but remained relatively flat compared to the second quarter of 2014. Similar to 2014, we expect individual and family submitted applications to remain relatively flat in the third quarter of 2015 compared to the second quarter of 2015. We also expect individual and family submitted applications will increase significantly during the fourth quarter of 2015, relative to the second and third quarters of 2015, as a result of the next open enrollment period.

Members per Submitted Application. We also experienced a decline in the average number of members on our submitted individual and family plan health insurance applications in the first quarters of 2014 and 2015 compared to the second through fourth quarters of 2013 and 2014, respectively, which were outside the open enrollment period under health care reform. While the average returned to historical rates in the second quarter of 2014, it did not return to historical rates in the second quarter of 2015. The lower average during the first quarters of 2014 and 2015, when individual and family plan submitted applications were highest as a result of the open enrollment period, adversely impacted our membership throughout 2014 and 2015 as well as the commission revenue we would have received throughout 2014 and 2015 had the average been consistent with historical levels prior to that period.

Approval Rates. As a result of the health care reform prohibition on using pre-existing health conditions as a reason to deny health insurance applications, we have experienced higher approval rates on individual and family plan applications submitted during the first quarters of 2014 and 2015 compared to periods before health care reform implementation. However, during the second and third quarters of 2014, we also experienced a decrease in the rate at which these approvals resulted in paying members. This decrease was mainly due to an increase in the rate of non-payment of initial premium by applicants, as well as health insurance carrier-specific issues. In addition, during the second and third quarters of 2014, some carriers postponed payment of commission to us for qualified health insurance plans where the member holding the plan is receiving a subsidy, until the health insurance carrier received both the premium payment from the member and the subsidy payment from the federal government, which further delayed our ability to recognize revenue from the sale of these policies during 2014. During the first quarter of 2015, we experienced an increase in the rate at which these approvals resulted in paying members, compared to the first and second quarters of 2014. In addition, during the first and second quarters of 2015, our individual and family plan commission revenue benefitted from carriers paying us earlier on policies approved during the recently completed open enrollment period compared to a year ago. We believe that the more timely payments of commissions resulted from our carrier partners being better prepared to handle large application volumes during the recently completed open enrollment period compared to the first open enrollment period a year ago, and we also took steps to work with our carrier partners to ensure that their processes resulted in more timely commission payments to us. It is unclear whether this trend will continue throughout the remainder of 2015.

Commission Rates. The average commission dollars per-member-per-month that we receive for new individual and family health insurance plan members varies based upon a number of factors, including the ratio of policies that we sold for which we receive per member-per-month commissions compared to percentage-of-premium commissions, the premiums on the policies we sold, the mix of our members by health insurance carrier and the commission rates we receive from each carrier. The increased volume of individual and family health insurance submitted applications during the open enrollment periods caused us to experience a shift in the concentration of our membership by health insurance carrier and type of plan purchased. For example, some health insurance carriers exited or reduced selling efforts in certain markets during the initial open enrollment period, while others increased their marketing efforts in certain markets. These and other factors resulted in a change in the concentration of our individual and family health insurance members by carrier, which had the impact, after incorporating the positive impact of health insurance premium inflation, of reducing our average commission rate per member in the second and third quarters of 2014. However, we observed higher commissions on many of the individual and family health insurance plan policies that we sold during the second open enrollment period for which we received payments from health insurance carriers during the first and second quarters of 2015 compared to policies that we sold during the first open enrollment period for which we received payments from health insurance carriers during the first and second quarters of 2014. We believe that at least some of this can be explained by higher average premiums on qualified health plans that we were able to sell in greater volume during the most recent open enrollment period and by overall premium inflation across the market for individual and family health insurance. It is unclear whether this trend will continue throughout the remainder of 2015.

Retention Rates. Our individual and family health insurance commission revenue is also influenced by our individual and family health insurance member retention rates. The member retention rates on our individual and family membership were negatively impacted by health care reform beginning in the fourth quarter of 2013, throughout 2014 and during the first half of

Table of Contents

2015. As a result, the number of new individual and family health insurance members added during the second, third and fourth quarters of 2014 and the first and second quarters of 2015, was not enough to offset the loss of existing members, resulting in an annual decline in individual and family health insurance estimated membership during those periods. We expect this trend to continue in the third and fourth quarters of 2015.

Medicare Plans. Commission rates for Medicare-related health insurance plans may vary by carrier, by geography and by the type of plan purchased by a member. In the first plan year of a Medicare Advantage and Medicare Part D prescription drug plan, after the health insurance carrier approves the application but during the effective year of the policy, we are paid a fixed commission that is prorated for the number of months remaining in the calendar year. Additionally, if the policy is the first Medicare Advantage or Medicare Part D policy issued to the member, we may receive a higher commission rate that covers a full twelve-month period, regardless of the month the policy was effective. We earn commission revenue for both Medicare Advantage and Medicare Part D prescription drug plans typically for a period of at least six years, depending on the carrier arrangement, provided that the policy remains active with us. For Medicare Supplement plans, our commission rates generally represent a percentage of the premium amount collected by the carrier during the period that a member maintains coverage under a policy. We generally continue to receive the Medicare Supplement commission payment from the relevant insurance carrier until the health insurance policy is cancelled or we otherwise do not remain the agent on the policy. As a result, the majority of our Medicare commission revenue is recurring in nature. See Critical Accounting Policies and Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 for details regarding our recognition of Medicare plan commission revenue.

The majority of Medicare plans are sold in our fourth quarter during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, we have generated a significant amount of Medicare plan-related revenue in the fourth quarter resulting from the sale of new Medicare plans. For example, during 2014, 62% of our Medicare plan-related applications were submitted during the fourth quarter. Historically, we recognized a majority of our renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in the first quarter of each year as the majority of policies sold during the annual enrollment period typically renew on January 1 of each year. As a result of a regulation issued by the CMS, which changed the definition of a plan year from being 12-months from the effective date of a policy to January 1 through December 31 of each year, all Medicare Advantage and Medicare Part D prescription drug policies renew on January 1 of each year, regardless of the month the policy went into effect, which resulted in our recording substantially all Medicare Advantage and Medicare Part D prescription drug plan renewal commission revenue in the first quarter of 2015, resulted in negligible renewal commission in the second quarter of 2015 and will result in negligible renewal commission revenue in the second, third or fourth quarters of each year for these products. In addition, CMS also issued a regulation prohibiting carriers from paying commissions during the fourth quarter on Medicare Advantage and Medicare Part D prescription drug policies sold during the fourth quarter with an effective date in the following year until January 1st.

Ancillary Plans. We market and sell ancillary health insurance plans, which primarily consist of short-term, dental, life, vision, and accident insurance plans, on our ecommerce platform. Historically, we have sold ancillary health insurance plans alongside individual and family health insurance plans and also as standalone products. See Critical Accounting Policies and Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 for details regarding our recognition of ancillary health insurance plan commission revenue.

Other Revenue

Online Sponsorship and Advertising. We offer advertising services for our Medicare plan carriers to purchase advertising on separate websites developed, hosted and maintained by us for a pre-determined amount of time. In these instances, we are typically paid a fixed, up-front fee. In addition, our online sponsorship program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. In return, we are typically paid a monthly fee and a performance-based fee based on metrics such as submitted health insurance applications. See Critical Accounting Policies and Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 for details regarding our recognition of online sponsorship and advertising revenue.

Technology Licensing. We derive revenue from licensing the use of our health insurance ecommerce technology. Our technology platform enables health insurance carriers and agents to market and distribute health insurance plans online. In our technology licensing business, we are typically paid implementation fees and performance-based fees that are based on metrics such as submitted health insurance applications. See Critical Accounting Policies and Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014 for details regarding our recognition of technology licensing revenue.

Table of Contents

Member Acquisition

An important factor in our revenue growth is the growth of our member base. Our marketing initiatives are an important component of our strategy to grow our member base and are focused on three primary member acquisition channels: direct, marketing partners and online advertising. Our marketing initiatives are primarily designed to encourage consumers to complete an application for health insurance. Our marketing channels are as follows:

Direct. Our direct member acquisition channel consists of consumers who access our website addresses, including www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com and www.PlanPrescriber.com, either directly, through paid search listings on Internet search engines and directories, or other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns. For the three and six months ended June 30, 2015, applications submitted through us for individual and family health insurance from our direct channel constituted 53% and 41%, respectively, of all individual and family health insurance applications submitted on our website. For the three and six months ended June 30, 2014, applications submitted through us for individual and family health insurance from our direct channel constituted 61% and 39%, respectively, of all individual and family health insurance applications submitted on our website.

Marketing Partners. Our marketing partner member acquisition channel consists of consumers who access our websites through a network of affiliate partners and financial services and other companies. We compensate a significant number of our marketing partners by paying a fee each time a consumer referral from a partner results in a submitted health insurance application, regardless of whether the consumer’s application is approved by the health insurance carrier. Many of our marketing partners have tiered arrangements in which the amount of the fee increases as the volume of submitted applications we receive from the marketing partner increases over a particular period. We recognize these expenditures in the period when a marketing partner’s referral results in the submission of a health insurance application. Growth in our marketing partner channel depends upon our expanding marketing programs with existing partners and adding new partners to our network. For the three and six months ended June 30, 2015, applications submitted through us for individual and family health insurance plans from our marketing partner member acquisition channel constituted approximately 42% and 47%, respectively, of all individual and family health insurance applications submitted on our website. For the three and six months ended June 30, 2014, applications submitted through us for individual and family health insurance plans from our marketing partner member acquisition channel constituted approximately 27% and 42%, respectively, of all individual and family health insurance applications submitted on our website. We rely heavily on marketing partners as a source of submitted applications for Medicare-related health insurance plans. In February 2015 CMS issued guidance indicating that third-party websites and marketing material must be filed for approval with CMS. Some health insurance carriers have interpreted this guidance to mean that websites and other marketing material of our marketing partners must go through the process of CMS filing and approval. We have described various risks relating to the CMS guidance in Part II, Item 1A. Risk Factors - Risks Related to our Business.

Online Advertising. Our online advertising member acquisition channel consists of consumers who access our websites through paid keyword search advertising from search engines such as Google, Bing and Yahoo!, as well as various Internet marketing programs such as display advertising. We incur expenses associated with search advertising in the period in which the consumer clicks on the advertisement. For the three and six months ended June 30, 2015, applications submitted through us for individual and family health insurance plans from our online advertising channel constituted approximately 5% and 12%, respectively, of all individual and family health insurance applications submitted on our website. For the three and six months ended June 30, 2014, applications submitted through us for individual and family health insurance plans from our online advertising channel constituted approximately 12% and 19%, respectively, of all individual and family health insurance applications submitted on our website.

In addition to our marketing channels, we have acquired health insurance members through transactions with broker partners. We have entered into several agreements, whereby the partners have transferred certain of their existing health insurance members to us as the broker of record on the underlying policies. These transfers included primarily Medicare plan members. The first of these transferred books-of-business occurred in February 2009 and the most recent in June 2012.

Operating Costs and Expenses

Table of Contents

Cost of Revenue

Included in cost of revenue are payments related to health insurance policies sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements. In order to enter into a revenue-sharing arrangement, marketing partners must be licensed to sell health insurance in the state where the policy is sold. Costs related to revenue-sharing arrangements are expensed as the related revenue is recognized.

Additionally, cost of revenue includes the amortization of consideration we paid to certain broker partners in connection with the transfer of their health insurance members to us as the new broker of record on the underlying policies. These transfers include primarily Medicare plan members. Total consideration paid in connection with these transfers that occurred between 2009 and 2012 amounted to $13.9 million. Consideration for all book-of-business transfers is being amortized to cost of revenue as we recognize commission revenue related to the transferred members.

Marketing and Advertising

Marketing and advertising expenses consist primarily of member acquisition expenses associated with our direct, marketing partner and online advertising member acquisition channels, in addition to compensation and other expenses related to marketing, business development, partner management, public relations and carrier relations personnel who support our offerings.

Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. As a result of the second open enrollment period for individual and family plans that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in submitted applications, compared to periods outside the open enrollment period. In addition, due to the initial open enrollment period for individual and family plans that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications. Additionally, we expect individual and family-related marketing and advertising expense to decline significantly in the third quarter of 2015, outside of the open enrollment period, relative to the first quarter of 2015. We also expect both Medicare and individual and family health insurance submitted applications and related marketing and advertising expenses will increase significantly during the fourth quarter of 2015, relative to the second and third quarters of 2015, as a result of the next Medicare annual enrollment period and individual and family health insurance open enrollment period.

Because the total volume of submitted applications that we receive from our marketing partners is largely outside of our control, particularly during any short-term period, and because of our tiered marketing partner arrangements, we could incur expenses in excess of, or below, the amounts we had planned in periods of rapid change in the volume of submitted applications from marketing partner referrals. Similar to our marketing partner channel, expenses in our online advertising channel will increase or decrease in relation to any increase or decrease in consumers referred to our website as a result of search engine advertising. Increases in submitted applications resulting from marketing partner referrals or visitors to our website from our online advertising channel has in the past resulted and could in the future result in marketing and advertising expenses significantly higher than our expectations. This has in the past negatively impacted and could in the future negatively impact our profitability during such periods, because the revenue (if any) derived from submitted applications that are approved by health insurance carriers is not recognized until future periods.

During the second quarter of 2015, with the decrease in submitted individual and family plan applications outside of the open enrollment period, the source of our submitted individual and family plan applications shifted so that a greater number of applications came from our direct member acquisition channel compared to the fourth quarter of 2014 and the first quarter of 2015. During the fourth quarter of 2014 and first quarter of 2015, as a result of the health care reform second open enrollment period, the source of our submitted individual and family plan applications shifted so that a greater number of applications came from our higher cost marketing partner member acquisition channel compared to the second and third quarters of 2014. During the second and third quarters of 2014, with the decreases in submitted individual and family plan applications outside of the health care reform open enrollment period, the source of our submitted individual and family plan applications shifted so that a greater number of applications came from our direct member acquisition channel compared to the fourth quarter of 2013 and first quarter of 2014. During the third quarter of 2015, we expect a greater number of submitted individual and family plan

Table of Contents

applications will come from our direct member acquisition channel, similar to the second quarter of 2015 and the third quarter of 2014. During the fourth quarter of 2015, as a result of the next open enrollment period, we expect the source of our submitted individual and family plan applications to again shift to our higher cost marketing partner channel, similar to prior years.

Customer Care and Enrollment

Customer care and enrollment expenses primarily consist of compensation and benefits costs for personnel engaged in pre-sales assistance to applicants who call our customer care center and for enrollment personnel who assist applicants during the enrollment process. In preparation for the Medicare annual enrollment period, and to a lesser extent the open enrollment period for individual and family plans, during 2014, we began ramping up our customer care center staff during our third quarter to handle the anticipated increased volume of health insurance transactions. Additionally, in the first quarters of 2014 and 2015, we retained some Medicare sales and enrollment personnel to handle the increased volume of individual and family plan applications during the initial and second open enrollment periods for individual and family health insurance that ended on March 31, 2014 and February 15, 2015, respectively. Accordingly, our customer care center staffing costs have been significantly higher in our first and fourth quarters compared to the second and third quarters. These seasonal trends are expected to continue in 2015 as we will likely need to add seasonal customer care and enrollment personnel primarily to assist with the increase in submitted applications expected during the next Medicare annual enrollment period.

Technology and Content

Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. A majority of our technology and content group is located at our wholly-owned subsidiary in China, where technology development costs are generally lower than in the United States.

General and Administrative

General and administrative expenses include compensation and benefits costs for staff working in our executive, finance, investor relations, government affairs, legal, human resources, internal audit, facilities and internal information technology departments. These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs and information technology fees.

Restructuring Charges

Restructuring expense consists mainly of costs associated with our March 2015 organizational restructuring and cost reduction plan, designed to rebalance our resources and help reduce our cost structure as a result of lower than expected individual and family health insurance plan membership and revenue.

These restructuring activities were substantially complete in March 2015; however, we expect to continue to incur costs as we finalize previous estimates and actions in connection with these plans.

Summary of Selected Metrics

The following table shows certain selected quarterly metrics for the three months ended June 30, 2014 and 2015 and as of June 30, 2014 and 2015:

Table of Contents



	Three Months Ended		Three Months Ended
Key Metrics:	June 30, 2014		June 30, 2015
Operating cash flows (1)	$	308,000	$	12,719,000
IFP submitted applications (2)	24,800		23,900
IFP approved members (3)	95,100		36,800
Total approved members (4)	208,000		125,200
Commission revenue (5)	$	38,526,000	$	37,396,000
Commission revenue per estimated member for the period (6)	$	30.40	$	32.45
	As of		As of
	June 30, 2014		June 30, 2015
IFP estimated membership (7)	751,000		568,400
Medicare estimated membership (8)	113,200		169,100
Other estimated membership (9)	384,600		404,900
Total estimated membership (10)	1,248,800		1,142,400



	Three Months Ended		Three Months Ended
	June 30, 2014		June 30, 2015
Source of IFP submitted applications (as a percentage of total IFP applications for the period):
Direct (11)	61	%	53	%
Marketing partners (12)	27	%	42	%
Online advertising (13)	12	%	5	%
Total	100	%	100	%


(1)	Net cash provided by operating activities for the period from the condensed consolidated statements of cash flows.

(2)

Individual and Family Plan ("IFP") health insurance applications submitted on eHealth’s website during the period. Applications are counted as submitted when the applicant completes the application, provides a method for payment and clicks the submit button on our website and submits the application to us. The applicant generally has additional actions to take before the application will be reviewed by the insurance carrier, such as providing additional information and providing an electronic signature. In addition, an applicant may submit more than one application. We include applications for IFP plans for which we receive commissions as well as other forms of payment. We define our “IFP” offerings as major medical individual and family health insurance plans, which does not include small business, short-term, stand-alone dental, life, accident or Medicare-related health insurance plans.


(3)	New IFP members reported to eHealth as approved during the period. Some members that are approved by a carrier do not accept the approval and therefore do not become paying members.


(4)	New members for all products reported to eHealth as approved during the period. Some members that are approved by a carrier do not accept the approval and therefore do not become paying members.


(5)	Commission revenue (from all sources) recognized during the period from the condensed consolidated statements of comprehensive income.


(6)	Calculated as commission revenue recognized during the period (see note (5) above) divided by average estimated membership for the period (calculated as beginning and ending estimated membership for all products for the period, divided by two).


(7)	Estimated number of members active on IFP insurance policies as of the date indicated.


(8)	Estimated number of members active on Medicare insurance policies as of the date indicated.


(9)	Estimated number of members active on insurance policies other than IFP and Medicare policies as of the date indicated.


(10)	Estimated number of members active on all insurance policies as of the date indicated.


(11)	Percentage of IFP submitted applications from applicants who came directly to the eHealth website through algorithmic search engine results or otherwise. See note (2) above for further information as to what constitutes a submitted application.


(12)	Percentage of IFP submitted applications from applicants sourced through eHealth’s network of marketing partners. See note (2) above for further information as to what constitutes a submitted application.

Table of Contents


(13)	Percentage of IFP submitted applications from applicants sourced through paid search and other online advertising activities. See note (2) above for further information as to what constitutes a submitted application.

Our insurance carrier partners bill and collect insurance premiums paid by our members. Carrier partners do not report to us the number of members that we have as of a given date. The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date. We estimate the number of continuing members on all policies as of a specific date as follows:

•

To calculate the estimated number of members active on individual and family plan insurance policies, we have taken the sum of (i) the number of IFP members for whom we have received or applied a commission payment for the month that is six months prior to the date of estimation after reducing that number using historical experience (for which the experience for the period from January 1, 2014 to June 30, 2014 was used for the calculation of membership as of June 30, 2015) for assumed member cancellations over the six-month period; and (ii) the number of approved members over the six-month period prior to the date of estimation after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate. In prior periods, we have used the rate at which approved members did not accept their policies over the relevant six-month period in the prior year to estimate IFP membership. However, we have already observed that the rate at which approved members accepted their policy is greater in the three months ended March 31, 2015 compared to the three months ended March 31, 2014. Compared to the quarter ended March 31, 2014, we have also received more timely payments from health insurance carriers of the first commission payment to us on applications that were approved during the quarter ended March 31, 2015. As a result, in order to estimate the assumed number of members who did not accept their approved policy for the six months ended June 30, 2015, we have applied the percentage of members who did not accept their approved policy from January 1, 2015 to March 31, 2015 for the first three months of the six-month estimation period and the historical period of April 1, 2014 through June 30, 2014 for the last three months of the estimation period.

•

For ancillary insurance policies (such as short-term, dental, vision, accident and student), we take the sum of (i) the number of members for whom we have received or applied a commission payment for the month that is one to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the one to three-month period); and (ii) the number of approved members over the one to three-month period prior to the date of estimation (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). The one to three-month period varies by insurance product and is largely dependent upon the timeliness of commission payment and related reporting from the related carriers.


•	For Medicare-related insurance policies, we take the number of members for whom we have received or applied a commission payment prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations, including rapid disenrollment).

•

For small business health insurance policies, we estimate the number of members using the number of initial members at the time the group is approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier in the period it is reported. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us.

Additionally, our carrier partners often do not communicate policy cancellation information to us. We often are made aware of policy cancellations at the time of annual renewal and update our membership statistics accordingly in the period they are reported. A member who purchases and is active on multiple standalone insurance policies will be counted as a member more than once. For example, a member who is active on both an individual and family health insurance policy and a standalone dental policy will be counted as two continuing members.

Table of Contents

active. We do not update our estimated membership numbers reported in previous periods. Instead, we reflect updated information regarding our historical membership in the membership estimate for the current period. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernible over periods longer than from one quarter to the next. In addition, and as a result of the delay we experience in receiving information about our membership, it is difficult for us to determine with any certainty the impact of current conditions such as health care reform implementation on our membership retention. Health care reform and other factors could cause the assumptions and estimates that we make in connection with estimating our membership to be inaccurate, which would cause our membership estimates to be inaccurate.

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, requires us to make judgments, assumptions, and estimates that affect the amounts reported in the consolidated financial statements and the accompanying notes. These estimates and assumptions are based on current facts, historical experience, and various other factors that we believe are reasonable under the circumstances to determine reported amounts of assets, liabilities, revenue and expenses that are not readily apparent from other sources. To the extent there are material differences between our estimates and the actual results, our future consolidated results of operations may be affected.

An accounting policy is considered to be critical if the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and the effect of the estimates and assumptions on financial condition or operating performance. The accounting policies we believe to reflect our more significant estimates, judgments and assumptions and are most critical to understanding and evaluating our reported financial results are as follows:


•	Revenue Recognition;


•	Stock-Based Compensation;


•	Realizability of Long-Lived Assets; and


•	Accounting for Income Taxes.

During the six months ended June 30, 2015, there were no significant changes to our critical accounting policies and estimates. Please refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2014, for a complete discussion of our critical accounting policies and estimates.

Table of Contents

Results of Operations

The following table sets forth our operating results and the related percentage of total revenues for the three and six months ended June 30, 2014 and 2015 (dollars in thousands):



	Three Months Ended June 30,										Six Months Ended June 30,
	2014					2015					2014					2015
Revenue:
Commission	$	38,526		90	%	$	37,396		94	%	$	84,103		90	%	$	95,215		94	%
Other	4,068			10		2,498			6		9,431			10		5,967			6
Total revenue	42,594			100		39,894			100		93,534			100		101,182			100
Operating costs and expenses:
Cost of revenue	892			2		670			2		3,005			3		3,084			3
Marketing and advertising	9,609			23		9,285			23		32,718			35		34,736			34
Customer care and enrollment	8,984			21		7,658			19		18,697			20		19,519			19
Technology and content	9,550			22		8,591			22		20,017			21		19,364			19
General and administrative	6,857			16		7,516			19		15,151			16		15,489			15
Restructuring charges	—			—		58			—		—			—		4,541			4
Amortization of intangible assets	354			1		288			1		708			1		633			1
Total operating costs and expenses	36,246			85		34,066			85		90,296			97		97,366			96
Income from operations	6,348			15		5,828			15		3,238			3		3,816			4
Other expense, net	(29		)	—		(9		)	—		(68		)	—		(23		)	—
Income before provision for income taxes	6,319			15		5,819			15		3,170			3		3,793			4
Provision for income taxes	3,296			8		69			—		1,700			2		125			—
Net income	$	3,023		7	%	$	5,750		14	%	$	1,470		2	%	$	3,668		4	%

Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Marketing and advertising	$	579	$	446	$	1,236	$	1,037
Customer care and enrollment	71		139		167		256
Technology and content	429		511		991		946
General and administrative	771		731		1,901		1,506
Restructuring charges	—		—		—		113
Total stock-based compensation expense	$	1,850	$	1,827	$	4,295	$	3,858

Table of Contents

Three and Six Months Ended June 30, 2014 and 2015

Revenue

The following table presents our commission, other revenue and total revenue for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$			%
Commission	$	38,526		$	37,396		$	(1,130	)	(3	)%	$	84,103		$	95,215		$	11,112		13	%
Percentage of total revenue	90		%	94		%						90		%	94		%
Other	$	4,068		$	2,498		$	(1,570	)	(39	)%	$	9,431		$	5,967		$	(3,464	)	(37	)%
Percentage of total revenue	10		%	6		%						10		%	6		%
Total revenue	$	42,594		$	39,894		$	(2,700	)	(6	)%	$	93,534		$	101,182		$	7,648		8	%

Three Months Ended June 30, 2014 and 2015—Commission revenue decreased $1.1 million, or 3% in the three months ended June 30, 2015 compared to the three months ended June 30, 2014, primarily due to a decrease of $2.0 million in individual and family health insurance-related commission revenue. This was partially offset by increases of $1.1 million in Medicare-related commission revenue and $0.3 million in commission override revenue.

Other revenue decreased $1.6 million, or 39%, in the three months ended June 30, 2015, compared to the three months ended June 30, 2014, due primarily to decreases of $1.3 million in online sponsorship and advertising revenue and $0.3 million in technology licensing revenue.

Six Months Ended June 30, 2014 and 2015—Commission revenue increased $11.1 million or 13%, in the six months ended June 30, 2015, compared to the six months ended June 30, 2014, primarily due to increases of $17.9 million in Medicare-related commission revenue and $1.1 million in ancillary health insurance commission revenue, consisting primarily of short-term, dental, vision and accident plan offerings. This was partially offset by decreases of $6.1 million in individual and family health insurance-related commission revenue and $0.8 million in commission override revenue.

The increases in Medicare-related and ancillary commission revenues are due to increased membership for the six months ended June 30, 2015 compared to the six months ended June 30, 2014 as well as regulations issued by the CMS that resulted in our recognizing renewal commission revenue for all Medicare Advantage and Medicare Part D prescription drug policies on January 1st beginning in 2015. In addition, approximately $3.0 million in Medicare commission revenues were pushed into the first quarter of 2015 from the fourth quarter of 2014 as a result of a new regulation that requires commissions on Medicare Advantage and Medicare Part D prescription drug products sold during the Annual Enrollment Period not to be paid to brokers until January 1, which is the effective date of these policies, and as a result of us not receiving commission information from certain carriers in the fourth quarter.

Other revenue decreased $3.5 million, or 37%, in the six months ended June 30, 2015, compared to the six months ended June 30, 2014, primarily due decreases of $3.0 million in online sponsorship and advertising revenue and $0.7 million in technology licensing revenue, partially offset by an increase of $0.3 million in lead generation revenue.

We expect commission revenue to increase in absolute dollars in 2015 compared to 2014, primarily as a result of a continued increase in Medicare plan related commission revenue, partially offset by decreases in non-Medicare plan related commission revenue and commission override revenue. We expect other revenue to decline in absolute dollars in 2015 compared to 2014, primarily due to a decrease in online sponsorship and advertising revenue, and to a lesser extent, a decrease in technology licensing revenue.

Operating Costs and Expenses

Cost of Revenue

Table of Contents

The following table presents our cost of revenue for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$		%
Cost of revenue	$	892		$	670		$	(222	)	(25	)%	$	3,005		$	3,084		$	79	3	%
Percentage of total revenue	2		%	2		%						3		%	3		%

Three Months Ended June 30, 2014 and 2015—Cost of revenue decreased $0.2 million, or 25% in the three months ended June 30, 2015 compared to the three months ended June 30, 2014, due primarily to a decrease in amortization expense associated with the consideration we paid to a broker partner in connection with the transfer of several Medicare plan books-of-business to us whereby we became the broker of record on the underlying policies.

Six Months Ended June 30, 2014 and 2015—Cost of revenue increased $0.1 million, or 3%, in the six months ended June 30, 2015, compared to the six months ended June 30, 2014, due primarily to an increase in amortization expense associated with the consideration we paid to a broker partner in connection with the transfer of several Medicare plan books-of-business to us whereby we became the broker of record on the underlying policies. The increase is attributed to the Medicare policies renewing on January 1st and our recognizing the related annual commission revenue during the three months ended March 31, 2015.

Marketing and Advertising

The following table presents our marketing and advertising expenses for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$		%

Marketing and advertising	$	9,609		$	9,285		$	(324	)	(3	)%	$	32,718		$	34,736		$	2,018	6	%
Percentage of total revenue	23		%	23		%						35		%	34		%

Three Months Ended June 30, 2014 and 2015—Marketing and advertising expenses decreased $0.3 million, or 3%, in the three months ended June 30, 2015 compared to the three months ended June 30, 2014 due primarily to a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Six Months Ended June 30, 2014 and 2015—Marketing and advertising expenses increased $2.0 million, or 6%, in the six months ended June 30, 2015 compared to the six months ended June 30, 2014, due primarily to an increase of $2.4 million in variable advertising costs, partially offset by a $0.4 million decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015. The increase in variable advertising costs resulted from an increase of $8.2 million in the fees we pay to marketing partners for referrals that result in the submission of a health insurance application on our website and an increase of $1.6 million in direct marketing expenses, partially offset by a decrease of $7.4 million in online advertising costs.

We expect our marketing and advertising expenses to increase in absolute dollars in 2015 compared to 2014 due primarily to increased variable advertising costs associated with the second open enrollment period for individual and family health insurance plans, which ended on February 15, 2015, and the next open enrollment periods for individual and family health insurance and Medicare-related health insurance, which are scheduled to commence on November 1, 2015 and October 15, 2015, respectively, partially offset by a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Table of Contents

Customer Care and Enrollment

The following table presents our customer care and enrollment expenses for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$		%
Customer care and enrollment	$	8,984		$	7,658		$	(1,326	)	(15	)%	$	18,697		$	19,519		$	822	4	%
Percentage of total revenue	21		%	19		%						20		%	19		%

Three Months Ended June 30, 2014 and 2015—Customer care and enrollment expenses decreased $1.3 million or 15% in the three months ended June 30, 2015 compared to the three months ended June 30, 2014, due primarily to a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Six Months Ended June 30, 2014 and 2015—Customer care and enrollment expenses increased $0.8 million, or 4%, in the six months ended June 30, 2015 compared to the three months ended June 30, 2014, due primarily to an increase in compensation, benefits, licensing and other personnel costs related to additional customer care center personnel and consultants retained in connection with the open enrollment period for individual and family health insurance that ended on February 15, 2015.

We expect customer care and enrollment expenses to significantly decrease in absolute dollars in 2015 compared to 2014 as a result of a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015, partially offset by the cost of seasonal customer care center staffing necessary to handle the volume of applications during the next open enrollment periods for individual and family health insurance and Medicare-related health insurance, which are scheduled to commence on November 1, 2015 and October 15, 2015, respectively.

Technology and Content

The following table presents our technology and content expenses for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$			%
Technology and content	$	9,550		$	8,591		$	(959	)	(10	)%	$	20,017		$	19,364		$	(653	)	(3	)%
Percentage of total revenue	22		%	22		%						21		%	19		%

Three Months Ended June 30, 2014 and 2015—Technology and content expenses decreased $1.0 million, or 10%, in the three months ended June 30, 2015 compared to the three months ended June 30, 2014, primarily due to a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Six Months Ended June 30, 2014 and 2015—Technology and content expenses decreased $0.7 million, or 3%, in the six months ended June 30, 2015 compared to the six months ended June 30, 2014, primarily due to a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

We expect technology and content expenses to decrease in absolute dollars in 2015 compared in 2014 as a result of a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Table of Contents

General and Administrative

The following table presents our general and administrative expenses for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change				Six Months Ended June 30,						Change
	2014			2015			$		%		2014			2015			$		%
General and administrative	$	6,857		$	7,516		$	659	10	%	$	15,151		$	15,489		$	338	2	%
Percentage of total revenue	16		%	19		%					16		%	15		%

Three Months Ended June 30, 2014 and 2015—General and administrative expenses increased $0.7 million, or 10%, in the three months ended June 30, 2015 compared to the three months ended June 30, 2014, due primarily to increases of $0.8 million in annual performance bonus expense and $0.4 million in legal expenses, partially offset by decreases of $0.2 million in lobbying expenses and $0.2 million in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

Six Months Ended June 30, 2014 and 2015—General and administrative expenses increased $0.3 million, or 2%, in the six months ended June 30, 2015 compared to the six months ended June 30, 2014, due primarily to increases of $0.8 million in annual performance bonus expense and $0.6 million in legal expenses, partially offset by decreases of $0.5 million in lobbying expenses and $0.6 million in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015.

We expect general and administrative expenses to increase in absolute dollars in 2015 compared to 2014 as a result of the accrual of annual performance bonuses for fiscal 2015 and anticipated increases in both legal fees and stock-based compensation expense, partially offset by a decrease in compensation, benefits and other personnel costs resulting from the reduction in force announced in March 2015

Restructuring charges

The following table presents our restructuring charges for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change				Six Months Ended June 30,						Change
	2014			2015			$		%		2014			2015			$		%
Restructuring charges	$	—		$	58		$	58	100	%	$	—		$	4,541		$	4,541	100	%
Percentage of total revenue	—		%	—		%					—		%	4		%

Three Months Ended June 30, 2014 and 2015—The organizational restructuring and cost reduction plan implemented in March 2015 resulted in additional restructuring expense of $0.1 million related to employee termination costs in China in the three months ended June 30, 2015. No similar activities occurred in the three months ended June 30, 2014.

Six Months Ended June 30, 2014 and 2015—The organizational restructuring and cost reduction plan implemented in March 2015 resulted in restructuring charges of $4.5 million. These costs consist primarily of $3.9 million for employee termination benefits and related costs as well as $0.6 million in other restructuring charges, primarily relating to facility exit costs. No similar activities occurred in the six months ended June 30, 2014.

Table of Contents

Amortization of Intangible Assets

The following table presents our amortization of intangible assets for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$			%
Amortization of intangible assets	$	354		$	288		$	(66	)	(19	)%	$	708		$	633		$	(75	)	(11	)%
Percentage of total revenue	1		%	1		%						1		%	1		%

Three Months Ended June 30, 2014 and 2015—Amortization expense related to intangible assets purchased through our acquisition of PlanPrescriber was relatively flat in the three months ended June 30, 2015 compared to the three months ended June 30, 2014.

Six Months Ended June 30, 2014 and 2015—Amortization expense related to intangible assets purchased through our acquisition of PlanPrescriber was relatively flat in the six months ended June 30, 2015 compared to the six months ended June 30, 2014.

Other Expense, Net

The following table presents our other expense, net, for the three and six months ended June 30, 2014 and 2015 and the dollar and percentage changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change				Six Months Ended June 30,						Change
	2014			2015			$		%		2014			2015			$		%
Other expense, net	$	(29	)	$	(9	)	$	20	(69	)%	$	(68	)	$	(23	)	$	45	(66	)%
Percentage of total revenue	—		%	—		%					—		%	—		%

Three Months Ended June 30, 2014 and 2015—Administrative bank fees, foreign exchange losses, management fees and interest expense on our capital lease obligations were partially offset by interest earned on our invested cash and foreign exchange gains in the three months ended June 30, 2015.

Six Months Ended June 30, 2014 and 2015—Administrative bank fees, foreign exchange losses, management fees and interest expense on our capital lease obligations were partially offset by interest earned on our invested cash and foreign exchange gains in the six months ended June 30, 2015.

Provision (benefit) for Income Taxes

The following table presents our provision for income taxes for the three and six months ended June 30, 2014 and 2015 and the dollar changes from the prior year periods (dollars in thousands):



	Three Months Ended June 30,						Change					Six Months Ended June 30,						Change
	2014			2015			$			%		2014			2015			$			%
Provision (benefit) for income taxes	$	3,296		$	69		$	(3,227	)	(98	)%	$	1,700		$	125		$	(1,575	)	(93	)%
Percentage of total revenue	8		%	—		%						2		%	—		%

Three Months Ended June 30, 2014 and 2015—In the three months ended June 30, 2014 and 2015, we recorded a provision for income taxes representing effective tax rates of 52% and 1%, respectively. Our effective tax rate in the three months ended June 30, 2014 was higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses. Our effective tax rate in the three months ended June 30, 2015 was lower than statutory federal and state tax rates due primarily to the change in valuation allowance, partially offset by certain discrete items.

Table of Contents

Six Months Ended June 30, 2014 and 2015—In the six months ended June 30, 2014 and 2015, we recorded a provision for income taxes representing effective tax rates of 54% and 3%, respectively. Our effective tax rate in the six months ended June 30, 2014 was higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses. Our effective tax rate in the six months ended June 30, 2015 was lower than statutory federal and state tax rates due primarily to the change in valuation allowance, partially offset by certain discrete items.

Liquidity and Capital Resources

At June 30, 2015, our cash and cash equivalents totaled $51.8 million. Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, consist of money market funds. At December 31, 2014, our cash and cash equivalents totaled $51.4 million. The increase in cash and cash equivalents reflects $1.5 million provided by operating activities, $1.0 million of proceeds from the exercise of stock options, offset by $1.4 million used to purchase property and equipment and other assets and $0.7 million to net-share settle equity awards.

As of June 30, 2015, we have in treasury 348,475 shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2014 and June 30, 2015, we had a total of 10,945,607 shares and 11,012,363 shares, respectively, held in treasury.

The following table presents a summary of our cash flows for the six months ended June 30, 2014 and 2015 (in thousands):



	Six Months Ended June 30,
	2014			2015

Net cash provided by (used in) operating activities	$	(5,102	)	$	1,547
Net cash used in investing activities	$	(6,840	)	$	(1,432	)
Net cash provided by (used in) financing activities	$	(24,744	)	$	273

During the six months ended June 30, 2014, excess federal and state tax benefits related to share-based payments resulted in an increase of $3.7 million in Additional Paid-In Capital in the condensed consolidated balance sheets. No excess federal and state tax benefits related to share-based payments were recognized during the six months ended June 30, 2015. These amounts are also classified in the condensed consolidated statements of cash flows as both a reduction to operating cash flows and as financing cash inflows.

Operating Activities

Cash provided by operating activities primarily consists of net income, adjusted for certain non-cash items including deferred income taxes, depreciation and amortization, including amortization of intangible assets, stock-based compensation expense and the effect of changes in working capital and other activities.

The timing of the recognition of our commission revenue depends upon the timing of our receipt of commission reports and associated commission payments from health insurance carriers. If we were to experience a delay in receiving a commission payment from a health insurance carrier at the end of a quarter, our operating cash flows for that quarter could be adversely impacted. Additionally, commission override payments are reported to us in a more irregular pattern than premium commissions. For example, a carrier may make a commission override payment to us on an annual basis, which would positively impact our cash flows in the quarter the payment is received.

A significant portion of our marketing and advertising expenses is driven by the number of health insurance applications submitted on our ecommerce platform. Since our marketing and advertising costs are expensed and generally paid as incurred and the revenue and cash earned from approved applications is recognized and paid as commissions are subsequently reported to us, our operating cash flows could be adversely impacted by a substantial increase in the volume of applications submitted during a quarter or positively impacted by a substantial decline in the volume of applications submitted during a quarter. . During the fourth quarter of 2013, we experienced a substantial increase in marketing and advertising expenses related to the increase in the number of applications for Medicare plans submitted during the annual enrollment period and an increase in the number of individual and family plan applications submitted during the initial open enrollment period for individual and family health insurance, which had a negative impact on our cash flows in the quarter. During the first quarter of 2014, we experienced a substantial increase in marketing and advertising expenses related to the increase in the

Table of Contents

number of individual and family plan applications submitted during the initial open enrollment period for individual and family health insurance, which had a negative impact on our cash flows in the quarter. The significantly increased marketing and advertising expenses during the first quarter of 2014 were paid during the second quarter of 2014 resulting in a net cash outflow in the quarter. During the second and third quarters of 2014, we experienced a decrease in marketing and advertising expenses related to the decrease in the number of individual and family plan applications submitted outside the initial open enrollment period, resulting in positive cash flow in the third quarter of 2014. During the fourth quarter of 2014, we again experienced a substantial increase in marketing and advertising expenses related to the increase in the number of applications for Medicare plans submitted during the annual enrollment period and an increase in the number of individual and family plan applications submitted during the second open enrollment period for individual and family health insurance, which had a negative impact on our cash flows in the quarter. During the first quarter of 2015, we experienced a substantial increase in marketing and advertising expenses related to the increase in the number of individual and family plan applications submitted during the second open enrollment period for individual and family health insurance, which had a negative impact on our cash flows in the quarter. Also, with the second open enrollment period for individual and family health insurance ending on February 15 in 2015 as compared to March 31 in 2014, a greater proportion of marketing and advertising expenses incurred in the first quarter of 2015 were also paid in the first quarter compared to the prior year, having a further negative impact on our cash flows in the quarter. During the second quarter of 2015, we experienced a decrease in marketing and advertising expenses related to the decrease in the number of individual and family plan applications submitted outside the second open enrollment period, which contributed to positive cash flow in the quarter. Consistent with prior years, we expect marketing and advertising costs to increase during the fourth quarter of 2015 due to an increase in submitted applications for individual and family health insurance during the open enrollment period and due to an increase in submitted applications for Medicare plans during the annual enrollment period. Additionally, we expect marketing and advertising costs to decrease during the third quarter compared to cost levels during the first and fourth quarters due to a reduction in the number of health insurance applications we expect outside of annual open enrollment periods.

As a result of a regulation issued by CMS, which changed the definition of a plan year from being 12-months from the effective date of a policy to January 1 through December 31 of each year, all Medicare Advantage and Medicare Part D prescription drug policies will renew on January 1 of each year, resulting in our recording of all Medicare Advantage and Medicare Part D prescription drug plan renewal commission revenue in the first quarter of each year. As a result of this plan year change, we did not recognize significant renewal commission revenue in the fourth quarter of 2014 or second quarter of 2015 and do not expect significant renewal commission revenue in the third or fourth quarters of 2015. Renewal commissions for Medicare Advantage products are paid monthly; therefore the majority of renewal commissions for that product will be collected in quarters subsequent to the first quarter. CMS also issued a regulation prohibiting carriers from paying commissions during the fourth quarter on Medicare Advantage and Medicare Part D prescription drug policies sold during the fourth quarter with an effective date in the following year. In connection with this change and as a result of us not receiving commission information from certain carriers in the fourth quarter, an estimated $3 million of Medicare plan-related commission revenue for policies sold during the annual enrollment period was not recognized by us during the fourth quarter of 2014 but recognized as revenue during the first quarter of 2015.

Six Months Ended June 30, 2015— Our operating activities provided cash of $1.5 million during the six months ended June 30, 2015 and consisted of net income of $3.7 million, increased by non-cash items of $8.9 million and offset by cash used by operating assets and liabilities and other activities of $11.1 million. Adjustments for non-cash items primarily consisted of $5.1 million of depreciation and amortization, including amortization of internally-developed software,

book-of-business consideration and intangible assets and $3.9 million of stock-based compensation expense. Cash used by operating assets and liabilities and other activities primarily consisted of an increase of $2.0 million in accounts receivable, a decrease of $0.2 million in prepaid expenses and other assets, a decrease of $3.9 million in accounts payable, a decrease of $7.0 million in accrued marketing expenses, a decrease of $0.4 million in deferred revenue, an increase of $0.2 million in accrued compensation and benefits, an increase of $0.6 million in accrued restructuring charges and an increase of $1.7 million in other liabilities.

Six Months Ended June 30, 2014—Our operating activities used cash of $5.1 million during the six months ended June 30, 2014 and consisted of net income of $1.5 million, increased by non-cash items of $7.1 million and offset by cash used by operating assets and liabilities and other activities of $13.6 million. Adjustments for non-cash items primarily consisted of $4.8 million of depreciation and amortization, including amortization of internally-developed software, book-of-business consideration and intangible assets, and $4.3 million of stock-based compensation expense, partially offset by $2.0 million of deferred income taxes. Cash used by operating assets and liabilities and other activities primarily consisted of an increase of $2.3 million in accounts receivable, an increase of $1.3 million in prepaid expenses and other assets, a decrease of $0.2 million in accounts payable, a decrease of $3.1 million in accrued compensation and benefits , a decrease of $6.1 million in accrued marketing expenses, a decrease of $0.6 million in deferred revenue and a decrease of $0.1 million in other liabilities.

Table of Contents

Investing Activities

Our investing activities primarily consist of purchases of computer hardware and software (including capitalized internally-developed software) to enhance our website and to support our growth, as well as consideration paid for the purchase of an intangible asset.

Six Months Ended June 30, 2015—Net cash used in investing activities of $1.4 million during the six months ended June 30, 2015 was due to the purchase of property and equipment and other assets.

Six Months Ended June 30, 2014—Net cash used in investing activities of $6.8 million during the six months ended June 30, 2014 was due to $2.3 million used to purchase property and equipment and other assets and $4.5 million used in the purchase of an intangible asset, the Internet domain name www.Medicare.com. Additional non-cash consideration for www.Medicare.com included settlement of a $0.3 million outstanding receivable from the owner upon completion of the purchase.

Financing Activities

Our financing activities primarily consist of net proceeds from the exercise of common stock options, cash used to net-share settle equity awards and excess tax benefits from stock-based compensation. Additionally, in periods in which we have an active stock repurchase program in effect, our financing activities include repurchases of common stock.

Six Months Ended June 30, 2015—Net cash provided by financing activities of $0.3 million during the six months ended June 30, 2015 was due to proceeds of $1.0 million from the exercise of common stock options offset by $0.7 million used to net-share settle the tax obligation related to vesting equity awards.

Six Months Ended June 30, 2014—Net cash used in financing activities of $24.7 million during the six months ended June 30, 2014 was due to $28.3 million used to repurchase 0.8 million shares of our common stock, $3.4 million used to net-share settle the tax obligation related to vesting equity awards, partially offset by $3.2 million of proceeds from the exercise of common stock options and $3.7 million of excess tax benefits from stock-based compensation.

Future Needs

We believe that cash generated from operations and our current cash and cash equivalents will be sufficient to fund our operations for at least the next twelve months. Our future capital requirements will depend on many factors, including our level of investment in technology and advertising initiatives. We currently do not have any bank debt, line of credit facilities or other borrowing arrangements. To the extent that available funds are insufficient to fund our future activities, we may need to raise additional capital through public or private equity or debt financing to the extent such funding sources are available.

Contractual Obligations and Commitments

Operating Lease Obligations

We lease our operating facilities and certain of our equipment and furniture and fixtures under various operating leases, the latest of which expires in July 2023. Certain of these leases have free or escalating rent payment provisions. We recognize rent expense on our operating leases on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

In connection with the Mountain View, California lease agreement, we entered into a financial guarantee consisting of a standby letter of credit for $0.6 million, which may be reduced in increments of 25% of the original amount thereof on the first, second and third anniversaries of the commencement date, subject to our compliance with the applicable conditions to such reductions set forth in the lease.

Service and Licensing Obligations

We have entered into service and licensing agreements with third-party vendors to provide various services, including network access, equipment maintenance and software licensing. The terms of these services and licensing agreements are generally up to three years. We record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements.

Table of Contents

The following table presents a summary of our future minimum payments under non-cancellable operating lease agreements and certain contractual service and licensing obligations as of June 30, 2015 (in thousands):



Years Ending December 31,	Operating Lease Obligations		Service and Licensing Obligations		Total Obligations

2015 (six months)	$	2,480	$	953	$	3,433
2016	4,860		1,029		5,889
2017	4,364		557		4,921
2018	3,191		—		3,191
2019	1,045		—		1,045
Thereafter	3,520		—		3,520
Total	$	19,460	$	2,539	$	21,999

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, investments in special purpose entities or undisclosed borrowings or debt. Additionally, we are not a party to any derivative contracts or synthetic leases.

Table of Contents

AITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our financial instruments that are exposed to concentrations of credit risk principally consist of cash and cash equivalents and accounts receivable. As of December 31, 2014 and June 30, 2015, our cash and cash equivalents were invested as follows (in thousands):



	December 31, 2014		June 30, 2015
Cash (1)	$	15,793	$	17,189
Money market funds (2)	35,622		34,623
Total cash and cash equivalents	$	51,415	$	51,812


(1)	We deposit our cash and cash equivalents in accounts with major banks and financial institutions and such deposits are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government.


(2)	At December 31, 2014 and June 30, 2015 money market funds consisted of U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations.

We do not require collateral or other security for our accounts receivable. As of December 31, 2014, three health insurance carriers represented 30%, 17% and 14%, respectively, for a combined total of 61% of our $8.2 million outstanding accounts receivable balance. As of June 30, 2015, one health insurance carrier represented 58% of our $10.2 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2014 and June 30, 2015. We believe the potential for collection issues with any of our customers is minimal as of June 30, 2015. Accordingly, our estimate for uncollectible amounts at June 30, 2015 was not material.

Significant Customers

Substantially all revenue for the three months ended June 30, 2014 and 2015 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three and six months ended June 30, 2014 and 2015 are presented in the table below:



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2015		2014		2015
Humana	21	%	13	%	24	%	26	%
Anthem (1)	11	%	11	%	11	%	9	%
UnitedHealthcare (2)	9	%	11	%	10	%	10	%
Aetna (3)	10	%	8	%	10	%	9	%


(1)	Anthem includes other carriers owned by Anthem.


(2)	UnitedHealthcare includes other carriers owned by UnitedHealthcare.


(3)	Aetna also includes other carriers owned by Aetna.

Foreign Currency Exchange Risk

To date, substantially all of our revenue has been derived from transactions denominated in United States Dollars. We have exposure to adverse changes in exchange rates associated with operating expenses of our foreign operations, which are denominated in Chinese Yuan Renminbi. Foreign currency fluctuations have not had a material impact historically on our results of operations; however, there can be no assurance that future fluctuations will not have material adverse effects on our results of operations. We have not engaged in any foreign currency hedging or other derivative transactions to date.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Our Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on management’s evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our chief executive officer and chief financial officer, believes that our disclosure controls and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We also have become, and may in the future become, involved in litigation in the ordinary course of our business.

On January 26 and March 10, 2015, two purported class action lawsuits were filed against us, our chairman and chief executive officer, Gary L. Lauer (“Mr. Lauer”), and our senior vice president and chief financial officer, Stuart M. Huizinga (“Mr. Huizinga”), in the United States District Court for the Northern District of California. On May 6, 2015, the Court consolidated the two cases. On June 10, 2015, a consolidated complaint was filed. The consolidated complaint alleges that the defendants made false and misleading statements regarding the Company’s financial performance, guidance and operations during an alleged class period of May 1, 2014 to January 14, 2015. The consolidated complaint alleges that we and Messrs. Lauer and Huizinga violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The consolidated complaint seeks compensatory damages, attorneys’ fees and costs, rescission or a rescissory measure of damages, equitable/injunctive relief and such other relief as the court deems proper. On July 15, 2015, defendants moved to dismiss the consolidated complaint.

Table of Contents

ITEM 1A. RISK FACTORS

In addition to other information in this Quarterly Report on Form 10-Q and in other filings we make with the Securities and Exchange Commission, the following risk factors should be carefully considered in evaluating our business as they may have a significant impact on our business, operating results and financial condition. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered as a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods.

Risks Related to Our Business

Changes and developments in the health insurance industry or in the health insurance system in the United States as a result of health care reform could harm our business.

Our business depends upon the private sector of the United States health insurance system, its relative role in financing health care delivery and health insurance carriers’ use of, and payment of commissions to, agents and brokers to market health insurance plans. In March 2010, the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act were signed into law. These health care reform laws contain provisions that have and will continue to change the industry in which we operate in substantial ways. Among several other provisions, they include a mandate requiring individuals to maintain health insurance or face tax penalties; a mandate that certain employers offer their employees group health insurance coverage or face tax penalties; requirements relating to employer contribution to employee health coverage; prohibitions against insurance companies using pre-existing health conditions as a reason to deny an application for health insurance; prohibitions on rescission of health insurance; prohibitions on lifetime coverage limits; requirements for guaranteed renewability of health insurance plans; health insurance premium setting guidelines; limitations on deductibles and cost-sharing; medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality and, if they do not, to provide rebates to policyholders; minimum benefit levels for health insurance plans, including actuarial value standards and limitations on annual coverage limits; taxes and assessments on health insurance carriers; establishment of state and/or federal health insurance exchanges to facilitate access to, and the purchase of, health insurance; open enrollment periods for the purchase of individual and family health insurance; assistance for member run health insurance issuers; creation of multi-state health insurance plans to be offered on the exchanges and with oversight from the Office of Personnel Management; requirements for uniform disclosure relating to the costs and benefits of health insurance; government subsidized high risk pools; an expansion of Medicaid so that more individuals will be insured under state Medicaid programs; and subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels. Many of the significant aspects of health care reform went into effect in 2014, although certain provisions were effective prior to 2014, such as medical loss ratio requirements for individual and family and small business health insurance and a requirement that persons 26 years of age and younger be able to stay on a parent’s health insurance plan. Health care reform legislation required various departments of the executive branch to adopt regulations implementing its provisions. In addition, state governments have adopted, and will continue to adopt, changes to their existing laws and regulations in light of federal health care reform legislation and regulations. The implementation of health care reform has increased and could further increase our competition and could reduce or eliminate the need for health insurance agents or demand for the health insurance for individuals, families or small businesses that we sell; decrease the number of health insurance plans that we sell as well as the number of health insurance carriers offering them; cause a substantial reduction in our membership and revenue; cause us to incur increased expense across our business and cause health insurance carriers to reduce our commissions and other amounts they pay for our services or change our relationship with them in other ways, any of which could materially harm our business, operating results and financial condition. In addition, various aspects of health care reform have caused and could continue to cause health insurance carriers to determine to limit the type of health insurance plans we sell and the geographies in which we sell them, to exit the business of selling insurance plans in a particular jurisdiction, to eliminate certain categories of products or attempt to move members into new plans for which we receive lower or no commissions, any of which could materially harm our business, operating results and financial condition.

Beginning in 2014, health insurance carriers offering coverage in the individual or small business health insurance market must continue to ensure that such coverage meets certain actuarial value standards, includes certain minimum health benefits and is not subject to lifetime or, for most health insurance benefits, annual dollar amount coverage limits. Moreover, health insurance carriers cannot deny individuals health insurance for health reasons. Individuals also are required to hold plans providing minimum essential coverage to meet the mandate for health insurance and avoid a tax penalty. The cost of health insurance has generally increased and various reports have indicated that it is anticipated that health insurance premiums for the individual and family health insurance market are generally projected to increase for health insurance effective in 2

Table of Contents

015. The general increase in the cost of health insurance could reduce demand for the individual and family health insurance that we sell and could cause us to suffer a substantial reduction in our membership, which would materially harm our business, operating results and financial condition. Moreover, compared to the increased cost of individual and family health insurance plans, government subsidies to purchase health insurance and the health care reform tax penalty may not be sufficient enough to drive a substantial number of new entrants into the individual and family health insurance market or incentivize our existing members to maintain their individual and family health insurance plans, which could contribute to a decline in our membership and materially harm our business, operating results and financial condition.

If we are not successful in retaining our existing members and enrolling a large number of individuals and families into individual and family health insurance plans during the health care reform annual open enrollment period, our business will be harmed.

As a result of health care reform, individual and family health insurance is required to be purchased during an annual enrollment period. The initial open enrollment period under health care reform began in October 2013 and ended in March 2014. The second open enrollment period for coverage effective in 2015 began November 15, 2014 and ended on February 15, 2015. The next annual open enrollment period for individual and family health insurance is scheduled to run from November 1, 2015 to January 31, 2016 for coverage effective in 2016. Outside of the open enrollment period, individuals and families can only purchase new or change their existing individual and family health insurance if they qualify for a special enrollment period, which requires certain qualifying events such as losing employer-sponsored health insurance, moving to another state or becoming eligible or ineligible for a government subsidy for their health insurance. Our revenue depends in large part on the number of paying individual and family health insurance members we are successful in retaining and the number of individual and family health insurance members we acquire during the health care reform open enrollment period. We may not be successful in retaining or acquiring individual and family health insurance plan members for a number of reasons. If we are unsuccessful, our business, operating results and financial condition would be harmed. For example, we have experienced increased member attrition rates since the implementation of health care reform. We also experienced lower than expected individual and family health insurance application volumes during the open enrollment period that ended on February 15, 2015. These circumstances have resulted in lower individual and family health insurance plan membership. Open enrollment periods of limited duration in the individual and family health insurance markets have resulted, and may in the future result in a reduction in our membership and revenue; an increase in our expenses, particularly during the open enrollment periods; and otherwise may harm our business, operating results and financial condition, particularly given that the open enrollment period for individual and family health insurance overlaps with the annual enrollment period for the Medicare plans that we sell.

It may be difficult for the health insurance agents we employ and our systems and processes to handle as a business the increased volume of health insurance transactions that occur in a short period of time during the health care annual open enrollment period and/or the Medicare annual enrollment period. We do not currently anticipate devoting as many of our health insurance agents to the sale of individual and family health insurance plans for the upcoming health care reform open enrollment period. In addition, we hire a significant number of additional employees on a temporary or seasonal basis in a limited period of time to address the expected increase in the volume of health insurance transactions during the Medicare annual enrollment period. We must ensure that these employees are timely licensed, trained and certified and have the appropriate authority to sell health insurance in a number of states. We depend upon state departments of insurance, government exchanges and health insurance carriers for the licensing, certification and appointment of our health insurance agent employees. If our ability to market and sell individual and family health insurance or Medicare-related health insurance is constrained during an enrollment period for any reason, such as technology failures, reduced allocation of resources, any inability to timely license, train, certify and authorize our employees to sell health insurance, interruptions in the operation of our website, or issues with government-run health insurance exchanges, we could suffer a reduction in our membership and our business, operating results and financial condition could be harmed. In addition, we have reduced our employee and other resources as a part of expense reduction measures. Our expense reductions measures have negatively impacted the resources that we dedicate to the sale of individual and family health insurance, could cause us to sell less individual and family health insurance, and could harm our business, operating results and financial condition.

If investments we make in enrollment periods do not result in a significant number of paying members, our business, operating results and financial condition would be harmed.

In an attempt to attract and enroll a large number of individuals and families during the health care reform

open enrollment period and the Medicare annual enrollment period, we may invest in areas of our business, including technology and content, customer care and enrollment, and marketing. During 2014, our technology and content expense increased as a result of our investment in our technology platform. We also increased staffing in our customer care center in anticipation of higher demand and application volume during the most recent open enrollment period. Despite our investment in these and other areas, our individual and family health insurance membership declined. While we may not determine to

Table of Contents

invest in the health care reform open enrollment period, any investment we make in either the health care reform open enrollment period or the Medicare annual enrollment period may not result in a significant number of paying individual and family health insurance members. If it does not, our future profitability will be negatively impacted and our business, operating results and financial condition would be harmed

Our business may be harmed if we are not successful in enrolling subsidy-eligible individuals through government-run health insurance exchanges.

As a part of health care reform, each state is required to implement a health insurance exchange where individuals and small businesses can purchase health insurance. For states that do not implement a health insurance exchange, the federal government has implemented and is operating the exchange for that state. The Federally-Facilitated Marketplace, or FFM, operated some part of the health insurance exchange in 37 states for the open enrollment period that began October 15, 2014 and ended February 15, 2015. It may operate the health insurance exchange for a fewer or greater number of states in the future. Beginning in 2014, individuals and families whose incomes are between 133% and 400% of the federal poverty level are generally entitled to subsidies in connection with their purchase of health insurance. A federal regulation promulgated under the Patient Protection and Affordable Care Act clarifies that states may, but are not required to, allow agents and brokers such as us to market the qualified health plans offered on government-run health insurance exchanges and that are the plans that subsidy-eligible individuals must purchase in order to receive their subsidies. In order to offer qualified health plans, agents and brokers must meet certain conditions, such as receiving permission to do so from the health insurance exchange, entering into an agreement with the health insurance exchange, ensuring that the enrollment and subsidy application is completed through the state’s health insurance exchange (or the FFM in states that did not establish their own exchange) and complying with privacy, security and other standards, some of which have been recently issued and contain requirements that are new to us. In the event Internet-based agents and brokers such as us use the Internet for completion of qualified health plan selection purposes, their websites are required to meet certain additional conditions, such as compliance with standards for display of health plan and related information; providing consumers the ability to view all health plans offered on the government-run exchange; displaying certain health plan and other data available on the exchange; and providing a mechanism for consumers to withdraw from the application process on the agent or broker’s website. A large segment of the population is eligible for subsidies in connection with the purchase of health insurance, and a substantial number of our existing members may be eligible for subsidies. We may experience difficulty in satisfying the conditions and requirements to offer qualified health plans to our existing members and new potential members and in enrolling them through government-run health insurance exchanges. If we are not able to satisfy these conditions and requirements, or if we are not able to successfully adopt and maintain solutions that allow us to enroll large numbers of individuals and families over the Internet both during and outside of open enrollment periods in qualified health insurance plans, we will lose existing members and new members, which would harm our business, operating results and financial condition.

In order to sell qualified health plans to subsidy eligible individuals during the open enrollment period, we must establish and maintain relationships with government-run health insurance exchanges, particularly the FFM, and given that at least a part of the qualified health insurance plan enrollment process must occur through the health insurance exchanges, we must maintain our technology platform to be able to enroll consumers in qualified health plans through the government-run health insurance exchanges in a scalable manner. If we are not able to adopt and maintain solutions to integrate with government-run health insurance exchanges or if the health insurance exchange websites and other processes are not consumer friendly, efficient and compatible with the process we develop for enrolling individuals and families into qualified health plans through the exchanges, we would not be successful in retaining and acquiring members, and our business, operating results and financial condition would be harmed. Moreover, health insurance exchange websites, systems and infrastructure must be operational and not suffer significant outages or technical problems as a result of the number of individuals attempting to enroll in qualified health plans or for other reasons. If exchanges experience these problems, particularly the FFM, we would not be successful in retaining and acquiring new individual and family health insurance plan members, and our business, operating results and financial condition would be harmed.

We have entered into agreements with CMS relating to our ability to enroll individuals in qualified health plans through the FFM. The agreements contain comprehensive privacy and security and other requirements. In order to be able to enroll individuals into qualified health plans, we also must satisfy several other regulatory requirements and comply with additional laws and regulations. There are risks and uncertainties relating to our ability to enroll individuals into qualified health plans online through the FFM. Among other things, we must maintain our agreements with the FFM which need to be renewed every year; satisfy the requirements contained in the relevant agreements as well as applicable laws and regulations; maintain a compliant Internet platform incorporating those requirements; maintain qualified health plan information from health insurance carriers and CMS and incorporate it into our web platform; maintain a privacy and security program to conform to the privacy and security requirements of our agreement with CMS as well as applicable laws and regulations; and adopt and maintain solutions to integrate with the FFM so that information may be passed to and from us relating to enrollment

Table of Contents

in qualified health plans and subsidy eligibility. If we are not successful in these regards, we will not be successful in enrolling individuals and families into qualified health plans, which would harm our business, operating results and financial condition. We also depend upon the Federal government for a number of things relating to our ability to enroll individuals online into qualified health plans through the FFM, including certain qualified health plan information that is required under the applicable regulations to be displayed on our website. In addition, the FFM may at any time cease allowing us to enroll individuals in qualified health plans and must allocate resources to ensuring, and otherwise ensure, that its technology platform functions properly to enroll individuals online with an adequate customer experience and that results in our receiving credit for enrollments so that we may be paid a commission. We also depend on the FFM to maintain access points to the FFM that allow us to assist individuals in applying for subsidies and enrolling in qualified health plans online. If the FFM does not maintain these access points, if the FFM changes them so that the technology we developed to integrate with the FFM does not work or if our technology and website or the FFM’s technology or website do not function or work together properly to allow us to assist with subsidy applications and enroll large numbers of individuals into qualified health plans in a short period of time, our business, operating results and financial condition would be harmed, particularly if we were not able to scalably and efficiently enroll individuals into qualified health plans during the open enrollment period for individual and family health insurance. In addition, instability or changes to either the FFM website, particularly the portions used by agents and brokers, or other FFM operations relating to agent and broker assisted enrollment in qualified health plans, would negatively impact our ability to retain existing members and add new members. A negative impact to our ability to retain existing members and add new members would harm our business, operating results and financial condition.

While the FFM has developed technology that we can use to assist individuals and families in applying for subsidies and enrolling in qualified health plans online, none of the states that operate their own health insurance exchanges have developed this capability. As a result, while we have assisted subsidy eligible individuals in applying for qualified health insurance plans in non-FFM states, we are not able to do so entirely online. If these state exchanges do not adopt processes and technology that allow us to assist subsidy-eligible individuals in enrolling through these exchanges over the Internet and without use of health insurance agents in our customer care centers, we will not be able to effectively enroll subsidy eligible individuals in these states, and our business, operating results and financial condition will be harmed.

In part to attempt to satisfy the conditions necessary for us to use our Internet technology platform to enroll individuals into qualified health plans as a health insurance agent, and assist individuals in applying for subsidies through government-run health insurance exchanges, we have incurred increased operating expenses. Increased operating expenses that we incur may not result in increased revenue for a number of reasons both within and outside of our control. If our revenue does not increase to offset increases in costs and operating expenses, our financial condition and results of operations could be negatively affected. For instance, we increased our technology and content expense in part to develop the capability to enroll individuals into qualified health insurance plans through exchanges. Despite our investment in this regard, we had fewer estimated individual and family health insurance members as of June 30, 2015 than on June 30, 2014. If we are not successful in leveraging our technology to enroll subsidy-eligible individuals through the FFM or other state health insurance exchanges, do not successfully adopt solutions that enable online enrollment through government-run health insurance exchanges in an ecommerce friendly experience, or either we or the government-run exchanges experience technical or other problems in connection with the enrollment of individuals in qualified health plans, we will lose existing members and new members or may not receive commissions for the plans that we sell through the government-run exchanges. We have also recently reduced headcount and other expenses across our business. We anticipate this reduction will make it more difficult for us to enroll individuals through health insurance exchanges and otherwise, which could result in a reduction in our membership and our commission revenue.

We depend upon health insurance carriers and government-run health insurance exchanges to adopt and maintain

systems and processes that can handle sales of individual and family health insurance outside of the open enrollment period to those who qualify for special enrollment periods, which may include systems and processes that verify whether individuals and families are permitted to purchase individual and family health insurance outside of the open enrollment period. The failure of some health insurance exchanges to develop these systems and processes has negatively impacted our ability to sell qualified health plans using our technology platform outside of the open enrollment period. If these systems and processes are not timely developed, are not maintained or are not compatible with our platform and processes for selling individual and family health insurance, our ability to sell individual and family health insurance outside of the open enrollment period will be negatively impacted, which could harm our business, operating results and financial condition, particularly given that we have reduced headcount relating to our ability to sell individual and family health insurance and will need to rely more on our technology to do so.

If we do not successfully compete with government-run health insurance exchanges, our business may be harmed.

Table of Contents

We compete with government-run health insurance exchanges, among others. Among other things, the exchanges have websites where individuals and small businesses can shop for and purchase health insurance, and they also have offline customer support and enrollment capabilities. Individuals who are eligible for government subsidies in the form of premium tax credits and cost sharing reductions must apply for their subsidy and purchase qualified health plans through a government exchange to receive their subsidy. In the aggregate, government exchanges have greater resources, larger marketing budgets and greater public outreach capability than we do. For example, government exchanges invested heavily in paid search advertising during the last health care reform open enrollment period to a degree that increased paid search advertising cost for health insurance related Internet search terms. In addition, individuals that utilize our platform and services to apply for subsidies and health insurance through government exchanges receive marketing and communications from the government exchanges after they do so. In the event our existing members purchase health insurance directly through health insurance exchanges without using us as their health insurance agent, as a result of their being eligible for a subsidy or otherwise, we will no longer receive commission revenue as a result of our sale of health insurance to them. The exchanges also compete with us for new members, and under regulations adopted as a part of health care reform, government-run health insurance exchanges are required to automatically re-enroll individuals and families into a qualified health insurance plan purchased through the exchange if the individuals or families do not take affirmative action, which may inhibit our ability to grow our membership. Competitive pressure from government-run health insurance exchanges has, and may in the future, result in our experiencing increased marketing costs, decreased traffic to our website, a reduction in our individual and family health insurance membership and revenue and may otherwise harm our business, operating results and financial condition.

Our business may be harmed if certain aspects of the Patient Protection and Affordable Care Act that are beneficial to our business are successfully challenged and held unenforceable by the courts.

A number of lawsuits have been filed challenging various aspects of the Patient Protection and Affordable Care Act and related regulations. In the event these lawsuits are successful and result in the unenforceability of aspects of the law or regulations that are beneficial to our business or cause changes in the health insurance industry that are adverse to our business, our business, operating results and financial condition could be harmed.

Our future operating results are likely to fluctuate and could fall short of expectations.

Our operating results are likely to fluctuate as a result of a variety of factors, including the factors described elsewhere in this Risk Factors section, many of which are outside of our control. As a result, comparing our operating results on a period-to-period basis may not be meaningful and you should not rely on our past results as an indication of our future performance, particularly in light of the fact that our business and industry are undergoing substantial change as a result of health care reform. If our revenue or operating results differ from our guidance or fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, when our revenue and operating results differed from our guidance and the expectations of investors or securities analysts, the price of our common stock was impacted.

Our business model is characterized primarily by revenue based on commissions we receive from insurance carriers whose policies are purchased by our members. We receive commissions and record related revenue for an individual and family, small business, ancillary or Medicare Supplement health insurance policy, typically on a monthly basis, until the health insurance policy is cancelled or we otherwise do not remain the agent on the policy. For both Medicare Advantage and Medicare Part D prescription drug plans, we record commission revenue on an annual basis but may receive commission payments from insurance carriers on either a monthly or annual basis typically for a period of at least six years, depending on the carrier arrangement, provided that the policy remains active with us and we remain the agent on the policy. A significant component of our marketing and advertising expenses consists of expenses incurred in search engine advertising at the time a consumer clicks on an advertisement and payments owed to our marketing partners in connection with applications submitted on our ecommerce platform by potential members referred to us by our marketing partners. As a result of any timing difference between expense and associated revenue recognition, our operating results and cash flows may be adversely affected in periods where we experience a significant increase in new applicants. For example, the implementation of health care reform open enrollment periods for individual and family health insurance and the Medicare annual enrollment period have in the past caused a substantial number of health insurance applications to be submitted through us in a short period of time and a substantial increase in marketing and advertising expenses. Because commission revenue related to any submitted applications that result in paying members is not recognized until future periods, the marketing and advertising expense associated with the submitted applications has a negative impact on operating results and cash flows in the period in which the submitted applications were received. In addition, if we incur other unanticipated or one-time expenses in a particular quarter, lose a significant amount of our member base for any reason or our commission rates are reduced, through a change in the health insurance products chosen by our members, carrier reduction in our commission rates or otherwise, the impact of our incurring increased marketing and advertising expenses would be especially pronounced and we would likely be unable to offset these

Table of Contents

expenses by increasing sales within that quarter or to replace lost revenue in the quarter with revenue from new members and our business, operating results and financial condition would be harmed.

Seasonality may cause fluctuations in our financial results.

The seasonality of our business is outside of our control. For example, the health care reform open enrollment period has changed the seasonality of our individual and family health insurance business. Since the fourth quarter of 2013, we have experienced a greater number of individual and family health insurance submitted applications in the fourth quarter and first quarter and a lower number of submitted applications in the second and third quarter of the year compared to periods prior to the introduction of open enrollment periods. The seasonality in our business could change in the future for a number of reasons, including as a result of changes in timing of individual and family health plan and Medicare annual open enrollment periods and changes in, and the enforceability of, the laws and regulations that govern the sale of health insurance. We may not be able to timely adjust to changes in the seasonality of our business. For example, if the timing of the open enrollment periods for Medicare-related health insurance or individual and family health insurance change, we may not be able to timely adapt to changes in customer demand. If we are not successful in responding to changes in the seasonality of our business, our business, operating results and financial condition could be harmed. Additional information regarding the seasonality in our business is included in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q.

Our revenue will be adversely impacted if our membership does not grow or if we are unable to retain our existing members.

Our estimated individual and family health insurance plan membership has declined substantially since the implementation of health care reform. Our revenue has been, and will continue to be, adversely impacted if our membership does not grow. We receive revenue from commissions health insurance carriers pay to us for health insurance policies sold through our ecommerce platform. When one of these policies is cancelled, or if we otherwise do not remain the agent on the policy, we no longer receive the related commission revenue. Individuals, families and small businesses may choose to discontinue their health insurance policies for a variety of reasons. For example, individuals and families may replace a health insurance policy purchased through us with a health insurance policy provided by a new or existing employer or may determine that they can no longer afford health insurance. They may also determine that they do not like the benefits and physician network covered under the plan. In addition, our members may choose to purchase new policies through other sources or use a different agent if, for example, they are not satisfied with our customer service or the health insurance plans that we offer. Our expense reduction measures have impacted the number of our employees dedicated to customer service in our individual and family health insurance business, which could cause a greater number of individuals to be dissatisfied with our customer service. Consumers may also purchase health insurance policies directly from government-run health insurance exchanges, including as a result of the requirement that subsidy-eligible individuals must purchase qualified health plans through government-run health insurance exchanges to be able to receive a subsidy under health care reform, and we would not remain the agent on the policy. Health insurance carriers have in the past and may in the future terminate health insurance plans purchased and held by our members. If we are not successful in transferring members covered under a terminated plan to another policy that we offer, we will lose these members and associated commission revenue. Our cost of acquiring a new member is substantially greater than the cost involved in maintaining our relationship with an existing member. If we are not able to successfully retain existing members and limit member turnover, our revenue and operating margins will be adversely impacted and our business, operating results and financial condition would be harmed. In addition, the individual and family commission rates that we receive are typically higher in the first twelve months of a policy. After the first twelve months, they generally decline significantly. The Medicare-related commission rates that we receive may be higher in the first calendar year of a policy if the policy is the first Medicare-related policy issued to the member. As a result, if we do not add a sufficient number of members on new policies, our revenue will be negatively impacted.

Our revenue will be adversely impacted if commission rates decline or if consumers choose health insurance products for which we receive lower commissions.

Our revenue will be adversely impacted if our commission rates decline. The commission rates we receive are impacted by a variety of factors, including the particular health insurance plans chosen by our members, the carriers offering those plans, our members’ states of residence, the average premiums of plans purchased through us, the laws and regulations in those jurisdictions and health care reform. Our commission revenue per member has in the past decreased, and could in the future decrease, as a result of either reductions in contractual commission rates, unfavorable changes in health insurance carrier override commission programs, or the mix of carriers whose products we sell during a given period, all of which are beyond our control and may occur on short notice. To the extent these and other factors cause our commission revenue per member to decline, our revenue may decline and our business, operating results and financial condition would be harmed.

Table of Contents

Our revenue will be adversely impacted if consumers enroll in individual and family health insurance plans that reduce our average commission revenue per member. Due in part to health care reform, some health insurance carriers have exited or reduced individual and family health insurance selling efforts in certain markets, while expanding in others, leading to changes in the health insurance carrier composition of our commission revenue. Since our commission rates vary by carrier, a shift in the mix of products selected by our new members will have an impact on our average commission revenue per member. If our average commission revenue per member declines, our business, operating results and financial condition could be harmed. Given that individual and family health insurance purchasing is concentrated during the annual open enrollment period, a reduction in our average commission revenue per member could occur over a short period of time and could adversely impact our revenue in future periods, which would harm our business, operating results and financial condition.

Our operating results fluctuate depending upon CMS regulations, health insurance carrier payment practices and the timing of our receipt of commission reports from health insurance carriers.

The timing of our revenue depends upon the timing of our receipt of commission reports and associated payments from health insurance carriers. There have been instances where the report of commissions and payment has been delayed, such as during holiday periods or as a result of the health care reform open enrollment period. In the fourth quarter of 2014 we also experienced a delay in receiving commission payments and reports as a result of a CMS regulation issued in 2014 prohibiting carriers from paying commissions during the fourth quarter on Medicare Advantage and Medicare Part D prescription drug policies sold during the fourth quarter with an effective date in the following year. Any delay in our receipt of commission payments or reports could materially impact our financial results for a given quarter as we would not be able to recognize the related commission revenue in that quarter. In addition, much of our commission override revenue is not reported and paid to us in accordance with a scheduled pattern, and some is only reported and paid to us once per year. The timing of our revenue recognition could result in a large amount of commission revenue from a carrier being recorded in a given quarter that is not indicative of the amount of revenue we may receive from that carrier in subsequent quarters, causing fluctuations in our operating results. We also could report revenue below the expectations of our investors or securities analysts in any particular period if a material report or payment from a health insurance carrier were delayed or not received within the time frame required for revenue recognition.

The implementation of open enrollment periods under health care reform for the purchase of individual health insurance may present challenges to our ability to enroll a significant number of individuals into health insurance over a limited period of time. Significant increases in enrollment activity over a limited amount of time may also make it difficult for health insurance carriers to timely and accurately report commission information to us. To the extent health insurance carriers have difficulty in reporting timely and accurate commission information to us, we may be unable to recognize revenue in accordance with our revenue recognition policies, which could cause us to defer substantial revenue until such time our health insurance carriers are able to resume reporting timely and accurate commission information to us.

The medical loss ratio requirements that are a part of health care reform may harm our business.

The federal Patient Protection and Affordable Care Act enacted in March 2010 and related amendments in the Health Care and Education Reconciliation Act of 2010 contain provisions requiring health insurance carriers to maintain specified medical loss ratios. The medical loss ratio requirements for both individual and family and small business health insurance became effective in 2011 and, among other things, require health insurance companies to spend 80% of their premium revenue in each of their individual and small group health insurance businesses on reimbursement for clinical services and activities that improve health care quality. The medical loss ratio requirement for Medicare Advantage plans is 85% and went into effect in 2014. If a health insurance carrier fails to meet medical loss ratio requirements, the health insurance carrier is required to rebate a portion of its premium revenue to its members to make up for the difference.

Carrier reaction to the individual and family medical loss ratio requirements was to significantly reduce the commissions we receive in connection with the sale of individual and family health insurance. Health insurance carriers may determine to reduce or further reduce our individual and family, small group or Medicare Advantage plan commissions as a result of the medical loss ratio requirements or other aspects of health care reform, including any increased expenses in complying with or dealing with the impact of health care reform, which would harm our business, operating results and financial condition. In addition, if health insurance companies fail to meet medical loss ratio requirements, we may be required to pay back commissions that are related to any premium amounts the carriers are required to rebate policyholders as a result, which would harm our business, operating results and financial condition. The medical loss ratio requirements also may cause certain health insurance carriers to limit the geographies in which they sell health insurance or exit certain markets altogether, place less reliance on agents to distribute their plans, or limit their health insurance offerings in any number of other ways, each of which would harm our business, operating results and financial condition. The implementation of medical loss ratio

Table of Contents

requirements has caused and could further cause health insurance carriers to reduce the amount they are willing to spend in connection with our sponsorship and advertising and technology licensing businesses, which also could harm our business, operating results and financial condition.

Our business may be harmed if we lose our relationship with health insurance carriers or our relationship with health insurance carriers is modified.

We typically enter into contractual agency relationships with health insurance carriers that are non-exclusive and terminable on short notice by either party for any reason. In many cases, health insurance carriers also may amend the terms of our agreements unilaterally on short notice. Carriers may be unwilling to allow us to sell their existing or new health insurance plans, or desire to amend our agreements with them, for a variety of reasons, including for competitive or regulatory reasons, dissatisfaction with the economics of the members that we place with them or because they do not want to be associated with our brand. We may also terminate our relationship with health insurance carriers, including as a result of expense reduction measures and health insurance carriers could determine to cease working with us if they do not like any impact the measures may have on our operations. In addition, many aspects of health care reform have caused, and may in the future cause, carriers to modify their relationship with us given the substantial changes in the industry in which we operate. For instance, in addition to the medical loss ratio requirements, health care reform contains taxes and assessments on health insurance carriers that may make their businesses less profitable. In the future, and as a result of health care reform or for other reasons, an increasing number of health insurance carriers may decide to reduce our commissions, rely on their own internal distribution channels, including traditional in-house agents and carrier websites, to sell their own plans and, in turn, could limit or prohibit us from selling their plans on our ecommerce platform. Carriers may choose to exclude us from their most profitable or popular plans or may determine not to distribute insurance plans in the individual and family and small business markets in certain geographies or altogether. We also depend upon health insurance carriers to allow us to sell qualified health plans and to pay us commissions in connection with their sale. In the event we are not successful in gaining or maintaining the ability to sell individual and family qualified health insurance plans, or if health insurance carriers pay us no commissions or reduced commissions in connection with the sale of these plans, we could lose a substantial number of existing and potential members and commission revenue we receive as a result of the sale of individual and family health insurance products, which would materially harm our business, operating results and financial condition. The termination of our relationship with a health insurance carrier by us or the health insurance carrier or the amendment of our relationship with a carrier could reduce the variety of health insurance plans we offer, which could harm our business, operating results and financial condition. It also could adversely impact, or cause the termination of, commissions for past and future sales, which would materially harm our business, operating results and financial condition. Our business could also be harmed if in the future we fail to develop new carrier relationships and are unable to offer consumers a variety of health insurance plans in each jurisdiction.

The health insurance industry in the United States has experienced a substantial amount of consolidation, resulting in a decrease in the number of health insurance carriers. Significant additional consolidation may occur, given that Aetna and Humana recently entered into an agreement for the acquisition of Humana by Aetna and Anthem and Cigna have recently entered into an agreement for the acquisition of Cigna by Anthem. Consolidation in the health insurance industry could cause a loss of or changes in our relationship with carriers and reduction in our commission revenue, which could harm our business, operating results and financial condition. In the future, we may be forced to offer insurance policies from a reduced number of insurance carriers or to derive a greater portion of our revenue from a more concentrated number of carriers as our business and the health insurance industry evolve. Revenue derived from Humana represented approximately 24% and 26% of our total revenue in the six months ended June 30, 2014 and 2015, respectively. Revenue derived from carriers owned by Anthem represented approximately 11% and 9% of our total revenue in the six months ended June 30, 2014 and 2015, respectively. Revenue derived from carriers owned by UnitedHealthcare represented approximately 10% of our total revenue in each of the six months ended June 30, 2014 and 2015. Revenue derived from carriers owned by Aetna represented approximately 10% and 9% of our total revenue in the six months ended June 30, 2014 and 2015, respectively. We have several agreements that govern our sale of health insurance plans with these health insurance carriers. They may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact or cause the termination of the commission payments that we receive from these health insurance carriers, including commissions on plans that we have already sold, which could materially harm our business, operating results and financial condition. Our revenue could be adversely impacted if we are unable to maintain currently-existing levels of business with any of our significant health insurance carriers if we are unable to offset any loss of business with alternative health insurance carriers. We expect that a small number of health insurance carriers will account for a significant portion of our revenue for the foreseeable future and any impairment of our relationship with, or the material financial impairment of, these health insurance carriers could adversely affect our business.

We may not be successful in our efforts to market and sell Medicare-related health insurance plans as a health insurance agent.

Table of Contents

In 2010 we began to actively market the availability of Medicare-related health insurance plans using our ecommerce platforms, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. We refer to these plans as Medicare plans. We market Medicare plans to Medicare-eligible individuals, who are predominately senior citizens over the age of 65. The sale of Medicare Advantage and Medicare Part D prescription drug plans are subject to an annual enrollment period during the fourth quarter of each year, when a substantial percentage of the annual sales of these plans occur. We sell Medicare plans as a health insurance agent using our websites and customer care centers.

Our Medicare plan-related revenue is concentrated in a small number of health insurance carriers. The success of our Medicare-related health insurance business depends upon our ability to enter into new and maintain existing relationships with health insurance carriers on favorable economic terms. The concentration of our Medicare plan sales in a limited number of health insurance carriers makes us vulnerable to changes in carrier commission rates and changes in the competitiveness of our carriers’ Medicare products. If our Medicare carriers reduce our commission rates, reduce the amount they pay us for advertising services, or the competitiveness of their products declines compared to original Medicare or the products of Medicare carriers with which we do not have a relationship, our business, operating results and financial condition would be harmed.

In addition, we may temporarily or permanently lose the ability to market and sell Medicare plans for our Medicare plan carriers. For instance, a carrier may terminate our relationship. Moreover, CMS heavily regulates the sale of Medicare Advantage and Medicare Part D prescription drug plans and has and will continue to penalize health insurance carriers for certain regulatory violations by terminating the carrier's contract with CMS that allows the carrier to sell Medicare plans or by

not allowing them to market and sell Medicare plans for significant periods of time. Given the concentration of our Medicare plan sales in a small number of carriers, if we lose a relationship with a health insurance carrier to market their Medicare plans temporarily or permanently for these or any other reasons, our sales as a health insurance agent and Medicare plan-related revenue could suffer significantly, and our business, operating results and financial condition would be harmed. The agreements that we have with health insurance carriers to sell Medicare plans may be unilaterally amended or terminated by the carrier on short notice and the amendment or termination could adversely impact, or cause the termination of, the commission payments that we receive for selling their Medicare plans, including commissions on plans that we have already sold, which could materially harm our business operating results and financial condition.

CMS and the health insurance carriers whose Medicare plans we sell must approve our websites, our marketing partners' websites and call center scripts for us to be able to generate Medicare plan demand and sell Medicare plans to Medicare-eligible individuals as a health insurance agent. Moreover, we use Medicare plan cost and benefit data collected and made publicly available by CMS. In the event that CMS or a health insurance carrier disapproves, or delays approval, of our websites, our marketing partners' websites or call center scripts, or if CMS does not timely release Medicare plan cost and benefit data for the following year’s Medicare plans prior to the annual enrollment period, we could lose a significant source of Medicare plan demand and our ability to sell Medicare plans would be adversely impacted, each of which would harm our business, operating results and financial condition. Further, if a marketing partner of ours does not consent to having its website or other marketing material filed with the CMS, does not make changes required by carriers or CMS or does not comply with the CMS marketing guidelines or other Medicare program related laws, rules and regulations, we may lose the ability to receive referrals of individuals interested in purchasing Medicare plans from that marketing partner and our business, operating results and financial condition would be harmed.

In addition, each time we or our marketing partners substantively change our websites or call center scripts, we need to resubmit them to our health insurance carriers and CMS for approval. We are not permitted to make these submissions ourselves. Given the review cycles our scripts and websites undergo, it is very difficult to make changes to them, and our inability to timely make changes to these marketing materials, whether to comply with new rules and regulations or otherwise could adversely impact our ability to sell Medicare plans during the Medicare annual enrollment period, which could impact our business, operating results and financial condition. In addition, if a change to scripts or websites is required by CMS or health insurance carriers, we may be prevented from selling Medicare plans during this period of review, which could harm our business, operating results, and financial condition, particularly if it occurred during the annual enrollment period.

Our Medicare plan-related revenue is dependent upon the number of paying Medicare plan insurance members we are successful in retaining and acquiring during the Medicare annual enrollment period. If we are not successful in retaining and acquiring Medicare plan members during the annual enrollment period for any reason, our business, operating results and financial condition would be harmed.

Our success in the Medicare plan market as a health insurance agent will also depend upon a number of additional factors, including:

Table of Contents


•	our ability to continue to adapt our ecommerce platform to market Medicare plans, including our development or acquisition of marketing tools and features important in the sale of Medicare plans online and the effective modification of our user experience;


•	our success in marketing our ecommerce platform to Medicare-eligible individuals and in entering into business development relationships to drive Medicare-eligible individuals to our ecommerce platform;


•	our effectiveness in entering into and maintaining relationships with marketing partners that refer Medicare-eligible individuals to us;


•	our ability to hire and retain additional employees with experience in Medicare, including our ability to timely implement Medicare sales expertise into our customer care centers;


•	our ability to implement and maintain an effective information technology infrastructure for the sale of Medicare plans, including the infrastructure and systems that support our websites, call centers and call recording;


•	our ability to leverage technology in order to sell, and otherwise become more efficient at selling, Medicare-related plans over the telephone;


•	our ability to comply with the numerous, complex and changing laws and regulations and CMS guidelines relating to the marketing and sale of Medicare plans, including continuing to conform our online and offline sales processes to those laws and regulations; and


•	the effectiveness with which our competitors market the availability of Medicare plans from sources other than our ecommerce platform.

As a result of these factors, we may prove unsuccessful in marketing Medicare plans and acting as a health insurance agent in connection with their sale, which would harm our business, operating results and financial condition. In addition, if our efforts to market Medicare plans during any annual enrollment period were impeded due to lack of health insurance carrier or CMS approval, or for other reasons, the impact on our business, operating results and financial condition would be significantly greater given the seasonality of our Medicare-related revenues, membership acquisition and expenses and the fact that much of the sales of Medicare plans occur during this period.

Our ability to sell Medicare-related health insurance plans as a health insurance agent depends on our ability to timely hire, train and retain licensed health insurance agents for our customer care center operations and our ability to maintain information technology systems to facilitate their sale of Medicare plans.

In addition to our websites, we rely upon our customer care centers to sell Medicare plans. The success of our customer care center operations is largely dependent on licensed health insurance agents and other employees. In order to sell Medicare-related health insurance plans, our health insurance agent employees must first be licensed by the states in which they are selling plans and certified and appointed with the health insurance carrier that offers the plans in each state that the Medicare-related health insurance product is being sold by the agent. Because the majority of Medicare plans are sold in the fourth quarter each year during the Medicare annual enrollment period, we are required to hire and train a significant number of additional employees on a temporary or seasonal basis in a limited period of time. It may be difficult for the health insurance agents we employ and our systems and processes to handle the increased volume of health insurance transactions that occur in a short period of time during the Medicare annual enrollment period. We must also ensure that our health insurance agent employees are timely licensed in a significant number of states and certified and appointed with the health insurance carriers whose products we sell. We depend upon state departments of insurance and health insurance carriers for the licensing, certification and appointment of our health insurance agent employees. We may not be successful in timely hiring a sufficient number of additional licensed agents or other employees for the Medicare annual enrollment period, and even if we are successful, these employees may experience delays in obtaining health insurance licenses and certifications and health insurance carrier appointments with our health insurance carrier partners. If we and our health insurance agent employees are not successful in these regards, our ability to sell Medicare-related health insurance plans will be impaired during the annual enrollment period, which would harm our business, operating results and financial condition.

The success of our Medicare plan customer care center operations also is dependent on information technology systems. The vast majority of our Medicare plan members utilize our customer care center in connection with their purchase of a Medicare plan. CMS rules require that our health insurance agent employees utilize CMS-approved scripts in connection

Table of Contents

with the sale of Medicare plans and that we record and maintain the recording of telephonic interactions relating to the sale of Medicare plans. We rely on telephone, call recording, customer relationship management and other systems and technology

in our Medicare customer care center operations related to these and other functions, and we are dependent on third parties for some of them, including our telephone and call recording systems. The effectiveness and stability of our Medicare customer care center systems and technology are critical to our ability to sell Medicare plans, particularly during the Medicare annual enrollment period, and the failure or interruption of any of these systems and technology or any inability to handle increased volume during the annual enrollment period would harm our business, operating results and financial condition.

Factors beyond our control may negatively impact our Medicare-related health insurance business.

We determined to enter into the Medicare plan market because we believe the number of individuals becoming eligible for Medicare is increasing and these individuals are increasingly using the Internet to shop for health insurance plans. We also believe that, on average, member retention rates and the commissions that health insurance carriers pay in connection with the sale of Medicare plans compare favorably to the member retention rates and commissions we receive in connection with our sale of individual and family health insurance. Should we prove to be wrong, or should these circumstances reverse, our success in marketing Medicare plans would be materially and adversely impacted, which could harm our business, operating results and financial condition. For instance, portions of health care reform impose significant changes to original Medicare and the Medicare Advantage program by, among other things, increasing benefits original Medicare provides, reducing payments to Medicare Advantage plans and imposing medical loss ratio requirements for Medicare Advantage plans. In addition, CMS has in the past determined to reduce the payments it makes to health insurance carriers in connection with the sale of Medicare Advantage plans and it may do so again in the future. These reductions have caused, and could in the future cause, the cost of Medicare Advantage plans to increase and the benefits under Medicare Advantage plans to decrease, which would impair our ability to sell Medicare Advantage plans and our business, operating results and financial condition could be harmed. They also may cause health insurance carriers to reduce our compensation, which would harm our business, operating results and financial condition.

The majority of our Medicare-related health insurance plan sales occur over the telephone. Telephone sales of Medicare-related health insurance require a licensed health insurance agent to complete and are time consuming compared to sales over the Internet. Given the resources required in connection with telephonic Medicare-related health insurance sales, it may prove difficult for us to continue to grow our Medicare-related health insurance sales compared to prior periods and even if we are able to grow those sales, it may be expensive to add the additional resources necessary for the growth. If we are not able to scalably grow our Medicare-related health insurance sales over the Internet or in other ways that require fewer resources, our business, operating results and financial condition would be harmed.

CMS has in the past proposed changing the rules relating to compensation of agents in connection with the sale of Medicare Advantage and Medicare Part D prescription drug plans, which could cause a reduction in our compensation as a health insurance agent in connection with the sale of these plans. In the event CMS adopts regulations that have the effect of reducing the compensation that we receive in connection with the sale of Medicare Advantage and Medicare Part D prescription drug plans, our business, operating results and financial conditions could be harmed. CMS adopted regulations that changed the definition of a plan year from being twelve months from the effective date of a policy to January 1 through December 31 of each year, causing all Medicare Advantage and Medicare Part D prescription drug policies to renew on January 1 of each year. As a result, we will record all Medicare Advantage and Medicare Part D prescription drug plan renewal commission revenue in the first quarter of each year. This plan year change will result in our recognition of minimal renewal commission revenue outside of the first quarter of 2015 and the first quarter in future years. In addition, CMS also issued a regulation prohibiting carriers from paying commissions during the fourth quarter on Medicare Advantage and Medicare Part D prescription drug policies sold during the fourth quarter with an effective date in the following year, which negatively impacts our operating cash flows in the fourth quarter of the year. This regulation also makes it more difficult for us to recognize revenue relating to our sale of Medicare Advantage and Medicare Part D prescription drug plans in the fourth quarter of the year, given that our revenue recognition policy requires us to receive either a cash payment or commission statement in the period we recognize revenue, provided we receive the second corroborating communication shortly following the period of recognition. If health insurance carriers do not send at least one of these communications during the fourth quarter

, our recognition of revenue relating to our sale of these policies in the fourth quarter will be delayed until we receive the first communication, which would adversely impact our financial results in the fourth quarter. In the event health care reform, the actions of the federal government or other circumstances decrease the demand for Medicare Advantage plans or other alternatives to original Medicare, or result in a reduction in the amount paid to us or impact the timing of our revenue recognition in connection with the sale of these plans, our business, operating results and financial condition could be harmed.

The marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws and regulations, and non-compliance could harm our business, operating results and financial condition.

Table of Contents

The marketing and sale of Medicare plans are subject to numerous laws, regulations and guidelines at the federal and state level. The marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans are principally regulated by CMS. The marketing and sale of Medicare Supplement plans are principally regulated on a state-by-state basis by state departments of insurance. The laws and regulations applicable to the marketing and sale of Medicare plans are numerous, ambiguous and complex, and, particularly with respect to regulations and guidance issued by CMS for Medicare Advantage and Medicare Part D prescription drug plans, change frequently. As a result of these laws, regulations and guidelines, we have altered, and likely will have to continue to alter, our websites and sales process to comply with several requirements that are not applicable to our sale of non-Medicare-related health insurance plans. For instance, many aspects of our online platforms and our marketing material and processes, as well as changes to these platforms, materials and processes, including call center scripts, must be approved on a regular basis by CMS and by health insurance carriers in light of CMS requirements. In addition, certain aspects of our Medicare plan marketing partner relationships have been in the past, and will be in the future, subjected to CMS and health insurance carrier review. Changes to the laws, regulations and guidelines relating to Medicare plans, their interpretation or the manner in which they are enforced could be incompatible with these relationships, our platforms or our sale of Medicare plans. For instance, CMS rules currently prohibit health insurance agents from enrolling individuals into Medicare Advantage and Medicare Part D prescription drug plans online. Individuals are currently able to enroll in these plans online after shopping for these plans on our website given that we have established relationships with health insurance carriers to complete the enrollment on a platform owned or licensed by the carrier. If CMS determines to change its rules to prohibit enrollment in that manner, it could harm our business, operating results and financial condition. In addition, in February 2015 CMS issued guidance indicating that third party websites and marketing material must be filed for approval with CMS. Some health insurance carriers have interpreted this guidance to mean that websites and marketing material of our marketing partners must go through the process of CMS filing and approval. Our marketing partners may not consent to having their websites or other marketing material filed with CMS. In addition, we have a number of marketing partners who refer leads to us for Medicare-related health insurance products. Given the resources and review required of us and health insurance carriers prior to CMS filing, it is unlikely that we will be able to have all of our marketing partner websites and material filed and approved by CMS, which could harm our business, operating results and financial condition. In addition, even for our marketing partner websites and marketing material that are filed with CMS, CMS may not approve the use of the websites or marketing material for the Medicare annual enrollment period. Moreover, under CMS guidance, websites and marketing material must be refiled with CMS if changed, which also will make it difficult to adapt and optimize marketing partner websites and marketing material in a short amount time. Given these circumstances, the CMS guidance relating to third party websites could harm our business, operating results and financial condition.

Due to changes in CMS guidance or enforcement or interpretation of existing guidance, or as a result of new laws, regulations and guidelines, CMS, state departments of insurance or health insurance carriers may determine to object to or not to approve aspects of our online platforms or marketing material and processes and may determine that certain existing aspects of our Medicare-related business are not in compliance. As a result, the progress of our Medicare operations could be slowed or we could be prevented from operating aspects of our Medicare revenue generating activities altogether, which would harm our business, operating results and financial condition, particularly if it occurred during the Medicare annual enrollment period. It could also result in the write-down of the value of goodwill and intangible assets acquired in connection with our PlanPrescriber acquisition and purchase of the Medicare.com domain name.

The impact that health care reform legislation will have on the market for Medicare plans is unclear, but it could change demand for Medicare plans, the way these plans are delivered, the commissions that carriers pay to health insurance agents in connection with their sale or could adversely impact us in other ways. In the event that laws and regulations adversely impact our ability to market the availability of any type of Medicare plan on our ecommerce platform, or the amounts that health insurance agents are paid for selling these plans, our business, operating results and financial condition would be harmed.

We may be unsuccessful in competing effectively against current and future competitors.

The market for selling health insurance plans is highly competitive. We compete with entities and individuals that offer and sell health insurance plans utilizing traditional distribution channels as well as the Internet. Our competitors include local insurance agents across the United States who sell health insurance plans in their communities. There also are a number of companies that operate websites, provide an online shopping experience for consumers interested in purchasing health insurance and act as a health insurance agent in connection with that purchase. Some local agents also use “lead aggregator” services that use the Internet to find consumers interested in purchasing health insurance and are compensated for referring those consumers to health insurance agents or carriers. Many health insurance carriers also directly market and sell their plans to consumers through call centers and their own websites. Although we offer health insurance plans for many of these carriers, they also compete with us by offering their plans directly to consumers. We also compete with the FFM and state health

Table of Contents

insurance exchanges implemented as a result of health care reform. Health care reform also has resulted in health insurance plan cost and benefit data being more readily accessible, which could facilitate additional competition. In connection with our marketing of Medicare plans, we also compete with the original Medicare program. In addition, CMS offers plan information, comparison tools, call centers and online enrollment for Medicare Advantage and Medicare Part D prescription drug plans. To remain competitive against our current and future competitors, we will need to market our services effectively and continue to improve the online shopping experience and functionalities of our website and other platforms that our current and future customers may access to purchase health insurance products from us. If we cannot predict, develop and deliver the right shopping experience and functionality in a timely and cost-effective manner, or if we are not effective in driving a substantial number of consumers interested in purchasing health insurance to our website in a cost-effective manner, we may not be able to compete successfully against our current or future competitors and our business, operating results and financial condition may be adversely affected.

Some of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition and significantly greater financial, technical, marketing and other resources than we do. As compared to us, our current and future competitors may be able to:


•	undertake more extensive marketing campaigns for their brands and services;


•	devote more resources to website and systems development;


•	negotiate more favorable commission rates and commission override payments; and


•	make more attractive offers to potential employees, marketing partners and third-party service providers.

In addition, CMS has the ability to regulate our marketing and sale of Medicare Advantage and Medicare Part D prescription drug plans, and government-run health insurance exchanges, including CMS with respect to the federal health insurance exchange, have the ability to regulate our marketing and sale of qualified health plans under health care reform. CMS and the exchanges could impact the commissions we receive in connection with the sale of these plans and impose other restrictions and limitations that make it difficult for us to sell them. Competitive pressures may result in our experiencing increased marketing costs, decreased traffic to our website and loss of market share, or may otherwise harm our business, operating results and financial condition.

If we are not successful in cost-effectively converting visitors to our website and customer call centers into members for which we receive commissions, our business and operating results would be harmed.

Our growth depends in large part upon growth in our membership. The rate at which consumers visiting our ecommerce platform and customer care centers seeking to purchase health insurance are converted into paying members is a significant factor in the growth of our membership. A number of factors have influenced, and could in the future influence, the conversion rate for any given period, some of which are outside of our control. These factors include:


•	changes in consumer shopping behavior due to circumstances outside of our control, such as economic conditions, consumers’ ability or willingness to pay for health insurance, availability of unemployment benefits or proposed or enacted legislative or regulatory changes impacting our business, including health care reform;


•	the quality of and changes to the consumer experience on our ecommerce platform or with our customer care center;


•	regulatory requirements, including those that make the experience on our online platforms cumbersome or difficult to navigate;


•	the variety, competitiveness and affordability of the health insurance plans that we offer;


•	system failures or interruptions in the operation of our ecommerce platform or call center operations;


•	changes in the mix of consumers who are referred to us through our direct, marketing partner and online advertising member acquisition channels;


•	health insurance carriers offering the health insurance plans for which consumers have expressed interest, and the degree to which our technology is integrated with those carriers;

Table of Contents


•	health insurance carrier guidelines applicable to applications submitted by consumers, the amount of time a carrier takes to make a decision on that application and the percentage of submitted applications approved by health insurance carriers;


•	the percentage of our members who did not accept their approved policies and from whom we do not receive commission payments; and


•	our ability to enroll subsidy-eligible individuals in qualified health plans through government-run health insurance exchanges.

Our conversion rates can be impacted by changes in the mix of consumers referred to us through our member acquisition channels. For example, our conversion rates have historically been lower with respect to consumers referred to us by Internet lead aggregators and relatively higher with respect to consumers coming to us through our direct member acquisition channel. In addition, we have experienced an increase in the percentage of mobile phone and tablet visitors to our platform, and the conversion rate for individuals who use our mobile and tablet platform to shop for and purchase health insurance has historically been lower than desktop and laptop users. We may make changes to our ecommerce platform or undertake other initiatives in an attempt to improve consumer experience or for other reasons. These changes have in the past, and may in the future, have the unintended consequence of adversely impacting our conversion rates. A decline in the percentage of consumers who submit health insurance applications on our ecommerce platform or telephonically via our customer care centers and are converted into members could cause an increase in our cost of acquiring members on a per member basis. To the extent the rate at which we convert consumers visiting our ecommerce platform or telephonically via our customer care centers into members suffers, or in the event the number of mobile and tablet visitors to our platform continues to increase, our membership growth rate may decline, which would harm our business, operating results and financial condition.

Our conversion rates are also impacted by changes in both the percentage of submitted applications that are approved by carriers as well as changes in the percentage of our members who do not accept their approved policies. Any decline in the percentage of submitted applications that result in paying members will adversely impact our commission revenue as well as our membership, which could harm our business, operating results and financial condition. Given that individual and family health insurance purchasing is concentrated during the annual open enrollment period, we may experience a shift in the mix of individual and family health insurance products selected by our new members over a short period of time. Any reduction in our average commission revenue per member during the open enrollment period caused by such a shift or otherwise would also harm our business, operating results and financial condition.

We have adopted solutions so that we may sell qualified health insurance plans to health care reform subsidy-eligible individuals and families over the Internet during the open enrollment period in the 37 states in which the FFM operates the state’s health insurance exchange. Pursuant to health care reform laws and regulations, the purchase of qualified health plans must occur through a government-run health insurance exchange, which means that a part of the purchasing process will occur through its systems. We are dependent upon the FFM’s systems for individuals to be able to complete the process of purchasing a qualified health plan and to convert into members for which we receive commission revenue. If the solution we have adopted to enroll individuals through the FFM during the open enrollment period does not work properly or its operation with the FFM breaks, as a result of changes that the FFM makes to its systems or Internet platforms, or if the FFM website experience does not work properly, the experience of applying for qualified health plans and subsidies is cumbersome, or we are not properly identified by FFM systems as the agent of record on health insurance plan sales, we could suffer a reduction in our membership and our commission revenue and loss of new members, and our business, operating results and financial condition will be harmed.

While we have assisted subsidy eligible individuals in applying for qualified health insurance plans in non-FFM states, we are not able to do so entirely online. If these state exchanges do not adopt processes and technology that allow us to assist subsidy-eligible individuals in enrolling through these exchanges over the Internet and without use of health insurance agents in our customer care centers, we will not be able to or may not choose to enroll a significant number of subsidy eligible individuals in these states and our business, operating results and financial condition could be harmed. In the absence of the ability to enroll individuals over the Internet, our ability to enroll individuals in non-FFM states will be adversely impacted by the expense reduction measures we have taken, which could harm our business, operating results and financial condition.

Table of Contents

Changes in the quality and affordability of the health insurance plans that carriers offer on our ecommerce platform could harm our business and operating results.

The demand for health insurance marketed through our ecommerce platform is impacted by, among other things, the variety, quality and price of the health insurance plans we offer. Some health insurance carriers have exited certain state insurance markets where we have historically represented their insurance plans and we may determine not to work with other health insurance carriers. If our ability to sell a variety of high-quality, affordable health insurance plans in the individual and family, small business, ancillary and Medicare markets is impaired, or our health insurance plan offerings are limited or terminated as a result of consolidation in the health insurance industry, health care reform or otherwise, our sales or average commission rate per member may decrease and our business, operating results and financial condition could be harmed. For example, the cost of health insurance has increased substantially in many states as a result of health care reform implementation and some health insurance carriers have exited the individual and family health insurance business in certain states. Moreover, there are reports that the cost of individual and family health insurance may increase in the upcoming open enrollment period. These circumstances have and may continue to adversely impact demand for individual and family health insurance, and if individuals and families do not purchase health insurance through us as a result of these circumstances, our business, operating results and financial condition could be harmed.

Health insurance carriers could determine to reduce the commissions paid to us, which could harm our business and operating results.

Our commission rates, and the commission override payments we receive from health insurance carriers for achieving sales volume thresholds or other objectives, are either set by each carrier or negotiated between us and each carrier. Carriers have altered, and may in the future alter, the contractual relationships we have with them on short notice, either by renegotiation or unilateral action. If these contractual changes result in reduced commissions, our business may suffer and our operating results and financial condition would be harmed.

If we are not able to maintain and enhance our brand, our business and operating results will be harmed.

We believe that maintaining and enhancing our brand identity is critical to our relationships with existing members, marketing partners and health insurance carriers and to our ability to attract new members, marketing partners and health insurance carriers. The promotion of our brand in these and other ways may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these branding initiatives may become increasingly difficult and expensive. Our brand promotion activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our operating results could be harmed. If we do not successfully maintain and enhance our brand, our business may not grow and we could lose our relationships with health insurance carriers, marketing partners and/or members, which would harm our business, operating results and financial condition.

In addition, we have historically received media attention in connection with our public relations efforts. While we cannot be certain of the impact of media coverage on our business, if it were to be reduced or if we were to receive negative publicity, the number of consumers visiting our platform or customer call centers could decrease, and our cost of acquiring members could increase as a result of a reduction in the number of members coming from our direct member acquisition channel, both of which could harm our business, operating results and financial condition.

System failures or capacity constraints could harm our business and operating results.

The performance, reliability and availability of our ecommerce platforms and underlying network infrastructures are critical to our financial results, our brand and our relationship with members, marketing partners and health insurance carriers. Although we regularly attempt to enhance our ecommerce platform and system infrastructure, system failures and interruptions may occur if we are unsuccessful in these efforts, if we are unable to accurately project the rate or timing of increases in our website traffic or for other reasons, some of which are completely outside our control. Although we have experienced only minor system failures and interruptions to date, we could experience significant failures and interruptions in the future, which would harm our business, operating results and financial condition. If these failures or interruptions occurred during the Medicare annual enrollment period or during the open enrollment period under health care reform, the negative impact on us would be particularly pronounced.

We rely in part upon third-party vendors, including data center and bandwidth providers, to operate our ecommerce platforms. We cannot predict whether additional network capacity will be available from these vendors as we need it, and our network or our suppliers’ networks might be unable to achieve or maintain a sufficiently high capacity of data transmission to

Table of Contents

allow us to process health insurance applications in a timely manner or effectively download data, especially if our website traffic increases. Any system failure that causes an interruption in or decreases the responsiveness of our services would impair our revenue-generating capabilities and harm our business and operating results and damage our reputation. In addition, any loss of data could result in loss of customers and subject us to potential liability. Our database and systems are vulnerable to damage or interruption from human error, earthquakes, fire, floods, power loss, telecommunications failures, physical or electronic break-ins, computer viruses, acts of terrorism, other attempts to harm our systems and similar events. In addition, our operations are vulnerable to earthquakes in the San Francisco Bay Area and elsewhere in Northern California.

Consumers may access our customer care centers for assistance in connection with submitting health insurance applications. We depend upon third parties, including telephone service providers and third party software providers, to operate our customer care centers. Any failure of the systems that we rely upon in the operation of our customer care centers could negatively impact sales as well as our relationship with consumers and members, which could harm our business, operating results and financial condition.

If consumers or carriers opt for more traditional or alternative channels for the purchase and sale of health insurance, our business will be harmed.

Our success depends in part upon widespread consumer and health insurance carrier acceptance of the Internet as a marketplace for the purchase and sale of health insurance. Consumers and health insurance carriers may choose to depend more on traditional sources, such as individual agents, or alternative sources may develop, including as a result of health care reform legislation. For instance, an increasing percentage of individuals are using their phones or tablet computers to shop for health insurance over the Internet and may prefer to complete their purchases over these devices. Our future growth, if any, will depend in part upon:


•	the growth of the Internet as a commerce medium generally, and as a market for consumer financial plans and services specifically;


•	consumers’ willingness to conduct their own health insurance research;


•	our ability to make the process of purchasing health insurance online an attractive alternative to traditional and new means of purchasing health insurance;


•	our ability to develop an effective process for purchasing health insurance over the Internet on smartphones, tablets and devices other than desktop or laptop computers;


•	our ability to successfully and cost-effectively market our services as superior to traditional or alternative sources for health insurance to a sufficiently large number of consumers; and


•	health insurance carriers’ willingness to use us and the Internet as a distribution channel for health insurance plans.

If we are not successful in these regards, and if consumers and health insurance carriers determine that other sources for health insurance and health insurance applications are superior, our business will not grow and our operating results and financial condition would be harmed.

We depend upon Internet search engines to attract a significant portion of the consumers who visit our website, and if we are unable to effectively advertise on search engines on a cost-effective basis, our business and operating results would be harmed.

We derive a significant portion of our website traffic from consumers who search for health insurance through Internet search engines, such as Google, Bing and Yahoo!. A critical factor in attracting consumers to our website is whether we are prominently displayed in response to an Internet search relating to health insurance. Search engines typically provide two types of search results, algorithmic listings and paid advertisements. We rely on both algorithmic listings and paid advertisements to attract consumers to our websites.

Algorithmic search result listings are determined and displayed in accordance with a set of formulas or algorithms developed by the particular Internet search engine. The algorithms determine the order of the listing of results in response to the consumer’s Internet search. From time to time, search engines revise these algorithms. In some instances, these modifications have caused our website to be listed less prominently in algorithmic search results, which has resulted in decreased traffic to

Table of Contents

our website. We may also be listed less prominently as a result of new websites or changes to existing websites that result in these websites receiving higher algorithmic rankings with the search engine. For example, government health insurance exchange websites have recently begun to appear prominently in algorithmic search results. Our website may become listed less prominently in algorithmic search results for other reasons, such as search engine technical difficulties, search engine technical changes and changes we make to our website. In addition, search engines have deemed the practices of some companies to be inconsistent with search engine guidelines and decided not to list their website in search result listings at all. If we are listed less prominently in, or removed altogether from, search result listings for any reason, the traffic to our websites would decline and we may not be able to replace this traffic, which in turn would harm our business, operating results and financial condition. If we decide to attempt to replace this traffic, we may be required to increase our marketing expenditures, which would also increase our cost of member acquisition and harm our business, operating results and financial condition.

We purchase paid advertisements on search engines in order to attract consumers to our website. We typically pay a search engine for prominent placement of our name and website when particular health insurance-related terms are searched for on the search engine, regardless of the algorithmic search result listings. The prominence of the placement of our advertisement is determined by a combination of factors, including the amount we are willing to pay and algorithms designed to determine the relevance of our paid advertisement to a particular search term. As with algorithmic search result listings, search engines may revise the algorithms relevant to paid advertisements and websites other than our ecommerce platform may become more optimized for the algorithms. These changes may result in our having to pay increased amounts to maintain our paid advertisement placement in response to a particular search term. We could also have to pay increased amounts should the market share of major search engines continue to become more concentrated with a single search engine. Additionally, we bid against our competitors and others for the display of these paid search engine advertisements. Many of our competitors, including many health insurance carriers and government-run health insurance exchanges, have greater resources with which to bid and better brand recognition than we do. We have experienced increased competition from health insurance carriers, government health insurance exchanges and some of our marketing partners for both algorithmic search result listings and for paid advertisements. This competition has increased the cost of paid internet search advertising and has increased our marketing and advertising expenses. This competition has increased substantially during the open enrollment periods for individual and family health insurance and Medicare-related health insurance and may increase further if these open enrollment periods occur over the same period of time. If paid search advertising costs increase or becomes cost prohibitive, whether as a results of competition, algorithm changes or otherwise, our advertising expenses could rise significantly or we could reduce or discontinue our paid search advertisements, either of which would harm our business, operating results and financial condition.

We rely significantly on marketing partners and our business and operating results would be harmed if we are unable to maintain effective relationships with our existing marketing partners or if we do not establish successful relationships with new marketing partners.

In addition to marketing through Internet search engines, we frequently enter into contractual marketing relationships with other online and offline businesses that promote us. These marketing partners include financial and online service companies, affiliate programs and online advertisers and content providers. We also have relationships with marketing partners, including pharmacy chains, that promote our Medicare platforms to their customers. We compensate many of our marketing partners for their referrals on a submitted health insurance application basis and, if they are licensed to sell health insurance, may share a percentage of the commission we earn from the health insurance carrier for each member referred by the marketing partner.

Many factors influence the success of our relationship with our marketing partners, including:


•	the continued positive market presence, reputation and growth of the marketing partner;


•	the effectiveness of the marketing partner in marketing our website and services, including whether the marketing partner is successful in maintaining the prominence of its website in algorithmic search result listings and paid Internet advertisements;


•	the compliance of our marketing partners, and of the manner marketing partners refer consumers to our platforms, with applicable laws, regulations and guidelines;


•	the interest of the marketing partner’s customers in the health insurance plans that we offer on our ecommerce platform;


•	the contractual terms we negotiate with the marketing partner, including the marketing fees we agree to pay a marketing partner;

Table of Contents


•	the percentage of the marketing partner’s customers that submit applications or purchase health insurance policies through our ecommerce platform;


•	the ability of a marketing partner to maintain efficient and uninterrupted operation of its website; and


•	our ability to work with the marketing partner to implement website changes, launch marketing campaigns and pursue other initiatives necessary to maintain positive consumer experiences and acceptable traffic volumes.

For instance, we partner with Internet lead aggregators who refer a significant number of consumers to our online platforms. Major search engines have in the past and may in the future determine not to list lead aggregator websites prominently in search result listings for various reasons, which would cause a significant reduction in the number of consumers referred to us through our marketing partner channel. While we have relationships with a large number of marketing partners, we depend upon referrals from a limited number of marketing partners for a significant portion of the submitted applications we receive from our marketing partner customer acquisition channel. Moreover, a significant portion of our referrals for the purchase of Medicare plans comes from a single marketing partner.

Given our reliance on our marketing partners, our business operating results and financial condition would be harmed if any of the following were to occur:


•	if we are unable to maintain successful relationships with our existing marketing partners, particularly marketing partners responsible for a significant number of our submitted applications;


•	if we fail to establish successful relationships with new marketing partners;


•	if we experience competition in our receipt of referrals from our high volume marketing partners; and


•	if we are required to pay increased amounts to our marketing partners.

To the extent that health care reform makes it less profitable or desirable for marketing partners to promote us to their customers, we may lose relationships with existing marketing partners or those marketing partners may refer fewer individuals to us. We may also have difficulty entering into relationships with new marketing partners. We may also need to reduce the compensation that we pay to marketing partners to the extent that health care reform has the effect of reducing commissions for individual and family health insurance or causes our members to stay on their health insurance policies for a shorter period of time. There is no guarantee that we will be able to amend our agreements to reduce the compensation that we pay to acceptable levels in light of these factors. If we are not able to do so, our business, operating results and financial condition could be harmed. Competition for referrals from our marketing partners has increased particularly during the open enrollment periods for Medicare-related health insurance and individual and family health insurance. We may lose marketing partner referrals if our competitors pay marketing partners more than we do or be forced to pay increased fees to our marketing partners, which could harm our business, operating results and financial condition. If we lose marketing partner referrals during the Medicare or individual and family health insurance annual open enrollment periods, the adverse impact on our business would be particularly pronounced. In addition, the promulgation of laws, regulations or guidelines, or the interpretation of existing laws, regulations and guidelines, by state departments of insurance or by CMS, could cause our relationships with our marketing partners to be in non-compliance with those laws, regulations and guidelines. For instance, CMS recently issued guidance that health insurance carriers have interpreted to mean that websites and marketing material of our Medicare-related marketing partners must go through the process of CMS filing and approval. Our marketing partners may not consent to having their websites or other marketing material filed with CMS, and we and health insurance carriers may not be able to dedicate the resources necessary to have the websites and marketing material reviewed, filed and approved. If we are not able to do so, our business, operating results and financial condition could be harmed. In addition, as a result of our acquisition of PlanPrescriber, we have marketing partner relationships with pharmacy chains that utilize aspects of our platform and tools. Our relationships with these pharmacy chains result in the referral of a significant number of individuals to us who are interested in purchasing Medicare-related health insurance plans. If CMS or state departments of insurance were to change existing laws, regulations or guidelines, or interpret existing laws, regulations or guidelines, to prohibit these arrangements, or if pharmacy partners otherwise decided to no longer utilize aspects of our platform and tools, we could experience a significant decline in the number of Medicare-eligible individuals who are referred to our platforms and customer care centers, which would harm our business, operating results and financial condition and could result in a write-down of the value of intangible assets acquired in our PlanPrescriber acquisition.

Table of Contents

We rely on health insurance carriers to accurately and regularly prepare commission reports, and if these reports are inaccurate or not sent to us in a timely manner, our business and operating results could be harmed. We also may not recognize trends in our membership as a result of a lack of information from health insurance carriers.

For individual and family, small business, ancillary and Medicare Supplement health insurance plans, health insurance carriers pay us a flat amount per member per month or a percentage of the paid health insurance premium on a health insurance policy that we have sold during the period that a member maintains coverage under the policy. For both Medicare Advantage and Medicare Part D prescription drug policies, health insurance carriers typically pay us a fixed commission amount during the period the policy remains active, typically for at least six years, depending on the carrier. We rely on health insurance carriers to timely and accurately report the amount of commissions earned by us, and we calculate our commission revenue, prepare our financial reports, projections and budgets and direct our marketing and other operating efforts based on the reports we receive from health insurance carriers. There have been instances where we have determined that policy cancellation data reported to us by a health insurance carrier has not been accurate. Although we recognize commissions reported to us net of estimated cancellations, the extent to which health insurance carriers are inaccurate in their reporting of policy cancellations could cause us to change our cancellation estimates, which could adversely impact our revenues. We apply judgment and make estimates based on historical data and current trends to independently determine whether or not carriers are accurately reporting commissions due to us. To the extent that health insurance carriers understate or fail to accurately report the amount of commissions due to us in a timely manner or at all, we will not recognize revenue to which we are entitled, which would harm our business, operating results and financial condition.

We also depend on health insurance carriers and others for data related to our membership. For instance, with respect to health insurance plans other than small business health insurance, health insurance carriers do not directly report member cancellations to us, resulting in the need for us to determine cancellations using payment data that carriers provide. We infer cancellations from this payment data by analyzing whether payments from members have ceased for a period of time, and we may not learn of a cancellation for several months. With respect to our small business membership, many groups notify the carrier directly with respect to increases or decreases in group size and policy cancellations. Our insurance carrier partners often do not communicate this information to us, and it often takes a significant amount of time for us to learn about small business group cancellations and changes in our membership within the group itself. We often are not made aware of policy cancellations until the time of the group’s annual renewal.

A substantial number of our existing members may become eligible for health care reform subsidies in connection with their purchase of health insurance. In addition, the open enrollment periods applicable in connection with the sale of both individual and family health insurance and Medicare-related health insurance condenses purchasing activity over a limited period of time. The increased amount of health insurance purchasing activity and member movement as a result of health care reform over a limited period of time as well as any member turnover that we experience may make it difficult for health insurance carriers to accurately report commission information to us in a timely manner, which would also make it difficult or impossible for us to accurately report and estimate our membership at any given point in time. Delays in accurate reporting of commissions may result in delays in recognition of commission revenue compared to historical patterns and our business, operating results and financial condition could be harmed. In addition, if we experience a disruption in our ability to accurately estimate our membership it could result in a decrease in our stock price as a result of uncertainty relating to our membership base.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was included in our estimates was in fact not an active member of ours. We also reconcile information health insurance carriers provide to us and may determine that we were not historically paid commissions owed to us, which would cause us to have underestimated our membership. As a result of open enrollment periods, we may not receive information from our carriers on as timely a basis due to significant spikes in volume, which could impair the accuracy of our estimates of the number of members we have for a period of time. Additionally, health insurance carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. For these and other reasons, including if current trends in membership cancellation are inconsistent with past cancellation trends that we use to estimate our membership or if carriers subsequently report changes to the commission payments that they previously reported to us, our actual membership could be different from our estimates, perhaps materially. Total revenue per estimated member for the period would also change if our estimated membership changed. Our estimate regarding the average amount of time our members maintain their health insurance plans also could be inaccurate as it depends on the accuracy of our membership estimates.

Table of Contents

Economic conditions and other factors beyond our control may negatively impact our business, operating results and financial condition.

Our revenue depends upon demand for health insurance in the individual and family and small business markets, which can be influenced by a variety of factors beyond our control. For instance, as a result of substantial health insurance premium inflation in recent years, we believe that many employers have sought to reduce the costs associated with providing health insurance to their employees, including offering fewer benefits to employees, reducing or eliminating dependent coverage, increasing employee health insurance premium contributions and eliminating health insurance benefits altogether. We have no control over the economic and other factors that influence these trends, and they may reverse, including as a result of health care reform legislation. If economic or other factors beyond our control negatively impact our business, our business, operating results and financial condition could be harmed.

We believe that demand for the health insurance and services we offer are impacted by prevailing economic conditions. We cannot be certain of the future impact that economic conditions will have on our business. A softening of demand for health insurance and services offered by us, whether caused by changes in customer preferences or a weak U.S. economy, including as a result of disruptions in the global financial markets or a decrease in general consumer confidence, could adversely impact our operating results. Consumers may attempt to reduce expenses by cancelling existing health insurance purchased through us, determine not to purchase new health insurance through us, or purchase health insurance plans for which we receive lower commissions. To the extent the economy or other factors adversely impact our membership retention or the number or type of health insurance applications submitted through us and that are approved by health insurance carriers, our rate of growth will decline and our business and operating results will be harmed. A continuing negative economic environment could also adversely impact the health insurance carriers whose plans are offered on our ecommerce platform, and they may determine to reduce their commission rates or take other actions that would negatively impact our sale of health insurance as well as our sponsorship and technology licensing businesses.

There are many risks associated with our operations in China.

A portion of our operations is conducted in China. Among other things, we use employees in China to maintain and update our ecommerce platform. This and other information is delivered to us through secured communications over the Internet. Our business would be harmed if this connection temporarily failed and we were prevented from promptly updating our software or implementing other changes to our database and systems. Our operations in China also expose us to different and unfamiliar laws, rules and regulations, including different intellectual property laws, which are not as protective of our intellectual property as the laws in the United States, and different labor and tax laws. United States and Chinese trade laws may impose restrictions on the importation of programming or technology to or from the United States. Additionally, we have recently experienced greater competition for qualified personnel in China, which has raised market salaries and increased our compensation costs related to employees in that location. If competition for personnel increases further, our compensation expenses could rise considerably or, if we determine to not increase compensation levels, our ability to attract and retain qualified personnel in China may be impaired, which could harm our business, operating results and financial condition. These risks could cause us to incur increased expenses and could harm our ability to effectively and successfully manage our operations in China, which in turn could cause our business, operating results and financial condition to suffer.

Our sponsorship and advertising business may not be successful.

We sell advertising space to health insurance carriers on our website through our sponsorship and advertising program. Our sponsorship and advertising program allows carriers to purchase advertising space in specific markets in a sponsorship area on our website. Health insurance carriers have and may continue to determine to eliminate or reduce spending on our sponsorship and advertising program as a result of various aspects of health care reform, including the medical loss ratio requirements that became effective in 2011. As a result, our business, operating results and financial condition could be harmed. To the extent that economic conditions, health care reform or other factors impact the amount health insurance carriers are willing to pay for advertising on our ecommerce platform, our sponsorship and advertising program will be adversely impacted. Since much of our sponsorship revenue depends upon the number of applications we submit to health insurance carriers, a reduction in demand for the carrier’s product (such as outside open enrollment periods) would reduce our sponsorship revenue and our business, operating results and financial condition could be harmed. The success of our sponsorship and advertising program depends on a number of other factors, including the effectiveness of the sponsorship and advertising program as a cost-effective method for carriers to obtain additional members, consumer and health insurance carrier adoption of the Internet and our ecommerce platform as a medium for the purchase and sale of health insurance, our ability to attract consumers visiting our ecommerce platform and convert those consumers into members, the existence of a relationship between us and a diverse group of carriers that offer a number of health insurance plans in the markets in which we attempt to sell advertising, the cost, benefit and brand recognition of the health insurance plan that is the subject of the advertising, the

Table of Contents

impact the advertising has on the sale of the health insurance plan that is the subject of the advertising and the effectiveness of the carrier’s other means of advertising. In addition, while our practice of selling advertising is described on our ecommerce platform, it could cause consumers to perceive us as not objective, which could harm our brand and result in a decline in our health insurance sales. It also could adversely impact our relationship with health insurance carriers that do not purchase our advertising. As a result, our business, operating results and financial condition could be harmed.

We also develop, host and maintain carrier dedicated Medicare plan websites through our advertising program. Our success in doing so is dependent upon the same factors that could impact our sponsorship program. In addition, since we maintain relationships with a limited number of health insurance carriers to sell their Medicare plans, our Medicare plan-related advertising revenue is concentrated in a small number of health insurance carriers and our ability to generate Medicare plan-related advertising revenue would be harmed by the termination or non-renewal of any of these relationships as well as by a reduction in the amount a health insurance carrier is willing to pay for these services. Moreover, in light of the regulations applicable to the marketing and sale of Medicare plans, and given that these regulations are often unclear, change frequently and are subject to changing interpretations, we may in the future not be permitted to sell Medicare plan-related advertising. If we are not successful in generating Medicare plan-related advertising revenue, our business operating results and financial condition could be harmed.

We may not be able to adequately protect our intellectual property, which could harm our business and operating results.

We believe that our intellectual property is an essential asset of our business and that our technology infrastructure currently gives us a competitive advantage in the distribution of individual and family and small business health insurance. We rely on a combination of copyright, trademark and trade secret laws as well as confidentiality procedures and contractual provisions to establish and protect our intellectual property rights in the United States. We have not filed for protection of our intellectual property in any foreign jurisdiction other than China. We have Chinese-registered computer software copyrights for an internally-developed software system and a project management tool and have certain trademarks in China. We have not filed any patent applications in China. The efforts we have taken to protect our intellectual property may not be sufficient or effective, and our trademarks, copyrights and patents if issued, may be held invalid or unenforceable. Moreover, the law relating to intellectual property is not as developed in China, and our intellectual property rights may not be as respected in China as they are in the United States. Any United States or other patents issued to us may not be sufficiently broad to protect our proprietary technologies, and given the costs of obtaining patent protection, we may choose not to seek patent protection for certain of our proprietary technologies. We may not be effective in policing unauthorized use of our intellectual property, trade secrets and other confidential information, and even if we do detect violations, litigation may be necessary to enforce our intellectual property rights. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive, could divert our management’s attention and may result in a court determining that our intellectual property or other rights are unenforceable. If we are not successful in cost-effectively protecting our intellectual property rights, trade secrets and confidential information, our business, operating results and financial condition could be harmed.

We may in the future be subject to intellectual property rights claims, which are extremely costly to defend, could require us to pay significant damages and could limit our ability to use certain technologies in the future.

There are a large number of patents, copyrights, trademarks and trade secrets applicable to the internet and technology industries and entities frequently enter into litigation based on allegations of infringement or other violations of intellectual property rights. We have received, and may in the future receive, notices that claim we have misappropriated, infringed or misused other parties’ intellectual property rights, and, to the extent we gain greater visibility, we face a higher risk of being the subject of intellectual property infringement claims. There may be third-party intellectual property rights, including issued or pending patents that cover significant aspects of our technologies or business methods or that cover third-party technology that we use as a part of our websites. Any intellectual property claim against us, with or without merit, could be time consuming, expensive to settle or litigate and could divert our management’s attention and other resources. These claims also could subject us to significant liability for damages and could result in our having to stop using technology found to be in violation of a third party’s rights. We might be required to seek a license for third-party intellectual property, which may not be available on reasonable terms or at all. Even if a license is available, we could be required to pay significant royalties, which would increase our operating expenses. We may also be required to develop alternative non-infringing technology, which could require significant effort and expense. If we cannot license or develop technology for any infringing aspect of our business, we would be forced to limit our services and may be unable to compete effectively. Any of these results would harm our business, operating results and financial condition.

Any legal liability, regulatory penalties, or negative publicity for the information on our website or that we otherwise distribute or provide could harm our business and operating results.

Table of Contents

We provide information on our website, through our customer care centers and in other ways regarding health insurance in general and the health insurance plans we market and sell, including information relating to insurance premiums, coverage, benefits, provider networks, exclusions, limitations, availability, plan comparisons and insurance company ratings. A significant amount of both automated and manual effort is required to maintain the considerable amount of insurance plan information on our website. Separately, from time to time, we use the information provided on our website and otherwise collected by us to publish reports designed to educate consumers, facilitate public debate, and facilitate reform at the state and federal level relating to the accessibility and affordability of health insurance. If the information we provide on our website, through our customer care centers or otherwise is not accurate or is construed as misleading, or if we do not properly assist individuals and businesses in purchasing health insurance, members, health insurance carriers and others could attempt to hold us liable for damages, our relationships with health insurance carriers could be terminated and regulators could attempt to subject us to penalties, revoke our licenses to transact health insurance business in a particular jurisdiction, and/or compromise the status of our licenses to transact health insurance business in other jurisdictions, which could result in our loss of our commission revenue. In the ordinary course of operating our business, we have received complaints that the information we provided was not accurate or was misleading. Although in the past we have resolved these complaints without significant financial cost, we cannot guarantee that we will be able to do so in the future. In addition, these types of claims could be time-consuming and expensive to defend, could divert our management’s attention and other resources, and could cause a loss of confidence in our services. As a result, whether or not we are able to successfully resolve these claims, they could harm our business, operating results and financial condition.

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. We have become, and may in the future become, involved in litigation in the ordinary course of our business. If we are found to have violated laws or regulations, we could lose our relationship with health insurance carriers and be subject to various fines and penalties, including revocation of our licenses to sell insurance which would in turn potentially cause us to lose our commission revenue, and our business, operating results and financial condition would be materially harmed.

Changes in our management and key employees could affect our financial results, and a recent reduction in force may impede our ability to attract and retain highly skilled personnel.

Our success is dependent upon the performance of our senior management and key personnel. Our management and employees can terminate their employment at any time. The loss of the services of any of our executive officers or key employees could harm our business. For example, we appoint a single writing agent with each insurance carrier. If we lose the service of our appointed writing agent, the duties of writing agent will need to be transitioned to other company personnel. Due to our national reach and the large number of carrier partners whose policies are purchased by our members, this transition may be difficult and requires a significant period of time to complete. If the transition is not successful or takes too long to complete, our agency relationship with particular insurance carriers may be terminated, our commission payments could be discontinued or delayed and, as a result, our business, operating results and financial condition would be harmed.

Our success is also dependent upon our ability to attract and retain qualified personnel for all areas of our organization. Recently, we implemented a reduction in our workforce to align our employee base and cost structure with our current and anticipated revenues. These reductions have resulted in reallocations of duties, increased employee uncertainty and discontent and additional attrition. We may not be successful in attracting and retaining personnel on a timely basis, on competitive terms or at all, and the reductions in force could make it more difficult to do so. If we are unable to attract and retain the necessary personnel, our business would be harmed.

We may experience difficulties, delays or unexpected costs and not achieve anticipated cost savings from our recently implemented cost reduction plan.

In March 2015, we implemented an organizational restructuring and cost reduction plan. As part of the plan, we eliminated approximately 160 full-time positions in the United States, representing approximately 15% of our workforce primarily in our technology and content and customer care and enrollment groups, and to a lesser extent, in our marketing and advertising and general and administrative groups. We incurred pre-tax restructuring charges of $3.9 million for employee termination benefits and related costs as well as $0.6 million in other pre-tax restructuring charges, including facility costs, in the first quarter of 2015, and an additional $0.1 million in the second quarter of 2015. The majority of the restructuring activities comprising the plan were substantially completed in the first quarter of 2015, and we also eliminated certain positions in our China operation in that quarter.

Table of Contents

For our cost reduction plan to be successful and build a framework for future growth, we must continue to execute and deliver on our core business initiatives with fewer human resources and losses of intellectual capital. For instance, as a part of the reduction in force, we have significantly reduced headcount in our customer care and enrollment and technology and content groups. These reductions could impair our ability to assist consumers seeking to purchase health insurance. They also constrain our ability to enhance our technology platforms as well as adapt our technology platforms and service to changes in the health insurance industry brought about by changes to the implementation of health care reform or for other reasons. The reductions will also impact our ability to enter new business areas and develop and enhance our existing products and services. In the aggregate, the reduction in force could harm our business, operating results and financial condition.

In addition, we will need to manage complexities associated with a geographically diverse organization. We must also attract, retain and motivate key employees, including highly qualified management, product development, engineering, sales, marketing, business development and general and administrative personnel who are critical to our business. We may not be able to attract, retain or motivate qualified employees in the future, and our inability to do so may adversely affect our business.

There may also be other risks associated with our cost reduction plan, and we cannot guarantee that we will be able to successfully manage these or other risks. If we fail to execute on our initiatives in these ways or others, such failure could result in a material adverse effect on our business and results of operations. We cannot ensure we will not undertake additional workforce reductions, that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from any existing or future cost reduction plans.

Acquisitions could disrupt our business and harm our financial condition and operating results.

We may decide to acquire businesses, products and technologies. Our ability as an organization to successfully make and integrate acquisitions is unproven. Acquisitions could require significant capital infusions and could involve many risks, including the following:

•

an acquisition may negatively impact our results of operations because it will require us to incur transaction expenses, and after the transaction, may require us to incur charges and substantial debt or liabilities, may require the amortization, write down or impairment of amounts related to deferred compensation, goodwill and other intangible assets, or may cause adverse tax consequences, substantial depreciation or deferred compensation charges;


•	an acquisition undertaken for strategic business purposes may negatively impact our results of operations;


•	we may encounter difficulties in assimilating and integrating the business, technologies, products, personnel or operations of companies that we acquire, particularly if key personnel of the acquired company decide not to work for us;


•	an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our management;


•	we may be required to implement or improve internal controls, procedures and policies appropriate for a public company at a business that prior to the acquisition lacked these controls, procedures and policies;


•	the acquired businesses, products or technologies may not generate sufficient revenue to offset acquisition costs or to maintain our financial results;


•	we may have to issue equity securities to complete an acquisition, which would dilute our stockholders’ ownership and could adversely affect the market price of our common stock; and


•	acquisitions may involve the entry into geographic or business markets in which we have little or no prior experience.

We cannot assure you that we will be able to identify or consummate any future acquisition on favorable terms, or at all. If we do pursue an acquisition, it is possible that we may not realize the anticipated benefits from the acquisition or that the financial markets or investors will negatively view the acquisition. Even if we successfully complete an acquisition, it could harm our business, operating results and financial condition.

If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements could be impaired, which could adversely affect our operating results, our ability to operate our business and our stock price.

We have a complex business organization. Ensuring that we have adequate internal financial and accounting controls and procedures in place to help ensure that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently and is complicated by the expansion of our business operations. Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all errors or all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.

Table of Contents

Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As a result, we cannot assure that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations and annual auditor attestation reports regarding disclosure controls and the effectiveness of our internal control over financial reporting required under Section 404 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder. The existence of a material weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause us to fail to timely meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock price and potential lawsuits against us.

Changes in our provision for income taxes or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results.

Our provision for income taxes is subject to volatility and could be adversely affected by earnings differing materially from our projections, changes in the valuation of our deferred tax assets and liabilities, expiration of or lapses in the research and development tax credit laws, tax effects of share-based compensation, outcomes as a result of tax examinations or by changes in tax laws, regulations, accounting principles, including accounting for uncertain tax positions, or interpretations thereof. For instance, given increased uncertainty regarding our future taxable income, we modified our assessment of the realizability of our domestic deferred tax assets and recorded a full valuation allowance against our domestic deferred tax assets in the amount of $11.5 million during the fourth quarter of 2014, resulting in expected minimum taxes recorded in the first and second quarters of 2015. The related domestic deferred tax assets remain available for use in future periods and will reduce the Company’s tax provision if taxable income is generated. To the extent that our provision for income taxes is subject to volatility or adverse outcomes as a result of tax examinations, our operating results could be harmed.

Significant judgment is required to determine the recognition and measurement attribute prescribed in U.S. generally accepted accounting principles (“U.S. GAAP”) relating to accounting for income taxes. In addition, U.S. GAAP applies to all income tax positions, including the potential recovery of previously paid taxes, which if settled unfavorably could adversely impact our provision for income taxes or additional paid-in capital. In addition, we are subject to examinations of our income tax returns by the Internal Revenue Service and other tax authorities. We assess the likelihood of adverse outcomes resulting from these examinations to determine the adequacy of our provision for income taxes. There may be exposure that the outcomes from these examinations will have an adverse effect on our operating results and financial condition.

Risks Related to State Insurance Regulation

Regulation of the sale of health insurance is subject to change, and future regulations could harm our business and operating results.

The laws and regulations governing the offer, sale and purchase of health insurance are subject to change, and future changes may be adverse to our business. For example, a long standing provision in each state’s law that we believe is advantageous to our business is that once health insurance premiums are set by the carrier and approved by state regulators, they are fixed and not generally subject to negotiation or discounting by insurance companies or agents. Additionally, state regulations generally prohibit carriers, agents and brokers from providing financial incentives, such as rebates, to their members in connection with the sale of health insurance. As a result, we do not currently compete with carriers or other agents and brokers on the price of the health insurance plans offered on our website. If these regulations change, we could be forced to reduce prices or provide rebates or other incentives for the health insurance plans sold through our ecommerce platform, which would harm our business, operating results and financial condition.

States have, and will continue, to adopt new laws and regulations in response to health care reform legislation. It is difficult to predict how these new laws and regulations will impact our business, but in some cases such laws and regulations could amplify the adverse impacts of health care reform, or states may adopt new requirements that adversely impact our business, operating results and financial condition.

Table of Contents

We are also subject to additional insurance regulatory risks, because we use the Internet as our distribution platform. In many cases, it is not clear how existing insurance laws and regulations apply to Internet-related health insurance advertisements and transactions. To the extent that new laws or regulations are adopted that conflict with the way we conduct our business, or to the extent that existing laws and regulations are interpreted adversely to us, our business, operating results and financial condition would be harmed.

If we fail to comply with the numerous state laws and regulations that are applicable to the sale of health insurance, our business and operating results could be harmed.

The sale of health insurance is heavily regulated by each state in the United States. For instance, in addition to the impact and changes in regulations resulting from health care reform, state regulators require us to maintain a valid license in each state in which we transact health insurance business and further require that we adhere to sales, documentation and administration practices specific to that state. In addition, each employee who transacts health insurance business on our behalf must maintain a valid license in one or more states. Because we do business in all 50 states and the District of Columbia, compliance with health insurance-related laws, rules and regulations is difficult and imposes significant costs on our business. Each jurisdiction’s insurance department typically has the power, among other things, to:


•	grant and revoke licenses to transact insurance business;


•	conduct inquiries into the insurance-related activities and conduct of agents and agencies;


•	require and regulate disclosure in connection with the sale and solicitation of health insurance;


•	authorize how, by which personnel and under what circumstances insurance premiums can be quoted and published and an insurance policy sold;


•	approve which entities can be paid commissions from carriers and the circumstances under which they may be paid;


•	regulate the content of insurance-related advertisements, including web pages, and other marketing practices;


•	approve policy forms, require specific benefits and benefit levels and regulate premium rates;


•	impose fines and other penalties; and


•	impose continuing education requirements.

Due to the complexity, periodic modification and differing interpretations of insurance laws and regulations, we may not have always been, and we may not always be, in compliance with them. New insurance laws, regulations and guidelines also may not be compatible with the sale of health insurance over the Internet or with various aspects of our platform or manner of marketing or selling health insurance plans. Failure to comply with insurance laws, regulations and guidelines or other laws and regulations applicable to our business could result in significant liability, additional department of insurance licensing requirements, the revocation of licenses in a particular jurisdiction and/or our inability to sell health insurance plans, which could significantly increase our operating expenses, result in the loss of our commission revenue and otherwise harm our business, operating results and financial condition. Moreover, an adverse regulatory action in one jurisdiction could result in penalties and adversely affect our license status or reputation in other jurisdictions due to the requirement that adverse regulatory actions in one jurisdiction be reported to other jurisdictions. Even if the allegations in any regulatory or other action against us are proven false, any surrounding negative publicity could harm consumer, marketing partner or health insurance carrier confidence in us, which could significantly damage our brand. Because some consumers, marketing partners and health insurance carriers may not be comfortable with the concept of purchasing health insurance using the Internet, any negative publicity may affect us more than it would others in the health insurance industry and would harm our business, operating results and financial condition. Changes in insurance laws, regulations and guidelines may also be incompatible with various aspects of our business and require that we make significant modifications to our existing technology or practices, which may be costly and time-consuming to implement and could also harm our business, operating results and financial condition.

In addition, we have received, and may in the future receive, inquiries from regulators regarding our marketing and business practices. We typically respond by explaining how we believe we are in compliance with relevant regulations or may modify our practices in connection with the inquiry. Any modification of our marketing or business practices in response to future regulatory inquiries could harm our business, operating results or financial condition.

Table of Contents

Risks Related to the Internet and Electronic Commerce

Our business is subject to security risks and, if we are unable to safeguard the security and privacy of confidential data, including personal health information, our business will be harmed.

Our services involve the collection and storage of confidential information of consumers and the transmission of this information to their chosen health insurance carriers and to government. For example, we collect names, addresses, Social Security and credit card numbers, and information regarding the medical history of consumers. As a result, we are subject to various laws and regulations regarding the collection, maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information. We cannot guarantee that our facilities and systems, and those of our third party service providers, will be free of security breaches, acts of vandalism, computer viruses, misplaced or lost data, programming and/or human errors or other similar events. Compliance with privacy and security laws, requirements and regulations may result in cost increases due to new constraints on our business, the development of new processes, the effects of potential non-compliance by us or third party service providers, and enforcement actions. We may be required to expend significant amounts and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures, techniques used to obtain unauthorized access or to sabotage systems change frequently. As a result, we may be unable to anticipate these techniques or to implement adequate preventative measures. Additionally, our third party service providers may cause security breaches for which we are responsible.

Any compromise or perceived compromise of our security by us or by one of our vendors could damage our reputation, cause the termination of relationships with government-run health insurance exchanges and our members, marketing partners and health insurance carriers, reduce demand for our services and subject us to significant liability and expense as well as regulatory action and lawsuits, which would harm our business, operating results and financial condition. While we have contingency plans and insurance coverage for potential liabilities of this nature, these may not be sufficient to cover all claims or a significant amount of our liability. In addition, in the event that data security laws are implemented, or our health insurance carrier or other partners determine to impose requirements on us relating to data security, we may not be able to timely comply with such requirements or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could result in our inability to sell health insurance plans in a particular jurisdiction or for a particular health insurance carrier or subject us to liability for non-compliance, any of which would damage our business, operating results and financial condition. For instance, health insurance carriers may require us to be compliant with Payment Card Industry, or PCI, security standards in order to accept credit card information from consumers. PCI compliance is generally assessed on an annual basis, and we may not always be compliant with new and evolving PCI standards. If we are not in compliance with PCI standards, we may not be able to accept credit card information from consumers and our relationship with health insurance carriers could be adversely impacted or terminated, which would harm our business, operating results and financial condition.

Government regulation of the Internet could adversely affect our business.

The laws governing general commerce on the Internet remain unsettled and it may take years to fully determine whether and how existing laws such as those governing intellectual property, privacy and taxation apply to the Internet. In addition, the growth and development of the market for electronic commerce may prompt calls for more stringent consumer protection laws that may impose additional burdens on companies conducting business over the Internet. Any new laws or regulations or new interpretations of existing laws or regulations relating to the Internet could harm our business and we could be forced to incur substantial costs in order to comply with them, which would harm our business, operating results and financial condition.

Table of Contents

Our business could be harmed if we are unable to correspond with our consumers or market the availability of our ecommerce platform by email.

We use email to market our services to potential members and as the primary means of communicating with our existing members. The laws and regulations governing the use of email for marketing purposes continue to evolve and the growth and development of the market for commerce over the Internet may lead to the adoption of additional legislation. If new laws or regulations are adopted, or existing laws and regulations are interpreted, to impose additional restrictions on our ability to send email to our members or potential members, we may not be able to communicate with them in a cost-effective manner. In addition to legal restrictions on the use of email, Internet service providers, e-mail service providers and others attempt to block the transmission of unsolicited email, commonly known as “spam.” Many Internet and e-mail service providers have relationships with organizations whose purpose it is to detect and notify the Internet and e-mail service providers of entities that the organization believes is sending unsolicited e-mail. If an Internet or e-mail service provider identifies email from us as “spam” as a result of reports from these organizations or otherwise, we can be placed on a restricted list that will block our email to members or potential members. If we are unable to communicate by email with our members and potential members as a result of legislation, blockage or otherwise, our business, operating results and financial condition would be harmed.

Consumers depend upon third-party service providers to access our website, and our business and operating results could be harmed as a result of technical difficulties experienced by these service providers.

Consumers using our website depend upon Internet, online and other service providers for access to our website. Many of these service providers have experienced significant outages, delays and other difficulties in the past and could experience them in the future. Any significant interruption in access to our website or increase in our website’s response time as a result of these difficulties could damage our relationship with insurance carriers, marketing partners and existing and potential members and could harm our business, operating results and financial condition.

Risks Related to the Ownership of Our Common Stock

The trading price of our common stock may be subject to significant fluctuations and volatility, and our stockholders may be unable to resell their shares at a profit.

The stock markets, in general, and the markets for high technology stocks in particular, have historically experienced high levels of volatility. The market for technology stocks has been extremely volatile and frequently reaches levels that bear no relationship to the past or present operating performance of those companies. These broad market fluctuations may adversely affect the trading price of our common stock. In addition, the trading price of our common stock has been subject to significant fluctuations and may continue to fluctuate or decline, particularly as a result of developments relating to health care reform legislation and the implementation of health care reform. Other factors that could cause fluctuations in the trading price of our common stock include, but are not limited to, the following:


•	price and volume fluctuations in the overall stock market from time to time;


•	significant volatility in the market price and trading volume of technology companies in general, and companies in our industry;


•	actual or anticipated changes in our results of operations or fluctuations in our operating results;


•	actual or anticipated changes in the expectations of investors or securities analysts, including changes in financial estimates or investment recommendations by securities analysts who follow our business and changes in perceptions relating to the economy;


•	speculation in the press or investment community;


•	technological advances or introduction of new products by us or our competitors;


•	actual or anticipated developments in our competitors’ businesses or the competitive landscape generally;


•	litigation involving us, our industry or both;


•	actual or anticipated regulatory developments in the United States or foreign countries, including health care reform legislation in the United States;

Table of Contents


•	major catastrophic events;


•	announcements or developments relating to the economy;


•	our sale of common stock or other securities in the future;


•	the trading volume of our common stock, as well as sales of large blocks of our stock; or


•	departures of key personnel.

These factors, as well as general economic and political conditions and the announcement of proposed and completed acquisitions or other significant transactions, or any difficulties associated with such transactions, by us or our strategic partners, customers or our current competitors, may materially adversely affect the market price of our common stock in the future. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against that company. As discussed in Item 1, Legal Proceedings, securities class action litigation has been filed against us. Such litigation could result in substantial cost and a diversion of management’s attention and resources. In addition, volatility, lack of positive performance in our stock price or changes to our overall compensation program, including our equity incentive program, may adversely affect our ability to retain key employees.

Our actual operating results may differ significantly from our guidance.

From time to time, we have released, and may continue to release guidance in earnings conference calls, earnings releases, or otherwise, regarding our future performance that represents our management's estimates as of the date of release. This guidance, which includes forward-looking statements, has been and will be based on projections prepared by our management. These projections are not prepared with a view toward compliance with published guidelines of the American Institute of Certified Public Accountants, and neither our registered public accountants nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person expresses any opinion or any other form of assurance with respect to the projections.

Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. We may state possible outcomes as high and low ranges. Any range we provide is not intended to imply that actual results could not fall outside of the suggested ranges. The principal reason that we release guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.

Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. For example, our actual financial results for the fiscal year 2014 did not fall within the ranges previously provided by our guidance. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the variations may be material. In light of the foregoing, investors are urged not to rely upon our guidance in making an investment decision regarding our common stock.

Any failure to successfully implement our operating strategy or the occurrence of any of the events or circumstances set forth in this “Risk Factors” section could result in the actual operating results being different from our guidance, and the differences may be adverse and material.

A limited number of stockholders have the ability to influence the outcome of director elections and other matters requiring stockholder approval.

A small number of stockholders and their affiliated entities beneficially owned more than 50% percent of our outstanding common stock as of June 30, 2015. These stockholders, if they act together, could exert substantial influence over matters requiring approval by our stockholders, including the election of directors, the amendment of our certificate of incorporation and bylaws and the approval of mergers or other business combination transactions. This concentration of ownership may discourage, delay or prevent a change in control of our company, which could deprive our stockholders of an opportunity to receive a premium for their stock as part of a sale of our company and might reduce our stock price. These actions may be taken even if they are opposed by other stockholders.

Table of Contents

Certain provisions in our charter documents and Delaware law could discourage takeover attempts and lead to management entrenchment.

Our certificate of incorporation and bylaws contain provisions that could have the effect of delaying or preventing changes in control or changes in our management without the consent of our board of directors. These provisions include:


•	a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;


•	cumulative voting in the election of directors is prohibited, which limits the ability of minority stockholders to elect director candidates;


•	the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;


•	the ability of our board of directors to determine to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;


•	a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;


•	the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and


•	advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.

We are also subject to certain anti-takeover provisions under Delaware law. Under Delaware law, a corporation may, in general, not engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction.

Table of Contents

ITEM 5. OTHER ITEM

Xiamen Lease Renewal

On August 3, 2015, eHealth China (Xiamen) Technology Co., Ltd. (“eHealth China”), a wholly-owned indirect subsidiary of eHealth, Inc., entered into a supplemental agreement (the “Supplemental Agreement”) with an effective date of September 1, 2015 with Xiamen Software Industry Investment & Development Co., Ltd. to amend the Office Lease Contract dated as of March 31, 2006, as amended (the “Office Lease”). The Supplemental Agreement amends the Office Lease for approximately 3,666.43 square meters of office space on floors 9FA, 9FB and 10F in Chuangxin Building in the Software Park in Xiamen, China. The term of the Office Lease ends on August 30, 2016, after which the Office Lease may be renewed for subsequent and consecutive one year periods. Under the terms of the Supplemental Agreement, the monthly base rent was increased to RMB 207,887 per month (RMB 56.7 per square meter per month) and the security deposit was increased to RMB 636,759 accordingly.

The foregoing description of the terms of the Supplemental Agreement do not purport to be complete and is qualified in its entirety by reference to the full text of the Supplemental Agreement, the translated version is attached hereto as Exhibit 10.1.

ITEM 6. EXHIBITS

(a) Exhibits

Except as so indicated in Exhibits 32.1 and 32.2, the following exhibits are filed as part of, or incorporated by reference into, this quarterly report on Form 10-Q.



			Incorporation by Reference Herein
Exhibit Number		Description of Exhibit	Form	Date
10.1	†	Supplemental Agreement, effective as of September 1, 2015, between eHealth China (Xiamen) Technology Co., Ltd. and Xiamen Software Industry Investment & Development Co., Ltd.
31.1	†	Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	†	Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	‡	Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	‡	Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	**	XBRL Instance Document
101.SCH	**	XBRL Taxonomy Extension Schema Document
101.CAL	**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	**	XBRL Taxonomy Extension Presentation Linkbase Document

† Filed herewith.

‡ Furnished herewith.

** Pursuant to applicable securities laws and regulations, these interactive data files are deemed furnished and not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act, are deemed furnished and not filed for purposes of Section 18 of the Exchange Act and otherwise are not subject to liability under these sections.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on the 7th day of August 2015.

eHealth, Inc.



	/s/ Gary L. Lauer
	Gary L. Lauer
	Chief Executive Officer
	(Duly Authorized Officer on Behalf of the Registrant)



	/s/ Stuart M. Huizinga
	Stuart M. Huizinga
	Chief Financial Officer
	(Principal Financial Officer)

Table of Contents

EXHIBIT INDEX



			Incorporation by Reference Herein
Exhibit Number		Description of Exhibit	Form	Date
10.1	†	Supplemental Agreement, effective as of September 1, 2015, between eHealth China (Xiamen) Technology Co., Ltd. and Xiamen Software Industry Investment & Development Co., Ltd.
31.1	†	Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	†	Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	‡	Certification of Gary L. Lauer, Chief Executive Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	‡	Certification of Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	**	XBRL Instance Document
101.SCH	**	XBRL Taxonomy Extension Schema Document
101.CAL	**	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	**	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	**	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	**	XBRL Taxonomy Extension Presentation Linkbase Document

† Filed herewith.

‡ Furnished herewith.

EX-10.1 2 ehth63015exhibit101.htm EXHIBIT 10.1 SUPPLEMENTAL AGREEMENT, EFFECTIVE AS OF SEPTEMBER 1, 2015 BETWEEN E EHTH.6.30.15.EXHIBIT10.1

Exhibit 10.1

Supplemental Agreement, effective as of September 1, 2015, between eHealth, Inc. China (Xiamen) Technology Co., Ltd and Xiamen Software Industry Investment & Development Co., Ltd.

Supplemental Agreement

Lessor: Xiamen Software Industry Investment & Development Co., Ltd (Hereinafter Party A)



Legal Address:	1F Area A, Huaxun Building, Xiamen Software Park
Zip Code:	361005	Tel:	3929999	Fax:	3929888
Legal Representative:	Hu Qi	Title:	Chairman of the Board
Bank Account:	Jiangtou Branch of CITIC Bank	Account No:	[Account Number]

Renter: eHealth China (Xiamen) Technology Co., Ltd (Hereinafter Party B)



Legal Address:	9F, Area A, Chuangxin Building, Xiamen Software Park
Zip Code:	361005	Tel:	0592-2517000	Fax: 0592-2517111
Legal Representative:	Gary Lauer	Title:	Chairman
Bank Account:		Account No:

After friendly negotiation, Party A and Party B have reached an agreement regarding Party B’s renting of office spaces on 9F Area A, 9F Area B and 10F Area B (Area: 3666.43 square meters) in Chuangxin Building at Software Park located at Xiamen Torch Hi-tech zone as follows:

Item I. Amendments

1. This agreement is an amendment to the Office Lease Contract executed on March 31, 2006 (and all appendices that both parties have been involved, including all renewal agreements and the Agreement of Assignment and Transfer) (collectively referred hereinafter as the “Original Contract”) and shall supplement the Original Contract.

2. Effective September 1, 2015, Item 4 of the Original Contract shall be changed to the following: “The standard rental price for the space provided by Party A will be RMB 56.7 per square meters per month.” Item 5 of the Original Contract shall be changed so that the total rent will be RMB 207,887 per month. Item 6 of the Original Contract regarding the amount of deposit shall be changed to RMB 636,759. All other terms in the Original Contract shall remain unchanged.

3. If Party A decides not to continue the lease with Party B, it needs to provide written notice to Party B 120 days in advance so that Party B will have sufficient time to search for appropriate office space. If Party B decides not to continue the lease with Party A, it also needs to provide 120 advance written notice to Party A.

4. The term of this agreement is one year. If there will be an adjustment to the standard rental rate for the next lease renewal, Party A should notify Party B 120 days in advance.

5. Any conflicts between this agreement and the Original Contract, this agreement shall prevail. At the end of the term of this agreement, unless either party notifies the other party 120 days in advance that there will be changes to the agreement, this agreement shall automatically renew for additional one-year periods.

6. General management service fee, public maintenance fee and central air conditioning fee shall remain unchanged from the fees stated in the renewal agreement dated April 12, 2012. As such, general management service fee shall be RMB 3.35 per square meter per month, or RMB 37,621 per quarter; public maintenance fee shall be RMB 0.65 per square meter per month, or RMB 7,300 per quarter; central air conditioning fee shall be RMB 12 per square meter per month, or RMB 40,429 per month (such central air conditioning fee shall be calculated based on the Original Contract’s chargeable area of 3,369.09 square meters). All other terms in the Original Contract shall remain unchanged.

Item II. Effective Date

This agreement shall be effective on the date the authorized representatives of both Party A and Party B have signed this agreement and applied the company’s stamp.

Item III. Copies

Exhibit 10.1

There are two copies of this agreement, each party holds one copy, and each copy bears equal legal validity.

(Below contains no formal contractual provisions.)

Party A: Xiamen Software Industry Investment and Development Co., Ltd

Authorized Representative: /s/ WANG Hua

Date: August 3, 2015

Party B: eHealth China (Xiamen) Technology Co., Ltd

Authorized Representative: /s/ Tom Tsao

Date: August 3, 2015

EX-31.1 3 ehth63015exhibit311.htm CERTIFICATION OF GARY L. LAUER, CHIEF EXECUTIVE OFFICER OF EHEALTH, INC., PURSUA EHTH.6.30.15.EXHIBIT31.1

Exhibit 31.1

CERTIFICATION

I, Gary L. Lauer, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2015





	/s/ GARY L. LAUER
	Gary L. Lauer
	Chief Executive Officer

EX-31.2 4 ehth63015exhibit312.htm CERTIFICATION OF STUART M. HUIZINGA, CHIEF FINANCIAL OFFICER OF EHEALTH, INC., P EHTH.6.30.15.EXHIBIT31.2

Exhibit 31.2

CERTIFICATION

I, Stuart M. Huizinga, certify that:


1.	I have reviewed this Quarterly Report on Form 10-Q of eHealth, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):


a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 7, 2015






	/s/ STUART M. HUIZINGA
	Stuart M. Huizinga
	Chief Financial Officer

EX-32.1 5 ehth63015exhibit321.htm CERTIFICATION OF GARY L. LAUER, CHIEF EXECUTIVE OFFICER OF EHEALTH, INC., PURSUA EHTH.6.30.15.EXHIBIT32.1

Exhibit 32.1

Certification of Chief Executive Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarterly period ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gary L. Lauer, Chief Executive Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)	The Form 10-Q, to which this certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/ GARY L. LAUER

Gary L. Lauer

Chief Executive Officer

August 7, 2015

A signed original of this written statement required by Section 906 has been provided to eHealth, Inc. and will be retained by eHealth, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 ehth63015exhibit322.htm CERTIFICATION OF STUART M. HUIZINGA, CHIEF FINANCIAL OFFICER OF EHEALTH, INC., P EHTH.6.30.15.EXHIBIT32.2

Exhibit 32.2

Certification of Chief Financial Officer, Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of eHealth, Inc. on Form 10-Q (the “Form 10-Q”) for the quarterly period ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stuart M. Huizinga, Chief Financial Officer of eHealth, Inc., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:


(1)	The Form 10-Q, to which this certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of eHealth, Inc.

/s/ STUART M. HUIZINGA

Stuart M. Huizinga

Chief Financial Officer

August 7, 2015

EX-101.INS 7 ehth-20150630.xml XBRL INSTANCE DOCUMENT 0001333493 2015-01-01 2015-06-30 0001333493 2015-07-31 0001333493 2014-12-31 0001333493 2015-06-30 0001333493 2015-04-01 2015-06-30 0001333493 2014-01-01 2014-06-30 0001333493 2014-04-01 2014-06-30 0001333493 2014-06-30 0001333493 2013-12-31 0001333493 ehth:MedicareRenewalCommissionsReceivableMember 2014-12-31 0001333493 ehth:AccountsReceivableOtherRevenuesMember 2014-12-31 0001333493 ehth:OtherCommissionsReceivableMember 2014-12-31 0001333493 ehth:MedicareRenewalCommissionsReceivableMember 2015-06-30 0001333493 ehth:OtherCommissionsReceivableMember 2015-06-30 0001333493 ehth:AccountsReceivableOtherRevenuesMember 2015-06-30 0001333493 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0001333493 us-gaap:RestrictedStockMember 2014-12-31 0001333493 us-gaap:RestrictedStockMember 2014-01-01 2014-12-31 0001333493 us-gaap:RestrictedStockMember 2015-06-30 0001333493 us-gaap:ManagementMember 2015-01-01 2015-06-30 0001333493 ehth:A2006EquityIncentivePlanMember 2015-01-01 2015-06-30 0001333493 us-gaap:RestrictedStockUnitsRSUMember ehth:A2006EquityIncentivePlanMember 2015-01-01 2015-06-30 0001333493 us-gaap:PerformanceSharesMember 2015-04-01 2015-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2015-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001333493 us-gaap:EmployeeStockOptionMember 2014-12-31 0001333493 ehth:TechnologyAndContentExpenseMember 2015-01-01 2015-06-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2014-04-01 2014-06-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001333493 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2014-01-01 2014-06-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2015-01-01 2015-06-30 0001333493 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-06-30 0001333493 ehth:TechnologyAndContentExpenseMember 2014-01-01 2014-06-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001333493 ehth:CustomerCareAndEnrollmentExpenseMember 2015-04-01 2015-06-30 0001333493 ehth:TechnologyAndContentExpenseMember 2015-04-01 2015-06-30 0001333493 us-gaap:SellingAndMarketingExpenseMember 2014-04-01 2014-06-30 0001333493 us-gaap:RestructuringChargesMember 2014-01-01 2014-06-30 0001333493 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0001333493 us-gaap:RestructuringChargesMember 2015-04-01 2015-06-30 0001333493 ehth:TechnologyAndContentExpenseMember 2014-04-01 2014-06-30 0001333493 us-gaap:RestructuringChargesMember 2014-04-01 2014-06-30 0001333493 us-gaap:RestructuringChargesMember 2015-01-01 2015-06-30 0001333493 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001333493 ehth:A2014EquityIncentivePlanMember 2015-01-01 2015-06-30 0001333493 ehth:A2014EquityIncentivePlanMember 2014-12-31 0001333493 ehth:A2014EquityIncentivePlanMember 2015-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2014-04-01 2014-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001333493 us-gaap:RestrictedStockMember 2015-04-01 2015-06-30 0001333493 us-gaap:RestrictedStockMember 2014-01-01 2014-06-30 0001333493 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0001333493 us-gaap:RestrictedStockMember 2014-04-01 2014-06-30 0001333493 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0001333493 country:CN 2014-12-31 0001333493 country:CN 2015-06-30 0001333493 country:US 2014-12-31 0001333493 country:US 2015-06-30 0001333493 us-gaap:SalesMember ehth:AnthemMember 2014-04-01 2014-06-30 0001333493 ehth:UnitedhealthcareMember 2015-01-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:UnitedhealthcareMember 2014-01-01 2014-06-30 0001333493 ehth:AetnaMember 2015-01-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:HumanaMember 2014-01-01 2014-06-30 0001333493 us-gaap:SalesMember ehth:HumanaMember 2014-04-01 2014-06-30 0001333493 us-gaap:SalesMember ehth:AnthemMember 2015-04-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:HumanaMember 2015-04-01 2015-06-30 0001333493 ehth:AnthemMember 2015-01-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:AetnaMember 2014-01-01 2014-06-30 0001333493 us-gaap:SalesMember ehth:UnitedhealthcareMember 2015-04-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:AetnaMember 2014-04-01 2014-06-30 0001333493 ehth:HumanaMember 2015-01-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:AnthemMember 2014-01-01 2014-06-30 0001333493 us-gaap:SalesMember ehth:AetnaMember 2015-04-01 2015-06-30 0001333493 us-gaap:SalesMember ehth:UnitedhealthcareMember 2014-04-01 2014-06-30 0001333493 us-gaap:AccountsReceivableMember ehth:ConcentrationRiskCustomerOneMember 2014-01-01 2014-12-31 0001333493 us-gaap:AccountsReceivableMember ehth:ConcentrationRiskCustomerOneMember 2015-01-01 2015-06-30 0001333493 us-gaap:AccountsReceivableMember ehth:ConcentrationRiskCustomerTwoMember 2014-01-01 2014-12-31 0001333493 ehth:CommissionRevenueMember ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2014-01-01 2014-06-30 0001333493 ehth:CommissionRevenueMember ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2015-04-01 2015-06-30 0001333493 ehth:CommissionRevenueMember ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2015-01-01 2015-06-30 0001333493 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2015-06-30 0001333493 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2014-12-31 0001333493 ehth:CommissionRevenueMember ehth:MajorMedicalIndividualAndFamilyInsurancePlansMember 2014-04-01 2014-06-30 0001333493 us-gaap:AccountsReceivableMember ehth:ConcentrationRiskCustomerThreeMember 2014-01-01 2014-12-31 0001333493 us-gaap:EmployeeSeveranceMember 2015-04-01 2015-06-30 0001333493 ehth:NoncashEmployeeTerminationCostsStockbasedCompensationMember 2015-01-01 2015-06-30 0001333493 ehth:NoncashEmployeeTerminationCostsStockbasedCompensationMember 2015-04-01 2015-06-30 0001333493 us-gaap:FacilityClosingMember 2014-01-01 2014-06-30 0001333493 us-gaap:FacilityClosingMember 2015-04-01 2015-06-30 0001333493 us-gaap:FacilityClosingMember 2014-04-01 2014-06-30 0001333493 us-gaap:FacilityClosingMember 2015-01-01 2015-06-30 0001333493 ehth:NoncashEmployeeTerminationCostsStockbasedCompensationMember 2014-04-01 2014-06-30 0001333493 us-gaap:EmployeeSeveranceMember 2014-01-01 2014-06-30 0001333493 us-gaap:EmployeeSeveranceMember 2014-04-01 2014-06-30 0001333493 ehth:NoncashEmployeeTerminationCostsStockbasedCompensationMember 2014-01-01 2014-06-30 0001333493 us-gaap:EmployeeSeveranceMember 2015-01-01 2015-06-30 0001333493 us-gaap:FacilityClosingMember 2015-03-01 2015-03-30 0001333493 ehth:EmployeeTerminationBenefitsandRelatedCostsMember 2015-03-01 2015-03-30 0001333493 country:US 2015-03-01 2015-03-30 0001333493 us-gaap:FacilityClosingMember 2015-06-30 0001333493 us-gaap:EmployeeSeveranceMember 2014-12-31 0001333493 us-gaap:FacilityClosingMember 2014-12-31 0001333493 us-gaap:EmployeeSeveranceMember 2015-06-30 xbrli:pure ehth:position ehth:customer ehth:class_action_lawsuit iso4217:USD xbrli:shares ehth:state iso4217:USD xbrli:shares false --12-31 Q2 2015 2015-06-30 10-Q 0001333493 18080207 Accelerated Filer eHealth, Inc. EHTH 8707000 1711000 0 289000 1805000 1991000 209000 318000 3355000 736000 8984000 18697000 7658000 19519000 -6086000 -6996000 34000 28000 0 569000 623000 702000 20000 22000 174000 205000 48000 70000 3 1 4068000 9431000 2498000 5967000 4428000 3791000 637000 1400000 9800000 900000 2100000 348475 9550000 20017000 8591000 19364000 200000

5961000

2066000

8200000

2462000

355000

5383000

10169000

1304000

8566000

299000

179000

184000

259007000

263195000

400000

3700000

1850000

71000

429000

771000

579000

4295000

167000

991000

1901000

1236000

1827000

139000

511000

731000

446000

3858000

256000

946000

1506000

113000

1037000

354000

708000

288000

633000

195000

130000

65000

27000

1942000

1450000

492000

1954000

1507000

447000

106664000

105627000

66475000

68759000

15793000

17189000

107055000

70382000

51415000

51812000

-36673000

397000

35622000

34623000

29000

3024000

1487000

5754000

3673000

0.68

0.10

0.11

0.21

0.09

0.64

0.10

0.11

0.24

0.10

0.30

0.14

0.17

0.65

0.08

0.11

0.13

0.11

0.49

0.58

0.09

0.26

0.10

892000

3005000

670000

3084000

36246000

90296000

34066000

97366000

-2035000

869000

602000

386000

2061000

2108000

0.16

0.08

0.32

0.20

0.15

0.07

0.32

0.20

13000

9000

0.522

0.536

0.012

0.033

8204000

8365000

3663000

6857000

15151000

7516000

15489000

14096000

6319000

3170000

5819000

3793000

3296000

1700000

69000

125000

-227000

-3895000

2277000

1955000

-603000

-432000

-3051000

159000

-123000

1736000

1282000

243000

38526000

84103000

37396000

95215000

10774000

10140000

106664000

105627000

26737000

17680000

6449000

6608000

9609000

32718000

9285000

34736000

-24744000

273000

-6840000

-1432000

-5102000

1547000

3023000

1470000

5750000

3668000

40189000

437000

39752000

36868000

422000

36446000

6348000

3238000

5828000

3816000

5679000

4122000

1000

17000

4000

5000

2996000

4647000

-29000

-68000

-9000

-23000

28256000

3859000

3754000

105000

4500000

2340000

1432000

6474000

6392000

3244000

1049000

9640000

8510000

40000

1286000

3089000

1456000

3025000

160

0.15

3900000

600000

58000

57000

1000

4541000

113000

3791000

637000

0.00

569000

37000

532000

289000

280000

14261000

17929000

42594000

93534000

39894000

101182000

4295000

3858000

P4Y

147000

62000

85000

26.53

692000

10.59

873000

1223000

30.86

21.00

P2Y6M6D

P2Y11M0D

195000

24.02

0.00

0.459

0.636

0.647

0.0142

0.0115

0.0113

4164000

3536000

1108000

17.86

382000

224000

211000

13000

21.79

34000

17.01

5.70

6.69

12884000

222000

1724000

1420000

18.50

18.56

217000

1397000

18.51

9.20

11.37

21753000

15522000

P4Y2M10D

P4Y3M0D

P2Y7M3D

179000

P2Y7M18D

P3Y3M22D

P3Y0M23D

P3Y0M12D

500000

1200000

400000

900000

114000

564000

1206000

371000

833000

73478000

81339000

10945607

11012363

199998000

19775000

19821000

18035000

17998000

18978000

18914000

17967000

17906000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable—</font><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our accounts receivable consisted of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare renewal commission receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable - from other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other commissions receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets by geographical area were as follows (in thousands):  </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">China</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,868</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of the market-based stock unit awards was determined using the Monte Carlo simulation model incorporating the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">            </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:55.79240037071362%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Seasonality</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">—</font><font style="font-family:inherit;font-size:10pt;">The majority of our individual and family plans are sold in the open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. For example, in the second quarter of 2015, the number of individual and family applications submitted on our website decreased compared to periods inside the second open enrollment period that began on November 15, 2014 and ended on February 15, 2015. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The majority of Medicare plans are sold in our fourth quarter during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. Additionally, substantially all Medicare Advantage and Medicare Part D prescription drug policies renew on January 1 of each year, resulting in our recognizing substantially all renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in our first quarter. Accordingly, Medicare plan-related commission revenue is highest in our first quarter, with Medicare plan-related commission revenue being higher in our fourth quarter compared to our second and third quarters.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. As a result of the second open enrollment period for individual and family health insurance that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in individual and family submitted applications, compared to periods outside the open enrollment period. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. In addition, due to the initial open enrollment period for individual and family health insurance that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our provision for income taxes and our effective tax rates for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands, except effective tax rate):</font></div><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.90643274853801%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation—</font><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the condensed consolidated statements of comprehensive income for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and the condensed consolidated statements of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, are unaudited. The condensed consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, and include all adjustments necessary for the fair presentation of eHealth’s financial position as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, its results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and its cash flows for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. All adjustments are of a normal recurring nature. The results for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.  </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font><font style="font-family:inherit;font-size:10pt;">—In February 2015, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued ASU No. 2015-05 , "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement." ASU 2015-05 provides guidance to clarify the customer’s accounting for fees paid in a cloud computing arrangement. It is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-05 on our consolidated financial statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income per share consisted of the following (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="33%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,954</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our cash and cash equivalent balances were invested as follows (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,812</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):  </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocated to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common stock shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,978</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,906</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income per share—basic:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.08</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income allocated to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common stock shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">702</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total common stock shares used in diluted per share calculation (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,775</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,821</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income per share—diluted:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.64411492122335%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense by operating function for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and advertising</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer care and enrollment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology and content</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the cash-based restructuring charges liability activity during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee termination costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,754</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility and other termination costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total restructuring liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,859</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: non-current restructuring charges associated with facilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges liability - current</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the total cash and non-cash restructuring charges recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee termination costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash employee termination costs - stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility and other termination costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total restructuring charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,541</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carriers representing </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of our total revenue in the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> are presented in the table below: </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Humana</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anthem </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UnitedHealthcare </font><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aetna </font><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;padding-right:24px;">(1)</font><font style="font-family:inherit;font-size:10pt;">Anthem also includes other carriers owned by Anthem. </font></div><div style="line-height:120%;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;padding-right:24px;">(2)</font><font style="font-family:inherit;font-size:10pt;">UnitedHealthcare also includes other carriers owned by UnitedHealthcare.</font></div><div style="line-height:120%;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;padding-right:24px;">(3)</font><font style="font-family:inherit;font-size:10pt;">Aetna also includes other carriers owned by Aetna. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity under our 2014 Equity Incentive Plan, 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Available for Grant</font><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,164</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled (2) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:101px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled does not include </font><font style="font-family:inherit;font-size:10pt;">62,000</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled does not include </font><font style="font-family:inherit;font-size:10pt;">211,000</font><font style="font-family:inherit;font-size:10pt;"> stock options cancelled under the 2006 Equity Incentive Plan</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock unit activity, including performance-based and market-based restricted stock unit activity, under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): </font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Restricted Stock Units</font><font style="font-family:inherit;font-size:10pt;"> (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:10pt;"> (2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value is calculated as eHealth’s closing stock price as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> multiplied by the number of restricted stock units outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:10pt;"> (1)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the exercise price of in-the-money options as of those dates. </font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation—</font><font style="font-family:inherit;font-size:10pt;">The fair value of stock options granted to employees for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was estimated using the following weighted average assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.31232622798888%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders’ Equity</font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Plans—</font><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity under our 2014 Equity Incentive Plan, 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands):</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Available for Grant</font><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,164</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled (2) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares available for grant June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,536</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:101px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units cancelled does not include </font><font style="font-family:inherit;font-size:10pt;">62,000</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options cancelled does not include </font><font style="font-family:inherit;font-size:10pt;">211,000</font><font style="font-family:inherit;font-size:10pt;"> stock options cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.</font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain our 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan, under which we previously granted options to purchase shares of our common stock and restricted stock units. The 2006 Equity Incentive Plan was terminated with respect to the grant of additional awards on June 12, 2014, upon adoption of our 2014 Equity Incentive Plan. The 2005 Stock Plan and 1998 Stock Plan were terminated with respect to the grant of additional awards upon the effectiveness of the 2006 Equity Incentive Plan. We will continue to issue new shares of common stock upon vesting of restricted stock units and the exercise of stock options previously granted under the 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:10pt;"> (1)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and the exercise price of in-the-money options as of those dates. </font></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of stock options vested during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of stock options vested during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes restricted stock unit activity, including performance-based and market-based restricted stock unit activity, under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data): </font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Restricted Stock Units</font><font style="font-family:inherit;font-size:10pt;"> (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Remaining Contractual Life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font><font style="font-family:inherit;font-size:10pt;"> (2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,753</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.59</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value is calculated as eHealth’s closing stock price as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> multiplied by the number of restricted stock units outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.   </font></div></td></tr></table><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on a straight-line basis over the vesting period. The fair value of performance-based restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on an accelerated basis over the vesting period. The amount of expense recorded for performance-based restricted stock units is based on expected attainment of performance criteria. The total fair value of restricted stock units vested during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of restricted stock units vested during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Repurchase Programs—</font><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> stock repurchase activity during the three and six months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. In addition to the shares repurchased under our past repurchase programs as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we have in treasury </font><font style="font-family:inherit;font-size:10pt;">348,475</font><font style="font-family:inherit;font-size:10pt;"> shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2014 and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had a total of </font><font style="font-family:inherit;font-size:10pt;">10,945,607</font><font style="font-family:inherit;font-size:10pt;"> shares and </font><font style="font-family:inherit;font-size:10pt;">11,012,363</font><font style="font-family:inherit;font-size:10pt;"> shares, respectively, held in treasury. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation—</font><font style="font-family:inherit;font-size:10pt;">The fair value of stock options granted to employees for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was estimated using the following weighted average assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.31232622798888%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2015, we granted market-based stock unit awards to certain members of senior management. Each market-based stock unit award represents a contingent right to receive certain shares of the Company’s common stock upon the attainment of certain stock prices over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year performance period. Once a stock price threshold is achieved, the portion of the award related to that threshold will vest on the one-year anniversary of the date of achievement, subject to the employee's continued service through each vesting date. Compensation expense related to these awards is recognized on an accelerated basis over the requisite service period. The weighted-average fair value of the market-based stock unit awards was determined using the Monte Carlo simulation model incorporating the following weighted average assumptions:</font></div><div style="line-height:120%;text-align:left;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">            </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:55.79240037071362%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> market-based stock unit awards granted during the three months ended June 30, 2015 and the three and six months ended June 30, 2014. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.64411492122335%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock-based compensation expense by operating function for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.90268767377201%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketing and advertising</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,037</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer care and enrollment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Technology and content</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,858</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Accounts </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents—</font><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our cash and cash equivalent balances were invested as follows (in thousands): </font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,812</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our money market funds reflect unadjusted quoted prices in active markets for identical assets and are classified as Level 1 as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font></div><div style="line-height:120%;text-indent:77px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable—</font><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our accounts receivable consisted of the following (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.05847953216374%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare renewal commission receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable - from other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,462</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other commissions receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accounts receivable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of a regulation issued by CMS, which changed the definition of a plan year from being 12-months from the effective date of a policy to January 1 through December 31 of each year, all Medicare Advantage and Medicare Part D prescription drug policies will renew on January 1 of each year, resulting in our recording of substantially all Medicare Advantage and Medicare Part D prescription drug plan renewal commission revenue in the first quarter of each year. We fully implemented this new rule in our first quarter ended March 31, 2015. We recognize a full year of renewal commission revenue at the time a policy is renewed, however, renewal commissions for Medicare Advantage products are paid monthly. As a result, the majority of renewal commissions for that product is collected in quarters subsequent to the first quarter.</font></div></div>

UnitedHealthcare also includes other carriers owned by UnitedHealthcare. also includes other carriers owned by Anthem. Aetna also includes other carriers owned by Aetna. Options cancelled does not include 211,000 stock options cancelled under the 2006 Equity Incentive Plan The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 and the exercise price of in-the-money options as of those dates. The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 multiplied by the number of restricted stock units outstanding as of December 31, 2014 and June 30, 2015, respectively. Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers. Restricted stock units cancelled does not include 62,000 restricted stock units cancelled under the 2006 Equity Incentive Plan EX-101.SCH 8 ehth-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Balance Sheet Accounts link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Balance Sheet Accounts (Schedule Of Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Balance Sheet Accounts (Schedule Of Cash And Cash Equivalents) (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Balance Sheet Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Geographic Information And Significant Customers link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Geographic Information And Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Geographic Information And Significant Customers (Schedule Of Revenue By Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Geographic Information And Significant Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Net Income Per Share (Schedule Of Anti-Dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Net Income Per Share (Schedule Oof Computation Of Basic And Diluted Net Income (Loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Restructuring Charges (Liability Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Restructuring Charges (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Restructuring Charges (Restructuring Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Stockholders' Equity (Schedule Of Activity Under The Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Stock Options, Valuation Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary Of Business And Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Summary of Business And Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary Of Business And Significant Accounting Policies (Policy) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 ehth-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 ehth-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 ehth-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounting Policies [Abstract] Basis Of Presentation Consolidation, Policy [Policy Text Block] Seasonality Seasonality Policy [Policy Text Block] Seasonality Policy [Policy Text Block] Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Segment Reporting [Abstract] Geographic Information And Significant Customers Segment Reporting Disclosure [Text Block] Income Tax Disclosure [Abstract] Summary Of Provision (Benefit) For Income Taxes And Effective Tax Rate Summary Of Provision For Income Taxes And Effective Tax Rate [Table Text Block] Summary Of Provision For Income Taxes And Effective Tax Rate [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Number of class action lawsuits filed against Company Loss Contingency, Pending Claims, Number Provision for expected and allowed claims Liabilities Subject to Compromise, Provision for Expected and Allowed Claims Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Common Stock Options [Member] Employee Stock Option [Member] Restricted Stock Units [Member] Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount Total Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Balance Sheet Related Disclosures [Abstract] Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Balance outstanding at December 31, 2014 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Balance outstanding at June 30, 2015 (shares) Number of Stock Options Vested and expected to vest at June 30, 2015 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Number of Stock Options Exercisable at June 30, 2015 (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Exercise Price, balance outstanding at December 31, 2014 (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Cancelled (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Balance outstanding at June 30, 2015 (usd per share) Weighted-Average Exercise Price, Vested and expected to vest at June 30, 2015 (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercisable at March 31, 2015 (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Remaining Contractual Life (years), Balance outstanding at December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Life (years), Balance outstanding at June 30, 2015 Weighted-Average Remaining Contractual Life (years), Vested and expected to vest at June 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Life (years), Exercisable at June 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value, Balance outstanding at December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate Intrinsic Value, Balance outstanding at June 30, 2015 Aggregate Intrinsic Value, Vested and expected to vest at June 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Exercisable at June 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Commission Revenue [Member] Commission Revenue [Member] Commission Revenue [Member] Accounts Receivable [Member] Accounts Receivable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Major Medical Individual And Family Insurance Plans [Member] Major Medical Individual And Family Insurance Plans [Member] Major Medical Individual And Family Insurance Plans [Member] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Customer One [Member] Concentration Risk Customer One [Member] Concentration Risk Customer One [Member] Customer Two [Member] Concentration Risk Customer Two [Member] Concentration Risk Customer Two [Member] Customer Three [Member] Concentration Risk Customer Three [Member] Concentration Risk Customer Three [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Number of significant customers Number Of Significant Customers Number Of Significant Customers Accounts receivable Accounts Receivable, Net, Current Component Of Stock Based Compensation Expense [Table] Component Of Stock Based Compensation Expense [Table] Component Of Stock Based Compensation Expense [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Marketing and Advertising Expense [Member] Selling and Marketing Expense [Member] Customer Care And Enrollment Expense [Member] Customer Care And Enrollment Expense [Member] Customer Care And Enrollment Expense [Member] Technology And Content Expense [Member] Technology And Content Expense [Member] Technology And Content Expense [Member] General and Administrative Expense [Member] General and Administrative Expense [Member] Restructuring Charges [Member] Restructuring Charges [Member] Component Of Stock Based Compensation Expense [Line Items] Component Of Stock Based Compensation Expense [Line Items] Component Of Stock Based Compensation Expense [Line Items] Total Stock-Based Compensation Expense Allocated Share-based Compensation Expense Income Statement [Abstract] Revenue Revenues [Abstract] Commission Insurance Commissions and Fees Other Other Revenue Revenue recognized during the period from lead generation, technology licensing and online sponsorship and advertising activities. Total revenue Revenues Operating costs and expenses: Operating Costs and Expenses [Abstract] Cost of revenue Cost of Revenue Marketing and advertising Marketing and Advertising Expense Customer care and enrollment Customer Care And Enrollment Expense The total expense recognized in the period related to providing customer care and enrollment services. These services include pre-sales assistance to applicants who call our customer care center and enrollment services to applicants during the underwriting process. Technology and content Technology And Content Expense The total expense recognized in the period for technology and content. Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. General and administrative General and Administrative Expense Restructuring charges Restructuring Charges Amortization of intangible assets Amortization of Intangible Assets Total operating costs and expenses Costs and Expenses Income from operations Operating Income (Loss) Other expense, net Other Nonoperating Income (Expense) Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Net Income (Loss) Attributable to Parent Comprehensive income: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net income (loss) per share: Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Deferred income taxes Deferred Income Tax Expense (Benefit) Depreciation and amortization Depreciation Amortization of internally-developed software Amortization of Internally Developed Software Amortization of Internally Developed Software Amortization of book-of-business consideration Amortization Of Book Of Business Consideration Amortization Of Consideration Paid In Connection With The Purchase Of Books-Of-Business Stock-based compensation expense Share-based Compensation Deferred rent Increase Decrease In Deferred Rent Expense The net change during the reporting period in the amount due that is the result of the cumulative difference between actual rent due and rent expense recognized on a straight-line basis. Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Accrued marketing expenses Increase Decrease In Accrued Marketing Expenses The increase (decrease) during the reporting period in accrued marketing expenses. Deferred revenue Increase (Decrease) in Deferred Revenue Accrued restructuring charges Increase (Decrease) in Accrued Restructuring Charges Increase (Decrease) in Accrued Restructuring Charges Other liabilities Increase (Decrease) in Other Current Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment and other assets Payments to Acquire Property, Plant, and Equipment Purchase of intangible assets Payments to Acquire Intangible Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from exercise of common stock options Proceeds from Stock Options Exercised Cash used to net-share settle equity awards Cash Used to Net-Share Settle Equity Awards Cash Used to Net-Share Settle Equity Awards Excess tax benefits from stock-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Repurchase of common stock Payments for Repurchase of Common Stock Principal payments in connection with capital leases Repayments of Long-term Capital Lease Obligations Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Stockholders' Equity Shareholders' Equity and Share-based Payments [Text Block] Schedule of share-based payment award (Schedule of Fair Value of Performance Stock Units, Valuation Assumptions) [Table Text Block] Schedule of share-based payment award (Schedule of Fair Value of Performance Stock Units, Valuation Assumptions) [Table Text Block] Schedule of share-based payment award (Schedule of Fair Value of Performance Stock Units, Valuation Assumptions) [Table Text Block] Schedule Of Activity Under The Plans Schedule of Share-based Compensation, Activity [Table Text Block] Schedule Of Stock Option Activity Under Stock Plans Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Restricted Stock Unit Activity Under Stock Plans Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary Of Business And Significant Accounting Policies Significant Accounting Policies [Text Block] Number of states in which the Company is licensed to market and sell health insurance Number of States in which Entity Operates Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Sales [Member] Sales [Member] Customer [Axis] Customer [Axis] Name of Major Customer [Domain] Customer [Domain] Humana [Member] Humana [Member] Humana [Member] Anthem [Member] Anthem [Member] Anthem [Member] UnitedHealthcare [Member] Unitedhealthcare [Member] UnitedHealthcare [Member] Aetna [Member] Aetna [Member] Aetna [Member] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Termination Costs [Member] Employee Severance [Member] Facility and Other Termination Costs [Member] Facility Closing [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning balance Restructuring Reserve Charges Restructuring Charges Excluding Stock-based Compensation Restructuring Charges Excluding Stock-based Compensation Payments Payments for Restructuring Ending balance Less: non-current restructuring charges associated with facilities Restructuring Reserve, Noncurrent Restructuring charges liability - current Restructuring Reserve, Current Accounts Receivable, Net [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Receivable Type [Axis] Receivable Type [Axis] Receivable [Domain] Receivable [Domain] Medicare Renewal Commissions Receivable [Member] Medicare Renewal Commissions Receivable [Member] Medicare Renewal Commissions Receivable [Member] Accounts Receivable, Other Revenues [Member] Accounts Receivable, Other Revenues [Member] Accounts Receivable, Other Revenues [Member] Other Commissions Receivable [Member] Other Commissions Receivable [Member] Other Commissions Receivable [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Total accounts receivable Non-cash Employee Termination Costs - Stock-based Compensation [Member] Non-cash Employee Termination Costs - Stock-based Compensation [Member] Non-cash Employee Termination Costs - Stock-based Compensation [Member] Restructuring charges Income Taxes Income Tax Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2014 Equity Incentive Plan [Member] 2014 Equity Incentive Plan [Member] 2014 Equity Incentive Plan [Member] 2006 Equity Incentive Plan [Member] 2006 Equity Incentive Plan [Member] 2006 Equity Incentive Plan [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] EX-101.PRE 12 ehth-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	Jun. 30, 2015 USD ($) class_action_lawsuit	Dec. 31, 2014 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of class action lawsuits filed against Company \| class_action_lawsuit	2
Provision for expected and allowed claims	$ 0	$ 0

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`!>1!T?#F.=LP@$``#@9```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_ M83)Y!5!+`P04````"``7D0='2'4%[L4````K`@``"P```%]R96QS+RYR96QS MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][ MCZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH` MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`%Y$'1Q8J%YF?`0``8A@``!H` M``!X;"]?6K#Z+VZU&'9WU]G98SMTKFP*WU5A(>F]76_>FBZJHC]97=T;;$[%T?O-,^G MKAO.R3:KG[-'V_TZZ[9[R48O17?T<9V]-=TYE-['X&XG>>@WZ)>OK?_/]LWA M<-KYQV;W6ODZ_E'AOC;(7#I(TT%*";)TD%&"QNF@,25HD@Z:4(*FZ:`I)6B6 M#II1@N;IH#DE:)$.6E"")`BM';P5Z*^E=&[UL<_16H+=R]%:@MW+T M5J"W1OI6@CR4< MO0WH;1R]#>AM'+T-Z&TAM'+T-Z&TO'W3[E-A0T#K6._DW>WX]T?';>IGR'NU^^$S0=02P,$%``` M``@`%Y$'1WH'5S*L`@``]`H``!````!D;V-0&ULO59-.XMKEFEE#ZU2K%A9=/.PP/T9 MCSQ2`^7RW%M1S:FT'C'\#[X&7AVVME9KD1NKPU]*/YDE@#53OS56RRZVN^:G MX?BL0N!J%^FWF85;V7;R+BT+;@68^V1.M?U/4E0Y-4*,S[Q.]HT+*/2V5B+&WWY'K MWP7JY03>2*8R(`NZ!K>G.PRU!(#"Y&A!'W$6WK]9ZGY& M5_-^I$O\?D9O%4Z^O+T*_TAZ*ZYRB1N,!HD;X?$1%V(X)P@&%.2.:HU:K-S- MZ^9L=[;GJ.CE!!\/X'PZ@//Y`(Z[#?HY9V]HY2NPE(M!O=PO<2]G["Y_[P2, MW7/?SW&?X/T<=_GW3%K3FT,XC7D(YY;31RZXF]-[PI*C5Y>.[NWAQ5W!W[WC MAG\!4$L#!!0````(`!>1!T>SEZ@(/P$``&D#```1````9&]C4')O<',O8V]R M92YX;6S-DTU/PS`,AO\*ZKU+N_$Q55T/@#@Q"8DA$+>0>%M8\Z'$4]=_3^9U M+0,NNW&K:[^/7\=)*5PAK([[:^)I@4 M#&K08#"P?)2SI'HQ&V,;4[)!7Y71<YL_/M/9I,H$Y$9`5`558.M@EAP[OT[N M[A.5067,6CC#?Q`0+VX]/$'@^J!/29=M`VU@O0T7W:XCV+R>N;&5] M>TC]B$Y>5?4%4$L#!!0````(`!>1!T>97)PC$`8``)PG```3````>&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?= MTXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%, M4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SOX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38: MC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5` MY3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@` M%Y$'1QB$3U),`@``=@H```T```!X;"]S='EL97,N>&ULS59;:]LP%/XK0AFC MA1';*4UI:QM&(3#8RJ!YZ%N1;=D6Z.+)5U!$NEJAO/J],2,U1/186Y7LF%9$CIJ2R\NI(89;79 MQ*@W\_VYQQ#A,`YYPQ9,U2`5#5<1O!@@X/;?B0Q'\.GLZY]&J-LOP(V3;Y.) M_W1^NXN?V85S"!S'CRR"P?P2>B\GG?K[>?7:#O7\==3_8=XAOC+$7I><.,P% M'W,T@PZ(P_H9K!#5_H%Q3P45$BA]"5J!13ABV'G<(4H220R8(T;HVL$S`]A[ MZ_P8X4+:V"[";IRI/T:211)!O_N]/%PRLMO!'(]0NGT\#<1AA93"DB_T!'3V M.96"3 MZFVR.>Y-VN-X09L/`?1N5%5T_9V2@C/LQ#IH(;K9(?I@#WTZSU7L&%"0-H8KP7@(RKX5[(YMNM86Q[VC.K!U;CEU5*-&/P*THFBS# M.6JH^DU60MG%"([V3R,_F`]>RX$B@J/]"V>D8==6P?C2C/\!4$L#!!0````( M`!>1!T=+9/R^GP,``'T-```/````>&PO=V]R:V)O;VLN>&ULE9=;;],P%(#_ MBI47X(4V=MMMU8K$+L`D&-,ZP;.7N*TUQPZVPS9^/<=INYW0TZ@\Q79R/M^^ M^'(:IH_./]P[]\">*F/#U,^R58SU=#`(Q4I5,KQWM;+P;N%\)2-D_7+@%@M= MJ`M7-)6R<<"'P\G`*R.C=C:L=!VR#2T<0@NU5[(,*Z5B9=:P2FJ;?3@-TX4V MZH?R`S(9,S+$RU)'5]?4VBZ!E;&%]B'.4W?;+RMM=:7_I'9#+JS< MXQ?G]1]GHS3SPCMCVJCTH@V"&L)+";0QZJ+S893WMVDF9MED",#?.NA[;71\ MGF5MVJC4D\$_76F'_S7%;#LXVREF'VW)+FT$"KNRZ\F#H4EM@(^ORK9B/]60 M\%=EOAXJ##IWME0VJ))!*CBC2QB5DIU)(VVA&`)Q!.('@^81'M!2!!(()/X7 M-$*@$0*-=D'SIJJD?V;?%^RL"=JJ$-KAFNNEU0N-0&,$&N^"MH/1SC+[6!2N ML3&@^`F*GQ`-B:YX6#E3@K=OV.6O!F8+11^AZ*/=Z"M;N$JQ._FD<)W'*.IX M-^H:4IO(&^6AZ=(K%'V"HD]VHS\KM_2R7ND"6_4R>EBO(?9KN(NZA=_?-T5L M//QF[!S:L>ST(^\(2AI:53HFV0.3MK4B`DK90G=!6-"<,+37AUQ@%%8T)QRE MC6!O80DP*KS#*"QI3EE*R$&"L*0Y82GVA`1@2W-"4TH9$H2%S0EC>^W)CS$* M6YP3&I/VD(W"1N>$TMO9=]3L\R%>Z+#2G%!ZW^S/82LM&X-16&Y.R-V+XARC M.NLOI3_&"]-R@^QB@L."<$[T=-,`JK MS@]>$[/TH+#O'LG-"]G[4"49AVSEA>WPT7GF$%(WH_"YPR!)1>$Y/TH++G` MD@M"\CT+WO8WQB@LN2`DWX/:%F,4EEP0DN]!?=6R/<%B%)9<$)+W;N?L+49A MR<7)YG#\>AZ&*P$LXV6Z+82V&CAN%^D*`8_U@6`T3MM"RG^#:\4L2V=_..8W MQIQ#V7?[U1!T=.GNAU5@(``/0'```8 M````>&PO=V]R:W-H965T&UL?97+CILP%(9?!?$`8VPN(1%! MFJ2JVD6ET2S:M0-.0`.8VDZ8OGU]`6)&A@U@\__G.[X<.QLH^^`5(<+[;)N. M'_U*B/X``"\JTF+^0GO2R3]7REHL9)/=`.\9P:4VM0U`09"`%M>=GV>Z[XWE M&;V+IN[(&_/XO6TQ^W_4#E0!I2"!4"R]>#G$G3J$B2_'<,^F0J MH_T]1?^NARO3OV!.SK3Y4Y>BDMD&OE>2*[XWXIT./\@XAE@%+&C#]=,K[ES0 M=K+X7HL_S;ON]'LP?Z)PM+D-:#2@V0#334,X&L*G04\=,)GI<7W#`N<9HX/' MS&+T6*TY/(1RY@J/ZTYFIDN.C,O>1QYDX*'"C`JD%2=;`6<%D+%G`'(!1CNR M[,@%.-N*T`T(78#0C""T[)';'KGLD;%'ECU>YF<4)UN1N`'Q!B"V[#LGP%:D M;D"R`4@L^]X)L!4P]?I)$I5?(*GAL-N0KUN5.YFDO)-`3MISMVONCS_U!+`P04 M````"``7D0='G73Z-L,#``!^$0``&````'AL+W=OPLSO@"K;*2&HZ/VX4A5']IG-G$VJ%Q28#<]W[[F MDG0Q?X^'2F_(X!S5UC$FBXZ:LVLUN.Y_[VN^VW=M85ZWYVD?#6].4 M_?][4W?7YPUL;B>^5:_G<3H1[[;Q/>Y8-:8=JJZ->G-ZWGR"IP+S23(KOE?F M.I#]:#+_TG4_IX,OQ^=-,GDPM3F,4Q.EW;R;PM3UU)+-_&MM]&_.*9#NWUK_ M=R[7VG\I!U-T]8_J.)ZMVV03'YO_H\#:,77,+ MV41-^7O95NV\O2Y7M%C#^`!<`_`>`#(8(-8`\1`0+\[FNOXIQW*W[;MKU"^# M<2FG,8IG56"LV3O2#A%X2C471+;_'<3 MR)D0BPFD\9J/%UR\7.(%C4]=B^E2Q")I9XF"#)!3%:Y*@J<6&?`BJ9?,S:(6 M+Y)D@01TSJD*JLKLS<=;40$KBEIAD^P522(RS1KQ:1P?.N!#$Q\B87UHDD.+ M'%DCCDBFDG>2!IRDU`FP3E*:)$L5/SB.RGKQ3)0LX"6C7MB"]QF=`@K8KBNH M*-?2,T_R@).<.A&LDYPDD8#\^%"1TFG..YG8ZK4R7?SK1;)>5LW]_I%\OSS( M4M]\`1:/-S\4;4+Q?H`FDDG.WT8!F>N')>7-#T6E8!/M5\VM<*4?D7@SY.JT MG<<>1RQ[5W8#A:](/2V$B`D4F8)')E`:HO7*5T15*M?@<1.")E!J"IZ:0)&8 M"+KW1`Z@;*3G^A[H%R$%%BN%8XJ2Q/?2(7P"92?DN%(X MHDS[2!'")U!^2IZ?0-F(&8]R1^2A)X3P"92?DN"E5A[B,$A@B* ME*"2)R@Z:$QUQA/4D:%.?7G\L3'!PRQ$RD[ M)<].I%3\`+G]>88[)'0]A0B*E*"*)RBZ!,U]0^;()/J>+QAB*%*&*IZA2/$( M&7L3%Z[(M]K"$$.1,E3Q#$5G$0J"?R06CBP5,O6-58BD2$FJ'DBZOL@A922W MNEE?Y1YTS.HF)F_*E_+5_%?VKU4[1"_=:%^ZYS?D4]>-QK:6?+1EGDUYO!_4 MYC1.N^E4__)Y8#D8N\OM:\?]D\ON#U!+`P04````"``7D0='SD@N$`0%``!& M&```&````'AL+W=O)%(`\U5W_UWM_LN=[:VL M?M3'/&]6OXKSI7Y:'YOF^KC9U/MC7F3U0WG-+^TW+V559$W[L7K=U-",;,ILA.E_5NVU_[6NVVY5MS/EWRK]6J?BN*K/HORL_E[6G-U].%;Z?7 M8]-=V.RVFWO6W&KQ?=8-_+LL?W8>_ M#T]KUHTA/^?[IFLB:U_>\S@_G[N6VIY_CHU^]-D%PO=3ZW_V-H/V?N:2K,EV MVZJ\K:HAW=>L6U7\4;>YV:_J_F(U)*2=N[J]^K[3:KMY[]H9$=$C$4(TA200 MX7=BT_9_'X2@!C'V($"XH#J((:$-.8;?-I(&&D'#E-0PY3!7$L9;.EY1\6J( M5S#>X2':828&Y-(CTDIO*"I&E-."I!)(>2VXIJ@44DYQ)FE=>D&7AKH\[D4/ MNC3H12CO*"B&D&*&A!((:6\L!:40\DH&EJ19T&2`)L-(309FP3NO2%&04D+3 M5`(ISCAW@M0%,2^U5+0PN["(+106F!BW,#$.QI.CC!P8I;'DY,60<9YL)X&, M9(ZCI3A+45&0]I(\UPT@9MRI#K(QJ9,6^:DU2, M*.,TN5,-;^!K21#CII@Q9*[]W1R%Q(FYR402:0,H@HK$#91Q?\G8.S9WVIX@;M`I%(&D&Y4/1)0NB MI*/OUA130H;R1IK[I`RZNR67?#0R0S]_D+F-,2-H*YM!@<6((!,2M51Q<%AR M6+KDX`ZEB_:>&%%&TE2"*&E]0!BBN`UM'DN5!X>EAZ5+#PYK`?I6C#FN%^9/ M#9,N2'%!NF:*(A5-$<15* MF"#KCK%X%K#NL(%:4RRYNX#N;FEW%]!JZ:<*A)#W>8(0.MFXE4"Q(I8,74!# MMS-#'Y]IA<2I5A05(ZI--4DEF#+S>V9\ID445RZDC#3V*=70V&U@WQ)+)BJ@ MB=K9G>O&N8%^QAZDH*AX1LT-Q(US@RFRJ70&A:H#L>2?`OJG8[0P\REAF)H? M44S"S&>$88BU6Q?\"9U*+3TJ"^BF+M3"DG4):%WT,WTD'+H)`T<:,<:.$D02_8EH'TYVKX$\A/')/WLC#%O+8DE&+.>/DA*9ZTY,<_= M!AR2%GGUVA]/UZM]^79INO2#J_BZ;IBSZ<]B7LFSR=MSLH1W_,<\.]P_G_*7IWMI.V'#,/7QH MRNMT:G__U\'N?U!+`P04````"``7D0='+E5S]VX$``!0%0``&````'AL+W=O MW)VT>KN\I39'*Q+?HO\F>Q^)GF]EXWW]NS,9WWLRRJ]G5U M[KKKRV;3[L^FS-M/]=54_3?'NBGSKG]L3IOVVIC\,`:5Q09\/]R4^:5:[;9C MV]=FMZUO77&IS-?&:V]EF3?_I*:H[Z\KM5H:OEU.YVYHV.RVFT?8X^OJLWK),!HDH^*OB[FWY+,WF'^KZ^_#PQ^'UY4_>#"%V7=#%WG_]FXR M4Q1#3_W(/^9./\8<`NGGI???QNGV]M_RUF1U\??ET)U[M_[*.YAC?BNZ;_7] M=S//(1@ZW-=%.[YZ^UO;U>42LO+*_.?T?JG&]_OT313/87(`S`'P"'B,(P?@ M'(`?`7J1LG->7O,MWVZ:^>\VT&-=\6'/U@GWF]EX[-C93NOJ9M7WK^R[6 MV\W[T,\L@5&24HEZ*#9]YX\10!IA#@<2#M(`&54$H3P"2B/@-`>D"W% MZRE>D_CH*0?1-(E)4HT2#,-8$F54I'3DRTX"QTP".A-+)D+'3$*:ZX2;#*:9 MA,2D+RDRJEB#CY:,1@X?$9U')/J(R"B@_%BTPD1^:*F^V.$DID[$0=*8KJV2 MC<3,2"+[2!P^$NI#7IF$ED^2*-$($\6^96T&?EFM#%\^O#R7\NQEUDSCA(BB M%R:*R!)R+R)^%B\4+HE8C^FLF1)"FJ),2\#2@PMJBE)-]IDJ2JRU2H)`G@Z3`421Q8^(ML4/95LB%E0Z M:Y:!M*7LF$I!;$N/BY2*HA(MZ6$DQ#BQI"=\2H_%C@N8BA(393XH2D,5B**, MB=;H!Q9F*A6G9"N:@BE)>)J?H]9?)*Q_/UW@0V!N9/(A8YK\ MHYI91=R,B+W%##(S8D&DLV@^Q$;R.8N)^M-89"MC=$$4-?,C4Q0I'N4MQ23* M5C0N?&+`G,C\1`I'E*&?,=&ZK^'(YL>%4`R9'YFA2.$8**WD,RB3]5GVK5O< M=0I%!E'U5*/S50A&S%&L0))E3!;Y^,LI?4,NJDK3G,8+O-;;U[>J&ZZ&2.OC MDO`S#!==3^VI>LFFJ[Z/;G;;:WXR?^;-Z5*UWEO==74YWGD=Z[HSO3__4Y^Y ML\D/CX?"'+OA8S2D=+KPFQZZ^KK<7SXN47?_`E!+`P04````"``7D0='X/I\ MHJ(!``"Q`P``&````'AL+W=O&<\Z<\:48 MM7FS'8!#'U(H>\"=<_V>$%MU()F]T3TH_Z?11C+G4],2VQM@=21)06B6W1+) MN,)E$6LOIBSTX`17\&*0':1DYN\1A!X/.,>7PBMO.Q<*I"S(S*NY!&6Y5LA` M<\#W^?ZX#8@(^,UAM(L8!>\GK=]"\K,^X"Q8``&5"PK,+V=X`"&"D&_\/FE^ MM0S$97Q1?XK3>O^-6E\]EWF>%^0/5L:C2@XH7=5&=;^<]C6?R M!2^+GK7PBYF6*XM.VOF3C;`_@T+L4RIYQ[]QP(L36/4AF'_0` MRO]IM9',^=1TQ`X&6!-)4A":98]$,JYP5<;:BZE*/3K!%;P89$]"@50E67D-EZ`LUPH9:,_X*3]=BH"(@)\<)KN)4?!^U?HM)-^; M,\Z"!1!0NZ#`_'*#9Q`B"/G&OV?-CY:!N(T7]:]Q6N_^RBP\:_&+-Z[W9C., M&FC9*-RKGK[!/,(Q"-9:V/A%]6B=E@L%(\G>T\I57*?TIUAH^P0Z$^A*^)Q% MXZE1M/F%.5:51D_(I*T=6#C!_$3]1M3(QJ))TWNCUE=O59X7);D%H1E#(^9R MAUD1Q*NO+>A>BYE.-W2Z3S_LT0_)X>'.X7%?H-@3*))`\;\1$^9RCWG\IPG9 M[*D$T\6K8U&M1Q4OZJ:ZWLXG&L_D`UZ5`^O@!S,=5Q9=M?,G&X^AU=J!-Y$] M'#'J_?M9$P&M"^$G'YMTI5+B]+`\D/655G\!4$L#!!0````(`!>1!T=YY$0, MHP$``+$#```8````>&PO=V]R:W-H965T&UL?5/;;IPP$/T5 MRQ\0@Y=TTQ6+E$U4M0^5HCRTSUX8P(HOQ#9+^O?UA25LA?J"9X9SSISQI9RT M>;,]@$,?4BA[Q+USPX$06_<@F;W3`RC_I]5&,N=3TQ$[&&!-)$E!:)9](9)Q MA:LRUEY,5>K1":[@Q2`[2LG,GQ,(/1UQCJ^%5][U+A1(59*%UW`)RG*MD('V MB!_SPZD(B`CXQ6&RJQ@%[V>MWT+RHSGB+%@``;4+"LPO%W@"(8*0;_P^:WZV M#,1U?%7_%J?U[L_,PI,6OWGC>F\VPZB!EHW"O>KI.\PCW`?!6@L;OZ@>K=/R M2L%(LH^TD(F;>W`P@GF!^HW MHD8V%DV:WANUOGJI\GQ?DDL0FC$T8DXWF`5!O/K2@FZUF.ET1:?;]-T6?9<< M[FXRK!=/'J6%3K4<6+NJHNM_.1QC/Y MA%?EP#KXR4S'E45G[?S)QF-HM7;@361W]QCU_OTLB8#6A7#O8Y.N5$J<'JX/ M9'FEU5]02P,$%`````@`%Y$'1XOD(>NB`0``L0,``!@```!X;"]W;W)KTQZYT;#I3:N@?%[1T. MH/V?%HWBSJ>FHW8PP)M(4I*R//]$%1S95B:.30L.S(794BIO?)Y`X M';-==BV\B*YWH4"KDBZ\1BC05J`F!MIC]K`[G/8!$0$_!4QV%9/@_8SX&I+O MS3'+@P604+N@P/UR@4>0,@CYQF^SYD?+0%S'5_6G.*UW?^86'E'^$HWKO=D\ M(PVT?)3N!:=O,(]P'P1KE#9^23U:A^I*R8CB[VD5.JY3^E,4,VV;P&8"6PA? M\F@\-8HVOW+'J]+@1$S:VH&'$]P=F-^(FMA8-&EZ;]3ZZJ7:L;RDER`T8UC$ MG&XP"X)Z]:4%VVHQT]F*SK;IQ1:]2`Z+&X?_Z+_?$M@G@?W_1DR8TRWF;Y=T MM:<*3!>OCB4UCCI>U%5UN9T/+)[)![PJ!][!#VXZH2TYH_,G&X^A173@3>1W M]QGI_?M9$@FM"^%G'YMTI5+B<+@^D.655G\`4$L#!!0````(`!>1!T<\E2&E MH@$``+$#```8````>&PO=V]R:W-H965T&UL?5/;;IPP$/T5 MRQ\0LX9MJQ6+E$U4-0^1HCRTSUX8P(HOU#9+^O?UA25LA/*"9X9SSISQI9RT M>;,]@$/O4BA[Q+USPX$06_<@F;W3`RC_I]5&,N=3TQ$[&&!-)$E!:)9](Y)Q MA:LRUEY,5>K1":[@Q2`[2LG,OQ,(/1WQ#E\+K[SK72B0JB0+K^$2E.5:(0/M M$=_O#JDV/=^BY\EA M?N.PV!8HM@2*)%!\-6+"G&XQ^T]-R&I/)9@N7AV+:CVJ>%%7U>5VWM-X)A_P MJAQ8!\_,=%Q9=-;.GVP\AE9K!]Y$=K?'J/?O9TD$M"Z$WWULTI5*B=/#]8$L MK[3Z#U!+`P04````"``7D0='WC>L5*,!``"Q`P``&0```'AL+W=O2%(1FV0V1C"M<%K'V:LI"#TYP!:\&V4%*9OX=0.AQ MCS?X7'CC;>="@90%F7DUEZ`LUPH9:/;X?K,[Y`$1`7\XC'81H^#]J/5[2%[J M/M/C+:]=YLQE& M-31L$.Y-C\\PC7`=!"LM;/RB:K!.RS,%(\D^T\I57,?T)_\UT=8)="+0F7"7 M1>.I4;3YR!PK"Z-'9-+6]BR@:RTF.EW0Z3I]NT;?)H?;"X>WZP+YFD">!/*?1DR8PR7F[EL3 MLMA3"::-5\>B2@\J7M1%=;Z=]S2>R1>\+'K6PF]F6JXL.FKG3S8>0Z.U`V\B MN[K&J//O9TX$-"Z$MSXVZ4JEQ.G^_$#F5UK^!U!+`P04````"``7D0='.0L: M8*0!``"Q`P``&0```'AL+W=OZ`!*WX0VPS9OU\_&$(BE`NVFZKJ:G>[ MG+1YM3V`0^]2*'O`O7/#GA!;]R"9O=(#*/^GU48RYX^F(W8PP)I(DH+0++LA MDG&%JS+&GDU5ZM$)KN#9(#M*RN]V8SC!IHV2C8"[A.@C66MCX1?5H MG987"D:2O:>5J[A.Z4]Q.].V"70FT(5PFT7C*5&T^<`KY% MSY/#?)T]S[8%BBV!(@D4WY68,,=/F/QKD61UIQ),%T?'HEJ/*@[J*KI,YQV- M/?F`5^7`.OC-3,>512?M?&=C&UJM'7@3V=4U1KU_/\M!0.O"]H??FS12Z>#T M<'D@RRNM_@-02P,$%`````@`%Y$'1Y$V"(*B`0``L0,``!D```!X;"]W;W)K M&UL?5/;;IPP$/T5RQ\0LX9MJQ6+E$U4-0^1HCRT MSUX8P(HOU#9+^O?UA25LA/*"9X9SSISQI9RT>;,]@$/O4BA[Q+USPX$06_<@ MF;W3`RC_I]5&,N=3TQ$[&&!-)$E!:)9](Y)QA:LRUEY,5>K1":[@Q2`[2LG, MOQ,(/1WQ#E\+K[SK72B0JB0+K^$2E.5:(0/M$=_O#JF_4^NJEVN6T))<@ M-&-HQ)QN,`N">/6E!=UJ,=/IBDZWZ?D6/4\.\QN'^;9`L250)('BJQ$3YG2+ M*3XU(:L]E6"Z>'4LJO6HXD5=59?;>1\/D7S`JW)@'3PSTW%ET5D[?[+Q&%JM M'7@3V=T>H]Z_GR41T+H0?O>Q25RO-+J/U!+`P04````"``7D0=' M+=(>2,$!``![!```&0```'AL+W=O2BE-CEZK&NE-`2T_B#),X M3C&GK8CRS,>>59[)WK!6P+-"NN>03)4*Q%7XLV3W2'#5R8&8&M^FQ!MBQ&.EG0R39] MMT7?A0QW2_?D/P+[+8%]$-BO2DS7)0;,>8VYW38Y?&-R6`G<;9JL,3^V3=)O M3-*EP#[>-%ECOOXNO+@='%3MFT"C0O;"M]PB.O?9/?&WZQ.>9QVMX3=5=2LT MNDAC[ZB_4)64!FP2\8TMM;$OP;Q@4!DWO;5S%9HC+(SLIE:?WYO\`U!+`P04 M````"``7D0=']^15K+`!```6!```&0```'AL+W=O*5US`!TC`ED8;VDCQEYVOA$0'PD\%D-G/DL]^4>O.+[\TE27T$X%!;KT#= M<(=GX-P+.>/?L^:'I2=NYXOZU]"M2W^C!IX5_\4:V[NP:8(::.G([:N:OL'< M0DA8*V["$]6CL4HLE`0)^AY')L,XQ3?Y0CLFD)E`5L+G-`2/1B'F%VII56HU M(1T_[4#]#F9GXCY$C4PHZMB]"VI<]5YE.2GQW0O-&!(PUQUF16"GOEJ0(XN9 M3C9T%IZYX5QP+YD4`>!?)=BZ=]BQ%SW6/R8Y/B/R;%3J`X--EC M'O\QP9N-$Z"[<#X-JM4HPVW85-\NZ;K@T%H__>3F.I[;N+!J6&[A^BNH_@)02P,$%`````@`%Y$' M1W2&UL?53- M;J,P$'X5BP>H"0DAB0A2TU75/:Q4];![=F`(J#9F;1.Z;[_^(117;B[8'G\_ M,S:>?.3B738`"GTPVLECU"C5'S"690.,R`?>0Z=W:BX847HI+ECV`DAE28SB M)(ZWF)&VBXK&F4"N,CQS*M: M!IUL>8<$U,?H<74X[0W"`GZW,,K%')G@ MU`AIX[^3YJ>E(2[G-_5G6ZW._DPD/''ZIZU4HY.-(U1!30:JWOCX`E,)J1$L M.97VB\I!*LYNE`@Q\N'&MK/CZ'9V\40+$Y*)D'PA8&=DT_Q!%"ERP4)2AV]%JM-EN.K$9HPB<6@))T,3'K,,FV1V3S!/8!$U\3!HVV=TQV7D"VZ")C\G")OL[)GM/('SQ M/N;KQ>/%8V(@+K9G2%3RH;,=:A&=V])C8A_C)[S(>W*!7T1'%$#LJQ_9E;>$;Y6S2N]V;SC#30\E&Z5YR^PUS"?1"L M4=KX)?5H':HK)2.*OZ=5Z+A.Z<]C,=.V"6PFL(7P)8_&4Z)H\RMWO"H-3L2D MJQUXZ&!Q8/XB:F)CT*3JO5'KHY>J>,A+>@E",X9%S.D&LR"H5U]2L*T4,YVM MZ&R;OMNB[Y+#W3H[^T_^_9;`/@GL;THL;DM,F-,MYK-+NKI3!::+HV-)C:.. M@[J*+M/YQ&)//N!5.?`.?G+3"6W)&9WO;&Q#B^C`F\CO[C/2^_>S'"2T+FP? M_=ZDD4H'A\/U@2ROM/H'4$L#!!0````(`!>1!T=F?G+JKP$``!8$```9```` M>&PO=V]R:W-H965TU*@5MVZI&VIZ#;P*)"4I2],C55QT29&'VHLNP&)XSG9)??"JVA:ZPNTR.G,JX2"S@CLB(;ZG#SM3I>#1P3`+P&C M6,_D^:'I2C";5A4YROPQ,+& M?\"+O.<-_.2Z$9TA5[3N^(2]KA$MN!#I@TO1NDLZ+R34UD\?W5S'1!T=$WWWOLP$``!8$```9````>&PO=V]R:W-H M965T8OMRMNLE^:#TNVD!+/H07)I3TEK;'3$V90N"FCO5 M@71?:J4%M6ZI&VPZ#;0*),$Q2=-[+"B329&'VHLN6"5NE`0)^A%')L,XQ"^[PTA;)Y"10";" M(0W!HU&(^9-:6N1:#4C'K>VH/\'L2-Q&E,B$HH[=NZ#&5:]%=G_(\=4+C1@2 M,.<%9D)@ISY9D#6+D4YF=+).WZS1-S'A9NY.]NL"VS6!;138+EK\L6PQ8LX+ MS#Y=-]G]QV2W$,A639:8[UN!9P4<; M^$UUPZ1!%V7=]0EG72MEP85([UR*UCW2:<&AMGZZ=W,=[VU<6-7=7N'T5U!\ M`E!+`P04````"``7D0='@18DYK$!```6!```&0```'AL+W=OC\??T@%"K4#;8OYW6Q33$J_68Z`(O>!9?FE'36]D>,3=6!H.9.]2#=FT9I M0:U;ZA:;7@.M`TEP3-+T'@O*9%(6H?:BRT(-EC,)+QJ900BJ_Y^!J_&4[)); MX96UG?4%7!9XYM5,@#1,2:2A.26/N^,Y]X@`^,-@-(LY\MDO2KWYQ:_ZE*0^ M`G"HK%>@;KC"$W#NA9SQOTGST](3E_.;^H_0K4M_H0:>%/_+:MNYL&F":FCH MP.VK&G_"U$)(6"ENPA-5@[%*W"@)$O0]CDR&<8QO\G2B;1/(1"`SX2$0<#0* M,9^II66AU8AT_+0]]3NX.Q+W(2ID0E''[EU0XZK7A839DOW+-T6V&\)[*/`?M7B?MUBQ)S7F'S;)/_& M)%\)W&^:K#&'+R9XL7$"=!O.IT&5&F2X#8OJ?`4>2=CX3WA9]+2%WU2W3!IT M4=8=G[#7C5(67(CTSJ7HW"6=%QP:ZZ<'-]?QW,:%5?WM%LZ_@O(#4$L#!!0` M```(`!>1!T&PO=V]R:W-H965TNB=,8O3!9O-!KUIZN9,"IP-;Y]O+3U<[L MIL#A^^-`BQ[UWK0`EIRD4&:5M-9V2TI-U8)DY@8[4&ZG02V9=4N]HZ;3P.I` MDH+F:7I')>,J*8M0V^BRP(,57,%&$W.0DNF?-0CL5TF6G`L??-=:7Z!E04=> MS24HPU$1#*M7B6ICP`"*NL5F!N.\`1" M>"%G_#UH_EEZXG1^5G\)IW7IM\S`$XHO7MO6A4T34D/##L)^8/\*PQ'F7K!" M8<*75`=C49XI"9'L%$>NPMC'G44ZT*X3\H&0CX3L(02/1B'F,[.L+#3V1,?6 M=LS?8+;,72,J8D)1Q].[H,95CV5VORCHT0L-F#Q@UI>8AQ%#G?YHDE\SF463 M?"J0Y=<%9M<$;J/`;"JP2"]3SF/*B%$!,T__>=!)5SJV@W>F=UP9LD7K&ARZ MT2!:<$+IC1-LW3,>%P(:ZZ?WWBG>;%Q8[,[O=/Q9RE]02P,$%`````@`%Y$' M1\P>"4_[`0``PP4``!D```!X;"]W;W)K&ULC53; M;J,P%/P5Q`?47&Q((X*T):FZ#RM5?=A]=L`$5(-9VPG=OU]?"(7(C?J"[>.9 M.7..L;.1\7?1$"*]CX[V8NL]3NJ=_R/<'I!&&,#OEHQB,?>T]R-C[WKQL]KY@;9`*"FE5L!J MN)""4*J%5.*_D^9G2DUC*/=V003S4V()D(T$T)XEQ!/A/B[!#@1 MX'<):"*@&P*PM9O.[;'$><;9Z'%[V@/6/U6X1>IL2D^8(+<'HGHG5/22AYLP M`Q1!T?\>!I1%@(``.`&```9````>&PO=V]R M:W-H965T,##((_U<::[+B9[%YL,IF+ MW6M:L9I!<8#6V;=?$.OBA)K>B,`YQ_,=!/*1\7?1$"*]SX[VXN`W4@Y[`,2I M(1T63VP@O9JI&>^P5%U^!F+@!%<3J:,`!4$".MSV?I%/8Z^\R-E%TK8GK]P3 MEZ[#_.\SH6P\^-"_#;RUYT;J`5#D8.%5;4=ZT;+>XZ0^^-_@OH1(0R;$[Y:, MPGKWM/DC8^^Z\[,Z^('V0"@Y22V!57,E):%4*ZDO?\RB_[^IB?;[3?UE*E?9 M/V)!2D;_M)5LE-O`]RI2XPN5;VS\0>8:8BUX8E1,3^]T$9)U-XKO=?C3M&T_ MM:.928.9YB:@F8`6`HPV">%,"+\0@'$VU?4=2USDG(T>-XLQ8+WF MF`:YB4M5)M3HM8#I+@=7+31CT(1YMC'(A2A7B'B!`&5@<8%<+D+C`JUY,&0;3&TP`$R>JM%&I^N?=7J(-+Y'M);LC$&^D$3^21K+A M(-E*(S9I)':=<9*X0*4-"N,["[O;<+);90'=`NE&%NDC660;#K('LLCL/R,, M(F<6-@A%"7);T2?'72]ZTHKCGH1SO\YY0/A((-"YV6XNT`.;90;-Y6;NO;(" MQ6$:?G$#K+-HP&?R"_-SVPOOR*0ZUJ8SJ&9,$J45/*F8&W7=+!U*:JE?=SI_ MH"``!N"P``&0```'AL M+W=O#:_E;B^4P2MR;^!MRIHVO&2-T]+MS/V! MIL\H5A"-^%/2$S?>'27^G;$/]?%K,W-]I8%6="V4"R(?GW1.JTIYDI'_]DXO M,171?#][7^ETI?QWPNF<56_E1NRE6M]U-G1+CI5X9:>?M,\!*X=K5G'][ZR/ M7+#Z3'&=FGQUS[+1SU,WDF0]#28$/2$8"*D_2@A[0C@0!F$P(>H)T840C1)P M3\"/1HA[0OQHA*0G)%<$KYM=O38+(DB1M^SDM-V&.A"U;]$TD:N_=K@VMMV2 MR]7ATOI9H"S,O4_EJ,<$&C,W,1A#D*7E9D!X4L"@(H!4]!$"@QY``18F`L>@ MAKM.5O>=/%M.,)Q)"&42=O,96O,9P0XBR$'4.8@L!U>SG773U6$:C?$G$819 MV!C0S]+&9!!F96+0)(`3PB,)82NA&$P(WQ>RP)80,.FEB0DF"$S(Q&23U#=_ M-[9N/))>;*67V"$[S).-26T,[J3'YA3`,I(1&8D5(H-"S!,C1!BE48)!)2,P M2TXZ(B<6W7M-WIEHP[ M:W9LA$K.L`YMWU.@KOTK^QQ-%PBP+]%T!=EEVG(``R-2LAS1G:5WD53D![*C MOTF[*QONO#,A&Q3=36P9$U1F*B\;U]G+YG?XJ.A6J-=$K5'7#G8?@AW.W>W0 M8A?_`5!+`P04````"``7D0='PY#9+X$"```X"0``&0```'AL+W=OLH1D>5U-0!#,,T:%#5^F6AUEYI69`KKZL6OU*/79L& MT7];7)-^XP-_6GBKSAD_E,=^46H#7WOB$_H6O,WTO_`8PV)!#R0FJE?[W!EG#13BN\UZ&,8JU:- M_;"3AV.:/0&."?#9A&A,B.X)JM!!F"KK&^*H+"CI/3J<18?DD8-U)%[L0]P.1A` MU[L?"QZ#VLEERP5;O3Y1F69?^%H`J]NG@N.G"G;Y&"2N__U4L.[D=-G'X-'( MBN/NS\<4ER>!TW"C$XP@")>DN0P'G&Z:>(P@"#[Q!%H_:C`]JS;-O`.YMEQV M#6UUO@IL5>-^6$_%1JHZW1VH+#ITQK\0/5\I\62K_`U!+`P04````"``7D0='!$P=Q9,# M````$```&0```'AL+W=OA,O M+J)]ZXZ<]\%'737=\^S8]Z>G,.RV1UX7W5R<>".?[$5;%[V\;0]A=VIYL1N2 MZBJ$*$K"NBB;V7(QM+VTRX4X]U79\)203M=DH< M):S;_2H7[68ZV?&9E@NFW&SNV/3$NNNO(+3M*<4@-2`#B:*!F=/4@?+Y`T$& M09D#95I$/BF$Y%JQ/F\AR%QH9E^QV#7F6>(@64TCT23D&G3B&DR34!"+ M;$&;29"CVV#U%2T&H@?$X""'F$F02XS5>/0<`#(>!G8Q.,CU+>)S)T#NQ)B= M@X,_:,`T M.9J!0XS/U@#9&LOL8N)'Q"#KFW[BIGIUQ@\.H,\?`?DCLVZ6%0IR:DZ073M> M1^#S1D#>&%LWY0H%.1<7\D_7FP/NW7.0\6F)]RF^;R?(?=*N^I'#W1E[:)R% M:MX>AD-E%VS%N>G5YXS1>CNXKD"=I:;MD#VM95?NGT@)\LEPU@T_$!6]/,4-1ZZ]$#V7RJ.YG.FC/([?;BJ^[]5EJI;`>$`=;WIQNIZW M;X?^Y7]02P,$%`````@`%Y$'1^$NF_`B`P``!@T``!D```!X;"]W;W)K&ULC5==CZ,@%/TKQO>M@(K:6).9-IO=ATTF\[#[[+2T M-:/2%3J=_?<+^#'0(O&E*IQ[S[D7/,7\1KMW=B:$>Y]-W;*-?^;\L@X"MC^3 MIF0K>B&MF#G2KBFY>.Q.`;MTI#RHH*8.$``X:,JJ]8M(051B-\5 MN3'MWI/BWRA]EP\_#QL?2`VD)GLN4Y3B\D&VI*YE)L'\=TCZQ2D#]?LQ^W=5 MKI#_5C*RI?6?ZL#/0BWPO0,YEM>:O]+;#S+4$,N$>UHS]>OMKXS39@SQO:;\ M[*]5JZZW?B8%0Y@]``T!:&E`.`2$4P!,G0'1$!!-`2A2K>E+48W8E;PL\H[> MO*Y?O4LI-PE<1Z+5>X^IP:[OKV@%$Z,?!8I1'GS(1`,&*&$ M"82"20:RR1@HD)[`2F$@8CM#:&,(^T)#(WY&8F1+$/4)(B-!9(KL,<\Z!F:I MB8G[4GM,JS!I$@(`[%IBAY98UP)BJY9X@998TX(S-*L%.[1@HR]V+7B!%JQI M^0:S>%9,XA"3&!LQL8I)%HA)##%1,BLF=8A)CS3D:=%D: M-#P-WQEO,C#IAH6@;3EW!L:UG"Y3@X:KX=#VOFSO0%8;WMV!9OXMH,O5(%XB M!B\1@Q>)<;D:-&P-VYW$!$%L7\S$6,QD=MNX?`T:QH;M+FN"YN08UA;'R+H% M=P;,I?K1V93>;`I_/)2XK`P!ESL/A1H@!&9V/G(9&8*N7HT\!@BG=SR!=NYK M2'=2!VCF[>FUY3*'-CH=TI^1/#<^C&?KK6C9XXPH=;U%P#H#Q4Q_0/\B+_)+ M>2*_RNY4MT M*AF@3EO'V7^__4!L30%?H"WGGGL.M)>;7S'YH">$F//=-AU=NR?&SBO/H[L3 M:B%=X#/J^),#)BUD?$J.'CT3!/FE;2/YM4(.O:Q>XMX6W^GAB8L$K@P]I]`:L*Q`(B$7]J M=*7:V!'BWS'^$)-?^[7K"PVH03LF*""_?:$M:AK!Q#-_]J3WG")0']_8?TB[ M7/X[I&B+F[_UGIVX6M]U]N@`+PU[P]>?J/<@%>YP0^75V5THP^TMQ'5:^*WN M=2?O5_4D\_LP>T#0!P1#`$@G`\(^(!P"@G@R(.H#HGM`-!D0]P'Q0P9/>9=O MKH0,%CG!5X>HSWV&8E>!56K7T60+'/O2Q#UF$!B-CHF MCFV04H>``>%Q`8.*P*:BSQ#H*FP)MCHB3JP:9DFJ$1)#9FB3&:J7%>HNEY&= M(+(11(H@TB6FOBE2838F!M@P6Q,3V##E$SS5&(]A*)XP%!L$H=60B8FLADQ, M;#7T!$\UQF,82B8,)09!8C5D8E*KH28+YJE&:H"P< MR6,MU[<\X?QA+A]`(R<,3%5U$,V?L=($96/?9ZK8@GA^ZY<]2.W&9*']TE4B M3^L/6D2.LC.CS@Y?.B8VD[8Z='\O@>@O'M8W8+4%EO52=(NR'[G3%_D9'M%O M2(YU1YUWS'A7(UN0`\8,<=G^@LL^\7YVF#3HP,0PY6.B.CPU8?A\:UB'KKGX M#U!+`P04````"``7D0='MR!O!D8"```6!P``&0```'AL+W=O>46(\#[:IN,;OQ*B7P/`RXJTF#_1GG3R MS8FR%@NY96?`>T;P48O:!L`@2$"+Z\[/,VU[97E&+Z*I._+*/'YI6\Q^;TE# MAXT?^C?#6WVNA#*`/`.3[EBWI.,U[3Q&3AO_)5SO$T5HX$=-!FX]>RKW`Z7O M:O/MN/$#E0)I2"F4!RR7*RE(TRA',O"OT><]I!+:SS?O7W2U,OL#YJ2@S<_Z M*"J9;.![1W+"ET:\T>$K&4M`RF%)&ZY_O?+"!6UO$M]K\8=9ZTZO@WF3!J/, M+8"C`$Z"*8Y;$(V"Z"Z('PKB41#_;P0T"M`B`C"UZ\[ML,!YQNC@,3/M'JN/ M*EPC.9O2X]K(S$!D[[BT7G.8H@Q#V.4@-@[B6;<79:Q,+PS3 M:29:A2ZFL!F4Q"YF9S-I%+F8OA!16A6T6H>!9F*D!TE7D[/0,4, M^JLW!MK94!1`Y(+V5/"@JF165.L>4V/FF<.6=9C\_D.V;GNN/>@0IY5NF#Y42I(#+KX$G.HI*7U+1IR$FHQY6:E3FWS4;0 M_G8+35=A_@=02P,$%`````@`%Y$'1RO-R#KW`@``,`P``!D```!X;"]W;W)K M&ULC5?;N/:F.0U#;>('OQUY;U9V;;X>UIS[?TAMO MZHX\]0Z[M6W5_WLD#;WO7.2."\_U^<+E@I=OO2GN6+>D8S7MG)Z<=NX#VNQ1 M)B$#XG=-[LPX=Z3X%TI?Y<7/X\[UI0;2D`.7%)4XO)&"-(UD$IG_:M*/G#+0 M/!_9OP_E"ODO%2,%;?[41WX1:GW7.9)3=6OX,[W_(+H&+`D/M&'#KW.X,4[; M,<1UVNI='>MN.-[5G=3787!`H`."*6#*`P>$.B#\"(@6`R(=$*W-@'4`_I3! M4[4/SI45K_)M3^].KQ[WM9*["FVP>#8'APV+O7H@PCLF5M_R(,VVWILDTIA@ MP#R:&(PA2&E"T(3PA(!)10"IT!D"4P64H#`1.`8U?$FRGR&Q9(:0S%"9%9H9 M,A\FB"""2!%$%@&R12;*"X7IE)5ID$"@P@9A'P*5)BA,<0J!]B8H"C(,%X47 MBL)640%,$"_8&J^Q-5E0D"S9BI6MB5EG%$.8PL3@)(,PI8E!?IA`H+T%"L*9 MK98NE)1:)84P0;9@:K;&5-E)9R7(FU_:JD&ZU!#TK+!`"4A46IC@\RNN?;6S MQ1!T>SX)V570(``-X'```9````>&PO M=V]R:W-H965T<7,C->L;?146(]#X:VHJ57TG9 M+8-`E!5IL'AB'6G5/P?&&RS5EA\#T7&"]P.IH0$(PS1H<-WZ>3;$7GF>L9.D M=4M>N2=.38/YWS6AK%_YD7\)O-7'2NI`D&?!Q-O7#6E%S5J/D\/*?XF66Z01 M`^!737IAK3VM?O?GG.1QI;@(8"6`B3'7]QTN\/ZI8J64/6F],00Y*8AZNR$BIYSL$!9<-:)1@P8,&L;`Z$+ MLK$AT80(E(!)!7"I&"L`6X6K0&$C8.K4\&62[9TD,YFQ2V9L#BNV78([/A-7 M@L0D2*P$Z$8C,D=A(*W1^!PM7*#"!J6Q&[2Q03%:Q"[0=@:*4.CV!!]X@K8G M9Y$UM.6Z'=F0&"Q2IR,;%`'H-#3#H/".H?2!H73V23S/JQC,>HY9N#"%C8DM M(19F,\=$+LQVC@%N0^B!(31+X&X1LHXM=';(1B2W=L8&?9EEBV8OY:?V!-;M MU1!^'.:&\$IV:J7^#*WH-)I>@+[];N+K:%E$COA&C3(S>:[I\ZS#1_(3\V/= M"F_'I+ISAPORP)@D2G7XI-ZJ2@W;:4/)0>HE4FMNYH_92-9=INDTTO-_4$L# M!!0````(`!>1!T>STZH,T`(``'T*```9````>&PO=V]R:W-H965T30GA5;MID` MB\O2#_VKX;4Z')4Q!$4>3'Z[JN&MK$3K=7R_])_#Q29$!M(C?E7\(JUWSR3_ M)L2[6?S8+7UD\K@V3COQG)+W%-([V^Y7]6R]7I__&)"]% M_;O:J:/.%OG>CN_9N5:OXO*=CQJ((=R*6O;_O>U9*M%<77RO89_#LVK[YV7X MDJ+1#7;`HP.>'*8XL$,T.D0WA_BA0SPZQ/\;@8P.9!8A&+3WE5LSQ8J\$Q>O M&]I]8F97A0NB>[/U9&_LAH;HVDEM_2@B%.?!AR$:,;C'K&P,(1!D;4/""1'H M!*8L,)3%&`%;[A@*4-H(DH`Y?$FRN4/BI!E!:49#L2);)8YA@A@BB`>"V*GV MK)1TJ,6`:8D,&4<2. M0K.$0JC20:4932'4>L8%1]S,N,([W4H>"$L<8;.4TT%88H5!3Q&&0*4+"A,( MM'9!(-'&Q:`4UD0?:**.)K#`*VI%P0CLE`U)YMMO[)-#@\$FV1"*,"PG?2`G M=>1DH)S4"A*#BLO4V5(Q*"=U<@7EI$[A""PG>R`GL^6$8)!5YFQL%!%0D8/* M*`51Z\P]2AE8G8W+E>([/_#F6KZKS'RTI(7@81I!7YRF&2HDX'&:H>#S-`,A MBIR_N=#`NEL;WAWZJ49Z6W%NE;DD+.LT.3UCF]"Z8F@O[[W0BBN5:`GW:>CG@6G141//^IOY#M2OL M'Q##6U+]+8^\$&Y#WSOB$[I4_)UT/W'?`Y2".:F8^N_E%\9)?:/X7HV^]+5L MU+733Q9A3W,3XIX0#X2ACIN0](3D3@"3!-`3P+,58$^`#Q4"W;M*;H@KQ`;=Z6%K(N#,Z>%;D?V(B&4S<=E,=%B)%5;B%@`N`:`%@"4` M;)-0MZ$QC6XCE'_N.G"B#C2C"!>N.AMHU(F6(#8+&;BMC8,CL-T##(S@]B8N MGH]V-YOH;F:E"-T"\XEUG#^SCHL)!XLG\EV8@0`8CN5KX9(QV,Z"P7`^EN_B MN7R7$]TMK7A&?B=R$QX-6#[\/N'(N3'U)J+HB8Q[D.X6+$??80LW&WV';3DP MFK&%>PPX,#;@&M.S.OJ8EY-+PV5`QNQPO+[&<@-_F-]$JVWDF-_)XUAM^'?Y M+&W1&?]&]%PVS#L0+HX-M<>?".%8>`Y?A/="?#`,@PJ?N+R=RZ;T$:H'G+2W M+X+ALR3[#U!+`P04````"``7D0='GZ)[5,8"```Y"P``&0```'AL+W=O_4"JLK[*H^-J^"'%=.0X_ M7&A)^`N[TDJ^.;&Z)$)NZ[/#KS4EQ\:I+!SLNJ%3DKRRD[BQO=5)S&ZBR"OZ M5EO\5I:D_K>A!;NO;61WAO?\?!'*X"2QT_L=\Y)6/&>55=/3VGY%JPQ%"M(@ M?N?TS@?/EA*_9^Q#;7X>U[:K--""'H2B('+YI%M:%(I)GORW)?T^4SD.GSOV MK`E7RM\33K>L^),?Q46J=6WK2$_D5HAW=O]!VQ@"17A@!6]^K<.-"U9V+K95 MDB^]YE6SWO6;I=NZP0ZX=<"]`XXF';S6P>L=D#_IX+<._MP3@M8AF'M"V#J$ M#R&.L]1>4R>;2^IEX:!$[GXJH MQ>`&LQEB@@""I$,(@A#9$(&QUV,<*;)7BB&EK0IL*%U"AVR'F"`$E0;%'B$ M`JSK+B7!K)2`E=VI")^G)#-!WM@%F&H`R*@XSQ^A`$NNBW8Y*UJPZ#H5T9QH M#9`7/)SC#/[F2UJ?FXF,6P=VJX32.K#V4]\K5F/"@WV#5EL$V%.TVNF9[IL^ MB:_D3'^1^IQ7W-HS(8>39I(X,2:H5.V^R+MPD7-LORGH2:C'A:IA/=GIC6#7 M;E#MI^7D/U!+`P04````"``7D0='6=0JV-(!```*!0``&0```'AL+W=OR2@.7E?@F.9&H0%_.Q@E(LY,M[/ MG+^9X'M]\GQC`2A4RB@0/=R@!$J-D-[X?=+\NZ4A+N=W]6=;K79_)A)*3G]U MM6JU6=]#-33D2M4K'[_!5$)B!"M.I?VBZBH59W>*AQCY<&/7VW%T*YD_T;8) MX40(9T(0[Q*BB1!](F#GS-;UE2A2Y(*/2+BS&(@Y\N`8Z*PWN/@7#A,[S!I MEF9;J'*)BOT@>]PV$^V8B59FLFV!>$<@WJLF<=7$JVKB.-U"E2O4XR$)M\TD M.V:2E9E_M"/=$4C_XVS29=?#3-O<776!XL/]Y9F?O^(/4$L#!!0````(`!>1 M!T=ISY2LAP,``"`1```9````>&PO=V]R:W-H965T1IP&>8D" MIP_=1[J!K!ZL?*^NE'+G,\^*:NU>.;\M/:\Z7FF>5$_L1@LQ M=2MI9(6[F95][V4FQ6[\RPMZ$OI5/<\3\I_6YJQQ]I%;M?Q MFEZN7'9XFY77VYW2G!95R@JGI.>U^XR6!T(DI$;\3NFC&KP[TODWQMYEX^=I M[?K2!YK1(Y<4B7A\T)AFF602,_]M2;_FE(;#]X[]4(\Z)WI.[AE_98\?M(TAE(1'EE7UKW.\5YSEG8GKY,EG\TR+^OEH1N9^:P8; MX-8`]P8S8C0@K0'I#7K'8(.@-0B^#`*C0=@:A+8S1*U!-)K!:\2JI=XE/-FL M2O9PRF9]W!*Y#-$R$A_SZ%1U9]E\02%V)7H_-B3P5]Z')&HQN,;$0TP80I#] M$()ZA"<)#),$BD$`4PP,X0YLPES;O!@/AWF=HA! MBSDHA<(3A+`C"X,C"X5`LV1D`=-J(0>GQ4!@CK9.(&0AAP+"*`+U4)F"F<89 M,%4[9[!",==0@&G424*L)`$3J?,BL)%$3;<%+$E@LT:0*2F1DG&AKZ$`4ZZ3 M)+*2!$RZSHO9M"2Q"@H1!-J-0"#38032E!EDRG*DI&>H*30(S,].MX6-;AA, MT-8+[%LL)06DJ3:QRC3>*5MQ;4`'+4@-RU0TL)+JNMT.@ZG>BHNQE;BF'1,3 M&W')=.F*52:=N$23S(JXQ*8(8E/YP4K1"'448-'HQ`VMQ#7MTSBR$3>:+H*Q M"@K!Y;T;,&UJ2GR1OG=Q%1)")JN?5L%1"+-'DA,)PN"I\O`5@&1 M2',&)\93/)G.B*T*BL8KR!O4J67.BOI+RD M1>6\,2[NH/6%\'=!B"\T!J:L=WW=AI0-7:63J,O>$L13=:5RU\PQ:Y-0W`_W:P M1OW6]NS[P'MU+2D?<++4&7GGJH$MJ5!K87C9VJ_>YNB%'#(@?E>P)\J]Q9L_ M(?3!'WZ>M[;+>X`U+"B7`.SR"7-8UUR)5?XK11\U.5&]OZL?![NL_1,@,$?U MG^I,2]:M:UMG>`&WFKZC_@>4'B(N6*":#+]6<2,4-7>*;37@2URK=KCVXDVT MEC0SP9<$?R3X\X1`$H('P9LEA)(0+B5$DA`M)<22$#\1'!'6$/4>4)"E&/46 M%O.C`WP:>IN8?B;0T2RC>8EFO$1:&&NS M0#R39KPDS62F@^3;-'>)XC%8NQ,V5S-%5FJ7R83`>L;F>HE-OJ).ML!??F=4 M8H33V#5.BUP#&2?%7H.8)Y=>*C#V*%6Q]?KA+*.#@J>ZCC*/M)`?!VV?&(5 MZ-92GHDR.AXK7GV^#SV-Y]YF[QG&#_P8,NQ;#_DL[<`5_@+X6K7$.B'*=K]A MJ[H@1"'KVGUA*97LH#0^U/!"^6W"XQ-'!_%`47<_"8W'L>P_4$L#!!0````( M`!>1!T>9@(L?F@(``/L)```9````>&PO=V]R:W-H965TT15PTZ<%C M)XK1KB>UC1?Z?NJUJ.[<(N_[WFF1DS-OZ@Z_4X>=VQ;1?TO13-G[N%JXO M/>`&5UQ*('&[X!5N&JDD1OZK1>]C2J+Y?%/?].4*^UO$\(HT?^H=/PJWONOL M\!Z=&_Y!KC^PKB&1@A5I6']UJC/CI+U17*=%7^I>=_W]JM[,?$V#":$FA`-A M&`(HR*GY.I0-3].2$[# M8)Z*CUDYK.^DZ@N*L)GHO111%N?>10II3-ACEA8F!3$K$Y,D$&1M0H(!X0F3 M@],0NPU)*_U!+`P04```` M"``7D0='[]46NG,"``"?"0``&0```'AL+W=OVK.3.`$M8&H[8?OO:V.3!=6X M7&)L9N:9<=[!+@;*WGA%B/#>VZ;C>[\2HM\%`3]5I,7\B?:DDV\NE+58R"F[ M!KQG!)]'I[8)$`!)T.*Z\\MB7'MA94%OHJD[\L(\?FM;S/X<2$.'O0_]:>&U MOE9"+01E$3S\SG5+.E[3SF/DLO<_P]T!`64R6ORLR2=.H2)+\VP3]8"K'^?,4_>M8KDS_B#EYILVO^BPJF2WP MO3.YX%LC7NGPC9@:8A7P1!L^_GJG&Q>TG5Q\K\7O>JR[<1STFPP8-[L#,@[H MX0!UXAHTIOD%"UP6C`X>TWO;8_47PAV2&W'R^+C(=/4R42Y7[V689D5P5X&, M#1IM#G,;!#YL`AG_`4$V2*@A:`')[0%"6X!(!PCG`3*PS#+566J;;K0!=D3D M0$0+!%PB8HV(9H@H0AD`*Z#8`8H7(&0%Q3/0IS"+\U52XB`E"U)H)24S4IRL ME.M,7*J'EI;CJ8AAND#X,%]I/XV@= MYNIG&&U0/XP6A:V37`T-%QV=KH6P=NHDEV237%Q-"-,M)6%K.UJ6`BXQ&(.&&-DOI4A^A<5S,[>'E_)#\RN M=<>](Q7R&!_/W`NE@LAHX$E64,G;TF/2D(M0CZDJ3=\?]$30?KH./>YDY5]0 M2P,$%`````@`%Y$'1]Y7T#BM`0``$00``!D```!X;"]W;W)K&UL?53;;IPP$/T5BP^(`9.0K%BDABIJ'RI%>6B?O3`L5GPAMG=) M_[Z^L!0DE!?L&9]SYHPO5)/2[V8`L.A3<&F.R6#M>,#8M`,(:N[4"-*M]$H+ M:EVHS]B,&F@72(+C/$T?L*!,)G45&/GP?H$KBN\\#HF0!JF)-+0'Y-OV:$I/"(`?C.8S&J.O/>34N\^^-D=D]1; M``ZM]0K4#5=H@',OY`I_S)K_2WKB>GY3?PG=.O-#A:]> M:,;D`?.\Q91[F&:+>5PPV'E8C.1[1D@TDJ\$,D+V!0!$%R,;!T];E?>PD M8F3`Y/LEBB]*%.L23^FV1!E+%*L2NXAF'Q%-X-7IC?0,OZ@^,VG025EW$<*I M]4I9<#KIG6MJ<.]S"3CTUD]+WVV\LC&P:KP]P.4O4/\#4$L#!!0````(`!>1 M!T>G@/A6+2\```[_```4````>&POMNXT:: MZ.\]3U$('*P-4(KNMH),`+>[._%LW[;MWF`1+!8T1=E,*%)#4G9K,3_R$/MG M@1U@GV4?)4]RODM5L<@J4I3MS&3.T8]VVQ)9EZ^^^ZV^R?-"?%[%2?Z'+^Z* M8OWU5U_EP5VX\O-^N@X3^&:99BN_@#^SVZ_R=1;ZB_PN#(M5_-5H,)A]M?*C MY`NQ2:(_;<*+=),4?_AB/!]^\>TW>?3M-\6W+]-@LPJ30IPG"_$J*:)B*RX3 M'C-*$]$3^9V?A?DW7Q7??O,5OL/OS<3;-"GN.")T6`X MM;^,XOM.JQ_.1ST_KG^V3D\O:`W7L?^;?W; MI1_GUC!ZC@]A%J6XP(5XZ1?6^'W MH1\7=QZ<3-!O&.("5IW!BB\!/SZ+?PJW]>^**L%Z\WQ1YX2<(16O] M*>PLR6%4^"U/XVA!4[SP8S\)0A@`B#`'^OET]5(<'YV((Q$EXOHNW>0PGGW0 M8:")8M($*C_/8';VP M\K.?PP*)6@&_\02S\#Y,-HU3`WH7V28H-AF.%@"^W]J#O:\?!= MFO0Z/$9D>)?&BS#+?_WEOP@1BJV-^DRT.3YM;72QB!"NL"[$UAZ07^"O(UBG MS2=#/]]D6Q['$WX!!Y-;R/(Q+$"8`NB`524`--PPD[L=8-N@:B>+]&"4&$``?/4%4$YD`Z MT,G29=-8;S6)XBC^XAZX692[),@&#FZ%6`+0Y"F3+(UC/`QK]6%PEZ1Q>LM\ M,0!8.I[Z#K@'"EV>>!4E),4+.$H;IAVH_WR5PM+_@[D3;#BJ\U0WC-,68-IL MFC!LF:4K]1X@IYL-R3&1X@9`O[<()9)'!5J!ZE<>2\R]^`EQPG;MK[.:5B>.8*!4`R31J+>.%GT>! M.`9*W>2+\KD32XI$\0:YP^XG?X!MW>&CYX#H_FTHWFU6-_`TX(NM1'E"#=RL MR)=+9#;3NK:&1[KQ.E277L?I0W03L/+HWBFZSO5AYJ)(4==*DP`43T1; MC6$I_44*VR8G=AH`.050J#+Y!HQWH-\Q`'L;;W@)X5PPS@O!( ME\4#`''7RS=I^G,O7?9N-L#+PCQ''I1'"TFR3OG=N_'SNI(CB;A%:W$0P1VP M'98W!I"(`Q$,VC2Q%EW5S<.8U[1I,.K@B,N`,!,W6W$L3_'$>8PVM[H'_MO^ MS(=-!FP95PS`7SN5XIU[46-T8M[OZ@@9=5CEZR@!W3/^H[D"N M90=POUHN83Y<;/@Y(,H1:/V*0%)1FO`,72Q&*5I0/P;AL@CYMQ/:5]DXF68!UFT5NQ6O?OK+_\I*OX6<0P$+W[] MY;]1-?"3K??K+W_!/]5#\L^'$'\!G09^W\`H?X%#`S*`5P'QR"NTS@"0@!=I M$L-,(`<`S0G'[V@@.&.PB9FJ6;VSL!TXB'\":'+T'O663\SK%X>'CHRSWT@`[7_: MI+!<9A$*4A9`8/0L@K<\XAS(BM8P?"Y0'O9NMCW\WV/QO%['6P(@_J4Y20E- M^IS@N?6$6GDO"\F*]&K`Y2%1FX@1Q:QUT2KZXH>0V4,(4[/#@`[$O_>CF,4: MH6=]MOI`+%Z`FV3Z4?I";CK*`5.+-(VEAK_8!+ZTMU`\J%R+E# MQ/#",*7B/`46@AZ:'.0+2I=%&`/@LA(ST*"V`(W'&O%V]G$!6`KD%VT@J&66VG(`W]=$3GB@2&!X/=3GV#"P)LS]6)*GQ#FF^!2%(2,(P`VVP$HR+%GB":TB!)2S1@2J1E2< M#F"52-&\*ECE2S0R(Y8X%VD,VG_D]P5J\:2Z(-'!B1&LD)E=(R8&`3,O-A*5 MKAZ8NOJ-=*12-`-4%ASKCQN`C(HK`/DRD)ROYZ6JSV+;,J,(-W&$XBX+V?[. MH\]BQ6Z*$-T4E0DG]`C-K+;>;6X46TLR,]2,7>?Q$%/6H:1ECPYMD_A`*C!- MGT#9"7KPF2]!^#(,0K+/E+-9/,`7H,;#%`MF>\0K>([JH%+[(&^5WB'3KC1A M@-#.DP39&JA-8#^@L@&6[TH,![U_TMO?HJ^?-VXM!XCB+@KN:%5+L)H6K#7A M:UM27"XA08*>&O8:[H2/8ZT-I^N<^\Z_1P=(F"`C1*%$4^)PV8)P@?;S MJ7_5!T%'?B)@)/!UN,8A_5(E6;,>"PS$0P6"WOCN_/R#)Q4!Y.TK8PU1&9_K MDVJ3(2M'?`7@;<4B15`H/"$F`GB(<'4.P0(Q30N&7X8*7\9ZL%X)+82Y8Q$Z MH<&PU+3R5$"FK-+D/OJ8B+/Y^=YT\ASD(5BM,('I&_X&L#2`P:-NH`9;^E%& MDE'Q8#(,6'4"T98;BUVG><0GX&2V$06.4'#1UZ6W[HF,%,=]`H\$E*L!`;DD M+-`'M`.<0I\O.MT0LQ._V(!>2+BAMK+GXJ1H5;BMA@?1 M"NP%O0\!H09I@EN1;VYRP&Q49=AV04K39\8A484'N/(Z(N"^K\`60WT`U3DE M65?^3VDF]3M$-Z>BJ=0[-*'3>*$4=DPH,%S0:F$D'I;$PC8`#KG$<$&>Y@^P M:0J(9T"M@:;?\^42N0XZ&RY(FPN*"F_T5>Q=6PN,D?PT<7>E3@*IL`--.KU@ MJ#X2#<#41P;@J1%R?&X!"CQH@^Q_1#BQDI!HGZ0;(!5]#LYF%14%D[UIKBC[ M=Z'4?M*<&$RX$53[S:4T`+2X8\/7)WGU+KWGD\6U:M1FQ$/V$-YD&R1H^;64 M:.8Y5Y3SZK'BZI?P`R"KX+)@ES\N4[_H,U.REHK"&+:@%7C0C=F#9%B#-!\\ M+D$&`)%B&6:(,H="WU%W#U+I3]94`6M+'W#M2!A`]HM2(?:(H`J8(&*Q!BSA MT3.OE4F>@9A\P$/XHY_P&1#S]$&_P"5XDLAQ21+6Z.P%,_\_2,^P5D3C^4]9 MF;2^E+HC(U#ZI*,L+]1!UT1Q!4FT)>8:"P1@='L7YH5S6(_5B,[#W81D0>.( M60-&FL2$7TOJ824[RC1)@U"_BLCZ`A9=.E-0D$JYAF^OFL)OI0N8/-!P];6;C1:;*4U4`&J!"I'AX,4_ M:<%Z:L1YP$1DSZ`@`8-=@7GOB1#_,Y\JP#[E&!<@+!B1J>3$!<;\.$P'C-0' MB.;(+-,\-)SE&2+7,@9!%;`.EDNA8RS?V!6`H\`80]7053*QG2U6O4PF=[;@ M^#0.ZG7!$>7U7)@,LX:X+&)XN@J1E,)'HAIN4YL3:NBRN'3N!6[J;*G(G MW11:\+A!VQ5E:JWNADL&V2&EL1JIQ(U)-/-:B4-=$5Q.< M`F@"`444[D/TSN*;I:I2G7-A(8+-9LN)7*=<>B0,1#:GS)O/GPZR#0D?0A*A M&0+;")=&"?%9=?+5+8%2$'9B^WZ>IQ@Z-7T*)LYV410[LW1)E)+S-:G6&+RD MY0JW&6 MY'.5H;A"N9Q*$E%Z0ZE:T0,KXO`YZ*-ITTIMU'8O5GF8VE3L"K]!V=QZ/D1" MS@0=!^_<9:[4U`\4<1EP)1F))W/63-WAR8!+9.B`9QF,6B)0$GJ6R?E03MH@ MI1@@=#*X\"RZV10ZV*H.SH9O;9P^)EL`W>7DJVR;43M0^5OV^)A%6(%B"U(IDTKF(SG!T^A]IPS+]Q%&IC6@E>M'+&6G@9?3_H'&`;2D M?=+@15B4%$V%F!/V$=[/JS%0+,T@=\#Z2G[]9?_O#2H MLK3B7VM7E?'R%:86^2"^7J3X\_C77_[[]?G5"QGQS#'5U?%T+CZMT5E'SY]? M?:+'WZ5]FJTW&(EC^%#]<2*^*-.(D,*.K]-U%(BSX>#D:W%>^C*D5E)]^!Q@ MMP4QVO]"&&/J<#QY$>4CK(4@^9-1@RC+R>DK8#\(03(**$I5H,6=A&B@DWT0 M%<2!*#AA/SJ!%&92\+-/A"2AE`D<[^*4*65G:!4O..,#%Z%]"&8\L'P`'4NU MR74@2R84ESJ5C'21@7?OQQM.R"$R!_TST!:)'A[^-@]'6F0[O;HD*<[7&5A< M!IH"^FG4@T%+M$(WZA=E9CKFG:D,=((MYQ[U8%!.U.I]`IA>R00M<7RUN2D( M\<;306^"N*=22,F3:Z`Y'N/K$";X@+E/"#MQ$:>;!>7W;NB1\RQ#!,1M5#!S MJE)//>=#_<>^MOI9QLP;Q);S#W,!%$9E(SW[Y`20_K87AJ5,K[F#@B%X1O@FA! M93)<2&95B@'R=17L[2$=4WMTC;D^&H])OCD;3$]@$D\Z(NA55&`5MY-9D^A( M*Z1:A1W:9D!Z/G*+N/@I`8L4+27!Z?OT(T90Z;A4N, MV>*;K`VQ^*+UL/=>^_+QPYC5HR@IDZS83XDH::VG+]XGXH\;P)&Y M5V<4_FT6\F`+$/1,8"5)$!>_V0)2A-+M>6G']`B;>)C-&GV%.)!T?(G>G53G0V2L44][:RSZI/?93*X,LH M!]8*REIK+II[!J$SZNB75V5&'4:1SAO2!/#Y>DB0]EW/RE-.`TK,6P'BZB0D M7RV`4(/32]DVX:@T>OP3A%4O7R,T4>5'\R4#`0MD=0,VAW0UP.Z)FBE&[-5? M%X4JZ+D!R-`D7*%`"76[(5BLRJA@^8)X' M8'E#!MFP,8O'/H%^2?`?=;WG8RCC<[M>W#:2%7AL4H42<]X!.>& MAW#F36`V\XF]>C'/C[[496]4A%#%C)Q=LKY61A96$AG8_+2&I&]"XY M;BCJ3QOAT-EPU).TJ9.S:NH!OXM!2U*=RF!E(5-NC1.H!3"?)TY*]LOC@J44 MGY3NQV>+WR(8G*^D*J(9L*SXTT&IR4JBR3>R.N4KV68D13&FT M4I^5"@X=,Q41-J[3Y[3=(D*OJ3K@2(:ET52Y2Q_@40)M?9!JYJT!0M!VT$\H MP_9HIQ%VQ=M::FI12S)HFH)$N1P4%X=RE%-=`$#:FV>DNT@?2356W5;^^X^D MH=CUK*4*Q)FG1I&1TI*P4C.7Q?RRU..#"N>V9/#7RFEY>NX,(#"//%?9-B73 M*X@]Y)3[#Z>OM)A+8-P93K"S^RPT+Y:+H8R%H+C]0E8-@BM?8Z&0]IHI2CK M[V%_/R#3BBCC=L?!\!_8!D4/BKH(,!;657R/IX MF9%2J7!C"\2%/YS8U0(M3(EN`11"@1&^ZK:7H$+)C(0P'*G0-?D*3*NVG4GI M]>V"&NOTCU\IK:NBYR32/F_'.#I^TD4PB!4E'"PF+8S](/I4*B="TZE*1Y)T M3NI6(2NS=K%*'P[DZ$8H'6#:WR5OS*74A0\ESY>BH"H&//1@A>NB+/&6KC)E M@,KR;E^FXV688)3(Y'02H!MJ2;$D;=0'J6(4@-.DBN%8E>*O%"@_H(&DO^^I M[S_JJ2Z,J=[@5,<4:3@1Y[=@PM^B%GR)<G\I1ACC*F%:AET[HXWAK.#@CV[E_-A.C_HP-Z3D!DXH3-+@C#>Y[ M`C>J?GX]BW%D'R`)2Z MT8,O>FRC*^KT)0=!!^U"E20BAT!;C[+D>2,664O7Q&,\)\BQCP;]J5@!5U*Y MT4?#_DA_4*WP^YV1)7.E9^9QHP8>UT!$9Z=(T.,! M4_=T1#S!.YV.-9-#'1V=&_WI7#&%'@<0O*2E=!`GP4:6C]&MT&VRCB/V)56SU!I@TP49 M7.X^!^57V)!,`'1-"0"0\*XR>7//4J]37BL"O"=3F.P>(;I:A%5&]->S@D@^ M$.E/H?E\K)SUD;)Z5#S+)5KHNJ?YU(FKR*V]+QMK?H^[I,B?;F;889,RYEFF MN9?9E6@>/V[72O?P"Z1.#HU4(*@IJUF<-?]L;U'[W&O3,G=> M7=NH/VQ<&TL7H_7(ARP%/%J1YPFLG#N?@D>\/C.@I13_QRRSDO:H[#1I-)5S M+`R/UMJGQ$,]_5JNLJ&"\"'DVDH4URI"-YZ<>9/3J9J'W(ED/QK65$XA6YB4 M.6"X6L?I-N0P/Q)3CGDI_F>2".BWP]Y\*D&P7I-AD@I:@JTR9K^`UP.?BR^Q M"MX;#KSY9.K-!J=J?V3:#;T!V!9CT*[YTWJ9]UTHB_(DD"0^]%[XW-&J9"+: M$=FB+!KBK838O?WNEK:`P6XD):-6D,,%O8_V;_9E^ZS[%.`U53TZF0)Q?BMFX/X/_ MJG_IYRES$_O-;",\'P3]EXZ?'Z/\Y]X2]TAY$6B=448E\*81?#WLP\J_K/VE MM4(%,>,\R1H;H#TZ[9\.ZG]>JHH$G3^OCKNB\YC*-$L7S)"1N*]RJQ%SPB0B M?2GQ59+6*XR*M`Z&'(`+C'-*(Z5D,!0+&>Y*9O.$J%"I&4M/#*=+4KT[:TJ6 M9X92+RJB1H]2REPI!WU*(Q8]"JZ8$DD)Q?>R?,R0UD@!^1W52Z+7_BX*[S&V M0IDA9649K4)NUA#7%*)1[Y/KBXS3@;'5>;N=&5'528R0KO'Q2%F MD_[I3F;03/K#\4XJG_5G[^1U;&OV5 M&N>34D_JD:OGDR)7%6$);'6&?K[Q*7D`O1&YW\[&XZ9H$3P"QO30FZ"SSAN< MS?'G:"J,KKYMT,$YSJ8#_G^$'KN)-YICGL,8/C][,O0Q=5`W)%RJSB:/E_Z_ MW3DTMLW%,SF=(V0F,SZ3,?\_&)^*MAZZ`LYP.)Z+X>Q4C.!XW#UTQ60T%]/A M4,SG\`^F:&ZB*TYAQ-,QC.K-!_AS"MCA[*1+#$']&P['SX0.#5UOKUW]:LOO MC&3!EJBW.=8NM"/=O[%S+E%:L[-I7&!FX M-QXBFDZ],_I_[`U)7QM30EISHV%Z9#1'G)[-Z>1/.<,(N,@K:W=B.NJSYH@_ MIZRCCOLH7]X[0:[27?:RI&4I%2@X"66P;HH4>\K(IA\T".:U&N>*YA8H5"ON MAX*58VG26W!-&F)/G-[<;,TBK/[SK)<-$BYF?,IR*1.<$[EA`3(/.*6>9^D# MZI`>U9IQ>E*Z7.9A@"Z,^`9I_.\8>&Z?:FAR>5& M9HMN5,`I/*'LX:J*=L.0"DQ=E,L.E8YXXD$SUTJ'L%5R(&AF6X++/Y%FT;NZDT45+&7E&Y64.L M0A#@BP:;0B9$2Q\=0ZGL/DYHR;G_+:OH&`E\5A6!*(:BA,AST@Q^-:O=XS10 M9%\YR",R%,:D,)Q*E6\B%8;9[$R\#).4$FAPQ!]V8BP/ZL#0X9DW/SW#=/@Y MZ,'X%^8[P%^@N[YSP!`TUAO>T9$8](:I.DE([GK@^H#,.V>[P6"`[ M+JOKRJY1TF,8;&5@H^"LP)6[\:ML_X9^+\5FD)A[2EYSOKPN1]O1855Z[?.R MN:B)1N3B"ZBN6G-F;*-"X'#R($_<;`HS=%+V5$6_4[BH9)"Q*\Z8G+0`"4]# M*ZHPPU86R*DWD5*MQ0,MONQIB3GV/2T`J@(R5YTB57=9@S`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`EN`C'DZ^M'R!\LB/SHS4Y8K' MP%$K*WV`:DV6(I"4RZFL9GJF4>QH.'C,A.]2?1NM:[N-$L$UJ+-J@F7V*I;R*VHJVY4`1H.6LJ**1Z3@T MU291D]'REGFN[Z=JT4&=*.3E1'Y^.XCIMN[,%[SNZ%D%9&^S=+.6;9W0XREBO/\) MDZX+TNSE\,T]_/#OV^8(+8]/U*B[!L)6>Q3Y<49J,0>G`H"CL9&IB12ETG!T M21M^H=WZ?&S*DT'WG:(5'Q/U'@WZ,ST6[HW84NN"/`/8TBR2N8I+/^!DE/!S MQ#<4YW8S>)VA;6U4QQ8JM M)S45+W0K+25SE)S3K0A>L4ZCON]PF'R"1V`3@4'/)88`S\Y'@,`_'@ZPK&``/_FLE&7NONAKG5NY@7BYSE>'0V4#T` M6LZJI^^7/Q*CL[GS/G!U!4Q"-_]*M[+C3L?6A[LES+0/\88:;7[@:T_)*``H MOB^[HX#I3MU,^+:J@6X+]T!EY.B^0X+#^#CA*!Q?[#_DFT@%BOEN+)^:/Q5B MD\M^2W=^A"FO+(COHG!IES-YXCM.-O`$6P`^K;3/Z%;2(\G<`CTX$Y MS1..E:V/^ZI`62+>]L7W&[H'P]<3J`]X#I=B4MXE=X'M@+4;Z1V& M!<,LJ=XUYX.%E&8)UIF\YTZ(,[.['@]122,@;@T0#OQ<-^7#DG@-?K_Z/(DO M["=07D>F;UUS/04R+[Q5KN^"._P`"Z&NN"M_@1F?<M2H=+6);]719B%5IK2N/`_#G_-2D&&:T,)?^:1W^07\G81; M:OI"?4R5+<$5&H&Z9"YC$P#_Q@%6%.,F6U*/17<2HVSZ*I(7RMU3P`NIAM4D MC%X5W*F*/U7=*!%K%V&XRJ7[NVP>65Y@8>(5J5[8/C+*T1^CTF@#U6I(Q/W5:7NMM)9067U1PEV\(Q"?;$RFJ*R#U::R<07PNE4 MW(.8!M&)9B??Z-*QD=Z#KGE2!JMY1;?RW.@[CUKN0D2>8GH2N",R4$>TLELT M/O(&87%,OVVM>^GY5LSWU5LQ:P^)SZOXZWSM!^$?OB`K+;L/O_CV<)_FX3[- MPWV:A_LT#_=I'N[3;&>DA_LT'WF?IIU-H>_7["2B#_=Q'N[C),OJ$^SL-]G%TXZ.$^3I>8/-S'>;B/\[>_C]/.R`CX3F+Z^XT]TN' M&]T.-[K]7F_5.MSH=KC1[6^%>WO]O4Z-A\S M.O9BR,WH)&;T_?7H":D2E#VE3L2/M!!Q'7XNQ(L8GK=R1ZY=1?*'7EG[],IJ MIUF9U?6)'*0(;>H4[3J&PQTNO*G#'2Z'.USJBV^C,?-NASK!&3C;*7*R@PX/ M=UL<[K8XW&VQW]T6;:3KO,:@.PWO(M?#C1"'&R$.-T+\OW@C1)MEY;AD49RC M!N-5166#U>2T\`X=SP\=SVM_[E1)'3A#.TIRRV_31>T\M#8^M#8^M#8V"[+^ M^JV-FSU[97I^V5_W^`67YIY05EIE'/2'ERUUL37R1V!4>[*%0_/CWV'SXTZ] M33O%38S.9%CU07TG$6]46T]CY.,W:0[:>&,W5B$=Q:#GS_VG+&>5_ M2/=M#_`.LR91S3L1QR_#PH]BFZ?!F?;UF5*2H&7D:KTR9V%O=A]6W4,P#@'3 MI+^\!>:TONRFG$#^^P4SS2[RKR,Y-:\K*LP"F$@H_RH3""R/ASYSL M+>FKUD2.O7LR=?"CRBIL>IFL:^KM\J4YK4Y<-/+5]S3ZJV^XK89/^F`JO>JUY^9<(RM_G$E M8Y07U32+BK,WK?=W&/SN1E==$C*K)%>1>*A2$D2<*%W_L#DOLYD;-"9.-CSI MR$LTBQ.4+M5TD+M2*QM>LW(M]QO>2++<,<'N)W\<-0'1"9JPJF,VC=J2.]ET M=!U>$7]NS,WY>/4)D[0;QO[;9I3N/IR_3J+G3HK>F?A9)6WI":PF3>JS,J7M M5XJ+`ZN3:?;MNL]P5+&%FI7DRN1-RMK.=,HF-#;R)AN>N-A)8)V2*)M>;DI- MW2NW.3H*--"13KS?4^A?;\A&ITI/"*"GC?0E& MM5"Y3IW?::1W7H?9RJI"4_E;HS%H_UN+8ZFOQ\IS-!HYGWM$@NE^!]6TL.$S MKJ>-SUC:@9S_5`%F>.9<2&,6;2,Q6!QECR$US3]]&:V[;QGN*8>Z>V>=SN;W MD6C_O_^CUO>___/D5/O]=:=]\^^KJI3U]O.H4;MRVCOI*@UP;U($5#[Y/NJ0 M(W]\EY[1GH'_N+<:B+,)`'N*LH8I'ZM_-`RGP/\\HSU>%=D;P'OI"22F7^R6 MY"_JDIQ)]S+!$`%%3'WG)X^6\185*5DU'$IAU?3`3`FSV;/(,C>>/LNH MS\G_]V/TP-:;.?WS%DVT3K6K:J)=0%CEYUW*)ZHBHF3_MI5J5!`T.#.U1MGT M_4@K5@,G,CH*#NJ/8*G!P,K:Q#H$^].&>H3Z8X/^P'ZWH3;!\B'TAU/K7:Q8 ML#YL*5S8J8>Z]7@LE[<7CG7PUH>[58M=)1"/"2ZYLKBZ>+/OVM, M57JO:P5>RUJ!1\)B#?H@B"M=`MTR[>[@SKXE*]52@G.CE$#/V>#7U.4$W``6 M,^'+?RJI,NKYGU!N?5>H-=K[KS?YJ>KE8+['VJ=J:Y38XCFT8Q M&]W^=-P?.QYU\KO+I.S09Q3^8[.E'O:O]-<1ITG$*LD84[WS7+?[I2@^W;>` M"U=WDEFJO3,9OB2@]&EI[TUTY#!!R@^NR_3U'79)FM+-ON MN=6-OE!K15KY['$"_PZ-E(Y]1==\:L>X#$:9=[A>I]K-VA(<[#A24S"D*<3Z MU%3NW;!SI'#O`MPN1):YW"\?FS(-LP,I;)9N>@/[8>D7%9ALJ+ M-D*0G!_]5EY-?%FV/L7]O^;6IY>ZYRGW+F@4X)6%9;`P#TD%/P.^9FF54YB/MGT71671?S/FE6-*9. MD(R=UD37^:X?TL;YL)CY"2-3)G#CV,XCVY\$'U'X\!AEVBJ.L/C?N\OK5R_% MU?7Y]:LKBQZ^OWQW_KQ[;:YL:,G3E#G_S?R2QO1J([8RE=',B2.]\^/8S@?Q8T--!\S=`9WAV#4M-0*Q/W5BMS7C#C`-G6-; MHW0&G#U_*\R;4DSBMB,:[A+N5B"B[ M!N]Y_7>^,_C?Y9W!7>RA9NISWT)1!T?#F.=LP@$``#@9```3```````` M``````"``0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0#%`````@`%Y$' M1TAU!>[%````*P(```L``````````````(`!\P$``%]R96QS+RYR96QS4$L! M`A0#%`````@`%Y$'1Q8J%YF?`0``8A@``!H``````````````(`!X0(``'AL M+U]R96QS+W=O1!T=.GNAU5@(``/0' M```8``````````````"``805``!X;"]W;W)K1!T&PO=V]R:W-H965T&UL4$L!`A0#%`````@`%Y$'1TIB%7VB`0``L0,``!@````````` M`````(`!OR<``'AL+W=O1!T=YY$0,HP$``+$#```8``````````````"``9&PO=V]R:W-H965T1!T&UL4$L!`A0#%`````@` M%Y$'1_?D5:RP`0``%@0``!D``````````````(`!IC8``'AL+W=O&PO=V]R:W-H965T1!T=G@O0PI0$``+$#```9``````````````"``:LZ``!X;"]W M;W)K&UL4$L!`A0#%`````@`%Y$'1V9^$`0``.`,``!D````````` M`````(`!/T(``'AL+W=O&PO=V]R:W-H M965T1!T?\>!I1%@(``.`&```9 M``````````````"``2Q&``!X;"]W;W)K&UL4$L! M`A0#%`````@`%Y$'1TN="^WJ`@``;@L``!D``````````````(`!>4@``'AL M+W=O&PO=V]R:W-H965T1!T<$3!W%DP,````0```9``````````````"` M`5).``!X;"]W;W)K&UL4$L!`A0#%`````@`%Y$' M1^$NF_`B`P``!@T``!D``````````````(`!'%(``'AL+W=O&UL4$L!`A0#%`````@`%Y$'1RO-R#KW`@``,`P` M`!D``````````````(`!Z5H``'AL+W=O&UL4$L!`A0#%`````@`%Y$'1P0UETAL`@``H@@``!D````````````` M`(`!LF,``'AL+W=O&PO=V]R:W-H965T1!T>9@(L?F@(``/L)```9``````````````"``=]Q M``!X;"]W;W)K&UL4$L!`A0#%`````@`%Y$'1^_5 M%KIS`@``GPD``!D``````````````(`!L'0``'AL+W=O XML 15 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

Geographic Information And Significant Customers (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended

Jun. 30, 2015

USD ($)

customer

Jun. 30, 2014

Jun. 30, 2015

USD ($)

customer

Jun. 30, 2014

Dec. 31, 2014

USD ($)

customer

Concentration Risk [Line Items]

Accounts receivable $ 10,169 $ 10,169 $ 8,200

Commission Revenue [Member] | Major Medical Individual And Family Insurance Plans [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 65.00% 68.00% 49.00% 64.00%

Accounts Receivable [Member] | Customer Concentration Risk [Member]

Concentration Risk [Line Items]

Number of significant customers | customer 1 1 3

Accounts Receivable [Member] | Customer One [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 58.00% 30.00%

Accounts Receivable [Member] | Customer Two [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 17.00%

Accounts Receivable [Member] | Customer Three [Member]

Concentration Risk [Line Items]

Concentration risk, percentage 14.00%

X

- Definition
Number Of Significant Customers
+ References
No definition available.
+ Details

Name: ehth_NumberOfSignificantCustomers

Namespace Prefix: ehth_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=ehth_CommissionRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=ehth_MajorMedicalIndividualAndFamilyInsurancePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=ehth_ConcentrationRiskCustomerOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=ehth_ConcentrationRiskCustomerTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=ehth_ConcentrationRiskCustomerThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 17 0001333493-15-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001333493-15-000060-xbrl.zip M4$L#!!0````(`&6"!T?^DUFA&L<``,U>#@`1`!P`96AT:"TR,#$U,#8S,"YX M;6Q55`D``[X2Q56^$L55=7@+``$$)0X```0Y`0``[%UM?/ MZS9"$D(=/=X`(68<.^V>;KMW=C]U8)!=7%/@`F[[F&YPB M7;O62.`CSR1(>9ZG(QWY[&;2V\-U&H7OBW^/0/`X>^\GHSA/'W\Y'N3YW?O3 MT^+2NTSY[VZ3^]/)Q5-=0_A$0R<8'5>WC=(4]%QVW^1J<2.9OS%08?,]<*&A MN1KD@VG['S]^O%,#Y47Y((RS4>K%OGKG)\/B/JH96)O>]>`/FD>6>2WD)S#9].6E0W1&'\?47KXO*UEZFJ>>R% M?M8L4WFI$`G-BQ0G<3P:-H\1Y.EI_GBG3J'1";12:>A/[UM_T_P-J;I9JHEQ M"E>KAEGH-ZL`%QH4R/*[=$E[N-)PPR@[N?6\N^D]-UYV70HRN=`PV7`E32*5 M-=Y37FF^J;!#\TWEE::;\E3=+K43/X7K5=/B0K"P-*;V'%^<:YHW-J7CIOEL MTW`50.,L+U;1M'T-HC]PV1IQSD_+J].F6=#4$+I%I__^^/NE/U!#[ZEQN+[Q MR50:\%1_^U`,]CXKKWQ1-T?EX.\')?`*KW!2+?IW(,GQY'(Q$;\<9^'P+@*= M3LM^QB[/3^)1'(4CM.L6]G_7_7#GE4%4;\,EA_EC^4OT4!L6/-Z%*CTI1 MU)P:%3;%^3^/SS10!F-,./YPNGCS>)33VC"34>Y@:27!W,!@B31W(#R<5;#2 M4-7!T[79.U0^)%V=6'+AA#,0206E]'RGY\^OL*:*/U$&;?"F+Y[:,* M0M]+U1<5JQ]>))+A,,R*_#Y[NN.C&EZK=)\VGRX_=5L4#\:_C7\,8/"'NRCT MPWPLUU$00IMQ26)BE_<_8Y?CL\(P[S1%4]/%W_ ME`]4^D7=JWBDLH,$TT8VZ7$TAZ/20KT_JB"TSAR=1P]D''U<.\BX]A(Y[/,C MJO='[?1'W4!/SXK:SHI>L)+VGROG"4H_O#288J/Z]8O*\C3TLY$#S;HIYC"#T" MWEJDO@IS8"0WYW$0WH?!R(OFIO:C%WNWJM"E>[/:J-G3["ZJ=F#QN@$*?T1> M?.$-9_E\<59%_C4"_&6=TJ8KY2N1X.&SG[KW$(J<.L1%,/X^>&\>>U,/Y#I3=).BS.IET.O+23M8EF'"[1;+]`>/63 M*ILQ5SF\BY)'IVM,=A^:O&XR!#4!,X7(OR>^5RC[E&Q<*7\0)U%R^VC%@2AZBW/Y<`=V M[.`VY@IM)RG`6G4/,B[,90%K(2-&60XM4@&4&:PHXS2)HN';QLUF.N\WCKSZ MV>.&%'(5>*HVOZI8I5X$9K2"81B'69YZ12K^-N%3-=I(ZP-+/7<$T*6*HC"^ M!5-^]-+O*H>_WS9VUBE\@+`A6_*!I^MRJ#;E56P"T!<_I`=0F`+6%ZVR1G/=$N45$ MN14I^K;@Z1G/P4-FBZV(/K=J16[5BDV('8AR>09QY.>C%.PG!EYZV\6#;1L! M9KFJ/27N/4R[/4P'B7#O85['PW20P_2T]]4+?6WA+[UW:;=W:0M4=N`O/50. MD[/LX%7ZZF\;JK\M]36-3RHB\B:>5&Q^6G"%<@?F3Q8?&>BQL#_W, MOL;,OM0#@`L*A]H4AZJ3#[XT2A0@9LF0Y$,[T9Y&20_W4@O MC8%(97^HM'Q`UGYL[N`-/C?T0NL`U>J#V0&T?"VIZ9\(>@-K]MT;M M`Z2O_1:R%M6?]^U)>X!V`:`MW8+M`=H#].!#?,]%.\9%VQ+J>R[:1I"^MB=M M2U;_"ERT]Z1=\J1MX*2+>QO3W<)?57*;>G>#T)^\ZW?R2?!OXJ)+8%JJS_'9 M1*'WXN)-[6'T,]BUO8KMU^#7RS\27, MOMN/MHK]P=!+O\^?D?>BZJ35S!OQ_S=)JZ?CLIG]Y#B'N>P>*5MGC)D#]$_6 M6(F(+0:O&[/:P)ZQY@%F&`O%Q&68*]XQKH*!\J)\4'SMKGOH6PJ`9M4.L&RW MD&R^B._J/H[:Z<5>'<1M2$2W\&>6RF.O>^!;'L6>].D]UXMXKM]&0Z^+D&FG MOYJUY@%ZJ7VD"3U@WP9@VY(F]'EMIP#[2GEM6[9V]P'8WL.^`0_;(L!NE+AT MU$FVT$\=3.K2T62WG6[J=3+MMB0N^PBK?8WPC=8(VQ)J][))U_O<-^!SVY)[ M;\(,NYJ-M#`A.!QFV-%LHJ5NZM6.$AP,-^S#:N?#ZB&QP#Z5>:.I3%NXX<(W MJ3<&L>67ARZS+\I7X;UW':D%1#?T-/W"\?A3!8L-JGGZ%+]IF"^SW'-A?H7A MJP\FK+5\J\G'\W^/NR%)ZA="OQ`.-6UL742X^I'T"^%5%L+4\@<8$;:MGTPP M/!R&66'_+^I>Q:.M%T%)63^JH'BZY3P.POLP&)6O1G6]81@]GL?9*/6@C^(= M>1U\B_#Z53$!9*,9][4<2P^ MM;R?=&/:IOITY&+;M[@D6I%N3!NMMOS+KH(]OTNAQW2/Z7UB^B7>+K'+AE=/ M97HJTV^GO7KQ=)"J?A_AE MQ6LO4T'QLD:8(Z^;+Z-V\6]7.]?PP M`I5%E&30\@UBJ6K8J&FK.5,K_%(/E`/V*#U0V@R4MI0DMB36/5`.E1)OZ5%Z M2MQ-2MP6O[0C)>ZK0X=(BW=D.SU8>L_2![*W&\A:X9MV)-B];SHPDCW&"OKH MI?Z@3\?:G([A+9&"VX"4,HPUN&Q;Q>HFS#.O:!Z!:$'IQ-\@@LK8M:T%>F3U M7PIZ^_->.V?=QYT6Q)T]GT/NF6E+F.D>O@2WR[SW:[W;<[Z+?^_7>N=\_"@. MQY,>CVI3-51>-DK5V:0W^+/JI[HRTW7145._=[`H"M[LV* M[TAG*R9WW&"7G@MZO-PJY>7=S%!]_GJN\_)1@7FN6]QS,8(I]O)D[CSVIL;[ MVYPT"UW-#.*H."FSP&7#K#'E_#B+O577GC2LV2A0X7L+'$=0.`\W\FZ/)NOY MB[J9*Q\>C]TX@/'$X;8A75.SD42$"DYMPG1#:H[K.$AW\/'9C1=E,$6USJ=# MBE&:%K^%&60^_U%>*L.SDRI\K1II M*HJ3^*/AM,4?I7]SX;=L`UDHE;9N,>IBEYC8!5$I23&62N"9,@W`M4Y=&90*I6PY, M!-)./L\/7'0]'4^6H5*HXB&)XO$A]?!/];@)`J3)N6XZC""#"\V`^:_TMDV' M://T8NE(BW(DPV$2E]L8I;_*/HWR(A8'0"#FA)JPJDL0*5!^.(1U!S]>N+/H M<)F0@AH.,6T#5HW$CE/-C"4-N+-P!F5OE4M'IF9JNL;F!%XATH+T;ABI5,!L MWB;I)C;DA'+#`*@"BHN%(Z2+)Q(R6]CV\9GE^RHJ7*@*CLK>9R6;&VY!E"_J M-@3R!2SFPAMN`B0I36E@*6U7IS"CW#:95LE"=8Z.S]1OY4L9_WYT'OOO9N68 M'VLJR%7J%3:Z?!Q>)]%&/@79X%9,FQG4Y=B47)@5E`W+D,=G\K>KW\8#S_5= MCCA^[:GOIR,5?/32[RJ'Z_*AV`13"[YDDH7-(N<$SP)'P(A,"-M@KF&;KC!$ M90HB781G@%,R#+`4`[!_.%TIPRY2@HV62FE09B#J&+H),EJ:*9`F*^?'F<$7 MI40,H1VDG.?PL`!NMS6GKFFFKH-1=63H4B+#XK0RI^%HVJ*@"R(V";"CE*O- MR8F0R+0,2U+'$=@6E3F))KF[**5N\IHUUX@Z3-(\_+^R\/WIQDZ2[_#O"+)< ME64B@=0I4./GU.IKA4S6RA+9(?8("?X>!,:FPS58O97LR+;=FH7!S=$9X3>5 MZUE4H:M5$4(3S'0`UY)C3BV=.U:%:NIJ9DT5SM&SJ9+Q%T:,#J6B4 MW*G@,KG)?X#?WWI6-(QTT[)MQJ7#`%G$AFG2=0$(,[%EH!JB--ZLR4JQGD63 M-9.BZP85V*"F;4/@U"P)_Q6:0,`P7>;67`T&@/V,)L++!E\S%>3)A8N5#.940NIW"0SPJ\1YR<%7V5TPR26IE-( MMY"K2PM8";/'@@/ZP?747:O!V7XDIZM-3J0.4\'L*LMF#/*L>@B@B.\B.?#85'F9Y':)*YEC`9DQSX]!17'#%>YQ3FLRD0QAMS[0UF`H*7 M8PC'MAP3<=&D0E$6)ZP\3\/K45Z\;.,J^717L*[FV5D5 M.QBQ.'E5CT`W!FRJ2;#$$[2+I2RF[TL-CKF%!N3`0-BU(NRS'KN;2 MP4@THI.V5=DU2Y%A9B/'XJ">A'3&M`BM:LW"!?[:H"Q9#,UMTG5E7:.@?(9M M%24]2)U-+GFEJVL8#FWTI,^JZT6YO?[IYC*\C<.;T/?B?/HIH<;:9$M?^+AT MZP+R'`YK!A(@6/V2$]VTW&D*Q)U9GOJT:X\G!EYEG5UMV-X7P2ZUH6OKR*38 MIJYC46DAH#1/:23'N-&&:"L;?LH'*IV\]6_K8,!UEQ8U9D<(T]:01HA;U:,H MT,A:281HQHS'F!UZ"X%6K6M+(/!)X+(%A"(I!(,4J=K1`R'%HD"<8/1S`JUQ MJC:FD@K3L`TF;`W#+6Y5-!*V@VJT6H=%\],"K2P&.0@A!JF]9!HVJ)"45!82 M#F4U"U%NL'4"-;%\^>!'HW)_J_%YKNVS1HO9L`XL&PE,+8XM758;6H*Y-JE! MCIF;S>X]=-9,S8=+ MES(=R6VL88"]>MU*8VMN24-B/3TW^ M\!Z+G\K"=KGPK@9>/*'^_P(I5'`>CP]@_%IL7!=',%PO3/_E11NZ#B.)9%%R,32NF:4E72#ES"0UJJ:C-I@RNRQ/``8J5<%5 M<@FC9C>/5][#GV$^&"11X7*_J+]&X3@;6W]<8IY>`Y]V7&X($TBL:TF3N]*> MDC-7;SI=A8E)&)VURI8B/BEXI?Q!G$3)[2,$-5$(_A-[DZ[%!+%TH)O41@QR M+2ZJC3)L.+79Y>6^<#6[*R397=Q59(XAQQ$ZU6T""YF9MH`LL2HB64MXU+-XU*/`DW79-3+'&+<.QS6H'U77F:GKCK5\ZRZI>1-R59VE;_&RDMC%5AQ'@9A-,K#>S53\5`^\*,\ MK*B1"MPT&1:^8Y1/3K9(N!W61E8=Z[:&1:*]P1D[9EF"81=#EJ=+'5!$-*Q1 M2T!"8#&*S$F%N-+FA00M+;'XDG#P?$6)8')L>;LC9I@96E&*LC@U;,>U"..3 M4T/"E9!%-B1F8XRM%F(G.5<=,G.(K5G(QKH&"9E+#(-,:Q)`<'1:7[N&L:N< M3U67"Y7O9%7;,B7X>$%-$UB\@X2E5U2?4E$_<&)6V-E$E)^3N59CNDARE?V> M>'%6?/@@C"'=*X-'U9_]^/3W_.OYZV//)NK9FG1(-RP;DD,;S(-L6%-$)U45 M1T>6K,\H,?3NV6C\=8D4UGZL?HSKMN-/7M1J>RO*788F;0M;1#H<_(Y#104F M`'\=^M7IJT[9J43.+M:A.B[R'ILX$M)IK',-5<<>BV<::D&=8A/OPSRKG)G. M=(?J!BFV21ULN(Q9T\TZRK!5BY0:FNQ[O[S0K?$/V&:,B^)_^Y>7O]_LOGS2]?;F_EI]]]E$SMP%&`*%$U`24+#!)D)ZR# M-AB&TG=WV^X4AQ!WVH,MV4(;G$,H1C)'6[PCB!F&)*?XF;9UUVGY\0?[\&$[ M\GMQ]>O%Y8>WU^GB]\NO%U>'W8S<";"5*R#1NP3553MDE9A-Z=1/L]R,W3W# M/!W'T;K$[,*U1%5<)"MJT,8$8(BBE5C7+MK7!L'S$;3^X]OMU^W`W)='OO_N M9N1"RL>/F_=?6_HS7^V1BSNXJNS!QXP>HB8'6-JHS'`EXCO"S`/A)/H^+?UG MY\U21*G8=\, M__RW'UO5=!B2#NPK9V!RQ6,8QP-M==U;-3B>:,A>=)WP*&.8=2HO_2BP54E4$`;DUYQ==4RI#P1>4ZJM%%EX+8Q:JCRL\,6!,A)R- MW;9[."^I^CAW1]@[&^U?`5.&[_F+Y"4WVYV8X['FUR2P^@\ MI$PA2JKNRE"Z$(],77)N7X7`S+<)W+W)KR6UXF(5(5(M;6JH%D[BCB4A21BA MX*(E_:%Y\;^;JROA@LC)=#1EK7X376!ET;3(/Z1C[6CASO.-`D/`[&Q+3:(HS556B05Y,++I[/?4O:1SW9*#0SGSA)PCJRW, MCXJQ-50!I;$#7I2!NYHCPXM9QP.8L[@;'X MFGASC.PY+EB1)9XX-SX2+,&?HP%/( MT*D/T4LZCL7Y:3!(XCLL.Y`TRFN?QU$=8V/W>H+N.U3%BQWE;([#1_84,7M5 M0O;D)8`:0>PDTN[?.OB%+_D`Z-2O*+!E>%%=BKY%3:YAS:6<6Z M\QP`^(H8W1?)>2KEBT`T%()$O%5X MCD)KLFI$KF71WTY+K7+GHGQMTMWX(MF[450I1&-UHL$AE1IG')([)^6+\ZW: MA]H0)5Q6(+)NXSBQD"/7CN<&\6C*'_1+G["=NU>'R4Q&)A/$(6)VS!(4)NW& M9K,0\BSB[;1Z>PK*S\>+^]:LIWU*_&/^%\S/D[9!Q;N9G+4A=%#9.,N)-`6) MT[V#<:04/-8Y7(BM]_GS1O:ZD0E,Q-IM&&L"8;&E)._%Z%*TP\.O"U#FD"O, MZU6/WY9,A<\2!FD$*IDM5(QZ0`].E<#.0=%,BW6OBQ4_NJ50XE`#@'C+!C(0 M'!8:;##HW@/2Y?L')XB\+2M_\\K.96U MH-:7S6BP1&CO>RE#/:;.A^7X0IW5,`R-].X^;'*#EJ:%JS M8";73W="T\,7R##VSLUG+9"WQ*?DLT8)&<5-BHI,BMB,: M)P3;%<%;U<+O25;;+7#H9+E*4?QFK"E6*BJQ'>3'B./HQZ78^MUB7/O,/8A8 M8HF'VJ(G:Y2SKG`5%S6$4LR^=I5,L.#\.A'M,4N^M,4*_[RX:K`EX6NZN+GY M0_1P!GZF48D+K/(4B[=D3;7H7*@QA>'=6POW^J8:,=^3T>F]J#K%.6@)^H!= MEF!)B2G@5D..8,;GAJC[!G.KT.F7.L:"Y%K/W"(:!UR-&&T<&WTY*.CL#0/! M"]W&HCE0$@>85$7D77)B'/+8>B.B5GHD0W#P/+=Q!V8T!4$_?+L+BV]%,BC7 MT)`^`[JQ&2+--%B]06-L;U+VI>^$!UMYM<`(.C>,7:M]C1P MGNY4I](:J[(%@Q:C*N*#5!N]&5M5J'_NDJ1*]^)V@)R=2D_05H["]88("?+_ M&FFH&%>PKNNQ$0G4O53M2_C]IL$C>.Q\5AZ0*DN\+_X+E!Z782IP/2[4Q)=- M/OQ`RI:82'+KBG(S^%"2%U^;!R8RL>F`Z`ZD;#HH/3_!O<=SW&N@&M@1)+E^43$RK9=R(!K1=/$FD+// M3_0:LB^)_N?*%"1@5R(3PO7A]2&'7B+8\ADXO;8%S0(GN8^:.`=7)*56@WB( M.-O>$G<.9F^B)U#78JW;7US\?0.KSVZKZ-QW76DC!,5W'),#D+GO$#\N_O'E MY@[VH^UR;7N6OVU[ENK%Y\NK/]Y>WW[;0N[^>G5Q/=.@HQ^^RU?E%7N0$+\O5Q?IV1L6-'CECZVPD_M^P:$<0?@,MLOEY? M++,G8F17G2TN%XO%U9('WVF=#?/L`?5SL.?ZZZ?-YV7^>(]1[(@DM:&(X&AO MXL`?SKO+=Q[P!WX*_OSWM\\7:_)#W-`72UO$'!C0`*8A,K;)!9CEC_XY^-/V M1FP^?-KN+6[X1,N&6CM39+&!<8+6OCG9\\> M%C[%UC?5H)1"5IF*AG'5O,^P`SE_;@O_[/S9Q\*#DU#:;Z,E7Q/:4F#H5C`I M[&R+>6#A?P[U.LS"*QUB@8PFIK9;W@47<>M&'GNYN8?,/` MXW?7*[QTQ84:B%6*P3>,H?NE(KZJG96^][S$_TA>_M^GF\T*-RV[5%MT9H.$ ML]X6]&-!MH:=4?$'DGD.'?[QN/FO+RL94Y1,W5,(:*LDDUD;&O!:)$?8&?AX MP$O[[+SDUYZI>PY612=)>N28H!K?%L!5DX6ODL3/"ZGA'XZQSQ3'B2D$@%HH MLUC#$`W5(4[)6M+W^?SA^0L99V'/'G&(XSI)\AN23URJ0K:74L=*#NQ#9#_B#/P5_#HOC+&AL"'X&,GBH'LK8 MR,]0=K8$G5N27G>F'K.IL4$C2@!22M;!)LB13207)$+QLXREYR^!',K8'R)` MUK74-F2B%5F7"7,8PA"C>6>J_9Z7?!9W\)"73W!XWGMC?'+M\8;(M_Z4H8TG M4+3S)SQ#P6S?$^[ALR2?EN1&!?%:D'2-$,9M.\X#S<>2/\X1]W$[$KO5H$K; M!*,QD9%S#7(:8BKSB9PV/\H1#_,<("?508[9IN%M\'R/0)Y(AW3*"L#MUW%16HQWS0>\L=6U?;M)5OO/I!]*U]`A:5;$8G`FV>C%M)FHW M=!D@*]=!/Z)2?!K"UL"GC&U!MOSAP4+QAG&\V.*Y[[NTZF1T+38F^5@5*5": M-3(D*T(W].]1,GWKBW+3I^XEPMH&@N^3]H?/SXLR5-_VE;[@?JOM,EE@@M!-3.@%>5O1Z;K=F:5UAI#C"5[<6")&*V5M M-0>?3.4:QC=91=GWCOQH@G^_$0JVX=+!%D';Q%$,?Z60L^2BX@T&(EMIMR-2 MJ\E>OX>??@!9*ZKN1=7;AG!H:P2\*/?]K#9[A7VK)4S@6QXEJYM"NKB]?+^/ M7]]YY5)!HA\Q0P#D':9@1DL4J9A)+_3P4=M`]T%4/TO*D<3^]CBQW")78LFS M)`9IN-/@A@1+!&ZZ%^XAL0\KIR0FQNXVF;#X=*K??L)*RK MU?-V6:R'.BX(+&8Z.+4CM?PXN=^).9K@)?X6A4:$%WR2J`4D5\9!D.DWTE>);@[=*6=Q_+O]]_:FNY_WKQ=?/N>GYVXO"<.0)6I<4HYR*B M4HT=^LJRMZ$?(IC@SQU"VPD/M>(#Y0Q8*MEBVD@7(,']*C=/OLM]_"G/-/9/ M2_31?C0)\9?7W^26W_V^N2O-[)4-[\*IIEK:3D9KK:05T>5Q)E$WA9DOUVH] M/=0^M)WR2+\]?B0P*EG*KC4VQAQUX!'&1"QLF2]V,9H7/5)OPW;G6'5I#Q*2 MIRA?;9&O0^IB=5;SQ4H%+WM+O2KM!+D5'`:P$!L:?O*YN/$Q*R0]+W@293[] M2-\!!?ZZV2X>_.7RXF^75]MY\J-2H)HR>O&)#B%8)A_OUT7K7'LSY_1DU>DJ M/4^E?BD?@F)(U6"SY&U<;17U'Y==0S9=LNEP`@UV(/7_?K^YO96;^I[C/[XO M;-PO&MH5;W_AX945DV+;793`!CFEMJ2':G*TH9^W1F,F/N@IY#[GP5>\5`9P M5%KM/!6.F3F.%C!1?8CYGZ?[QU>2^^FX^;CEYM[;]X`7H337VX^B*6Y^>/M MU\WGV__Y6*I/F,FCT5'`R84-,/ZF0+&]S56 MA%V1>,;#O"C3%I&$)360A"YZ#L8K,+;`$+%E7V+WKH(P>6S\*9FV8CJYAFI] M%)?EJF+`[/SPF->0NSM7S.X_0=+6T!]?-[13/5BFVM9S!'&JNHJT M`@4>$>]\*3,(0FK.#IR(V!7]$[]:'*G@BLF5)=OT,&3.$A:43I3,G/:=CM0E MOL:209%3B145[3WSN*`W&DXS.]'X&%IWL$_>7@^]@K]>_-$:!0^/;'W647%P M-0K-6<(L-1@X'0-UHOM&3X#(5DEZZ@'6V@5T:O-CCK.DP>U-&.J(?]%@Z'H, M'><[QI_D!/?MFH=O5K`Q8M)-$3-*QH?:C;.FXGZZ*H1([4Y<+6FVS1+,*TIX#XYJ M?1<^OS&J$^J0'>+RF=+BO MTM&Q2AB3BJ+645<:^M`J%]*]2<\U\H=&6M`U-Q(FF:*J\I5200$65+SU+IOP14)@H:R?=4U=&'%&]!K M>O,(::ET,D/ MMM60$](?I>9)5"]:IFPR:TEW,97(3?S5D,H4U'WNY@@Z__<,5*^D"4;RF2;9 M9+T*;"@J-T)SH9NVN+2,$[L,['FH7BQM)NT;9J#/)(I8G87@QDQ,/-G_LW=M MO6T%NCK(L`F]DF<+/(4,!)M6O"3EK/_]J1IIFISI(8>7 M$:W$1H`$5FBQJKJ[[O5558V6C/;]I4.I[NY]^F&^?D!?ALCXM)0G%=:)%.`] MTA@B%4&0`CL3()`80'C5HD?[.$T3,+$O5>I-\-P1PBG3V47LKB_SZ];%`1QF M*OJQ\)%,;*E].*@&'_#]WM,1`V#?2KUIW4@-S-5VB4( MC7G">+\`B!//8M4NRY3F.\D=JJ^>6P[FEEF3L2VVZ>N&(&9SGZ-PM5NIE2$G M$HCIM5.$*).2F=@DO5%:*^DW&QR%R;:N`PIA=Y&XH>$4*O=)DM"@)#AY/"NE MA0O:M@8E\LQ55=%1JMQ25/]W__N_YU?K-70.V>`>:?/YZ>?=I@?H\WRW1 M4T&X?JQ@W=S<_3&_#C>SQ8=Q^/LND#_FSKPD/EB>H@F,PUMB$.3BZF)NZ^L[ MS,V)M#XYZ[W3["\.(RE:$[V7'IYD]-@N[D+BAGF58Z4GGY#UN]7J(:'];GY[ M]?GU_!9-Q<,'?V@:98YE+6270]0R@PH"AUA:9X`UR:U$G+)MU^?J9K9:_09_ M">C][6;VQPHT)&BI+5Y'B>OP4G:W-J753_/E&D11-KD>[3`+"C1+"6YPCDX* MKE@4)8($QZARAQ3I:H;]])Q+^MX\!05;%J06H-6DITYD779D<,XKQ0M/CYI+ MT3X&:QMXP%Y/HWDT"#X321E@9D%J1^@%$UITW;C#J9N,J;'HAJB,C8_&X<+S%'PHO6D\45%[2SW@X6DY M^N[VTWRU/N^8(+;,Q*5,D!&J+'>Z[1XV*NGJE;]0IAS;@ M\%0\24H.XFF`N,EX&GM-2A@1#!$"O%((],QFZCD06V^PIK*W@^ETEC;5^.,! M`2Q%K%3?(&T%B+2I:NM:WEA3*VC"*B6P^?HC"=LK3@C[LZ$:'-\0/.=)V?:* ML.`'BN!"5R_Y-,)&K#'7+E#.LB+"X<8!O5E2%4@(E=:46DY'V-YY$,R^XAH, M*U3*28.8"CX=N&SU4@FES*&$E0#IE+5>1N3D#4E"89[>)N/+7'!&+(H^8>`Q M]!H$^]]_/'$;]*CU;#W_`!_^Q_SNW7+V\3W"&S6P'TT9<_GYM_##[M<"JCB& MH-$)SI1[)4L^$/R6>FN*Z&47+LK'SS_M/A&7(J>6^::+V86(S06/)Q)5G;+G M%DLL$W*RMV5>6*MP3@;"#`CL/?;-E^LB5>VJ*]._R&<3-\UU`>]7>6PX/1WZBX4^PPZS2)EDF*6GVN."Z,S+"##HS$IY*RZZ=WZ`B).('$'2 MH`;;+:5RR@.=N2!1,HB+ZGN`<'J3$SF&V&/AQ1DJ9*"@JN$:4E$VVSE0F(U)2Q$!0PA`;P\"?C&R+,U2P&N+%]!K^1XG$0O9CQ>/$/+!RWKOD M$Q/2"RZM8J6SCP>EJUXAJ737:@_2<`J5>YOI(R>@785B3@AO4LBJ;&AS.5?9 M:D%[2O9`*@>V[#3MKW?+^>+=[4,J_NKSF^7L=O60OW.WU\V?;II^6'?][_O5 M&A7PR7ND7+:>1Z%,8&`0>=;&%D`U2T.]W;)FJ7/Q%Y;3WH9#1D`M MNQ`X6`I&?4RD=7^2-+)Z>/*+R.GXNH@8H$EIQIART-,7.[Z6SPONJ?%$H,//%#*`6#<-63J*F M0JDLA+`4XIAL2-G1G;&47B>0!VSI3G+.I7QOKLY*X9T6(HFH%+,JE_8N%0.K M;O^+7C#VA)2/Z3>=C"51<*%QW--S47HOX);40Q\O+B;R,85#&-?@:FO!=(P2 M`O(RB0N7J&X:>='+R1U!^>O99U0KJ(E^G'^\7UZ]GZWFK]YN+<<\'I?$11Q4 M`/>YLI"X1B:LO-9?@;->M\H;)KB89)^IL'L9&1;1!KU?@7(C3Q#H:2[N_ M=/7,PD3$K];+^ZOU_1*.[`2@0(8Y**8-O%>AP+BWL';1<@@V!KH9[6ZI;U%R M%KDE`='Y-.(_@H6#G\V7G^8=:.VV3?JG^:=YTSA7`^]V6WZD4TE+G71TV%AO MM6Z[FHV@`]FB_L[/Y\$V\(+&Z'.XN.*H'38QOZXN9R[J+8#K27R]1F:\_(]@^WB%LGOOXH7*= M#C@$A.F2UJ@H+;/:P(O9W!WGZD-@7(PO7,&>-* MDZ6WO([X^A724UGJ]*G#Q[9R"2?YX-HH[W(FDD<"C,!UV\`46%=/*()CVU-F MXQ2=S\$^WSP8'4)64D$$J2G$$XBW^^@M0Q@_GH.[J_G\NIE#;JSK MJX_-_''ZWWQYM5@=AK_7FY'+,A,E+;CL5,I$LB^MZO#^ZY(H$_U#&"'I7`;& M!C+`W56@8D'4,VC>VX=*4LB.I\"]3$89[)UI+SP5KLJ2FF;\[12: MP9M\5%.OWO[S[O;=F_GR0YA]7*QG-__$N9E7O]\LWAV.Z-8-\B`B8M$DRAW/ MU!JG;!GC$[;&W^_)_0C2IF-IY!402AEAQ!KB5:99)55P-.$YZ]K9F(HE\*<6 MV&7:O)Q3\P4L91],)-J"/N4.3)MOGX+A8.8&9L)4C_XA.DXE=:]7)QT-0)R* M#M1+=C[9-D%@O2<5J9STJOL3DCJ2$7#$-#O4X)%Z&:/1O-2]K1ZHWU,AGTRJ M8Q!CD6$<#1>`64.5!GU>+@!QM"*5DQY:P:&DMKY_$Y@THZD8IK0UT-<0CCSH M_IO%A\7MK`^W^L`)_7X&<>[IQ6;:\4_AR<+!F*Q,RCQ@*J0](V8Z^::/C\3! M0:D^YT>S-8%D7L^7B[OKQ\TMTXNIL_0.?4.N:*".&X\!OS0E`A2=F=&MA3/R M7"%U.-PML?!^MGS7J]H/BF`L/&Y6\;0I`53!2`:0]`B]L9IU"!_80O9";IL$ M3W`$2VI"N82+98-JQYG@QW5[*+>D;Q1J)B\@A<.3!-O<*BT:?'LFK8T05%AO M6-$@D=<3,I,S>Q#J8#21LQ1(T)E1XYA+I5P?P6SO":DG)?"X*XF58H03KF]F MG'F1DFC?>I(1/-WJO+ZX)$Y-V45)E`XY.PAJ M,V$QRDU%@<=4U6^>#:/')>DHP6W+,6N,P'QV1JFR9P0Q-B_"YG[,3">BU!"\ M,.9-5JUSI56L.Q*?#:-'/CV?)42QP9$$QB4+9FBIV"?MJH3@]&R. MH:8)PSB$I5(X@Y![5)>N)1UEJG2]-$]AFN4SL7PB)8,@"S9I\%<4_)=R(I2S M&1NM^044T9&2./7Y@?YG)`N";E:>&9@&/!M"#SURI?2'% M$Y+YY=^AR]$S`:J)\D#@J,`6MEE`S4D]A$U[*T6^C#A.KAP+$2PB10B(!S77 M*;G62+C,:IP#KNUS./W3GB.'ETC!P&<)MSPKZV,!=7!&BRK!J_@YJN>1WM'L M?V='N.+7QUTW%H/2D@,W5AGK+7B794E8UO4:G^EYW-LS+HD(F3KC MB%,,^U]CFQFAGM1Z7ZJ!A/4D)#Z]QQ&YH$9EJYQ"9>ZE**]*^AK'<-^SORRG M1^JWQ""*95H+(9@6DL=KN:NK^P_W38HWSM\NKOJXSZ.04"E3D2S3.'KJ,O:\Y%;<\.>!90M, M]O:6T!ANS]84\_V"&`=OKNVY1LCR MZM9:;.$ZAYZQR;0H%>$L999PVWW*B959>RG=P-2M.4\^8^$/R5Y2#G%:I)'Q M$&A9+DP0`6P`7(^:OMH<(&AXG='QD-N6POMT<"@8#Z>*C?T=$@Y,UB?3-_]?:[V^O%I\7U_6-9LOV_W\]N9P_? MV5KESAPKH8IHB"IB2,Y`4!6="R`3)U-0?_O[:_'K&-^G,36-M!Y0";^[18/U MT/Z!_6=OWL]N'YN@\MWR[7RQ1FB.AR\>%6;S>]]\_MCU;WKU^=J_Z8XTJ\`# M)RX$):-28`FT+,H,M.UV;+Y"QE8M),8$PCY>)G_NL_@9)+GZ\:>?'\ZD?`H[ MM'Z8?=A*PCC0AJJE$DOBBT]S_-18GB5I'6(@N#!#,U`8WI0(,!D:!LY2L6]' MV3O*P>,`7^^0X^B^+8YXMEK_,;G9O0#A7`VZGA\`9,I%%EL!MS[A[7LBR M1U=PV?/C-TN;F7HI^04/ZB"!7>@,FR]>[7U0_S=Z2O"7W]XM/V"NH2%CH,FF M^YHDUCA((A+]`/!RLW/)^P01C'&&NB%+=9&7U)7&\SF"R5T%9IT'YRM0S:)B M.GMBVYR/DY:[(?-B+V5?_@RG,)UE052*%"%>051+&9)(N72TI]@9ROLJC^)9 MF!;-A.(<5["FR"%>2S:STOV1^Y/O&]-"R4MI+W]0S\6Z_'#7`$C.KW>A(F^7 M&291;$3;H!@73`>/T$YH6S:*3.V2YE MQLE+HRYZ0L].CYUP>!.\KNW#"]PXZK-!:'6&6T\"V8QA<6-V!CGTY86?UW,Y MO%?WZ]5ZUJ#@]TCZ:A6+#8'1NGWY"L_L5^:!W_9$-9P;PE$KIF9K#V%$*K,HR8P<(-.QD'5G^D% M\D5.X5G$34JIS%.02B1O9)32E\W$2G+N=EHK\9*PRQ_4A4Q6^75NM;K_T`[. M/RR>B5A-F]]>_PA?>TAYO>/8)6.BBXA'I++FCCC7=O"!'NLTU&XF_B9Y$(=R M]`SD]^MN^:D@D\!>STB-0%A36?"1J",Y?Y-?W;ZP+3\;HLZ$*ZXSST*8H%U! MW=,L?[M_`TT"V_)SD<,_B5.EF)"6IA#:`H;3FGV3W[D]",-B)\$F0QC15)E` M0-3-%B*6I-=8GY!?@]A_N4,846RF/-3P=(>IM+/84RDMF'N:1'!MCA3ST*(O^X6(J=:.!\[B3YIL0=YB@3C.SCED% ME<`-XKCL6PC9WD0?LQ@6HN)3I+7^9$+<9B[*"!IXNI]$'<.*%LD2XL@(,IVQV2'`;?N=K MD.">.TBM#QZLC:1.V<0H]:7D'K7O[#_YRB4X@07:%GQR4B9EX*5+YV(B8/T? MPR'E#,UAE^"G:*&[K.#+%JL:!%OGV]7%R=U`9PD+RW\U9,JIPMW.:L#?." M2!_*TF_+E=[9E*:GZ>,X3B1/<0SSTO'VYFX]NP$+L5S/$,:DTM_J8T*HUG)OO)9I28LR2#*TZ$])1' MFGB9-PN$N:%>2W#CO\E^$E_&F("[&33Q5LMDG:.^5?[,&.F'3.U$'9;/4_:' MF^-I]5&G@$>8M92;H*UQ&FPPBVWB5/X_>]?:W+BM9/\*:[)))56R!P^2(.W- M5O&9Y%8FF9K,UM9^I"7(Y@U-ZI+4V+Z__G:#(O66+8FR))OY,+$H"H^#[D8# M:)SFKN]N",X3;>SCMX%5JZ,V'Y;^2[XA$6K[]DQ0P'TSU(U`9R&@&1A@_9OC:L+(F\-WAXBJS?$Z M-`2I9(SK'C7"0%C<:+CF=3VP]0T./*&'0O&58J!:1'A#1$7(/$=1.1G<(S1D M3)!:1'WF+-)Y=PBO635MBCG38;G##>+N3?L0/.> M![5!0!<3A4S'Q;PT6W3UCCDN,_'HFW9>7G:#:?MM%\-S7,<)0\&0G\_EG#XFRBLB]IU/]8"<"R86]IDG&6\IX#C-M3!.LAM4W>[(%S0==?D+"1TC&&H;O)4^UTJ9.UKAH]FFN+4 MVZ8;,E(?5.B692UE/66T)6:V?>%YY4%ZU3F"^F"V'%.8A%F$4<\-C#I2T/1L ML>H$`P;OM0?F`%/'\Y4>W901G5+PUYEOA[9##?B[H4)%_K6U+`5HREKT&K=CVH/>C>`7O)M(LG;0V9Y1&Z>U]F;Q6J?O>Z[ M9HZ;T>:#L*_,,P&'.A>^'SK$"ZV0$HLU*29#PW66F(#!$S!6G-P>"9\3'J@6 MF%86DM\)3BS7\$Q#&*[P=*XWB>H==YG2GAK&JKV/LQZH37="D&%B!4]T?>8U MQ=&W+9?JA/B>AU(/KG!MC:CPS$`1/K-/=(E%XR`-/B8N_S^'2Q@*;G)J&F[H M6L(@GM5L8`8.)J1X'[@8B_)B4NJ1T`S"4-&D.X;5<.VZ-C>'+I"MO#I9Y M<:&.;EL&LW33IK#`9RQL3HL=B^CN>X)E?Q;ZT/<]UW)T(S`QO2DEKC`FQS?4 ML`)=4?N(3_R,T%R.QYV?'.CK['0$'-/1VWY(*!>A[1K<:Q8$GC5'P5AG(VEG MTGRV_X>"^85L3,]+\]9#,'/G45#3"?"B([(JDR!LJ$MT9@HZ$6=8!QP$Z)GS<8EFV%,`(GCJ&<:*N'IBF M`R8)_A`B\%E8W[O235"9R<#0-E6C/6`.,%[UCDCC&&Q81LW,LL9L]$-@6'X` M?HM/::#[O@53KN5[CL$%7B]9SA-,5AQM'J`CQT-K,?O2+%J"NS2PA!4&H:T' MOC`<3P>T7%U@=KIP*>\896\;KA5IR.:$R_(,7?>YRX1C!99/#68@7`[30YIM57`Q8[R;C?17O,054)OK#G==Q['QMCD53AT\("Q?L)771A=B8+;NWC(Z MU1L8^8YS1EJ\*)Y[?L?0LP6X?AXUB66!ZEA^DX'&]MU%NDO,&KNB%TO-V+6E MF]+1>6X8FJ;A.!06!\PEE-DUY#;A<_P4M4$T#]749W(BFKH9NJX!ZQL]-*CN M6DRO(XQM;K@K\M/2`[9T$Z@&FV<5^%4F M@V?AG!]\`386:OCW;>D-C/]D(WU!W=(0'' M'>VPEE].A5@VO#;\-R_`RTW8NH6;!-A@KN%:'GA]8'2%&0:L2:IJ..`'[M_" MA957C;@?)V,\FE/`KSWI>\$T[!$S=)`XR/+=T'-"$I+:#KNA9:]*UD=M(>;) MP;=L9.L=W#31V-3TP0@2TX))V?2(Y367?SV#LE5$)K`Z9/1T.OC,G`_*&W(P M2(;A@*9:-&2TR28.<]5*JV01?D(C^(RK0/W`%:;M.:;+&*>FHWOUK1Y8R.LK M1U`LJMD!.KCT(SZN; MV'+G-B;%MFQB!398#-URN"/`R7/JSOFFLUHX[84%R]$Z]UP&\M`V#<)#F`-@ MX>]0UVPBB'7;$2O#YH5MBI/IW.9T[P*6.CY,N\QQ"?<#SZOWZ$-/]U:2)@A[ M8>6S?>?PEO757_T[.1CC8:73[V?CM"R^R+Z,O^'QR5?U#_3$36#"?,%9,'@Z M-A4L\$,'%D%Z$+(F<#50V<3_YX>DO![$W[2B?$KDSQ^&4.3%,+J/DZ>KK_$] M+!/^D`_:E^P^2J_5=T7\;WE%R:B\_O##;7F]\/,D3N7%G>KX%2P%O[_&]EW$ MZ4"FY95NC1[7%H+/5S4B3N]@B5`N_J[ZB*]?Q664Q/WJR4-5]0TXQ571-8;: M%,0?HOO1]7T;)QK43UN>3-N*.Y%C%M8B'=Y)[5AEB39`TZK M/\8I/,G&!?2P^.EJVK2E)GT$:7VQX()@W:972'4@\]G&LC7B/XH&J-$7B1R6 M5P2D?5;\\?-L-2FFPDVNZ]^4V0A1>)P67%:]EDDR>>?G#[!LQ<_%*.K7G[=7 MW/LHOXW3JI'1N,SJ![EJEGKR$`_`%-GDDAB6+FR#,VIRH7]_?9/EL-R\Z`/R MT:B05_4?LWAAP3.]R)N_<-&&;4]__@".2YX]5'_3YMV/Y6#Z9[ZR!-6RGS^8 M_/NY$J8EKRQM^D.ZZ^_,UZ[P;79PW;A.Q!CFRC+N1\E$E&ZRLLSNK^?TBH&. MS"K-[.?J_;E'E53CDV>;.:/)B^*\3OFWL'#3W[W,.LV#W327?]B,U41#)TC0 MT:-69$D\T+Y3IPGD$%ANQF_9?.X]\2]-\UM,G.LA/C$1S*`A0YC?KN[B`4P@ M;0'8B>!A1/"%+M$:>'WA,15\[$*<"X7^UA+%>[HS'J8P\_NXFU_J)C/*?/Z19*C]\;/KY&@+QCB?,SLZ\;SMC]0S3["S- M(5V@M^7I."MVO2ZT89[=:QE>[(/GWV0ZEL4N7CM[QFO?!6W5=?&8]7>RVH'ZQ1K4*ZU%5 MS>AQBW>^7;>*/)WIZNTH%[/M3K5>;=E$SWX:4XF,5L4,M"9%`]89L'DO[:.*ZUOY_HJ___OCEE'!JR*)?\_2V]_C;W+@%(5$ M-L9?9':;1Z,['"X'+^%L'5FL&[;/><`LBP2^)3R?D_IBJ,L8,4'&3VO;]L0C2(\?GF?O!I"]-CA/W='H%AOM[TEVLM3F[EQG MJ=Y:H''KTM=%NI^2>7N'`MC%N1]JC^%_TQ@O-_Y51N56$5Y=F.G[#C/E=D\8 MK07"G?S@[[L5=T;6YN0FQL[4O'-38_9TO0MI/ZBW\[:<&N\N3J-=7.]GHYT. MX'H?->A)YZ(UQ7H&FU,1CD-/Y=V,_9[UB;7G$[\3?3K@ZOR-!!D>1J+:"LA9 M-Q)G$6+Q>I$Z^[CBYQ'"HY,>M5XQA.>L!:_;4#C1#87.2'9&\K";&99I'1_0 MLQ"\%EW+/0,@MPUF7`Z(S(9%DR=E5.5)B3!'R?3[)CE*-OP,%A-CYM)^E:H$ M3VD*_*[*OC+-U+AU"*7C>*[00SUTF!NZGD>\)K<&9V%@GG<(Y=<[J3U,*'`O MHHH#5QL"KMHWQ34_X?"\C_*_97FAQ@*J0.206U=3`U)H#U&A#60I\WMH_$`; M%V!IU.\^(;R:%^5)IA7Q_3A1PZ'=9P.9:'':S_)1EL.SR>M3JM"Z35K=IF@Z MA%<;I?E9*&=4;Q9:JNLM8SLSU;[N7XOPG&D4JF%<"IOIA'!!!.4F:R\FU=@S M)E6<2Z@G.\50S]/SN`\Y)]Q+H[N+?=#]TS=JD[YE MZ)(E9^F5KQY_+@WZX&(O6%>C[@QJ;$YK=7\4*07TQ:.Y` M>XIE,NA\I!,R46_'1]J44>90$M;9MA/P#PZ)U9>X^/MBF$NIQ1C2+XM2RZ/R MJ#3G[]52G9U!HI>T-6ZZSN"<@QMP2!#_;_TN?N=0=3'WIWS(_19B[LW+%LEX M3GWH6]R!V^N8^36.B&<.IF549&F$FV6?LR3N3_[=YC`YU`T2A-RQ'6XYGAW8 M)K?J?*R>[UMG>YA M`H"X8S%&AJ%TH%6E:*,D2@ND',+@D(&F6(:DEHUDJLDTSY($Y5,;04T9$A9I M`SFLCLMA./+J_%O"7U#H9Q!)?/=SGI6RKX[,L1YG"`(\4&>N'E;C]$OU/)=) MI,[*H8(!5E+4E?\JHZ2\J][&-X/!N%\=P7^1(*W].(FKCU#4I19FN28?`;]$ M]NH2"GQOH/UK'.6POD$`4*Y[ZKM4))28G9?#`>1Z.K?CZ"E`ZW,)C!A1XIX(&>;L@;0\BXJM1MY&Z58P1_@ M(*C&85OQWKUJ%\!3U1_*FQQZ]%1_;5PN9UQM(ZB@]7B-G2SOZ;2^\:P6M:K) M'K:L1"@K0_@'Y+B6PL$X;R),ZA]&:8KBMR08/>WA#@2F?N]"0E]C5*&IS%;U MC3!\10DHB%__+DIOE=B!$]W4X0R^13#%W%;*U#S^#*W2?&T$R_]^'JM)1!OD M8\PC7_OB6;X0X/($`W@)!0YB?#U*DJ<>J@BFFRYC_*C!/[O7/,*I*99%E8T- M1?X?45I)/,(MH_Z=:D(/7BC&B8K`F6"=@YK=IO&_\=%RB^KL;KNW#`9X/C>< M2I;2C'2<%V4]T`!0OP\F#YJ"^,P)R45M]5:556AW(.*X&[.J6!")&*3IQ<7= M2,1"E9BODQ7EC0(O+,]'4L[8S?\7@Y&F15D!U\1`&&:U! MEBLAG$SA540;CBN.4310GKB*6Y./,,$4H#J33-8J<7CS$$H>Y[EB'(0**N59 MF5E\5V#:Q&'B$T,/'J:B.>TY2&R9@DRB3$-GTXFKH93CKO(<8/H=YY%"<^-D M+E%M9-Y7RE2BGZUPK?(AX4>%8E,UVCJP0.@$Q6!O2O@F3GJ:Q/_-OE7*1'Z+ M41G!4$6#.)OX.V64WU9]Z,.4$@%X!;HD62&G(X6:':=#\/VA^0.DABPFSN=, M\V=Z!7#`HSPMP.K,C^WSS@?:]]4^T!*.^_DIO9<(+LCHQ*.:F2@7#%;ER%75 MS1G'J8M79W*';BJ1P%+JHI7,K.[Q2G"+WDKO+AN7C7NW&MI+S9_V89TS^@), M&B]S=;_JK[%;VW1@!N!U[?\-G/?)--^#]R7^O((RQGFU79&"YO_9+S.4*("& MSTO3IR@'I:N9J'I3;VPKF9HQJM"8R3)AI73QM=*E]ZI%2_Q-P7$'PP&N(#*V M@K[+!,#&7TY7!O-U#I8D8GF>G5:T:KA!M_'H&:N?2O1LE<5Z06AQJ7#T&7MQ M7^69'8Z9O9#Q/0C-TY]#6*)6!AH6C[^EH"+R:_0H"R<=!,-A!3$\^`*NU=:1 M]QYU;:0N=JGA63;UABR:Q48KVQ_E'1YN8G5%_-A*B=H]/+PK)F:IE2)7 MLITM4^WMU%KL>BLEK21@VZE)\ZZ"_^ET'=B:7*[H.=AT\O6LU)Q76 M<&1J8G':=#I+/+#[G\$MG;A]50[Z2!EY26^?57?A')W&S9[SQ MXW[RUIF]-T&(_7+&A./+;$?-_I:IV<],$E_,T]Y)8B>)G4WL)/$=2&*7NZ(% MN:T.:+0;.YN/<>IUW@^ZN)Q#N>/SM+\[XMC=&S M.DO369K.TG26YM"4LSTJ2&=I.DO369K.TAS8T@B[-0Z(DQ_[?2W-^9\+[@WA MYY/_168$W907:8Q\YE6'L3$!G`CH3 ML$6G:4^0UK8M3F4D.RO068'."FQC!5AKX6.G,HY'V3=X+PE3@Z5K@UN(SSND MD3;897L9B]\W?W1W)WB'6'*XY>M;3!WFM=I7J=Y+S[; MN3S\Z?#[4+R]*:?W)3Q2W$GCXN(VBD97'I),EHJ;#W[H0?,!7YDB8ZG^QPQS26N?9CW4!&KC_EDZ?- M,WK]4Z^AZBID&F>Y]BU&DLQ<(N]A6L[4-8S3"`0:&0'KNOXJD.OI7J7C!P+*4>=PO07W&4&I-$_8'P`4#D$Z_SX:: M!R,-+Z1Q=#F=J[4_D4/P23-[,R3@56%(LHTQ`/DJ5W%P)S.SOD;UMS?M1DLA;@%NQ,E;%RT"3%>3S!]QZFUJ=&$<1U,2,JHVE2@YYV M.X;&**[6BJDTG["U3O@24;)5VVK=F#!-(OTVC.J$%A+Y&!NN:'W"CKY#SQ]J M0NBBR(M:7?!)(\K?XJRB7/ZK(IXMIK50\N/-3^IM1GZ,?JI)6.%%Z$J)O-;! MXX2BVZD$EMJ\(C/],DYP6&\N#+S@=C].;FN9S*5BVG]A9PHI_R[49YD649D! M'(/H/H+^@:R`'Y2G\JF8&15M*">\?/VL*`M%K-V?$$F#ID7U9RSH7D8XP6.[ MFS+EO\`^H$N96?+KUTT*!TE<*.)#R/^V]:9/B M2+(N_'G&;/Z#K.[T>:O,2%H+(*A>S$B6GCIWNKNFJOJTS:=K2A$DFA82K26S M\OSZUSTD@4C(9`M!A/"Q$^CW'&B_49`6P-7,X>[C, MPR7DPL1YXH:B%V0U9O,?01<`9T6(F2G@(1,T*&-2'[DZS@NQHK0)M0<')$** M,98IKNQ=G("*X!+YW/C"Z2Z-]]187[E MUASGBSQS8XH1@I0[O!O.:-!MF];(Z(S-GM'7^WIG4'3#,<>M44_9`J_[VLRW M3NSQ2L4?03E@\R*D8\GD%<)LJ.,"D$W23FX4WL%LXPG>.2`E9F%BEE3!$KL0C[S86<5.1&X'( MVOFTU^>Y\BQ+T'ANF/2S5DN?&$9:>)L*[/=AZ#?_=XD;["V4\^F&_8@=F3QP M9I:.]:HN?\G!X^W*"B=OL&K*4_0Q*#F+G:*'UX:J*TTBGH6I#PN)MJ\SR5N> M9(Y6T?/D,*J4.Z\%89(UC$D(N1ZR(W,):^H@*V;K4G%G MZ8ZQ``-O60\/6"&']Y;BL.;+_UOSE0=8Q)P(L M>`L?'7;@='['3_W^QT9^'`NM^GEI#%[`HS/(8L]Z60&O/6F3$#FGP!?OKY5' M.K8^(FNG$89)QFX1A@RBK+7-R3HGBW8[ M6M9H`X.3:<1W)0(G22.6*:5"+I`D$!D`1=JCF5'H&X^W[9KP?E9\9[-HB<5I MGX1H(V/?+YY8?$1V_[AF&VVGV[9XQ[NFX;+?,VCX^.#&/4 M4CNIXQ=PI/."E$`@EP$KRZ&KQ'0V6*QR8V3-S!>M?K&1I]@;O(GQFN;$(4T6#9N M]'S^JH/&PON*KVY8?^;SX6DO#B_;A^5_HI?TX/@HN;8,NM1+\.!QW\.@L4F M@5=X;\M'Y^_F.X2K23F/3H2]T]'2GOJ9(`XXK'F+RM=6<7MKN-7OSAQ#&?&[ M]X+C3W5HPF;HNDQMUZQZ]K2J?=.N"]ZGS$#EGN!AYX5!3,E59(QZKKU&+>JY M5KOS0,1QY^ZY5BN9MYVBI[$D]7BA;D-R"$?B1.K`1IRH+"=*)A/WIQZQZ36Q M*;5G$[5U\_X8GCUK1011K+E1+N$R@8OC""=,$,I<.$\A7,JK3PB;A$W")F&3 ML$G8)&P2-@F;%\7FZ4VDU*_Y_$LZQU,7L/15`//<5?8DA)@L"UVU(B-]1;`@ M6!`L"!8$"X(%P8)@(IV4[RD`7AW`N.WDO>E6Q?@5`^C$(2QD5)41'_$/\0 M_Q#_$/_(R#]5[G=U53>8?M]9NBZKM+99JNX8]MR90[OC+*,:.;:G1UBZC9XM MSO$YEJA7D7]+\9ESY,83KCFN[4:O8Q.N"=>$ZUKA&O2UN,H8A&O"->%:"ER# MOM8[A&LU=B]JE7RZ+)']7ZOVJW>'UF.I-J.[#MND*NV&ZDU#F"R292&KM@9( MZ9,0J)D0L$P2`B0$2`AT.R+*0)`1(")`0.$@(F,*RL&59R(L$$22* M&%::&IGUZ9*_GFO-CHW7/N]8(7Q)IY()880P0A@AC!!&"".$$<+JBS`ZG49U M3BM'D2P+3<%,>;0.P8)@0;`@6!`L"!8$BRN"!=4YI3JG"NPYUZ12#]4YI6BC MDDDLTG,;29KR?53GE"0-21J2--5+&JIS2I*&)`U)FG-X3U3GM.*X3LUVDD^M MTEBR6N9#6$90:=5B-TB2W&2^@B=!&ZUG27P)*XA"Y"%Z%K37<)+$Q;=W0)J"U;YT8O MX2+QPB"N0PCD9#)UQ*6QRK+R%!*41P4IAP>J,49P(#@L[[-UJKY+>"`\+-4# MP4&$KT'=)K6(Q4GDN?ACMEN4!EY2B4]RUN8V%PX37+XIE2RL1Q$Z!?3?]4"S M=?GVKH1,0B8A.S-.WQ%HMU;W1+V'B^%M3%-,8 MW%`OT"99SX15-T8-:.*FOH,;9MI;XUWU>+:`-R=A>N>S)7,>=2)4WB:KO89M M5Z1RMQ#O*IJI4DR6X'@L'+L-W2(X$AP)CE+`L=?HF@;!D>!(<)0!CG:CUZLH M='NM<*2S=?O5:5TZH1FB02V8WTT.;^HG7/1)'RNA8D/E^_2F(G,7:+^Q1^Q3.G>`[[:4A;0N]/7J39)918"=7KK/^ M_A_K#;!',D,>\$)830:#F&@;$SGF MO;B^*]KD"[UYR.681_/!"WD2\IZ0!S6T1\8Y/69N"A=YZ]7S@.I.`JA(?X[O/^48U((M6P<-[2Y-^(KEN)U&X9Q_=N(XG<,RL:\L M_L@`T#F(.=SQ3GC#(DTR@,--A038]GI$*=SB`?-,I\Q-M$<^^)GSP#(D.S"' M&_X$#[Y",8!O*!AI`2.&6;))4_LR6ZM@42+*X_,S9NO/S.?-2;<^G24I#ID0 MR*38B_'G'`G3T`>7!0?REM,G3&,86/SNO0!(EWADK=9GZ9XUC8:[7V4Q@)_+ M#PW":.[X:R:XH9>5H#"SXQEW9X:%H<.<\BU.4'*^LXC9^^*/#3VVW5)9*4=S MZ\;P'I8&'\P/;RSKFP.-G/Q&HWWLC>>^CP:JYD`/MI$O$*QYQ>R\3%WBY7#; M)YZ?J/B8A(L:+1)EG?&/F0J$^?F3W&Y'\TS[&:VR6!MQ)`X M;L5QG[VOI_$;R;Q+GAD30TM1>7SG8-BM?B3)0N+$2W"BL`0MXD3BQ#K)1&$) MT<2FM6+3O05FE:#\K[.H<7!3X?":5)"#`LR@>0DD-J9L-<([0:K3:! M2TH>(7"I#BZ3\F6E9!!"ENK(,AIM2D;?FT<$-&91W>GZM+7N\68B4D6%SI0& M6^=LE1IEX9:JM1DIK2N&4ZLG[KPFX8GP=.UX*M7I(%P1K@A7HO142YR'=25X MJG#;RU#>!>.GFJKAJ&TUO43&/:HH$%9%$<,S%A1]B;Q744N-HI5G4:@$ZRS6 MV6M5Y#$2L`G8!.P:;`\2J@G5A&HI4`WJNEU1/T@"]LO^]LO%;[;]_?VW:7QS M[SB+]R,G"H#/XH\L^HQ'S;_`=&_]T/WCQ[_]]2_?%U=]X`?2OSA?AU[L^F&< MEB[D!3/@PR'->(AILO\R__UE^$;S)O"%XR8WNGEK]VYU:]3MCT>=\4@? MV;=F9Z0/Q\/!J-WIO/GQ&='+!-QQR'O;FNTJR"(V,3@CC@;48:\GLIYAA,>S MU<6*?'Q9*V>0U0*(T_G`ZK$01:8LH?/!B+)2`M1KRZ@@)TIN7T\!+LDH/ M6'H!OMN7Q?UK=MP:Q/Q3J>%^OHM9L]O=.R3+O5;5M=W1!8NJ-S8NF.UMGK/IBJ M%*B@"=($JWRA^AE\%SZI;U.M"*I.Y`4J)44 MZ`@+C`2\"Z@\JRDLP$S((^01\O;>VVE6OSM\'<#;JV;4V9Q3E4NO5%H5Z=>M M-8TT7O"&*AJ)&>VC$VLS6$^&9:(<;$GK)&D21D_:E$U8Y/@9<1(D_*JJU"3% M$R,>UJ?RG[0DU(#5;V"^*2P5EL;QP[N[)Y`2&ONZ8$',XN9J_*^OZMJ"K-.R M.#F.LV_S@8-".G'<^$H7[K_G`WAP_-3!9KR:@[6XG,!E#6WA@`2%ST]:.)W& M+-'NGC07I*H#-TR\V(T8CCYA;#-$)6(4P+PG16!"R.7T#"'0O8 M%!N?1]6TQ8ZM`;20;.5AC5TGGFEH\<.C8@V,O9GFP"RXA`?Y"#P3+H"Y M$D1N^5I8`[C>T:9>`,-<_NH%^'M3(ZP76!=3_J^AB1EB$(HAGAC)`UJ=P45N M>!_`\R>OZ]7->JZO56I=*^GZ"WOLNRX"!ICR8Q0&\*>;8>`CX,)]ROX]I,RK MH0]ZX_:P/>QV[=;HUAJW!X.\S*LU'`P'E9=Y?>Y@5:6ZLX]X^7N46IZ;?;-Q M7/L3PT/AVHK.VCJAA?#=?ZWZ?X$@';.[*'7`%,0%:G!A,\[$$;!D:2"?$^!/ M)YIHMR'^^[9XBJE_-^Y_OEU^-+Y[IWEQG`*+;KD[UGY;H`1=N[__^;>UVW\) MFWPT-[JIO84?BP_OM#>#I1!&P?KV2[CP7*UKZ._>:WV@T"2#1&ZKKE_F9NT,;\!B>_!*WDA(OP11CQ\<-CO>1)FZ=QHH$HGX;1'-\R`7,V MF@-7:8\SEJ!?X,%RS,+47],72Q,X>5ID5H'/[H&\_*D>&/S:AP2(5K+T,4?9 M"8(4+EH-`E[LA5BW%"6%A\4#O'GQI?;H);.LNBDHMB=PJ>&Z.W;O!5BM67.F M<+4V!/::W\$?N-)(@*8V MO;RI_;-%R`!\`=.^.+Q\+F\./@- M>$!KJG>ZY,Z5$C[>F1#J.U09T!#N20#V^^#>^67@`Y"7X(5E6`&QK36T-Q\" M0/$]^JRQ=J/]%(:31[#[.#?^RIG_1ON`C`$HNOD-N/!S.$T>D2_>?D[O$@Y5 MJZW?M!"M`T`2Z)UH*8SL[^*RP$``C!F\"`T^SG7:P`_3"8!ZODCY)?TH0N@B M`ZQANIW59YC`S?[JR_?8IO7RS?[O*WN\NW.Z6W MOP;?_4'[_`;%T=L6A-Y-D^502V3-C.&-K<$PY[9U/YA\RLRK/BX<%\;'5:R_ M'8W'(]VZ[8W&M^W;5JO5'1<5ZX>ZK2M>L7Z-:-H`S-#[$TK7GRN`\_I?4HX> MA/+/3N3.`3O?R=WA:&UA4,2X(9@H*]]S`0XPF"DQ MF+B9#Q&QPBE&;,+]\!\WKXL_8_XBNY?ER(UQ!MD+6.:K9H$.;L.L`HH8N72S MZ`>0SINDN3N3S1B>Z_@)^K6`*OYJ/JHYEV;QS%OP:R/VP(*4E9ST?LSCB868 MP9LX29CO@XZ:$JP$\L5C&/T!*LXMQX>]3-@GS)T% MH1_>/^7<"(P++^)_YTI7S#"%D\,K""(AI M'J9Z9&B[Q<("E!VQL\(%YT;EJXO4*'$@VAFPX/@K+-W4<3T??3;V%7PR/FM8 M?>P=,G?^$T;X2RY7MJ_^,JP235;1P*D7@43\$_QE-,C@_EQ,SUCVN[.T(KBE M&&6L60BO[)FQ39+CUC+D=LTT-7U1H M^T$3I`E6^<+#3BJ!L)*KO`EU>WF-6AN5DGO'D:OW8H#K#+U>SE.;B=HJ5[\'@K`.S_+*36)3:AI#G*@L)Y+`)#95@$VOIJ., MO'Q[UH.QQ%.F#"4N=X/8?,<.J5:(IZ$5NFH2NQ(JH)4!:F* M>F*35(4HJI[>X:`&!0FW)0'RS+=+QA5DHLHLHIV\-[(TXY8%%LE&*C9]!$RN&" M8H2$!D(#:0G"!>'B97)T+,HN$>%][.FHZJJ[)5]X4;RM)?"$N;=K9S>MQ5=M M$J98DNR4PYMJ)_T+V^C>2=N=?"SD$$G-J(TK;.W&ZBITI;#)H?S8^ZH6PW/R_<#<5H4_N)%]I/;+=+J`?%\_NV MDY5J59^W5O7MLH-ZWO-8E/=.83KBV8IX=I_FZL2IQ*F7Y]2/SA.V[I:,58D; MKY,;P4X]0M%3APHJ;:P`58D=B1TEHBJQXZGL2$T9SLU]5[%M3M@D;!(VY<0F M%2.A#A54AI8.U(O3YJ2T21;42A9026J2`B0%KET*O`4QT!;>"GW%Z@JM_SL2 M$B0D2$AL,Q6HW)"(^,*UM*ZX5!74^M0=IM+>%(X_I[J^0H@)K*%'T")H$;1* M/J6A[WULX636NFY7DY!'R"N7[[),4FI5NG#K'%'+PK#+*@'".*F22C$J9#&< MKR#,A2BFAN>[L_J+"KQ4M0U/!@-),9)BPJI7M'75\U#AK?+IS;W;U:ES[(TAZQ2Z_JAO0ZT-H+<06 MNO^THW3]C98;ZE7H)%(]%'DB_B'^(?XA_E&%/I5L[,EB3$FU=R=-!-SLGF]O M3A9.$!@%?[G)U;:_O_\VC6_N'6?Q?LTT[0>33\S'@'`_:Z;DL7CHQ:X?QFG$ MO@`E;OW0_>/'O_WU+]\7#_CLSM@D]=FOTWZ0>!//3^%.]IF!1%B0`*G^B4U_>#,>8L.`?YG_ M_C)\HWD3^,)QDYO>8&QW;^V^/NIWN[W>>-"V^F9GI`_'PW%''^MO?GRVBN45 MV=$N9QL3G+\O5I#.[UBDA5,M3),X<;+BM%G16C;1'.!\YYYI#M#\IB"Z%B,= ML7&6D\"E$=-83GQM"M3/&FJME@`?SF^%WP.6:%X`/S)M`:_E#\)UB+T8?X8K MD[5F7<][0NVG`5ZC:(D0:K=;RGHI&;HNL(N2>6(7)>OH+DIM1=KBT$`5'>@5 M]W@1X'RIUFCH).7(/V[4;?\RBQC;WFR(W#7Q[CYQW,O-K8ZPVTGFG7U+3`PM M56IM`2Z4\')8)`N)$X_B1&''Z(D3B1/K)!.OH$<:L6F5`E/U7E15AMH'X7P> M!G`7!IC#!<8_A96,KZ[6QB4W9`Q+7$95W>MN*`0RZ93#-4*KT6H3N*3D$0*7 MZN`RJ0:BE`Q"R%(=64:CK1.X*O7&ZN5T\>0BS\4,DLSQ2@,OB35A+%3U5M,E MP=815VYT!YEDX9:JM1DIK2N&4ZLGKHHHX8GP=.UXJKRF)>&*<'6%N&JUQ'E8 M5X(GZENTJQIV-1RUK6KG9:H-7#0HTJO(43N$O$H4$:!HI1(*E6"=Q3I[K8H\ M1@(V`9N`78/M04(UH9I0+06J05V+Z_A-P-[7WSZVZH#XH@$OU"08./&L'TSP M/Z,_4^_!\5F0Q%]PU(?4&[@U1KUN1[=&M_:@WQOUK=[(*NH-&&U=\7H#_1@/ M^&\L_S&/&C*78>&"E=2SC(:V-=?^F,?S[LM"GH1']DJ#U/D@-SWY8Q[=T,(4 MX`4LQX?+_V!+YM/N'-\)7.`(7J'!"QX8+['@Q'EYA9B**^PJKM#K-;MZ6^]T M3;,#\^NVQ95:Z)Y8::%S=*6%8^_KJ%)/0.X)JI^N<^%CN3MK(Y_E;(]DQW<. MT(>T6T@L6`4+[FGIT)FRP\^4@65W21A+GT(KKM+A+H9286O?:#?LGE4Y2619 M?(H?2AH_)%%3?U%C-PR!]51E7WR!$4U%?;^32?@S$.U)FSO1'RS1IK#41_4` MVU7?X>34O',#R6HW.J:P/`!9%KMJU4P:N,Z0:`$DA)FQ=8$$):'N2D)]<4=$ M7!V62MJ!*[W7>[Y>`Z?8S6KD&+2-1DM<]3I*,B#O7\KL(1*2)"1/$I)=@Q*G M%3@="O;[-[>FJU.JVW9?=TIY2)+9?2^?$+*+6V;.(3%6R@6B"+]RGS$#EGB#U9C@EVFE3 M=Q#J1W/6^#IQ'/6C.4'F;:=H'=(0%:MR3PFQM4V(58P3J4$-<:(I]_&SM-E`A?'$>XJ-I<4PJ6\^H2P M2=@D;!(V"9N$3<(F89.P*4O"U)$'O=1/QO\EG;/(26#IJP#FN8^S2`@Q61:Z M:D5&^HI@0;`@6!`L"!8$"X(%P4*4Q[&G=ZLK[XJL3C$XOA^Z#AYM2$(\_C`/ M`XWW#+VD_)&^\`E5O5FK3-#0Q14FD'[M*4XIZ0E;DC2UES3MAMW62=*0I"%) M0Y*FXL8F+9LD#4D:DC0D::KVGCJ=+DF:*N,Z-=M)'K(@G'O!T7O)NY+M*Q#* MAU%(PK@H*2KB'^(?XA_B'^(?&?FGROVNKNH&T^_\\!PV^P,Z./=,"U)L#H4E MOLI;7EFYKE@+TR1.G``GIJ-D[X9IP3;B^G+X65QF#<$VX)EQ+@6O0UWJ'<*W&[D6M MDD^7);(SH'=-P_SN[M!Z+-5F=-=AFU2EW5"]:0B31;(L9-76`"E]$@(U$P(6 M]7XD(4!"X+J%@"YL=T"6A20A0$*`A,!!0L`4EH4MRT)>)(@@4<2PTM3(K$^7 M_/5<:W9LO/9YQPKA2SJ53`@CA!'""&&$,$(8(8P05E^$T>DTJG-:.8ID66@* M9LJC=0@6!`N"!<&"8$&P(%A<$2RHSBG5.55@S[DFE7JHSBE%&Y5,8I&>VTC2 ME.^C.J31B4 M=@<(%@0+@@7!@F!!L"!8$"QH+UDL<26K(2Q+EKF0LH("RP#7/2Y`$<@SZ+0: MH4ML,5Y"%Z&+T+6FNP26Q"5T$;H(76NZ2V!AVKJC2T!MV3HW>@D7B1<&<1U" M(">3J2,NC566E:>0H#PJ2#D\4(TQ@@/!87F?K5/U7<(#X6&I'@@.(GP-ZC:I M12Q.(L_%'[/=HC3PDDI\DK,VM[EPF.#R3:ED83V*T"F@_ZX'FJW+MW\=F2>OB76:JGNC7X)$\??FJ*8QN"&>H$VR7HF MK+HQ:D`3-_4=W##3WAKOJL>S!;PY"=,[GRV9\Z@3H?(V6>TU;+LBE;N%>%?1 M3)5BL@3'8^'8;>@6P9'@2'"4`HZ]1M1:';:X4CG:W; MKT[KT@G-$`UJP?QNA(T)&A(T%Q*T.ATCIL$#0D:$C15"QIQQZ&D7WJ!89UO$^?.9UNO MW_+W]]^F\?W9G;)+Z[-?IR(D"X(KX(XL^8PCDUHD]MQ],AEG\XPL^ M_PL0X]8/W3]^_-M?__+]EF?,%W[XQ-AG%CUX+BN>PR:#<+Y@0'->&CJ1OM?YK^_#-]HW@2^ M<-SD9GS;,?HMJZ^;I@T7]'O#VX'9&>G#\;!E=ZS;-S\^6\_RVGSQYBS6?F&/ MVJ=P[KPL_4JW^U[`;F8\Q_Z]8>K??,?YPPM`>";O6WAZ0"2#?)DQ;1H"O1YA M932^Q%J:P*^3-.)/@.=M,-;[^34_O-'?\,\@H=WB\^%(?O0FR>Q]K]WLM%J&T>J9AFE: M5ON;(OH/*L!W%C%[7_SQW7.QOQIB.7Z^4AV=K7LF>X3@^=!^>-.ROMFIE=95 M7WZC<>Q]YKE?2!,4?)\R`Y5[@@)*EUQX"^R4JJ3\XV,FG^]"?R)B1]L^,9VZ MXJQI%W03BT09:ML)^(4;2#]G-LV(VS1HCFA@A5S2&ZY9M(`X;L5QG[VOI_$; MR4'1#.)$XL4XR45C.)+%IK=AT M;X%993ZJZNFHG_DIR<,+AM+.Z77OG+8[5`O\;`QQQ98ZLG.PK M3W*&Y`S)F0N=`VR8U'^!)`U)&I(T%4N:KB6L(87T*W^JG%%_D_!D$GZ2IHQR MQ;O6E>CTKCB=OH,ZLO!+U:J=-/A5(ZK5)D01H@A1PN);#;W;(T01H@A1XA!E MGJW@=UT05>$6N:&\"Y:5%=YU_*T:EA-5@.VEI5*B()FX`-+.^FPG1)BJ(&45 M)GRW75'5]4/HJ03?56VG4)B<9"3)2"EEI"FN``W)2)*1)"-EX%62D>)HV6J8 MO3-V%5":[TA&DHQ4A5=)1HH,17;;9ZPMKS3?"8Q@[E>=[+521&4.["S6RPS9 M]D)LV2T!I9->&Z]T9<+NGK1PP2+X$FZ?IH'+?YV&$14,HX)AAW!]Z36U*!C6 M:O9TL].U.[9EVT!XF0J&43TMFB!-\!(35#\']I1".0(R(*A:$]4'.V_.#7$< MU0>[N-BCFB+JE[ZIAS@D3J1R8,2)RG*B9#*1RH$1FU(YL(IV87YVHC\8#\QC M!-F9<&+$\/F2,D#Z8\YTP'VM-)@M[D"3["N/]U%FAX29'21G:B]G6BTJV$-R MAN0,R9G*RXA8)&E(TI"D(4E3M:31+6I\76DCZ!%T")H50$M2F.IUAFKE\_U$PM8Y/AY?N[< M"[PXP5H:#X<4(*YO!,.F'1^*Z%%$;X4'B_!`>"`\K%)L>CHA@A!!B%@AHBVN M\VU=$$&[/CLZ4J9NDD9X3M"=.=$]NTA#ROK$`#*1U#4-4UR4Z5CBR<)F%(93 M0-L11`FB!%&"*$&4($H0)8CN=#8-BZ`IS688M>8\A>5$M0M1H3O#^;J"7(AB MRC?:5(&+*$Y=N>9$[!9C18-2J*CO^Z'+__IU^HFYX7T`,YI\A!F&<%VC(=8M?I?YK^_ M#-]HW@2^<-SDIC/L6=WN0(>?3-LRK+&IC\S.2!^.A_W1P##>_/AL'D=@`TG7B61[+B[9EFFB^Y]QYOI<\:4`O[P'_F&17".L?64G7 MR%?TR3'/WMH^LJ)>C:_!]C5>NKA,VA6P:&4H#>Q)WC.X$K+'G@ MW*14+7)&/'LTSPX./H-!G$J<>@E._>@\86UJR5B5N/$ZN1'LU",4O>IG`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`1,`UBP`R!T@6D"P@68#W46]5 M46&$:^F9]DMQO> M'8-"T*IM#Q'$"&($,8(808P@1A`[BDZ&81&TJO3F:N:T7:K1M7+`HM@HQ4;/ MH(F4PP7%"`D-A`;2$H0+PL7+Y.A8E%TBPONXEIXVV[HZYR7PA+FWE7035#KI M_WRE2G?RL?(MOJJ(=1Y-526XK_)(Z?E2YBB(19%<,'"BR`-*:1%;1$#W`&DEIE&( MH7\CY#E:&&GS,&):.-7"-,J;M439BFN\8\C5]U_9+$MYU&AQZD*>)*XEC`,+ MGW,F4#!?[:QOR1U#NT=LDY@Z]%TQ=%U@QQ7SU(XK';G;4BC3/^.:!GJ>%PIH MG7SA3=X+-R5I7WL3B#,T):'0+?';I9J.D,C;8,&=QUC4+D)#&?B0Y"'QH0Q\>#5-0JK<1OE'.G<"1Q2BJSL$?>AS7T2&=BG9IKB"G%WACH$A#O"G2R$4R-'Q11F_HL%I1))*X38 M6B%6'E!VY`2E>11#(="JI0[K"3MQ1B7ACG!'N-L;=SKACG!'N"/<*8J[ M:]PM8TG@B/$&+=HL$XO&ZP"=?/A22ZV45 M>S[[58_;MT*:;2_$5D@34%]JG;%;BZ]'C^@9K(37[LM)KQ>2/*X0Y`MU)3_/8+%NG9A-!N%\P8*8M^3LNXGWX"5/!]>2 M[/4-8]@RA[WN:&2/A[?=VT$[KR79&;=:YEEK2;8M<9(R^XB7O_<2T"UN]LW& MJ6,AC/5EQK1IZ(-=`\N9UP*,T_G"Z6'/RU=%2F&?$2T;BH7MM]&>*WWX( M\'"U]\"TC[X38/5$O?/2;T:OU]4^)[BX^`6OCPC7M\O?O<7*>@S?R?RG1E:, M,B_W;>K?K2Z,E]\:W[W3WO)*AF$:PR/C=^^/%@SI9J=K=VS+ MMF'9Q!4RM$ZL8]CI'EF3SJ)B=E39Z3A:ODZ_C2(1IXOPS8)CJ`!CK?_@>#Y' M_C2,M)\B!R@K0I0?OF+JL_G)'DF^)L[:FMSCFFA#YK+Y'6@]RWBA+O`9?7,U MSN.V&D9'W)%<%0[1XGV2=LTTE` M=GKFV2BD9'QM[QWOT]6D^E#\=8'.NG#LJ0TQ2[A)0$`B9;>N[%PGP(``?"OP M0'L]55Y76%'2%^DC"[-`*E59"F/EN,YON&C6;N&)GLBRVQ'Z:\D!Z M)892E-371):,/F^_234B+U:C;8FKNT3=^O:4!6+S+0S=N$S"A;"-*.VEP6\3 MFMDV5:N[CRA;Y]ZJ=G*`;P]ATM=V$,M9`:?G%[R8F'(HPF&&!^%P.[]>R@6: MA,!M09@421!B&NQUS`:()R&/TJ)=4\@VTG%G^[7-$(%LQ-M"3DCY@[?^#./G(BFKN.KSF/3C2)2P/!Y[V>1+./ M\#N$:=:`P07`Q>4[B4`E1*"`JA52B\!-I[0:F6<:ACBAETFZ<&/H^\@Z84;7 MM@RV0U+.#LI:6VDJGI2$*8EQ'^7JT>ELP[X^ZG8R^:R1LS[>NF#1%-.J@(=N[G!5>!X9/.FSL'=`4V.K\LR._#=(%J<>P:OG#M>@./#A8[@ M72DH6M^;,FWB),X[$8UU*UV?HU3FY49+;8K/E^MGG)KLUVK7OL6NW*UY!=QG MJ3)0R@^M/C^4?]Q,1Z>$4=$)H[^D//\PG&JER$AFM'"+4XCUOEJW"U=,K]GQ MS'*R/+'V<];^/3>A;_JY"?U3EG/K)$P;.UZD_8_CIXS841@[RL:"^ZNNB[#C MIZ5'-RAY=/]$C^[M$SA),8E*$I7GXJ__UC MJY0-\3)!;QT?HU-:F"9QX@0\:H7;.=/J#I1<8;Y#UZZ^'^-5)#,HA%KI]);X M4UY*L^+?S\9SRHLO2V]VJV^3IP37D`"35(!53#@U@&HVV^<[1D><2*J45.G! MF2P-NTW.P.5..=3L6-!/=,)UE1DK[@RY+,M;M;E)NEP:/,BKE562`8;>;`LK MR"K+2I(44$\*"#,9-C!RF6)IDA%(.@;:.S?H9)6B/KO41:Y2A9!7B/L_+*:R M5SO/2/:JKP*RR2(*&;%R%I&IF>XZ7SA3%K:2(F(IC1@R6TV]^GT#6=:^:F^* M)(WZA%/,H):("-TAWS`B+JFHK'?QB>;5C'L]EGI`G8>"[-,B7(N!'#7*>^HFW\#U8A;LG MWML@6-8.?D&Z;T;F:3D$+4>C:,($.LY_.EVY'=[BY,#^)`?U/N%/S/O4'-WN MQ&[KK:YE=,;M`?S9[K2,5C=O=])JM=N#L[8[$=Z!:D>[DW*_G&5C$E7[DES< M4JK#X*@'R3:+<&4'40^2RNY39J#4@^3T[!.*RU/+D?P^_O&5EB.9$9+;>2<[ MN<1_&_Q'Q>Y?:<2@%8T81E]9Y'HQTSYBX(#X\#S[D]00A!J"D(R45$:>K2'( M_AMAE`I]8"IT0MU`!)+8:-AF]?2C3&:Y0"N=VCI?RI<2K"A%/I@B`JS;;%>? M`ZT$UY``DU2`43\0N,]J6H8B!*TO)Y(J)57ZLBHU&]TN.0.BD[*OMH83]0,I M:3]AN))E=:NV-DF52P,'>96R2B+`,)J6L"IMLJPD20'UI$!U1VPE+)E##$05 MEJY0KE([D%>(6V3&4$>0'<MWE9"F@*4-`4Q:VDB)F*8T8ZC5-*G)$ M@J;>>W@U]L`DHIQ:+$>ZK?:ZS>I2G:-*7=J:>:[4%N4@!]84F-M*;5$HVDJ; M=M>V:6<:3;M'P662`I>6`E?E,A(#T:;=%.J) M0A%510POZ>-J%%%]?AZP0S%5DC2T77B6#8RF7CW:B-E(K5VY6C.I(4JU;G2] MO.7_83&O9AQ,-/85ZVEG/22POT1E7K/26X5&P^K1X1P*TUY<+\O".U>YVX?. MH[`B%;*L)$D!]:2`W!Z?L-[8Q#JD0&JE0$R#C$@1WIA$H:`S'$3DS44JV\RL MY=E$HV'H78J(R,@CI*`I\EJCR*MA-[NTH4B2AC84SV-!-SO"W$N):*86LY%: MNP*U)NQ8@_0K+]"%W=Y>]OG?I7EM]*XL,PD_D%AN3-D5WD%]/]E`/=,SUI.\ M9_K^;66NHF-,IBQBFAM^QY)&QX,!6ZAO=9)1HE+UZ+(X6"<&*=F_9 MY&!F7G`#/]S,0=X]Y3V3XWS2R2R,>2=C%CW1)[9X?MC\[3'&0G M;])=?APV=N+OZ,=Q.L^^.[C;]G#4&O;&O;YE#-MF^W;<;1OFL-\;W(['\-^. MJ6RW[>PC7O[>2P#.;O;-1LLL3M$;3FBMO'!+=)F;;',L]*>.%^58!QXM]_J. MM?NLF#1FL;#YP@^?&)!V&F9MOX6,()E%C''PQ]Y7(4_4`'K)+-88+%^5(F7S MD/M1HQ4F]X1).>T1Q!6+$V_.17[*17BRUB)^HW.[LT+[^U<%V@%Z_"2EMDG3 MTIO7+`39VY3;3W.:H"P#E7N"BJ3; M2A>!6P[7OD"KU@-.@/\G!04\?1)J>&Z8F5^X\?5S9B^-N+U4[(:+"E,1RRG# M9T4V.SXW]8A-KXE-+WJJB`0F<2()3&)3 ME=AT;X%)^=2OY5,79UU9-#^&=7<56ZLNF?IU2HG/_V@U3>V).5$L2CS6/@M$ M(8S)JQNN"6`6`8P`5FN`B;*Q5%9O5)&0H$G0E%(Q7@4T%=F&.(O;]Q#Z3N+Y M7O)4!3[5,T';36%)_INKKU`M@F_DB@%>ASI3#BX=JRGLH"?!A>!2<[B0=B&X M$%Q(NU0&%]KIVL/E@?=Y@-R)]N0Q_Y"VD%<8DG_MS%)5@:]Z0U0A-*JKZ@B` M!$`"(`&0`$@`)``2``F`M/^U=M\G+_[C9HH'Z#S,5<4F'Y&3,`J[P'U&LR6L M<\YU`$H^[*BKN!2$B_BC.P07@DMMX4+:A>!"<"'M(I-W(U',H4HB_IZ7_KHI M2G^MZL==4AI)?TZ#"B&OR22[J0OK^2;]VN-]=!#@,GJ=),UU2YIVT]9)T)"@ M(4%#@H9,&I(T)&E(TB@N:R,].%X.#9ON]7W2Q"TX/SC1IVF MGUAX'SF+F>=J'X(I5F-'JO+"^9^!Y;PI<#6\9I#&P-!LQPGG,\SB>+9];7"7 M;DFQ?14VIG.\$N3I.7V%N\,TM#"--#]$Y>L]\&8Y,4MBQ&_LQ7AL8!%Y" MY^`D%U&X`)'\Q.?&_DR]!4J"AG8?AI-'S_?Y]V$"[]-PV:=>X"4L?[(7)$YP M[_$.QME+\.+7+VEJOVX='D@TS4F2R+M+\U8?V.OA?K7<((0RQ'F!]@A?S/"" M)WX?_XE-FMH_-QY[]U1ZAN/CY8[VR"+>`2CK)!%K;^&1R2Q,8QA^_.Z]MJ(S1?$UYJ))'G[!T/7Q35\Z)[8[Z%CG;N8?D>5JO]R3_#@?FQR;5J91^HW M\R0W:^_2FA70ZG7Z;%3'[!U'H-Z+-A?7PY=T26OFLA,O'>ZND:12M`BP5-Q7 M^!(EH]]XH7\;B3=B0/$,N*?'2:E(![/J;^CN3K3/"794I?@YQ<_WI(;5:]AM M81G$TB_^J1%TA:2-=(J11,V5BYI.H]425H%(^L4_5=30L=+O!C,O<(XQO7<> MY[YL=\$*2N%9MC!@[:"-+,Q1M2HGC7W->#+%V<17@J<*O7-#>4WV)4PH$HP'@44)`TH MD)`D(5EM,*/;Z5Z>H$HPGD#3\N6\Y;,-;-_,5-L^?V:J@*3!M>1:\_Q3V"^/ M^7@EPW-K/Z=W<0)O\!S??]+@'RUB#RQ(F38-(Y[T*>2-R0QKHF$^:NQ]%?)$ M;0Y?SF*-P0)5F0:\F1%PU&B%Y2H+RTS6'IU8NV"XNT]9V59O:P(DB#R^+V")B,2`$=)>8^1GZ9D6.HZ8'[#L/(X99U9B"G:#C MN63N?%K$VS7E;>%ZJ_'WGAA-2VW)LHU6?_?>$6P\^9DA]Q)8_Z60.U+,J1IJ@8\5O)D_QZ M&K>1R%-PWWB3EJ(Z45?/L92*7Y_\!<7Y4'B95.)#XD.2A\2'BO(AG5(2P+7_ M2.?.01F]YR.:-#O+9O6%\S89I#H"R5OH7R+,2:[42+,R MA9G_8D&I1-H5(;96B)4'E-4?XKP.3:G(_H)(VO2#9,;FI^3-=(M'O37>73(V M)`T<#6$.XW6@3CZ`J:74""P$%@(+@87`0F`AL"SO$W9B]CJPHOHVF4BB9<=, M_L$%N;]Q5 MWR>-<$>XDX5PA+NZX>X:=\M8$CABO$&+-LO$HO$Z0"6<6>SWY]VR]1HO`0/G]M?.N,W5I\/7I$SYAC^:AMB8-' M>6=9+J/CQZ'F!:Z?3EB<=ZEVBTIQX6/`)M@`.KNXJ0:!MFP='D.@C7W-_4CU M_+:FS*3:XE'&.' M]Z)F8M$/GE>A2T)M[OP':RRR"6_E#@/Q'KQ)ZF0]ZK-7:#/.N_!CG$9.X#)M MX3M!S$M/.HM%%'[UYD["X$(AO-/I"JH=*:RB8:`_`E$U-312T94-!JTZ!K>,3@-'0'F>>.],FH1:$26$&:/$ MJWCKT\J#@A=GI@3\ZOF^$\&XHW"2NDFLQ2F\$88=S\(HN4E8-&]H6!E[`DY/ M&"`%@L3Q&YKO35E#>_"0^QK\D8[K>OCKBR\68:$(M3W\"HN]"[=$>*=XK>C8 MK16-NAL"L2X&XZOBV[=I M:G"5#Y)#D#I,$RZB0,B@%`K3($'FD?(8T">B06T M>#RW13DJ0OG3T"_&H+^$A9._58@:^C?;Z_EO>ZB3;&H+<9*F0O[GEM8=\SVP M:;DUNP@3QEMS\&8<6(L=)1-8O6#\I@P<"`_,'2=X6MK%2^)Y8']Y`;@5/MHT M"F`?9!0L982+^.33H)@^7^)YMNJPU+)/C'MY:,;B5")8R]># M>,7?WW^;QC?WCK-X_YG=SX$+/K$%&*9`GJ$7NWX(EB;[`F;7K1^Z?_SXM[_^ MY?OE]3.PB6>A/P$^&/V9>LE3/YCP+V^=F$T^.D_XN'AY,_!5@`;<)S;]X!+QPWN6GW++L]'K3[M]U^MS\:&;V^;G9&^G`\[`RZW>Z; M'Y]9B&7B[&@^L&VOH2KKEW_;?<3+=S0[PD70/J+[MUP#5UO-A"L=N+Y=_NYM M(<T?)U^&]5AJ]"E:&?$6O_!\7R. M?+3=?HH+F1YV*0(^:V7QIXX-AR>+*),#ZKY8&BMYV>>38* M*9E8M_=1E]/5I/I0_'6!L37AV%,;8I9PDX"`1,IN7=FYN`?@^_"MP$J6]51Y M76'=B%ZDCRS,-^AQS&L[9@/$DY!'88;DZU/(-M)Q9_NUS7+,2^)[[2]=HLW@DCO& M`@VSL;V`YWCSE*<\1Q./7^`CYLX?/,$,.!'-7G2B25P:"#YO1^+-'L+O M$*99`X;PI.BCY#N)0"5$H(!RM5*+P$VGM!J99QJ&.*&72;IP8^C7*^NJ.N]1 MLN=>_^NU&5YL]+\S6"(O2.#_=RQY8R,U#-/%GJ60-?)US0Y$/3)M$;$'+TQC M_ZG8IU@R)7#((HU/":\#?RU+U M\,097OLZT'D"]Z/G^SRGUL-SB?`RGJRM!:`]5ZNRMB+\=0^8[@S(AA]?,+!P MHGQ07UGD>C'/A%\72UN88S_YM`=-FZ^'#>GLVK;[=J2>EE?O>1XJ+EDI&W0] M`[0!3."R1:(MX$K.5:N4>%BZ+"T+5M\!N\"Y9\!1*)1P#,B8$;P*#V+B449M MXB3.N_=U/Z&HRN`H*7>;&;\R7D_-RFVUCTVN-<^2E7O!^Y09J*7*0"F16^:B M3(!/'?!O]9Q'^;_/=[8<+VDP]O"C[\M'2E!B57ZI_H2KU]`H\@OFAY^9KQ)LG( MUWBS?W\?L7L$?\!.-$+8L_5_L?Q4S'E+U8+=L"F+.40O4S0VZS8Q7I1C`K/ M8%UABI#1L,WJZ7<5&4`*@58ZM27^:*32K/CWL_&<^@*LVVQ7WR9+":XA`2:I M`*N8<&H`U6I:YVO?2IQ(JI14Z:&JU&QTN^0,7.YH4,W.TOU$Q$7VD\8KF19 MW:JM35+ETL!!7J6LD@@PC*9EDQ0@*7!I*2#,8MC`R&4*#$I&(.D8:.^\G9-5 MBOKL4A>Y2E5U7B%ND1E#U>)V'"T^X]9JO8M<44!3(O4N?2$G*6*6THBA7M.L M?H-/EJ6OVI\B0:,^X10SJ26BG%HL1[JM]KK-ZE9?CUF6E;^(2ULSSW50E-$0 MQC45I(%+@ZZWIL#Y(T MDDH:B0A7\:D^O7JT$;.16KMRM6::M%%8J1M=+V_Y?UC,JQD'$XU]Q1K>\"$) M>N\GGM M^M+?I7EM]*XL,PD_D%AN3-G%9N@7D`W4Z#YC/_?5D;-1O?8_==9]NCQ MECUZ'K!'C^9A&WG?37W>H1H[:\/E$V\Z91'#U/`[ECQB0WCV#^;XR2QC_:YI MV-_!C7X88\IXUD!X@1W1>(_YZ68W&;YKOD'G8Z:#\9P5`%\,[)R&ZXTFU]GD M8&9><`,_W,Q!WCTM.UX[>5?N,.:=C%G%$>[B/W5B>QRX+OAG]S`XJ]P\U&#-9JFT,$VM(C% MF&CD/3#_J:D1=U]0.6@BF;HEE$_$*5<86J]*%A:B-2YES^\[OK95@5:;AKX? M/G)$<[2IP:8+*Z?\K-]"Q9-PVB. M9_YN[IPX3V:$Y_S!DOR+70\#AQ3,.I0J64?FC[X#,N>M%Z#YD\;PO+@!9I/+ M%@F^3HMG3@1B8PZ>;!+SUST6/76=O)=IM.QEZH:K7J8^]C(%8\IY]U[V]3G* M%;[<:$^G9NFQ:R>72_>L6:;Z,\,4/YO%YV[(2YTL\(DCG+O5:S MIYN=KMVQ+=L&C?%-<202W#C?6<3L??''AJ>VW1=?N7_6UF/A>_C2?&@_O&FU MOSG0C<]O-,QC;U3E/F4&:JDRT/.\4/VC!*>4:^`?-YHH5UO.XBK[4O^2\@@4 M^$>?5C9-9K3\!C9-+-B?%!%'I`S.#=:FENM;6/OWW(2^Z>RHVPLN+_JN@@[?EIZ=(.21_=/].C>/H&3%).H)%%Y'M[L+W>^ M/BQWOK9+QQ/5O[DW3U/R]H$5J;9O*0H3W]=7=ZIK5Y\.1D6EY$*M='KK?,ER M2K"B%)ET:H@O2S]']K@27$,"3%(!5C'AU`"JV6Q77V&'.)%4*:G28Q%J-.PV M.0.B,]JOMI<.#T2+ZZ2C]''J3D^8\I-E>:LV-TF72X,'>;6R2C+`T)MM:G5# M4N#B4J"ZT\D2]BXA!J)6-U3>"K2)Q5"/72J4[:*[ORO3*CJ>L45B5)0WME9X%;4UQ2OT0T M4XO92*W57JT9[4;;I!R0(YQI<>&N48+*E`G<8K1?@QO+]&.]Q80`P"$>[ MSXY4:DFHA6F$+4G<%,NI:^%T"H^-XM>KJI_:8N0Y+<\N'8X1C20KE)`5^]=, M4U-6'-AZZ;`>2QND.V:$156U4M.,E\JK'?-X)=H^:?/43[R%[\$JW#WQW@;! MLG;P"])],S)/RR%H.9YWO2F9A^=IJE769[9]&6-WW_%5TD%KO;L0XN$%%(`$ MRXV8[0WBRD(K#++6T'I M64OS]>6N52^\A]I7*=._MX#T>"YV3<;1UC%(*) M,(^7]H2Y.=MC2/D[TV:.(.X+0C%PR,1BM)I\T5RN+!W7!)M:,JFI?0`C#3B. M6WB919>UP8M+LY[DG?0PI+=PXJ1,D$7.#2(]RTH=MD=DLP>,<&A)Q)PXC9[$ MC-IJ=1LM6Y";GZ]!,G,2&'&$=&8/7IC&_I,&0XZ0O:(L!L#F"S]\8GAUJ*&M M'D^?M,3YRJ.Z,\`Q\&D,_,JG[(9!@#(45IL'?'*3[;FZY"!R4?&'1JF_3T5]ODUS:5EFA'3UB,LZEBS:*;>*,HGG. MPR=I7-@;J_:Z&^UIG3A.YQG3O)?"/MZD:>G-:ULTLO==M9N685IFQS3M7A?^ M)[#O:N?4OJMG;[Y9^WZM-$%9!BKW!!7I#RM=SN1RN/8%&L$=<,KN/RDHX.F3 M4,-SP\S\PHVOGS-[:<3MI>+LU`$D)9:K!\N=H]/@9^_K:?Q&9X5V4?QW-0C-KTF-A5VV)D$)G$B"4QBT[JSZ=X"DPIQO,RWHR+1#59L?@SK M*E/D\V12M9JF]L2<*!8E'FM_:$\AC,FK&ZX)8!8!C`!6:X")LK%45F]4\HF@ M2="44C%>!305V88XB]OW$/I.XOE>\E0%/M4S0=M-8_NOHTPAGD&[EB M@->ASI2#2\=J=@@N!!>""VD7@@O!A;3+9>%".UU[N#SP/@^0.]&>/.8?TGKK M"D/RKYU9HK;)56@TB="HKJHC`!(`"8`$0`(@`9``2``D`-+^U]I]G[SXCYLI M'J#S,%>587D:)V$4=H'[C&9+6%^"ZP"4?-A15W$I"!?Q1W<(+@27VL*%M`O! MA>!"VD4F[T:BF$.51/P]+_UU4Y3^6M6/NZ0TDOZ(+&N/ M]]%!@,OH=9(TURUIVDV;6C^3H"%!0X*&3!J2-"1I2-*H+FG(I#E`T.S5]?ML M`RL1[;PM"TN"YO6_I!S]AT#[V8G<&6_*P?MI%)T)UMI"KUJ&%+T!DW#96F3. M6X?P/B(Q"SS>4CIP[ADVYFMJ(P>>_NK#L/E,Q.#6)-8<[&>"O4NPJ1\'.+XI M8B[#GM/%&_-^&GE[2.SCX`1/RUP4WK@VG,_#H'C5(F^(N-XP?$O)NA M(Z9QP#1,(R$/NL$#YFL-#HL>B[_B!Z<\!=Z\*,8N,=@T$8COL0BH>5C2;S-^(1&YH M<7KW'^8F11^BHM7%_Q?GRYPB.^0-RN&]87H_TQ@R3-'!!I_:7.O4(;IK9<3^ M3+W8@\$7`RGWKWQ\.2A;3'P'4+#GPX1A!2\`=KGI`U;K!>9U(C_48F^.C9AQ M>O-PPGS-"]PP@N5R$N],/2*>JYJRV#%:PONJ[RLU1?_UG#PEDJP9>)(WKVB# MJ=(S6[INV;IM6!U37/.*]HF]*VQ5&@J8'7D;"DCDI0C*:QV=N:C"DRIF1-K9:(DM*)*4JK MN.ZTBDZS0Q&X(^2XY&D5%Z?:Q;(FOL!/N#<,_VP,\)CG!:&0Q^S:BBY2.R9I M5.PJ)[Q1\3SDC6/96N-8GA*B.<&D="%^BKVO+]_0:FY2A/AI#WXJ[>]G.\=Q M.H?EA.OB;"7S576WIT*XN/F[MK)".&IMU07Q:)EUA#P2^6]EEQ2,*&:T.'4A M3]K:$^^H(;WU,!DG3&,86_SNO8`,L])KS#(K*YH;T6LW.ZV68;1ZIF&:EM46 MEQMA=$Y,CFA9YTZ.,!7)QJ`)OG2?,@.5>X+J1V3-(^T,O(]_W.C4>EK4T;Y` M9US)6MU^X0;2SYE-,UHSAR\9(*E9`(DX;L5QG\'].HG?2`Z*EH/4(5S]1O;U MD(_$B57VJB=.)$Z\)IDHK.$HL6FMV'1O@4DY"2_S[6>^/1-FQ_8NB7OI=U1I M,WVM1D%'F):0?N7Q/JJ%0DD[)&?.+VME= MZTIT>E><3M]!'5GXI6K53AK\JA'5:A.B"%&$*&'QK8;>%7BK!=P(CF"\7K-NW%%&9`SN+ M]3)#MKVHK`G5:W,]=KS2E0F[>]+"![K9Z=H=V[)M(+Q,!<.HGA9-D"9XB0FJGP-[2J$<`1D05*V)ZH.=-^>& M.([J@UU<[%%-$?5+W]1#'!(G4CDPXD1E.5$RF4CEP(A-J1Q81;LP/_/6+1B8 MQPBR,^'$B.'S)66`],>#()!VD,@V1`1"?*\AU9 M$(6^/V=`O2,"C[N*152\,2T>4>*J!\NRY%7K9U+#-8:#80D+S1$>"`_JXZ$C MS-PB/!`>E,>#*:ZZ8UWP0+O%KYP$8^XL@/G=/W'?PX5+*G(\A!+THA!KF;0[ M2K%$B914?:#5-JA7$$&+H%4!M'H]@A9!BZ!5!;0HC:5:9ZQ>/M=/+&"1X^?Y MN7,O\.($:VD\'%*`N+X1#)MV?"BB1Q&]%1XLP@/A@?"P2K'IZ80(0@0A8H6( MMKC.MW5!!.WZ[.A(F;I)&N$Y07?F1/?L(@TIZQ,#R$12US1,<5&F8XDG"YM1 M&$X!;4<0)8@21`FB!%&"*$&4(+K3V30L@J8TFV'4FO,4EA/5+D2%[@SGZPIR M(8HIWVA3!2ZB.'7E-@?)+Y)?PN37.9M@JL!%)+](?I'\4D1^G;E!I0I<1/*K MAO)+%N:22D1)(X7.VP)2%EX0&-K:KYEC\??WWZ;QS;WC+-Y_GCD1FX4^$"P> M_9EZR5,_F/`O;S%.]-%YPB(Y\1>@PJT?NG_\^+>__N7[YYZ;'5+=N#U:_*)37]X,QYB#>I_F?_^,GRC>1/XPG&3FW9[W!UU MVKWNV-*'8VLX;AN&V1G!WT.KU3&L-S\^6Y4RA7=TC=NVJ*_UR#ME5?G'S28O MO.OCDQ9.M=LTAE?',<]++Y%/6]%/*PCX*A><83+'L^AK@ZNJYV;V$2]_[R6` M5_>%Q1BRV(V\!8][EA;DM4VQ8^C&_L$\I:=^2M,_;M!.`>) M\]18?F5\5_ZYN/F%GQ]9^8S+N%PNJAZ-<6D??@)$P+`UP7 M,+_2R&5(AAE_H>8%<1HY@_!FZ2.'STNIQU\ MR9M6,NVWP$L8,'8"+XF;VI=9%*;W,PU>HSVRNQA^U$`)1=D];T\E].:2<](_ M/CXV"%@*T89S.0=UJ(/BU>Y9H?Z8AP$6;1N%\B=0-0`+U M(@_N:O"M&ZQCMX`AQEKL3=C-W=,-_K>1'7=:+/PG#F#\M`"(ST"5E]#,O\_& MVM"*E;F)F`^HG32>@3M[9.!ZOH\Z;&-#U$Y",-BR*GZ3U.4[6#"G.3PN M\D!4\9GO>D\#OG#]E)-Z^:+^Y`%4L7//5E31/J=`388V$'_C\ON/3I1H0Q"H M)74RB=+[@AXKN/T*PH_!\&')X>U)J1:('X<:"]!NB[44!'6H39@/)(Q6/+)4 M2_9WFZ3'A?8R`L0:\YF;1&&`YC"L`3SL119J:GV@GP9#3_T$\`F*P)O#HZ99 M?9(XB9@SYPH"EQ`I[[.O_*"+H&61.(5#3?"X3=0\[2<"(+VWJ@0<#]@\L`PIR&`1'BFA# M#]N\.ZZ;&70\TSO$&6=[[`$/<'$!=.?X&29F##F6[[9M-?G.?4"-*5Y+M82&IDERFU4[BGW@P"-]$]L$8*-"7;E.(SF MFJ'?_-\E;IZ8$^5\6DQ.*^8$!MW,'%C[Z" M31;<,S!3YG,OCGE()-!^=L!66]'*Z&0:)5O`-557FD0\"U,?%I(!#SA\*C#Q M_Z2!RRWCY0CVIPH.L##>`^X?81C1`1MC#T(U7W-W+Q)&D]>:.LB*V;I4,P=4 M_AUC`;I#Z)KR%<+'11,.:[[\OS4_-\'=Y64YP'F`G]D"'^FL(I^+"+#@@;B!WCM29N$R#D%OKCC M`"(%V7#K(S*W.`R3C-TB]F?JX5SNGE8CX0/)/**$;:5&!I.EV#N5D&$66(L= M,*?NN#WKQ`?+ER/$B@J"-PMWE)?7F?PGC9-LV@%#-Q-C%L7TIHX7<8^]\`60 M'?*05:IH\ZN*^.C<^4\8Y3M`:(INW8HJ-H`B MW)?V)\66,E@P0:E=4P$/[G)/N3>8PG+D0&$37O3O(T`/K_T8@27O+FW[_G2* M'@EF`@WX?H^;K+F98&,'DZ7-C`_,;,/L:NXQ%QM.8$:#X>UZOI=]A$/V9W48JF=?YSN[DID0Z"5"G!JE(_%^\3G\YRMM$O!=AS5*UMEJZ#"'EE M"O\`'Q=<.,EJTB!3+&]T,O=P@S$PG`0,L]Q093!7#R%4R@[A[X/+:MX^5(3PMC"1QP[*D.P@R:K[<@&5Z()O,#+`@Q@(QW] MYD6>@P6R(6"/R/+_[009QW.GT7%G?`B-7+'CD'):@^T5W@?>__(`V<:(^/.< M4T:6[X87`;N(/;`@9611?^G,NJ;'_!BY8"-&XJ@E2EY M,L$%RG;J<5VS"KL\$Y?O[^>'B7F\-O;B+`ZQ_!*>#)X)XPJ\2$'8&EDYEC`B MZ;#(LU^U\''%FJN9`\_`0C""HG(D7YO9.@L7(^!Q< M4"D.$"]&DR2,V6JE$-E>,/7!*7&S*&B<&Y^EX9=F!>2`KZ)@/;VD\']>-S[6 MLPW+-M`&'4^S4QK[,"[P:&Y1E13E,X&5&7+9Z]:$X\K$R_D?I[G<_R@>S7EF M^XRW$G>5]K5FW85ILC3OMI.VJ0U7YB[K1>YJ-3*G!0,,F.D%RP&F(`8)`.\,TW7QSI5GL/[.R09';.K9U8NV M+?=JG[?$T>57QB\S@D!7@33V,@KUX75W\Y%QNS1"3@Y84B3H>`%78@6LUMD$ M+&VVEZ)WXCAT/6[];14(^_BZ>^O+7.+E:N6EZ``\.!N^^TKKYY=G,&5X[RI] MIZ?[5!B`B$J_Q,#F?O?<#,/S[,[2C8;R+-7>M:6DN>3GH'[L4T>QO/ M1%B)G<(87_DK_((Y5Y\Q.'GA2R/=%!?;!ULD'KP6)5@3YFCXO+H^7"QM;9ZW M13'MBK@\,SC1?HA`Y'O_6V001VL%6[.7@>2-,,LX,W#0]0(D8;(LWUM=O?0% M$R`C"%\9''CDW:6Y@UQ:N$WZ/GM.4QN$`>`NYEDUK[UQF9"5_9IM:)!$!^BZB&E`6R^D-1J16Z\V!C[]K#^)^:R M9X<`HS"`O]TLAT-()+X4V?]0$LZK>/1XF?90&LCG!$#C@&5X&^*_;TMGS<;] MS[?/3IO%*0!ER]VQ]ML"4U36[N]__FWM]E_")A_-C6YJ;^''XL,[[6" M@OCMEW#AN5K7T-^]U_JKJ'WN&:Q?W`>(/8$%VWRCE9Z91RCS7)K\DLP30"W! MHQTHV6`:R9,V!RV%0....3^GD6"T,V`8'.4^NI<4*7"EA!S-!1'IH,!^6C`N M>GWP,OSLJ1Z>D/N08+"-3:>Y-9WM!W*9LAI$CO`BW27+@BK+&:X24%A@2!*N M`U_&"P(NJ:>H'98Y@BM%/'(BC$A.PBRT"(-8QF_+9V-6%^`6RK.7+X]P<"U2 M=F?R,QX\\O/@^*F3%((+=*?C+J,"R\?#Y_+BY%&1G;E-QT<#Y9=Q5W-AP!0S(/^L7:C_12&DT?/SQ3MKYSY;\"NP]"/ MX]_\!ESX.9PFC\@7;S^G=PF'JM76;UJ(UD%N[ZWE6Y4$!@)@S.!%'QTO2R/4 M!GZ83C!'=9'R2_I1A-!%!EC#=!O9#HP`N/D^];+,0]R*\)T(CS;Q//5M;W?6 MWS[%MR^6;W?YV]WEVYW2VU^#[_Z@?7Z#XNAM$WJK1>_/SE-NPK^"W=:-WFN4 M#X9_RHU,;EH.T!F!E]DD5Y@KBY7O=279;@]W MAY?[YUO>_:ET>:[#.WK[7>FEC3Q`S1^%OG>A@0'(Q<;:ZO5\9Q(T+\PEB*?H MW0#KSCUT!N]#'A_%G:3HP7,9-PX*^,;[G]F^)8)\8SQ-[==`^^\44-=K/!?% MSGW$LH=-P$?)1-=*R'#+XNX)8,;R;=`/F]G6')_98](%[AWB@_*T`_:((,RL MNKVMCYUBR2Y+GA<%'J?T^J,S5QN6XRX7*3CFS*_TN'IQM&G*MTZ3*%S&'6&H M\W#B33T>VRC_`AY3%#KN;)N8Q$2MI:BL1`)RN(B1@%NJM>Q5<&6]1LOR`+/C MWV;';#[C*9NA%X-J`Z_TL$HMHX%EW^JCT="Z-49CRQKH>B^OU-(S],Y0E4HM MXMR[+<=.L\-,G,R%;1/+E@NGBM;;UX4>8-8S2A+^!Y8R`N"R)>'%);3UU3F8 M)BQUN=(C"UQ2XJ*QU:(M=YTF?-\;V'-95B(WUW-GW0L>6)P'8K,31I@S%*"\ MNXD7*'\QOHFQV@B<'E#$=V$PR?>J0`)R_<_/^S2>WZYA&020CT_:'7@[V2W9 MR:#,1%D6UN!J=IZ/VL>88@1\^K^EDT.EAX9WOG=?;(3U$^*CJOF(U[S`E=/2 M`!8T6YA[QPNX-88A[WQ%'\&R\O@2:_EU669V*0?F^6V@YK,]HN)T<_G-I6CM ME2?:R\:%6,2J=8B=E6JD0S)RJ-9E4'+,'=XSQY*Y<=>)!<9Y8 M&VMOLZA4&L/M\;OW8HU6\P4;?ZVR:,W26;O>[UF5V_KG:YI=F!^W?8W1;E1KOL7 M,7M?_+&Q5;4:8KD/S;+\:'=KRZ$].MGPD?WPIF-]L[.PZ7H5U?Q&X]C[.N=^ M83TG>'J'HDLW*#*/U`/F@7KJA<9AUHF-PRJ@Y>OT<[E#(M1%WE+H=&]]2'7, MB06K8,$]+1UJ+GXPLV*0ZY(PEKYKH+@R^[L82H7R^D:[8??$M924??&/"FY3 M-U$=5R\Z4U4J*+ MXOD:W9UB-ZO1I+-M-%K[!\ZJ(Z@2C$?>OZ3>/PE)$I+5"LFN(&!\V'YMOQ%>*PRY8IIY7$6:3K`G=!$OPNUGUEJR=6WY??LH> M!\G+S#AQS/(F#?P`A0]?9&%")N M%TCVE3\U1*F0#)).89*TV3%T_&]F4X"+R:NMX:$`%SB/Y=7@406\8'7$&&`FP=2M-A4S_*M(F*A]N M]9W,GK5DQK_O4]_)^R+P[B%W3]K@Y\]%T\*L@\4D;^8Y]?*V'?Q>W@@16T]D M`?ZLO[MAWN3UA//N=1L]*[)[L5L![^?QWTZ0=8>$:\'-N9^M6DI8!F^]X,`X M\#4-S?']5=.]_N3!"1+G?KV?G_816Q8.M07,THV\K"_#)$KOLU=Z6/;4XVTD ML`$&_+9Z__J[5FWX\E[U6>=4_")KYXG-,[#U,/:6.&E<2,:MF2%9>Y.7.CTN MQ\H;6&!OC*>UGI3)##M=P"2CU&?%)-:?DI5\7FMHW.9/6S59R;MN\&6&E[XR M3B?AXTP\[$):++`79[=@1Z)9^`B7-;19.[\)XRP*\O6<<9Y&Q889OY0'!RF_P)S9I7CE]TQ<779GRDO_QYN M4O_@?AT'--_@73M`2/SQ?AJ&"5::_R=\T+[RKZ(0P3Y+DL7[;[]]?'QL?KV+ M_&88W7\+!KOU+?[\+5[X)K\>&\[]\`8>S1?Z#3X[?SB\*K]F%F&;C__#VWKH M9O]V9`RMSNU@T#4[W7[WULK;>HSMV_YM\5S?N6-^W@IDUSW_S[_SU\<#[W:2 M,'JC?;M[0'9OT#&MEFD/;N'!O=%XW,\?WF_WVNVM`]IQSTD#,OKZR.Q;@]90 M;QMVO]>VQIW\X8.6V1]L&]"N>TX:D-GKW]K#P<"PS6''M,>W>N]V-5NKOVU` MN^XY;4##CFYWVWVS;;5LL]4V]7$K>_A@;%OV<.N`=MQSTH`L?63WC7Y7O^W> MFLBI8[N=S];J#\;C;0/:=<]I`S);`WNHCSJ]5O^V98WLGF[F#S>QE\[6`>VX MYZ0!M?6!81CC46O8!NSV;SNM\3A_^-`<=;W([UE@[P#?&\= MT(Y[3AO0H'_;[X_'MFGV`+V69>D%A#OFL-7:.J`=]YPTH,[`&EAZ?S#HM(>= M3G=@V>U"ZH[ZAK650KON.6E`MF%:7;TSZAA#HV>,>\;('N0/;QNCH;UM0+ON M.6E`7D@_<=F%S0US&_8 M*QX^ZG7'H^T#>OV>TP;4'9@]NVOKMSV[/>KU^\9M07ZSVVUO-3]VW7/2@'H] MZ[;5MWOFH#_J]P$VG=M"#;2'+^BR7?><.*!>I],;=$>VV6FU>E:WV[<+S=VZ MM;O;!_3Z/2<-J#_HM<9@;XVZNM4:FT.[/RAFVVKW],ZV`>VZYZ0!W5JW[>ZX M:X,*&MG6"%AR6#PUVMPK&7?><-J#;7MDP8T'(*M9>C#X;`%VFG<,KJ=XN$@A5M;!>.N>TX:T,@R M8;J]X5@W+'O#MFY:X_9H-.J-8`ER!NU: MQE8*[;KGM`&-6R!;A^.^/AAWQX;>Q;XLN1?:ONUOE=2[[CEI0`"6GC'0^\`1 MQL`VZ9\\!%8&#?N1J/#3-0\_9;4[D[@@BY%=\.\41 M%8\J;L>8WC%^?P@WY8^Z,3H&T'K4ZX&@'73ZHZXQSLD^,D"4]#9G"4.ZR`P/ M"2249]BWNE:[-;;&QGC0;X^&@]OA;3%#L]V19X8'12:47,.#0AU*KN%!L1,E MU_"@8$QYACW;N#5`;K;MT;C=`P>A5\0H1L9H8&TQ-"\UPT.B.^49CO5>'Y3& M8&BV>F!^M*V.T2IFJ,/Z2C/#@\)%Y1FB2NZ`2V[;?7-DFJ;5[]HK'`ZVZ,1+ MS?"0^).2DN:@@)::,SPD0J:DI#DHY*;D&AX4PU-2'QX4%%SCTO[8,G6,`*'[ MW`4VM[K%#%M#:XL7?[$9'A!E5))+#PI;EF=H`V@-_HQ0Q[ M,NG#@^*@Y1FV###1VY8];MF6U8%+P<\L9CCLF5OB!!>;X0&!525MFH,BM4KJ MPX-"OTJNX4&Q9#5G>$AP6DDN/2C:K:0L/2A\KN0,#XK'*\FE!P7XE;3:#MHQ M4-+R/F@+HB(/]=#W+E*YOHKST2/868! M%F:&24U"F"X\HYB[9AI&0]=U+4Y"]P\MW+@A#4`:\2QI&$='&_V98A+VAP!/ M7V#6_T=XX=$$.D3[54*@+S`OY_X^8O=X>,$+DL@+8L_5'AP?D_.1$+Z+9RBR MK@?\H(0WG;*(`0&T.Y8\,A9H+,/_?V'9=OL[N,D/8SQ*D-&4MUO(&R643C]D M!6#Y,0)>G'.],"?_A+_Q,Q9?6>1Z,LE, MNP,)K,4L>N`+!819L&B*%>@!9C=W3HQ5]:.\3TG^^0$>AS1V(]#`D>=H]Y&3 M'8T)^6$8`(V;M1$XUX!8``'SB```5`!P` M96AT:"TR,#$U,#8S,%]C86PN>&UL550)``.^$L55OA+%575X"P`!!"4.```$ M.0$``.Q=6W/;N))^WZK]#]Z<9XQQ!S@UV5.VXTRY*A.GDLR>\\;"U>89B?12 M5&*?7[\-67;LV+I1)"6[]L47"0TVOFXTNAL-\+>_7X]'!]]"/2FJ\NT;\@M^ MDXE,W!21U, M$_S!]Z*Y//B'#Y._#F)=C0_^4=5_%=\,0G.J@]N_1D7YES63<'`]*7Z=N,LP M-A\J9YK9DR^;YNK7P\/OW[__^#<',+YRLD;_\Y:_7J``8'![_5U2A\#O$@_?[S\]FC#L)E,*/F$BBF=2+YQ57CP]3P M\-B,T@=?+D-HCIRKIF4S`382-[]>UB&^?1,NFTL8/!%8,IR&_K=E-,W-57C[ M9E*,KT8P\L.N64M#]]-1.(]WGWP.+H!.V%%X%QI3C%IQOT&W@PWPQ$PNCTJ? M?IW^[Q1X&<'4F'0RR+6Z[GF@7Q.VK<;QF+)#-D^J\;AHD@6:)'2JL@%C!4:K M6,WG&J3#,+JF?JS?0Z=LESZ4DY">-ZE&A4]&_J&$UV![W1[Z9OM+`S]G^-U. MI_>CZGL[]I?VM)-AG)B1H]V-Y5%W@PZH&E_50%].BF_A#)R/\#A"T>OW/`/H=OH9R&XYL_S+^JND]5V?29.X)F/5^O?8\=#NO6G'\U MUZOY?:9I/XRLJ3B+*?IA:SVI+B3HD*F/H;E]S*=0?[DT=5C%U$*"/IEZ$&3" M>ORN&$T;,&NSKR:GUVXT]<&_KZMQ/@A<57S$T[&9 M%`[,PFP(P=_3)1>L,Y"V?V:?T*PW\U:0=CWV M/*SUYN=JR@[9_-)4[J_+:N3!>4HYO^9F%7N+*7IE:U-M7K^'7ME^F$&>*=W- MGR5\^VEDRG75>:M.!QK<>U/4_V-&4_ASUNS\*BV0D_31K;L^F4S'MY]U,.KV M3QL(CEN&'@EGUKPKL6_2_T!#GEFMPLU28M#JS[)H^AM_ZX<-!,;L.W`.4ZYP M?!7*R4PM3Z_3GQ"+GU^%9(G*B_?3TJ5O.H!DRT?N`S!]HS#DD-=;ZE?1=YPEX/:V(OHZ@&['/3L]VJ_ M;KMNGQV@,R,W'V!'Y,I M3ARW..K'PQ^E$J"JOA-,K^-?,;R<\^B5I!HY:RAB#GJ1RG)DG-'46F^CRE9Q M_T"QCFIW4-6PF+Q]0]X8:9D.Z6@ MKT@I.@7P@;K\=OB3I>[1?#_G['6_<*Q=@S3HHP=:-3>M#!IH<;S=LUYB(VX; MY"%&1[B/"`P@12$XC8(/&9(\8*R(S8AUNUG>;AD\F=8U2'?E0.;MYP6OC5BJ;@$9:FE[&;[;[I6AE22?6=#ZP&L( M77D:$'T,S1IV80E9SCWE0>MY!IYR:T.QKH@3#MU8"], M';I%:0AM^%2'*U/X>0H6C-QYKF)NW9S"J3816\2G$#Z/=2]5A,EBL7B-*& M(\H%>&I&:<2D(8`IE3@S4@G!]W\1VU819ISPPB/V",GHT'"18JP#009[Q57'&9$9+M)F3U@?;7G M^[1Q3CSX?MXZZ!I"?RD%N&Z:1>1)4,EN>_#M]CE?TJWHJA[P&C)?\LGXQ`PL/F=(,@I##"Q#WG&A&656*/I"M*&5P!8D2K9&:0@=.!U? MC:J;$#Z'4=J/V,@PK*3-@W>,8ZM@!@&"F'F%%$`(TTC&8#6E3*ZT@+L,?#K6 MC#X`6ZXD3XMKTB=)1>MI\'^8^J^0-L+FR-M4CA0!$SS"#' M@D14!EC1):'.K]P5VF5TTY&`NP9IR.3H_%SF^GG1QP2Y84P2'M+U,QS\?8\5 M\MP[Y'RF+,V,P<'NN7Q)PNT!IX%#W+7RF,^VSZ.BPCCCD'5>HLCA.<10@6*(F>=.8QK4 M"W'E>@WYMH)L"'78*,?Q#$X>1\9AP4)$AUDO M>T7H!*]!ZFJJ\;@J9^RN+*'YJ6GN`L>2F>WQ&4+B7]-%--/Z9BV9/VV<8TL-RZ@'KR55^CB&$3$]G2"7BP`*"7(_9.(!I"\)]3?6L9_*FI2W!6)N#!3,?3608"@I7"%(3!3*)_E[G( M&W23QRB\!;DC93.0CA$>A8QPA`55%E.C,5FY7=;39E",P8%1.;UVEZ:\")]! M3.?E\X-;MB^T034,T5@9")GW.9CH3_0_;Q[U MB^H02T(J$09&/]75MP+F]O'-GV`8SLK[&R%^W(:T1+O6[P0LH@PD6(4H@4@^ MB(B1(2)".(]%\)(Q]1+/+_:@6[UB.I!F/;WF^'GE^=$N#Y*ZH*U&/.7FJ*04 M:9%I!.LEYXJ+D(F6ASN&L3U]B>VI=FP%VI"[F?>7>=[=-Q-*"+K6V=9<0)EK MRYGR$-1+"\$:B8H@P\"MDIX91RV3"N]U#<-`2M(]C,.H#416KGATY?BS.O*C M60[ANMYWO&$PAML*LW;[GN*J;XM^S9U;Q MK&Q"#6'2Z.9=^!9&U15$'E5LOC^X3??)+NBZ'>3'_$@I2ITU-% MWAW+]UR>TO?D7:!L*"1XJ' MB&*F)")ICXFI3$9BGD,O6&.H3R.U<[*IX>IEVC*.N0` MIM?8BI1,E!JFAI0`)O$(4\RP9\P'T3))JH;9GAM(<7H"<[=J-"\U;Z5#<]K< M$*D"%0Y!<`>^>8`(+S)PUIBB*K"(960M@V']F@Q/'T#N1GD65Z-OI$>+N\FI MY:G:P2"5Z8`\<19)$UB"PTLL;%"LY5J6O6Z5ZA335I'4LVJ^T9F!]7O(,TY, MH,$B&C%#VL,/%JR9UTTJBEW;%`O!KT%1^L=S-Q;HIUKYC53*W#R1WHSVWM1&WM;9M%Z\%?4`<8;(L M.`KSAC-D;8HV(P.8&6.$22\SU?)0-WE56=\^$=V-5CV^N68C97I,FH=T4:R- M`1&M/6+<@Q6F(4/<8FY-(-;0EA$98:\\)-L:R8Y\GA^FL6P6:\3ZQ+EV)J., M:)1)DZY(,QSAJ.]/B&069Z2E3KR>U'%?4&Z]I7`>CZOJKQ_WTJ>:)D"A7I3J MVZR#7!!%&9,".6K375@LW9_GZ7Q$(G-"^I;*\2KRP[W#V8G5*,H6I^\VZB3W M*BCKM4JE'@YYHR/R%&+`N>I+;$S+LUCD522)!X%TAP539^4W&,.6!5//=)(+ M;83U5":<>2I,CT@2,+%1$?#[&>':[O76]JX+IKK!=`C-^F1N9@6X7ZLC!TC5 M8>$%?4LT:_U.%*(=-P9@_D.U&L#;;/5]+F-C)-M>1(9B(@ZIF!YPN"2*9#%)HKQ5M6"P]T"&U7:M0! MDCM<\-X7I2G=E@O>,YWD1BKM*/;IZ!5!(4J#-,8&(DLO8-%7PNN6\=@PX=BN M%[QN,!W$+M65"\%/TAO$'[ZJ\_0ZU*Z8!+_,+JVBS2.Q6L1TKX=R'@GE'!(I M-HU6>Y\I&6Q;/=II\GEK\3Z]!;AS(%L%;6FP:8A-!2._?;%Z:)I1N#V>=?3= MU'YAK+8.;:Y3F2N5!.$`$0N@1!&F0=P%GQ"WL!>Y4'6E$7TB.80Y.;UV83+Y M:J[G]E MR5V;H:%!'M+O?E_5G\/5M':7,);S^.!RBC4<[\7$.7!#,6&&I8`JW?$$@?Q4&K5U#R0>[?2WG%"SG?"<(YN=QB%4=[D\5 M!H@5F]J`@,#(UC=G@.SLRCV@!-"!OXO94:,P69:W[O&I.77:2:=!8EP*9&VR M]H8"XIE1/#.,9/M].=H66O.TK&./4!Y"F^_W+]>R8L^TSG$P1`@2$)&<(1%@ M2-S)])(,1J+7RABYUR]6V!N9_WP?;R=8#^.&SZHPE_O8MTUR:T1&)7B1(;UT MQZNH$00/`D4?"+$FJLSM==9Q:ZD\<91;`S/,8C=W16FRJ&FNJ29<2HNT=`H%ESGD5'3I$!A36`!L=/NKA_K,;71MFSM`:"B9G\?5 M!U(>M^VSZ(1'%BL"'@46$)DP M?[\Q29G?Z\VV3F3=%U2M1/TUN,NR&E47-ZDF!D+(U5)>0I)+23&L:A01YR)B M,=769>[^O4U!@UW;Z^*@S@3<+4I#&/C?0PG^RVAF><9%64R:Y,U\"ZLM_`K* M/)V"S%@D8*9Z%8+Q);X%(>,7H(#C&\*\.F9?*"TYD2[]`O3PMZ`BA M0;+W*2/QL2JKQY'OZA5C.6$N"-?2I#?;NVC!V8T<<09#QIYE&BLE#-GKF&!O M<_I=PS[9C*S.HLM+[P8KL*T MTYW&+B`:S,XL*#%Y#_.HN"AO[T]P-U]K4TZ,F\FG]+/_YM+R_X*8*X58:Q2# M]//`/%HOG/$8X0RFE9$ZP#+N!5(J1FJ-)"9LKX`OL.YB;^`>H++K7>6FB\ MO$LOB!KM%4M?W&7PTU&XK2_\`"KK;]WTXYL?W4"8E\X1[37[\ZSS\V160LK0.G&'F,SXWU<"7-L#P3$Q&TXV M+^G3:EE]JY66W^MJR2*_C[D"9T=TP,D0JT(2]T&-.-+\SUCN7-7L%T"O<*_I M5\'<_BA7=9QM:2X%TFU7=:B^9>E/?^M-YWOW2D'JG[?1K_T1P&_P4MKPGC3M M<<41,7P?YGD9VZ^&C`2;^!H\C4=W4S\95]WZ#FXK_=MZ\[*!Y^#R/(Y0L3-+ MRBUHXXP+K@N5C!@97"-I9$RC3ZD2F69%=G*R$54FO28T?7N^1(;+R15XX[6S M01X^)6`I)T7A-!'<:^&+<%%.S?*'PCEG[?\UKF2G9\N)C!%6W9:8!L[59E.5 M)AB$8,;OU]VNT+=B-N>4D1=2`!=!9-IR0Z!0&0'IU"[TY'5&)V9AP_%2,#0& M0ZKS:4LSQ5C:9@_'VOYY>"X'Y_`_5F`NG.>>I1GA+`TOB3'!&51J%^:2S*JI M^=5QHKW+TJ,+B1C!P^V1&!RJ.1:(P*QSE\)SN]_+]IE,[`AB.'#5Z]C,_-#M M.7"5`0A+,NM<3*GB2.HX$"-$QD$9Q;.3'`*O=7'BO,VF>F8[]P_F"0/0+$GC MRHOP&E-!2<*!$R^E9!GCW-E%[Y#Z>#>.1:4N(2_TV&0'^OLDU>B>RK56H!(C M"3CF"&@AB$ND([2@X)E7'-*)2QFP5B$CZ,5T82&,3D,F^P:J=A$&DIL_A.'H MW'N'CED1X0S;_4]]X]>(W?]]!`>S5&W7;Q]"E55,88>E`F.@KJ&L?L*J#G\/ MDQ#%4ZT=>PD&J#VW`+0MNB-!-KD9'M5?]TBX.$"Z73@+4F]C8>!%>DL+>C42#H./Y^C(X>8 MV24DA\'4#T:5:/A.Z\7P`[E5PAI;,&(3K8D%$[]FZ`5AJ3'*6J6EG)AS"8>? M(^C%Q22'0-;[5AZ)E,;NJK;[//G'(>GN^W5AU+M;KTI;+A`0.J4]%V#S.\KU MOWZ)ETQX!\+!/U!+`P04````"`!E@@='3R-Q]U$F```Z"0(`%0`<`&5H=&@M M,C`Q-3`V,S!?9&5F+GAM;%54"0`#OA+%5;X2Q55U>`L``00E#@``!#D!``#D M75MSV[B2?M^J_0_>G&>/<;],3?84KGM2Y4E2R6,Q$FUK(XD^HI3$_WY! M6I2MV!(IBJ1HGY<9A\*E^^L&T-UH`+_]_<=L>O8M6623=/[V#?P%O#E+YJ-T M/)E?OWWSY^=S]=F\>_?F[__]G__QVW^=G_]3?[H\L^EH-4OFRS.S2.)E,C[[ M/EG>G/TU3K*O9U>+=';V5[KX.OD6GY^O:YW=_S6=S+]^B;/D[$YA\^WR3)4HU&Z6J^S`(9.36_WBR2J[=O MDIOE3<`)4L`PR%'ZV[XZR[O;Y.V;;#*[G0:0+MHF+6=]O)HF'Z[*+Y^241+4 MY\LTL7]9 M.IV,\_7@L81KD%VWA:[)_KP,_RWPNQ].?II^;T;^WI9Z92.=W2Y"_7DV^9:\ M"\OZ++E,LQ:8VM]NBRR6MD90:1GGW;GZ5+F:%T5#%1IVZ+9+Z/TEZO8AO M;R:C1_V$OC]/KN>3J\DHGB_-*EL&K!:5$FC2UHE8J3D]'='DB1A[6%POT_GU M9=#TLI\IV@TA-15G=XUNR*HGU9T56B3J?;*\[^9CLOA\ M$R^2*J)V5NB2J$<^65B/[62Z6H9IK?@I"USIU19-.LXFHS`M%"PDXTV]W`1K#:3C^^P2FGHCKZ):BP1^2K+E M8C5:KA;!Z3*AJ^MJZO;5Z9BTRTG\93(-%K$:A3$P6=;W,INUUC$[[^/%(LX' M\Q%,[&JC8]*WOK4BC7HM=LQ6O?%97;-%,C\OT]'7FW0Z#L93'B);WE61M[M& MIV0=JLWU6^B4[,F//Q9/&_\705_BR*?;C- M%\@L_W1OKF?9:G;_K06NF_?6$QSW!&T)IRC>EM@/:;\GEHM9:S(J0F*AU)_S MR;([_AMWUA,8Q6_!.,QCA;/;9)X5:NE^Y'\&7_S#;9+/1/-KOYJ/\E]:@.3( M+H<`3-=C-C=)!)/Y\F(\F5VLRUS$ MT^DVM3O2%,K,@SR[@19,/*K9)D'A[WQ7)YV?CY.K>#5=-B1O9SL=$9O.XLG\ M>%JWFFF5U*+E\UDR^Y(LFM+Y7!MM$GD3VEJ,5E^2\PTD#4G=T]*S!`\P^;%,@L$T[K3+@Y-.-E05-`6JINGH.<0+M*_B[$L! M^2H[OX[CVXM\5KM(ILNL_%+,<^<`KI.?_K;^')74O$^723[;7:;!8'P@+0"0 MO%LFLPUQT_A+,GW[)A`3'=I$A)PFTE/#N+96&B2(9H@Y""2%TBBT#<`T3P!+ M%Z54.D/@J60*1@HN`C=^,@_"#%/^`T>%?;('D(8M1I@!#*GU`F&L%3!:,[+& M!R".1!4^#WJK%J.S=!$LJK=O8%EK/90/6GGRG+VNA9V>`KS`:_A03$V_CJ9I ML)7?OEDN5LG#QW2^#$/038O$AC`K)=?Y'YUK8UVF]=TC``)+ZL>D]A@]L-E( M!UQEP-)X"2'2$"IM2FB=U+0GO=RS/G&?5Z MKGA$L77"``1,]:_]UICX[[K3>_[[E<3R2^X$M1,(; M0*@B4#ED+?60,%CRXXUS?:G"]"=41#6 MHJ#OTR3[6B>FOKM2I(C7DEKD"=<(.B_#"N6I=XPC1Z''5>ML3UQ6!K("T$IAY"*.N@ MV/YXU([B$4+:,**80PP1K@2BB)64*F7[LB!JQB':`SYM'9O31*)V2KVJ2D2I MATY8:BVPF"K)I-M`19F0PPHMMR[YEO$YS>1^5R.984^MB#A/'0K*#6@`CQBH M*"]YM%*`GG1@8.9@0WA.H@*UMI/WU,I],.$A6*E(+#F\JXMPX(3#RRCM*@<=*@9+#8`_UI@(-[8,FLDI[A:R7F6$=TWT" M3Z7=6%$SXH`0"@FR1"DO#<00;D`EG/F!FX]'J$0RUUVCE".64;'!!9-F&0K=30!M22/M$J5VI?S'][2AE#S3 M200'-KOWL(G8')U&X_W]*F?YP]6^9("?Q_F^.A$"7#%C;1@9F"#,>/!UUC1[ M"2@9V$S>GD3;AN:EYA1Z[;3$6GNG+;(6!^/5E5PR@P:64MK!D&X1GAP)2A^+\^=[Y7I,:64T?6>= M"$`&`%#*`HG#RH8@6Z>OYP,**SK<'9869/:S%K2,TNO3AL'MK`Q)"9H*/TM& MOURGWRX*\W!QE\L>E__(Q8X?B7W].?KS\S/R??@Q8@9+#X`FS$#A,`J&I"YI MM;:_=*AZUG8+F*='0M"MN,S[/>(R[R-NAK:'/#O1DSM[?USHK\DX*?,"'Y-6Q\>MV4+DC#9<2\\!QX!``HSB@%`N M)!;(@,K074>&ST8X3_CX64SY%0ZWZ2(_?+>>NK+Z]SXU;CTRW$&,O#6<0<,Q MES[,<&OS6=6#G%5!]X3A89[W]!$GI@'%,>Z,ITX`BIX`K@3&8 M#/*\3*\*<4`VY6%8OLR\.>RDU1H!J9V`UGE@!2YY9):"X?KZK4CN@`2Z9DB] M3JT8G,\_-&5X^=F4B&/B!9668":H(I(&S[E$38JA;[?#]!,A'6:#7(@JTHWQC M"SFKFL4A3GA8]T#Y'@])'V+=MG@J#,*GA2.H@NVCG2(6,^^!QE"`DB,N3+,= MC;"4J\9TXA1!971"I;\6V`_9I5+4OG""0:22=_X[Y?3\Z6#Y2@P5I!IPAUWEF%);$DG MEKJ9H]/9&8>6)=8*)LU&5K*LFO8>%8FH9Q)+Q91AABN/,'X(W7)$F\UZY(5( MJ3D0+_4LH6-.40E)<.L\YLX0`C?NG&*BMYS6>N+N.B&C1:@&E:O5RTWB]]=" M_Q'_Z+.G?FX*?]1A+U"^3Y;W70;]^WP3EHN^^WOTJE@87/W!8_9>[' M:+H*O?LP//-[P5?+0O4^7#UIY:3O/0:ZQR7=R6BU"/#LH=W%B_ED?IV5I%_6 M>0^RI2XB#"6WDGG*-44$<*NM!51)!X31'%<>-^LZA_!(1@]X1K*%CB*E*(24 M6>`)H#FF$(,234=`7W[;_MU>=W:]/]H_Y8+,0C\1"WSW?0-6;E=WU&F%) M!>.(:<"<05Q"!C?ZX:GM:\NPZ9.6O>KFST?2!R.67FXU>);8W+^J#'9658V` M,1PC(A`FCGBI!-(;"1#JT'!#WX/0@5IZ>33J9*_E2DC;+\NUL/Z$SP;/B#E\?E2S_/CL[CV*3KH+N`>HE4(2>*`T1/E%2`$I@ZSC M7+Z,^:,'-W1`,CB=W7.\*K?:?A1F;RN<(LX!BY2TREFT%J(EMN&39#U/@3V& M4$X!>N>["KLCP>G5%CLZSB8C-1\7L>%DO*F7/PM9+_[;6?"ZEQ!],5&M1LL@ M]OFU"=U>GZ3+RTG\93*=+._4*.AAH8&GC+IODYAF^=.=X5NR^%8KHEZG>N28 M$110X:6&C`D.D;^_,T%JCYQR5=-4U]'R+28*!J;Y'6A[&9'_C\"9'*Z-K..I%"T"`AB<32 M>0F4-9Z6_&$)!OS(4&N22[O%ZO7IQ.!"K<-3A1/&29-O26%8UH^2;M>(`!0( M(<E"6]W8E0ST]L04:[@J-'X=*'S'T\*IP#$VR8P'>EQ)\M M'YG@GB+H+`B>L<>.&V1PR1\KR>WCZETZE/%]_CQ;BN MU"=2JU.%`7(BZ5(8YI M83C'%@J.U_?%YM:S;S@%]*,`Q\BHANP/A*;1WLAS@9_[.&-^(#/?I_D29[FW M,[L-!E$1H-NU[]&@J4@PRX'@G'IGH=%:<;29Z8"GS6[#[VS^;UOX/<'6QTSP M,;XKSNX&*+88VC,;[*H24:2YE\1Z+4WQ4B)'Z_G3`,YXL_-7G9WFZ6I&:`F> M4RT##_?1'K@@/%2,-%'`&44@M0(3`CBAN.34-GUOEKXT16@5I%.I0_4C1GMJ M12HL6APH@:FA'A&,D;,;E8>X60(6>PV*T`RASO?ZGEO4WL>+_/33MY.>W>AC M%XEII8#$$'M-.1/!9P/W9IN&A"O_;[.+A)FC0GG&3)\(X]BH_ M=":0EOG=6U:[DB]E;+-'[$^0)W*H%K2)2N\FX[9I]'Z5T_SAZF/@(!=$YJ:3 M0JF3VNDCM1N,O(5>$8XD@PI1[8!?I^0&9+0T`WN&M=,@9"\(#E>W/B:+23I> M7[;6NJ)MM1X);XWCFNS*MW@ M^^(1,X)A;9S3U!&M@C&(?,E5L+J:34W]9#=TJB3-\#G)3N:V>$$\=!#-:%GX%Y.@-QJZ+TR M&D"I!0.6"KVQLJ1KZ)-T%E5H?VIH`Y67$D&BSA#HM&7$&*.M)=:@DBMO05^W ML[0906KJB;:`STDB2+W<(U5,A#?I-,@W<_]:A='Q_^U=67,;N;7^21?[4I47 MK!-7)9DIVS-Y1#%2C\2*3#I<7*-_?P'2W=9&-@GV@J;U,@O%9@/?.0)NYT;0CS^^\KWL2J5*C5,\9Y?_>*#1.!:"8VNP=(KC M>%9%8=!`"LTD;Y_;U[=?K76+ZT-[/-WK=N$[@K(06,^U4,9))[%#LL&0<3J4 M%^6H3VY(5CGHL1L6Z&+]>?L=Q36V#5!X^KV@`(?&2"4P\AHRB2TP0&&@^2D9^/R8V>+V]\>9HN3VLWW\;I`HZHL,27$:L)% MM(:M0C6J0AA9KK'G#E@/K.LMV@6YPS<\*<.CR'_E:M=J,#HX&PG^W6 MZM@X\$3@$E`!);71$$P33)51=+\WSS0NK2?8N.1]V4.B$T@'B9/,-TE%^;"X MG7^;WVY;:T;?_'YP#E"HK()$61C"FU[0,"F0E+&3#]NOFOEI] MOI\MWMS$+_'YC9UMJF8WA](;!EM`H%0I0ITG@"'G.790NAI-Q_506G^Y_%PT M/08YO5-@\F/U=;NZN4_;L[M8['X#>\/XV#G<^G!0RGOA$82,$>.=DA`U.T8: M%E;3,>:)VC66^6?C^M.N=5Z$NKK]O/P4,5C_^?AY]E?2<5(,>]=C[W_;^6IO M>A\]YL[\K3*J$1X;8RB-D+(T/95;T^R5P+S>Z;WU1QWQV.D6R"(" M/$>]R.F*;L[55ANCH]<$!8A)0S`](-K1I-AJ5:-HHJ*;Q8Z]=6D=VZX8!_6B M>7>?,_9AD?+E=J?Y2]5SIVRN:]6S#[X^^MZZQ*!H"(CSE1L[S"'*`JA>A,67Z%A?- M'H.L';@L5?R(U*IPZHXT_U:E51PO,3W^5$"8(@6%(JG9C@5>&D.M4H@+27F\ M-\L*!.:"ONP+D%Q"`I9#R"-/A6B,>7`'1&R.T"& M.&#S"DZ`XU8S"!TU1&$J$6/-/KQ`>8&ER20TYNI2EV!8A(-L`MG[CA(J`+`` MIG[WW$H(4'-U:N7*5>PRN6.(-/X\4-]9MAMTB]-5)\RIPW/HKLQ^?K.I;GFJ-Y]+D@@6/`::4(]I@S+(&!]3X5=X6IR..2^JW>#!T!6\01 MEQVA^-=R\6V7-'7:R/1A%Q*$8&D0@6)6&)!.%:5L,GHPDC6W!$;F6 M).B>6:\K">F66D7+P@23'*+"Z11PB@$@O&/0`=1X:"!AUY)@/1%9Z9=Z1]5%>MOM$A*5W M`A8M1,_WN$W*YN+6_?5UOMH7M?8I.J>^.Z2Y8%H[X*Q.J'LD+:CQUC"S/*2\ MO/Z)"$Q/9!LU\[0IUHLF5_I:7=H7/]K#LEYOO^P_>T])/>Q)TAIXH@5"(AZ/ M4D)L(IEWR=!<88E;^P&^IZ16P6)EN?$.$(6$5,18AKYC"`!@0WG8^TY)/9E5 M>DM)/0_H8E-2N^D490V&@%F$?20)=TIY86LPA,[422>3I'HR*YS4*>H\+*^[ MNP]@%""EJ'':>048-$PTR%K&RDV+N)"V%[;YR.JK!97$DB"J>;,;*`J;8-P;K=HZ19T'4]&=HAJ;[(GQ%4'/COB^*&),5@!LNCVK MQ>T8[/_TW0%PBS&PFN%X00,,#&>ZQILI?GT-K8IB_@M(,3G6_SA?_]>OJNK# M8E.MJO5F2-9_Z]U!"0HX!\:B>*XP:<`/WXAB4.?-6"TO6ED8ZW=`BJ)9_\T4 MA7]7\[O[*.\JC3.]JT[JK3G22H*3QJ9F6!81H2BF$@/:J*#.YN5+EA>3'%$L M!B',J%''_0Z?=;W9??V]]4T++PJL&(98"D$)0YPZY^K(,O*$M*IC[W'&*FCA MK$>(1/'0P,DHVKHN8T'"4G4E<<:36:6W..-Y0!<;9\PLV%8>4N,()=PHCA,6 M=:(ZBI08JL'22''%DTE_O&#[+`R+4/LF4/T*C#.:&B$P-@(;9J!J4+7&VG(C MDYG<,409;!ZH[RS;#;K%!4`GS*G#7QX"\1EQIF-=/N.1H:[:]4AHMBKC46WQ+OVXWZ\ULD88F[+?=HX/QU;N" MHYIP("50DE#D&%)-HR_DA2J1MPMAL(Y=C)>29@JL/GZ-J`#41?/7:$`H<$Q' M6)O+$X!,AU._"037R>Z7$V<0AD_:UX?U>OO65*2G13KNKVIU,X];/<;/9_]8 M<`(2ABUP/%['4=-3$-(:$:Q97H"GWY!_H>S:-_93.'[++K!$V&.,E/?`0FCC M?UC06$K15B\QQE\HKQ=&JBF(QGY^XGZ[^QS/9?IH2-W\U"4$IA!@'C`!'-"& M*"E`W:4-,6/SBO-*3H*\R!PMCR)3D(?OUV`*(/7.^*_>%2"76`N%*6*"6B\] M=:S!$V46V92:6.2IU=@ M:6WJ?T^L0=8ZE7?F+,_3V:'!"Q">`Y&`$_)$^U,@+I;19#. MZ]39&1,<\6>.8EL/VT'$Z;S4J/+]H04(T6A$G(0@U1L<79;.6DAP7B!OE/3$ M$@NH4T"+IBV[SYQF4+Z_=@+BU"<=BY"H2YUZ(VE[%ZTK,*)XZO!&J+(F&@K0 M\*9K/".9T\W+]QD7(&\%D74*XM?N2AQ)_BY;6,#*8NH-XPYXK#D%A./FH#0B MKV57R15HY?JB.Z33%"3JB>MR)-$Y<07!I9F'@!*$J8/.>N!XT^L=X\S`)GN7 MD8$(,@4?]^%CX&.5J!X_-\O%3B78SAY2_QK4)AC#KB8HK2FW#ANC--,R,I!M M!EI1#O.\>?Q:A:1HXDQ!8,Z^3@^!TTL#L,X7&81&W@.#$.&(;F8/@['[*:\/0ABKM=6(1_N0:^TV!6@`]HT`3QRBFE@C:'%+.FLR.*U>;M#8!&DW, MO'B^UX&LB!5)PM=&1$H@P:BN^CU%P5_,D MQ+MO_1[?\]Z7[VP>5(3%HTP*;0`DB`&(FHEOR&GRLL M=])"#ZEK"KR4&"JWMN^^?">S2G]]^$FQ`*X^FA'B MLG52W\3[\IU*^J-]^<[#L`A+:`)-SBQF"C#II(/<(N`D;AR)R'`*I]*7[V3N M&*+;61ZH[RS;#;K#L^I9??DFQ:G#<^@+TZ"U)]^;WP]>$6^98\E/3)0&3I@Z M"PQ!2C(-TM'LT5Y)N^P>T"*.LD.890W^[L.2RYM`'G4G"2/DG#J`F>".VJ8$ M7RLQ6%O2P5PMV;9+R72Y$@GIKV7"N6L(QF-J@+7..V>8(?Y'*CWBS`W5^[QO MN>B9.8>7H2SR35M\GE<\CB(]SY<0-.?$*2/C'6^$(98C11K^@"9/IRXOZ'LM MPG,1]:8M._LPX*BR\WP)@7NDL'<&.9JZE2I"0!U>1$IF-DTNKX?/MK2*:J@Y:H:00GD*E!)"B81**>9X$E9=#<2T2="D!IRU$I]E`7OL"?)`62F\Y%Y;'Q5Q)3C6'EE<8J.4J_4O]$BXGT4("Y>\$`U= M9"1Q`!D,D61,^D;_$,!QS`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`B2&. M&>1\O%LC)/%>I?4^,,H<;=9;"+5;8O>'4Q:]/U7U.)77K M@\$*:PB-BW4,,42)A;Y!!D*;U_Z@-T]?#U3N&J(ASOA?JD4TZ1_B@M7MEPA_ MFK.RF7^K3CWH3WH^2"A2_`%I2#7F3$/#3+UO(F!AD9Q^3OL^D!JL5'M[L]FN MDI_X?K:ZJ]:GU6N_^5!`A'`=-T00%`R9N#'`FTL-P;QAR+WY+/OAA<[@&8(! MU,.."-7MV_[;[_Q[A!E.^X$`@=9Q]T)HX``S0F(DZYU+G-MDL6O&&,AGU2MV MY;J8C_N3ZS5WO[R=]Z?WUVZ_?)FM'G_]4V_7D3'6ZW@7?)K?+>9_SF]FBXVZ MN5EN%\D*^&WY,+^9E[>>?\U6^SMK(#*=N[[=OQ^/K>IO_Y?^E*(\\7_^'U!+ M`P04````"`!E@@='=[?AKD!X```TB@8`%0`<`&5H=&@M,C`Q-3`V,S!?;&%B M+GAM;%54"0`#OA+%5;X2Q55U>`L``00E#@``!#D!``#L76MOVTB6_;[`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`4$ MHMCS(TH)#A(/)UYD>^ZD?>*$+4__N.@`M!\):^$=#PV/&2Y8F:^*Z3I+U=": M/+U&^[<=**M#97WITII/1=*Z9FG>U!1YT07B0;C@8FKEQ8P5=;W3_59:3%_P MQ^8;9].\SN"WU>F!:YJR1[PEN?"86Y-3F_(D,8_Z49POR[JI65N>M8W>?Z[[ M850;^G42V0BZV$.>8WN^CPGUD[AK$P6^,ZFV">3%[C2J(9X.53V3U([TJB@M ML]+Z>&5]JK]4E[TMQN<[DP0B^TF2,@[Y1.D`ULE:F.ZM+YL_&X16"U&U/AVC MZXA""6'9$(T28TLN(0Q[ZA2[J6XF%RPM\V4ZSZK[=7,/&X5Q``(/@S@,*4"V M'2=VTC5**'3[")68EB0KU1Z^GOHDB,#C`J6>.SZ%VH,V2)YD,#K;S+&TO<@@ M9@]P*6/X00)HS&YE'7@.:$6]%Q%/J+I8`C7+NF!C'DI/5($2_..(86Q M//MR16'.J;,7[+II])S=YD4#93>Q$"*'V#2V(X0<$+AU6Q[TJ`U"GP3()CV[ M\^#GRZSZ6DC6%I.^J;+GV#G2`T<3:DA/&V]'+CC21O85ZN"K;KM-@' M/@BA@W!LAXZ-(R]TNJ:=P`UYBA(1[4FN0WYE^761WMYD4^O]\BHO%NU@P<++ MF76172^SJVR:-JO'J[+*%_7C.4L2(8P/DRW99(]5L!T^ZXN^0J,':QS*-H9S M0T5NE$DOZ-UXNGI+W_OEM.Z_G].[79M;M44>]`F@08B3*';#T`D):9O$D"#' MZ]L!QS0AK^.M45DUK(,>IZM\.$+2D7XF@EI#^I<04W+QD<*X3A@1'(`P`##W0=].9N`;EZ?@!1BNMN_@&I;6#J:]4 M[LW@D<)9O!<,*:,E&);+#F#17?:IX3/Q(H1Q`A(G"0.$7<>)@PX+"AR/9_I. M"@#IZXK[73J^28MKQCMI)X=X0;(IFW,)"FK&3-\09L.[?C$#J(`V;X7V%$+PJ<4.T'< M>T^LR$9E;I+=XFQ[_`%2(R89N9@\NG]6AD<,Z=R2C'NTPU8>A;V[\X>\+'=- MWW]BR^;(:#Q/LT7Y^VIQR8I)XMBN[Y.8T,")HP0FT/&ZEBD*N.HF`?B]76=VMK[)YG<+3Z[0Y!5IW\,5MNNR[35EE M-F]KIXO5Y?^R:?4Y;_IR;7U6LOT9*GIW6_]K76PM9W@^S[^SV1K?)'1#!U&0 M1#%$#HT=$OL)P3&)G)#$"4)-L]+0&RBN5 M"AS54TK-\A&GU.[`6QOT5I5;._PGUJ$'Z;X'-U9L9%FU'(_F_9AU5WXK@DP<2UJ>N'*'`A@39`.*0@B)$= MXI[:,?CY\A2A@U377(75@M(W*'V.GB,==S2CAG3'\7;D@D.-=^/L](;-5G/V M\0K7A=PLFZ^:!;P+-ET5;4^G=]/Y:L9F26UZT]E7ZS7HCU'C1E@F81&2GW],%(_DB MS983$,>^`]T`.BYUDQ`',-IF11=1KO'1Z,;TY(D3JX%H?5F#%),O>!@>(_J2 MR!6BW+UY5:C@.[ZX97@`U49KZ1![>@GB8*+Z3Z\N;N?Y/6,753[]^O&VD=O? MV'IY#P(21:$+_(#Z#JW_5E?YFP9]X'`MH@UO1;*.-1L]ZI%YB\M:`ZO+I#4V M7OD:067/J6HE+'+.56\P'5#8@T$YD]7/$71LMGHTJ89(DP!#'LY7"Z*&;^]X MUJPNM4UN&H.A3R,?)Z%MVZX-?91XM&L,A\B>?&/%9VHL]F$=#5&>D$4_MIAY) MB:KIQ@_9DKVOV*(><-JA3T*OF0A%L-9$$I'M@#/R':QP;K$_*$T3B=RK(XU% M5FN2XNE'#O\JF6N4XUHQ$XMRO&KB=.36"_+F'OD=;4@N4&^WV%G%H<3WNW[D MCR6KVVLV3NU`[N4[?KAXT=QJ.`$Q#B#&,`0)P)$-8>+Z-=88$NK[8;]QNE:` MDC.1)+-XKK_0YOKCB>G5>)TO2?T[.YSC%I37X/AA=Z,H#X!^=Z1(@O5$(6*$ M?TVX3T4[![E!'4[M\+@#YR`24.Q2"@C$(<&4P$TE15SB!PK'QCT122Y'VM>Z MJ1W)]G6%DF&L!"]H&<.>6)Q9P8CAZ[,I0X]WW\;`E==HL:/6093WS@)1.F_> MIWMQPUBUN=MB=P)^=YE0`D(4@9"&L(Y;@.K_@O7]7Q'PO"B)>FJ+H-;DB<<& MH-4BW-X:LX=1WTF=?MP=Z?J"R3>D;XNV*I<:L;PG?%:WM_/V91;I?!_)'H3= MK3..ET#HP>9&"A)&@8]MNL40^3CF.K\CLF')%==AG]V\#(3[2GRA3/=30VTD M\VGB/DSKD.P#8=1X73X'D<>.LLCPAR$R*<>VA\=0Y!'86S)W;7V\:NHJMBS; MPFHCWG%>5F5;5UVF)9M]2N_7MP!U0DXQ#2BDP"?0B8+0(3!RUF\'"NOQ=@QZ M=FW)*.1U]KV+LNIAT3[T;374@C]9CY).6_Q69X"^ZF@H1SKB6,6IW-F&Y!D-AC][9%HM]?W79]H6ZM]I#[T!G-@HIBYR M_1C[3M,FZ1JA%`"N=1:N)\O>2-AV\0;-P$/(?#3U7`.1QA#G6D9_SXC3=9WR:R>DN.;6C!$J/E9$Z M/6B(BNOEX&%QJ=\AXG+*#\,/A2CPIN"THI:1W+.8"CRH9[L\R+S8W*-.+>^ELPBT&+> M/"*:;+ZL+[^QLF*S]67SFUF8\CR?SY.\:+XXH3Y"*(Z; MEVW``+L1!+[?(<>1;7-G%;UP)6>=WW++BBR?751I44D><0W&R".< M#\WAWA:8[^!9:641-FUOG;`<^\2JE^1+AG MEZ;76PGWC(QQVN@H,"F?Z2%`U"A.D"N49:M?ZR]6Y?OEIU:S?RWRLAY_`D0C M2.((N`A0+ZK1AAW4YH)#)7.#(_!)'K:UD&K1TI2$!GE,31J2[2Q]B6AMF94M MK;5MS2>U=:\L&3WA'XGI:$PTO)&$-(H"P2EIO#OZ)Z5F.NM]6:[8C+1OX5ZW MN1["[5U=6=([5DRS&N^$!K;K.010W[$=;&-LVZA#XD0>G2S9=;.ON&?6$0^@ METZ%:YW:Q]I_$;R#,CBQ2&"]9][01+?VM-#9LY<95*<$;NJ/*;X\/YHBZ!(M M?*C7LLE4-D9(\N**955[>G8YHW>W6=$^89M,)M!)'`?B)`'$MDG]`P';?0Y^ MC`-.]=:.5[K8Q\T\UWRN;Q0AP*=JQA2*G*D]E>S9V;Y%>,]2?)!/?*BD9*G>;Z_IW/?B*2-($#^?#^7*Y1)UC_:1?6U MS+8OC?^<-Q\]QN]A"+P$>`&@((I='`;`[O![,8E4+@((`ZUG0Y>UQM^6=6QC M@57E5K/!88CP&1X8:L8%6F)"W_!@+X3H7@@U'[^%9?*^WI28384'U!M)LN)Y M$9Q[)3E.64K>S/\U!],W0&T_=*(`.PAZ`2))F"#J;8%"SU.9>_G1:4JR>T"- M2:H#7*LF>\KUJO8%F<:N5YH)'WE&8LH;'@5O)+>-($!P$AOK"O6G@/YDV?5- MDWB_L2*]9NWV`I)6+$FSXA_I?,6V=WT!QP8@\:(XMG$2!DY(2#T4QBZ)(2$4 M\P\ES8(O.=]U0*T-TNVBL_6IR*9,UVDA@>[G2'EF(7\=.7'O--&C6&J-MQKK MK<9\J[5?WY60ZGVLXKR1^(`S*?T:RI"L\TBRG*ECT>J!+5UB:?/*Q$EBZOC( M#V+BV2"VD>UO3R%C![M:3RV-0J[D+%.'\/3IM'UB7?8^[+0J9U:-PVK'L!K/ M/(T+%S4#6QTQHB^U'TS\#BX4C1P']W2DFN55(:%D4M(VB19Y2[$"W:;@OK\G M]^D?-2&D281]&CFN4\/W*')(U)G@THCKAE&3<"L:43^;FKV5Y6)Q+Q^1B#8'U6O*Q#FJ$78XHVWWJ\O+VK$\O*V@2 MP"3&8>(2EP!$,8B"C15QF&"J-#6+A:X[.^\=E-.;GP5'A*(4K2\8-&;I)P[J MO;E$S>58F;E:3H2]E70MB1W1&5NF$\TYN7C4*,_%OA^'U$68Q(A2._;CSBBO M-E/E-BRYENA.Z7O'(;5.=DN.%S53X.:$BKZ)\5ZG*5]=!2#3\3J/8@H)R-=2 M'YA!ENHCG`)=;-Q*>12X!,'0!R@.8@\G24RZ?>7-$H.M\=#G*-P*CH*^6!GT M.RO:MV@P4K9?STIGWX!Y(U(LG!9-*YU\;C/H*.KQ]5M,')3$GD]!XD0^`J[O M;(><<0#-.J`ZRA3=PS.^\ZM:1W"R@TK-$,Z@>-(WANM_Y/5M#>/&.5_K"5DA M4?E&J@=5;"D_32O0R3K.V!Z?Q_;K$@D@%SJ(VI0D@/K=+=VQX^!`T\G;49AU M5P\/#N;^5CO]IMO=K+M<$!87:NH"'2&AKP`X.,S[MG)\3T>J.?LK))3>2-86 M3HN\<\("W:;L]/#S9<0Y:]Z86W\>Y\OV_-0JG7]FQ0).@XE;?%:>X"M#]D5L_YZS]*B_.'9*=A'!Y44GT26$DH< M:=PPZ*\CI1\?MC\=C8W]K^P<\@`'2SR(+#/<3$K[IE(D^"BR?'>:70[$-"&> ME\1V&,21[U`_ZE[[&`=^&`]:;37,!ATKKR-*@8,%@/^7:D.#Z=]9JOM29()4 M<[E3F51SSPL_9Z$]"2*8)""&T/6A[T>DMFJ[6=@#CJOR/BB%9JF>A^TCZ#PK MNXK'=RH#3LVPS]!8>Y4KO&]FJ"@N*"26)1HB]XU4*SJ8$US$:'.^LMKF^4GU MYTT)_=C%07-U"/(`\0&"?G<]9TQ":JLL8F3@-[%:.7;%L^+J1$K(J"E#=$>+ MJ0O*;Z:D&.!@B;6#S'![(T6"5(H$5P/RW:GC?,_[&G&V++-I>X7G)(A!$-H1 M"'%S)BD,_&9.IMO%A@C4>O9ZUE5JSFP-#`^3DJ=>(N2=RQKE&M6[HW=W?7S.JW3^$'L0 MDR@B$?0='/@1I0YRMSO*`IIHV!H]#K#D$>Z1E+B]P4K/;N>1?E:ZU5F=B[4/ M2P\OIWK=&;&/]^1O;A83/&\D3XKE1,ZV9I$.,V`8Z?F)78,.?`^C.,%V2-SM M='<<8JCQ8@A.I`HV)/$/(;5O.WHS0X:^[G\C4BB`"&5#!C[7&'1YP[8_/S`( M$6`G'@*12SWDH-HRM_082;UWL,P-@K?2)Y70)3RVQ?$N%;'UII#P/;$@\"-"4T2+PQ];%,[P=M; M_PCU8DT[:'AA:I]&-&P[#+>;E>]ZD>EA[;.(Z\TM!B1=*;Y2LT]E:("8E#8U M,R%OU\DXY_1.?''#=;./I6G_/"N_?FX:GY#ZP8!&V(-V0$+;C]P0)2BAG@^I M#WVN"X(&-B$YX1R@LAI8UI<6V)&700MEL%\^4$`>GY8/X4V*^C[-S!'E'$FE M(:HWUHI<:'R-59OH/F++Z3=6NP?:\I&+C MB!JA9UVK)&]V"4\\GR0!@+;M0`"11P,_=+IV$VC[X_2,LS&M>K;&.%[1>`D> MJF@2N16I:"_2JDC3#NGBTK2!3!NK:4/M>5'31A'UHJ:QF^JF;G2QR,JR:9%] M8\L5^ZW=O3Z!,(H]%WL4>M#U<0`1]+JV,":]QH.C&I"N71TL:X/+^K)&UE>Q MQM%W7*64,<>K3'I)F^7353.#TO80_>0=P)%+X@-1;TQLI1IX#FB%^IC13XBS M$(XT"[(8&W*!0<-93.+I-%\MJ_*<35GVK1F&;]I#*+%I0!`A@#@(AUY(MT*/ MO"#D*2('-R)[_6>#R]H!XQ63\3SVJQ654,BGQ,/8DU(:/L?.D9)P-*&&E(+C M[<@%1]KXZ;G/]1/:$;1+$T2;&RT`JJM.-[8Q^C_JKFU)3ES9_@J/G@A[@OOE MO"&!3CC",^VP?6(_[(<*NHKN9KL,'4"UM^?KCT0!57TI2JD+X(>Y=(^'7%J" ME:E4*A4,)I,H!-6SR=B9?Q'+H"G+Q_'S*9R*TT*E])J5B\6Y$G`#1;#<&YC8 ME>B2DJ%#Q/1'DV&`?;G]2GX[2ZF3 MHNP:A%'1_4L]9"K2IY6DTTXD@?8SX=2N5:%$AG)U9U.4'K[4V5_9?ZKZKWQ7 M;-F)KEWQ5.P.V3XN=R3[4>Q_?2R;0\V.]WRF;V+3QW%!@-,P=&P2D]3S3.+$ ML3G@H&M++MG29ERSEG60C1ZS<0)M4-3&$;8QXC8ZX$+I)2WSPI&O6WI*8(KX M6\\&(!&X]*R()0GUS`Y?%E&`L4L91IWDKR'[J'5\U4QO,30J/S1M]2.O7[G; MP:SINI[EVHD;QR3"EF-9HZMU`Q_43T/6EN[HO(=GO%4C)Y;+E&:7,TJ?D5A@ MI"[%J9YH?9JLJ8A=$=EY*Z4)MZ-[Q>V!A`WY9!T3:T`6T'$Y!+' M<>HFOA>.BP;'30![X-*VYE(RBDAP3U>>3JX]\5F9E$XRK()7T+;YK/R*[J#+ M\LR[G7Z-C,L[Z\IH7$.8JW(XE9ZW38GT?_M9]69#WPI,.T`V=BT2^7[L!/%@ M-C)MKAUX5;;FDGZ*2*U$`>B4D7X]3*J3_B5Y52']>OA5+_U\/$M*_T@&6/KA M-*Y:^@6&PR7]HC3)2C]]'0:?X[*;/,(X2GUD>9:#0_J+P3".<*Q`_`'69I-_ MADFQ4$%(E7(!FOA4Z`069E>)(]#$L@97P,FVK#,X$0)W!P)DKMLAB`R(SR4( M4R5>:O*I*/./;?ZC85O'B/6P)BYU159*(CM%8^F=11RI2A-^,_,7FOR;@3,Z M=-)U)@`Z!SC)`E,UW%MQP]"T^T-DLCTN*[$EK>B69^.V(SJSFA.Z(SM M``^RV),CDV,)/1N/,&GJ*;RY,\Z`C>NY&2D$K)-GHU)L?2Q,*=^B>&KTEQ;# M2AA;PR)8S4`JU2^3]/G3OW-JM:[IN[8A*$61@Q!)46(GB=/=Z=3;]+'-5?R@ MQ)!F\1Y/4M8C..GCIQ`:^2+*V1B$R?8;QU#?&Q39>Z/'MOA9U!--$T&E$G97 M$E2J&9WCD9@%M680I;Z# MO32Q41(C,PH]G(8>9,-&I5GMR^(>;.?C&5P#O>ZXVR,&]KK4,0E<&SQ+\0]= M2?]>U,,:IRPT!<+M5%1.!7>C%7Z2+F\-Z6!Z#>&QII%5VE]38`#]L=S2`/TK M?6.[7L^?&.G4='KH'8E8;22H53JWSPU"M6?BH[< MF!KS3!28ENF&*;7N#D9M+P9M(,E96DZEQ!HI2/(JI50:*%6F5[K3F..!;PJSZV]Q`BHJ<4KI MYLE;SL\T,&&Y=I(A&VK^U_4,*[*]I75)$RPZU$CJ6_[MN9G77?NO>/>C*(NF*_=]RI\;CZR0H(38R/*0$_C(PCX>C+NAQ545 MH=:B9G?0@^SS).P-=I!O M@6XY!C]<>V*NPP/.P$$IXLV[:60'FFT[0EE./UZ2,9E8$^1M)8HACO]5$DV* M"(!;[>\Q.MW$WK!+CO*\V?A1A(F%W3CR_32)'!3%[F"2JA)H52%C1W]2K$<$ M/I(BP1UO6#(/;=#09+@'[0Q6MSO)@,T>G5RD:#)"D2=V)9JC9"BO(A55]/`E M\6_:A[SN-6^#3#-R+>001.4.>Q%!5C@8B!V$N?/SH*=J5ID."R1["Z.$(T&N MC0V8>'0P#%BX)D`((%.MC1BQ)'2/A+5'JN[+XI]\9^R.6Z44)VO#650[@\F` ML<^SG7'?U0,P"^^-]E3DMB^V=#D^'+6IRCW+53>/]#NNZN:A>.Q^G9V=;:)! M1O%4M$7>_"F;S#XG]%*>6HCT-:2@Q8!7LN^;X-IO0U+/#BWDN@%)TB@Q0S,= MU3H-['#3LDPJ;,UW]:$@+1WM`Y._M=2*[SHQL)6>4D[$5G@++>LXEG/>PTO[S'5=.RR*S/OI[6BP'"89*&3N2'88KB*$VM>##L MHQA!%F_RUG0'5P-`8\L0=KXM[S'^#U`@%%#+IQSSL@H,TD9"\4CH`&^Y1-)5 MQB:D2!W;*]$HA0.J=+V8X-[[37MS-T1&L>N;7A1[KI M=R0Y6[4#M4.64#XQF9%+F+I<;>PRL]Y,$S4A0(H87HDBJ1I-I>4U5-EO9&,3 MG'I!@&+7,BT')XGG6F/NW$^XMM346-(=XPR=&+:L$T.W'ALAJNQV<9U1CLSX MK&0"`R*.CA;S\JFP;XA27@6/A3_D1I>!'/(%YVGWHCQ/N=?YOBN&;"OCL:Z> MBEV7;YAXSXTFKY^*;=[\:5`S]-'#S_3!V_UA1Y]^DB&`:\_N6%?HH&&M1 MB,G?_5_&B&8'=M8O@GU@VR,X13TXKC/(X;7F(@_FL*;[;,S&GYKN)4IYU.Z@ M[JKZ?`?X[+6E#NC-WX])VF*DLZ>=2%5=NB?E`W1O[B7FRG_EM4[3Y M,[S4V>5[]AR#M3IMZ5\O_K2TDYJ8ZDO^2<7;L0;7I&068?N"-9DW.@[VJ;&EV3^G.5 M=?54F4@+J2)Y)7DA9<.!=5`!TB35.V43!"0.3-,F@>TD.$W,V!_+?PCQ[,U3 M7M]6,GU3KIJ`?%KG:`#U*>?]/K9'6`I:I5PGCT^;M+,&$Z0WVZ.LH"O*9)V/ M!(,K41NY,7#T0`$2PG]&_$=5M\4_791^<_>1!L[E?7&[S^.FR=MFXR6,,6(D*U/*$3HD7!)>D]^31$THE"*&5Z)5JD;S\H2W2I)`53_G548;.[(#"Z'8]"(< MH(`:M,>:R%W!N M3"`"(O)\S1K2=X;HC@#U2E*54-T0XHU/.G13!E./4RESS]L[!NB/I4J73YQ, MJ(@,@RL1$JDA7"I(%J:#7T[8V:R_J[)Z;G),;.,XB$SBL;U6=@8_L;VQ\#FF M>$"G*N1,:4XP'X]I]D')>Z/,>?<^53')J37SD0B4G8Z_@2:JF MU$@-QVL1)D6C>:E1*DD"=L5B@DCH0-DN7%$>J/&;,2Q`^5U5Y\<_]RW[;]ZD M_VWKC+)2%&S_6!65=+AIFJ1-^TF3%!BFYX9QG9"S,#%:3(JK)VR MAM[\4=22..>)QFX[_,?*,-8NH=L<+X[_K67C$;KO=J&9Y=/>WV528<+]+$H\ M!MFGH1FGL0TSWO_Y;GCOC6<#//:&?6\\'Z,Q#'*1-FY:IFO">:SA)5F)YUD% M%6^VI%O#]`!]'H72^U9T+$K:)`[K*1_$B/[-B9,@1"<72^@J`7ZW.MR&YJ#\ MLUKO(L`AQ#/HI4](U2FDL7WWNQ[5W''X!7*N:J@XG:O2/XEAO*E=LK1PZ\[? M>7N6?_!L)[$CCQKQ'1+XB1VCT4@86R8D.H8]67,\2\'TR@+4%"`_?$JBCQJ8 M?C!6GD>&<=O6Q>VAS=AF:%L9G[-ZLD!W-'16ILGD#"-$JH7>('CAMZ-HEL:CJRK`A9?FB%L+X& M\O8TQRS/(/;*`NW)HH16WGW/>1F%;H6>D_E,D.@R,^]Z)U"D[R^HTW*M6SAH MG=Q553JFB[8_LD;]KL5)EU'%O_>?0M.RHS(!Z$SF.B5`4!%&2T/`N=0@>#VL[-H'ON\P/4;/, M]LB-;0_=:$]HC6R$*[*)L\!T`C9_UCV3(IM&DR(_S/,P,.-L9%V-S-G8C-/@ MSKW#$OM.RF?IVG[5>8K`4_,5,2.DEJFM9H MTO5]4'61C!W->8"WXG9U8?MU%J7#=:4$SAJFKROW$ MP9S\@,>@@(XW9+XW.DP+RTV'`:`U,!Y7*C3`05Q1&1%*A"4F*?:'-M]M8M_% M%G;HJH60Q`J)$WJG5O$X`-4OB-K0+#,]#/5"P\VAF-3HH$]>;'I4"\M-CP(@ M.%`V5RHYX&%<$1TQ6KAEYU]YGFYM"R[H.L MI>'IQD%JE[AQB%P48411>>EX7!WC(('HD7+CFH5JP&OT@(TC8K9N/V(VSD"/ M7R+7]MI,D\,G=(O."TP!-4Z)%IV$4CLAH-IF:27*JF]\U4RONR8M/L:AQ(IC M-T782QV')$YD$SQ>#VW[",,Z>*BU#?G>A1IZG%:F7:`X=7!S#JK5RJIZCK5J MZA*K6Q"5"C04-B6_F8`"!R>HGB(4RDIG[^Y?8=DD2>CYGDG,&+MVX@=\"KRG1B$D2!Z?@NPB9&3HC-:#"2T@4H4$8!3YZMNNFW M.&#(R]9ZOAP1\),'#&$4\#=['DN@FV_5EYP-L-CGSTQ_JZ#?INF[41"YJ8-< MY"1FZH:8#%A]VP;M]"T"4//7=S8F5J1;#Z-B7='&+@Q5]].6.=?#T9^>M7D] MQ370HX_+3#A?Z+/ZN88%1R^F>1R0\?KP-_W/OTT8I6.6)CS!HB_%2AS*LAR\ M[.J]_(1PN[?'YB329BDCR2NJ/_/%;8FI%45SRM1267#J?2\CF#M>J2187&\ M<9+8MNT$IH>BB"0D#2+''/416RFHF!?T8.VJ=,)RO'SN[,X(L#I!"..5(DU< M077G!&-V>3F9GM02`:)6(QPBV%^IA#`!?#!Y26VF20X\"+330?K%B(^]WW*ZDSJ7E&_OJ:IA_IA-V`U MFAXLY-)@A:1/"\Z"?`-7M:^O<.I1&B-,X^NR5`-N:UZ&W,3X%IV2[Q`FNP;CK8%7(Q.7Y@%94^"19!_J8^0B7 M\#$W=P9#V?USX!JO@&M!)S,?YPJ<#.7\&3[C3%/*X(S5SL#9WI&A4E]R12M+X:PK[X]/Y MCC5`RK9.XN["5?[ M%H7FYMHXFFXEIHU,CIAV?AYA648AUVD!?@%Q+'S\RP6P[)H MM*N>>:"_S8W=H6;%$RW];9T_LHB&_O28UT75E=6PWV<_J@.=A=TAIS]FK5$T M_1]O#ONNJ)_]1*$<6.?()_K(XHX./*=R:-SF[<\\+UE-SB';=U])]QRVF]'] MT'OLKL[GOBS^H5/.-CL,MO7-#FY\H(.BC\F:HOE3-DSFFJ%+(;+:Z5U#>*QX M1)6V;P%^9]$+XV-Q!BS;;CY45EA^%V"&F:X=A$I#0=P*G1X""T(F`UQBI M,JO9:>'NRV]>5,UU]\YW'^:^R&Z+O5`%G4KN^<+KA6@7]''O!IA_,/9/M6L] MU.4*U_AIG(C0-;IGK;[[DV[QX8HUS-]@-4>*@ MU$%):EDQP4[J#[;#B'ZV97Z?M?E.5#0%3')]M]'QNSU'QY_VZS&Q**4'):V+ M(M2**J(N3E5JX-&$24O>9KGZR8C?$ MIL1EK:+-*+&<.$XP0C8:[=*_+%F9`YK3+G$]GF$]=@P$J^Z*C&-D*"UX4()% MQ4X'LRJ%;F#Z:E)C)I%[SA=(X`2I7JVXB8[GJK!)$:4@?ON<_>K4U(OL('*P M[:'$3'W/#ETG'@RG01#+K7>AUG07)0P1Q>,1C[*0C9M-V7A-!Y%J@[7/UZB= M.5+K\0B%:5"V5RMCP@/B#M#$J)(0LO3'X[[ZE>=?\GT7VYPR5)O(2E#D6ZZ7 M6BER'-LQR;#5A3PG!&UW*S6L7][JP\L-:/`=BXWI7;6Q;G6&@#?Q9Z%>SB M#W2/0(=%[V)T2^WGST*[^*9^,7JIW>BEKNSN9Q>_!PV;[9?HX]]QEYZ`_V?O MZGK1I5=)KWN=?1#N3_LGE:'9FIE#\O=UUI* M.82"I;B(LXS723S()!@0)!!J-17U8':F?'IWBDU5%BIP4W*\B61;9-7S\>QJ M![9A_@7:B-V<^0D)]GP1L,NQW4;"+HL>Y4@WD79#=(BYM"//QM)IE^1-*6E5 M1_/L::>*J$_WE$@!8RH`D5F>LH(#(>B0TB-(C+JRNK/J>1IJ8)V6K4ZO6K6E MUS;5GH-9)Q-/RW6'-*@=[RL4FM6K3@Q#L+GX9,=>KU9U0IV'QO]JGYVAC&!* M$EG$!8`RZZ_?4@!!OCA4A^5&3Q,=FC42Q0&A]OC]O>^0^^VT;^I3WS?U4K]< M;^\`O!X"/=V\$?MFPFG1]S_89O\CXNDA%H&HIP_/K)OZ&Y(W53]_VWZO\]K+ M?6@+PC-,N(""U@0@;(,"#`\94&QQ,SLWH%#PUK#?=(-A*Y#TE[= M*/_6X6P*VLH>Y-1+"2[CH*>[TU4,H`M%4'YY5WK_CJ1KZV_90?\3K+YN2-%JPB!.:%S$L),]C2&F>23[L MO<(\Q1.ET]C>;(K9-?7MT#F21G-Z+171#Z_.A/`(+R*O$#N/]IWS92)YUER' MJG3V#KTF3A',NNIT*Z#$0`>]5:NRO-O+FHZFZ_+[;ZIF;B]^E+O5ND:U*-1I M%&`2@XS&!!>\@,/QOF!2F$CK=&N>E52-[V\=R$A](E'905-K\%7U^%AMH[U" M'E4M=--E^'2^-9?ALU)MN`Q_P7"#+NK@10.^N9?AK_$UM@QWQG4@4NC0H?-E MN&.J]$K]E=@JB3U4]0!O.FI_+`^'3:DV-0_/Y,_E[FZ_(#''*28(9:)`*$D% MP,/Z'TB9]=N+GS0+_9T8M=AC_&31,'18?KW]^S9M'?K%46C.84(I)+PK'`J.`)CH]]':$T6"(XM#K/&N&([GPK MQ+(280K/9J4(OKF=5HMP7^VBE^2V`-N-D1M5(URG3*,WW]^^J[==:#!Z[%PC>J:M>[[]LUE\;]=TO($U("D`ALCF]__JG>_EQU#WML%'[3W6"G MD=#3Q-E#8"6.1Y1*#Q7.M_6:XW%X1J6!&IU@G5DF#5@WXL?[6N5'^HT[?U6 M@2+;._4OMYJ-Q*H;/,TORB-VTUU4I_'0W#2]52@,]TB'*/1`(X54L<]Z M]IM?"!WV_>R(&C`YM@'J(R"!J*H?W\ZW-_T1J*VLEZW]T70&/N_MLDA3!F(* MA,QD`6`LTP(.ZLX9BDUR4Z>&9\A.+W557KM35+=QT%/4FX7`HBSBDFR^B5JL MT84653-+J@F5(Y+J)2*!2*H?WZH9/FDGDDKJ''JW>Z[3Y?]>;I[*!C;N3"`*5^TW=D_'I:[PQ1%-;5K,H[/(9H/Z7/5C):'Z$OY=;W= MJC6G:@#0F'`BIL81F**B/FEW)I]+M?9O448-S"!4\XPZ8[FTI3YHG;1V2DL@ MIU'F6!GC%&Z$?BEQJFV4U;CU(PR[7':U-@\5)N:P7U7.[F].Q;>#'?DRQ\'NE$G MT*G@>9&P>ET*,2<`,(9(FHDD+I"(LQ0MOI>[+Y7NIIMS\R9C]Q2I]LAMSN$[ MQ'_I2H<-CCZJ&\>]J4U7US;:S/'/Y7*]:S2^NJ]7 MK_?5[G%9\]GHS-^WZ\->_5ES9DWV^Z?']G+4)_46Z]&!)$\*2%(D)90)K',Y ME,D8)1F*L4`2:;6`#P^UYT.4WA>5:^U/9*7SM[W=%/W'Z5]33K?+)_7_3OSN MKBPVGK^)!M^C$^?_LY8IY7^D)5:A?U#C,TYX@#U.5?__&=E_1@97S8(";O(Y MV5U9"_JSTKL*-V?$+N15X7XU(5S-"Y.8*O0!;[J\[C"^O[]\F:6KIWD^0Y." M@B.<$YE34"_X*6.PB&'].X5(L,@SD[H63Q#F2L[>W_?U:,^U@-4C(E(/WZH> MI*;GKKYBH;GXOGT8[/.:Z[?^AMA,F#XGJ_-YR#5 MF3R?]B.Y@@PP'.<%*0#*>483BM,4],@2'#N5:@=P9I3MTRX^YQK>_ID/%7<1 M,C>*/G.T?*C[BT9,OY+8O\[]!.%W&-A?9!)PZ;'AA."<;&>30_,:Z'IU*.^. M*XVF\<@5F'D]>3')N$P)H#`1"4J'.8RC.'4Y4[C&-N.T<81^LFTQW_SA/*IN M)I-;!M3'S'(QRONV!],O-,\8AF7"I./K`_A%9B!O[AM.1W[#,&ENZLXU&S2G MLZ;&[E>.62(QRD&<(A837@"<]"A3R>*I4Y-':#,>$EZH/6@%ZZ=$^>(6NX.) MRF>([>>I0*+K9IJR"&R8TY1]5`QGJ1G"'_`D-8?W&G/4;$&PF*+$X[=-]5R6 M'\O=]_6JO++QMVG"6__J_?V';K>9&.?=.W%OZ4QH>B1_JUR-W`4*+K.DD%7)0[>>KWJNHHK"6Y:NQD15V>XVX9&?[);US;OUROU M,N9J53UMU;M(?U2;]6I=GEA7QU<\S7*1)HS!))<%%&VA:0Y1PLW666Y,^IZ& MGAX?E[MG-0O1I_UZJYK*$E7'?40?'>%'/7[3&M%Y> MB[LQU79+?B@2[-BKZO]T_[13!6^F M;=)>.B)E<'H/Q\2P8+<2HQSAW.[3761L12I>YK4@IP)BRST1;WAFW+;OH*MNAPWX:$#_1OW>X$#4 M>]`MAW6O5DG(Y.?ZUFX%)?K<@C$681-^ M-,74$S6&HJC)BA]U.U(PIE(61(6B-C;0SU7#VGWMT?]2>\B/]7Z1D%I8J""0 M@TS*F((DCWM+.#<[#+/X\9ZUH`<3?59H3,7`ABX]3?#,E)DT:)/D11M^IF)$ M(B;P%HA23/&@[`+1_K9.:%/5X]+M?;!<`Y1Y)F&4TS1!+"*$EZ@SS! MT&C?S=J*[]VV&IA:3+Q<042?6W2FJC*!3,W=LEEXM-685TGSLQ=VC9.Q';#) M/`:B.0X<.=_M-Q2@0O:)X@&HL$@MY`FG*M:Q#F M/]6SPK183!*/&KL>'-D5Z_39.O;L@B_8,A-"O MP@YX-37X)C)'MH>'\K$S@!D$ZK`@BQD14C*9BL%`GB*@+7-&/]6SS+58K,:T M&3D:,N>-%S.9FXT2`YGS1HV=S&E3I"=SI]Y=DSDK!D*0.3O@U=3@F\B MAGP5R:P`!ZF[WR>5U:\V(Q\M]Z6OQW* MQ_U",,HP+22.<9VY)K!.9/&P4&>QT0&%*YN>=;$#]^:G\PJ%,&H@FIY9.&-; M[P3C%D2;:>TTCOV\U:E'VLB!AVO:`SG^<.[6^>.<7FBS*/]MFHL\K0Y/._74 M\O;N0[E9'LKN"EM3529BSB%.N2@@@;4D8A&(/KIQ;6K);.N MZ=/6T1>&E;G&^+[3I0 M/]5_W:Z`;C*E>DHX)YNF::(QD5XT[A6&1G3-%;>!:)DS=RH_GZ"A9JDOZDPR MNSHMAV3NE6-W4TD:S(UM]AFX-%,BDZZ M4G60;G5=Z0HW8SMG$]D,1(,FNW&^,^:$%FW]DK,^/+--M:_%KC/&!(%I M(GC,*9=`8)8RT!O+&#:ZX61GP;/V]*":'97WAP?UQI$K%;*D5$^#_+-IID`# MD1V@6^G/15Y&U&<:CX%HST0G*I>?EKN=HY/=_XSE*$:Y+&B293E.4DF'%:`@ MPM'VD;[!6?>0%,ANQ[>!.>4PT@W=D[>6_#`]97_)DN2Y=YQTCB*=\AZ(PKGU M27\#RI8P._WKC'ZH-AM9[50_Z04E.4P*1D1M,&,L89`-&_8T!4:-)J;:FE7U MAG&H$$8=Q$ER9\.NA=)Y)G:*R)ERZE_=?B9+5]@FT!RBIDUQ9TS.)M,T25_ARWI5\D6<,$H)3H?5:BP1T:[9]V'<#6$;&[GN`^,GH7&2S8 MNC#%>"<^A(L17OVK9OJ"#5/B[F6H?9UYOT"U0"G%LH!Y]TE_<6]O2&IU%.SI_@J4]0GMXACFQ/8-Z>;%?UJQFF1Y2=%_M M7M:6S)P@7^-F)$F>3&<@B?)T/RK'WYF+Q3C/I2@DP*!`O)`Q!Y@5O:U"B'XQ M+K9W$Y;BKQDQ7XKW>/2K(;9W6JOP8)>5NAP&,EJF^:"SK#0C9-(H^;WV^6FW MJP?K@D(2"T9@@G@.((PQ1*"WRC'++&;IB1;GF:O?E?O]?T7;:ONVPQ7M7N37 MJRZ_7N[WU6K=7$+Y*,A<-8D39(ZUIDD]:(6QR0'B"&90@!2P8<<)`%:#2YR*AE;9T:,M5-TC M>?L/Y:I7%G\O#^1+C6.Y4D8E`1`3R&-4%)Q`2KKS!113!'67_=.,^!M1 M/:[H"*S.`\I#]+D'-_=I_2A3(P/+#<.!#"U'SE0^/D+KC@>]^=^K0[E_5RVW M>[*]D^MMO69N!GL/JKTX#+(8U"F)S%,`*(D9I1GLX:0XM7SXW2T&S_G#Z77\ M'KC*TFOH;Z(&?%-`.,`_&<23.R,X#I:>2H80)S/]]!HBSQT4C#@>45[?40M$ MD[V[>;7+@D]:C=.DUT"H1](&0+6)YD8UK0&I_3,FBR1):9(0RGI,HJ#(1,R] M`O&^(AQ&OWVC!K^1,,MG;QX$TP6D&?]>,UP;[C028*\A"42+Y_'U2OH\`\$& MNVRGEKH;XPAPD7/,.$TQR;,<`1;WMN(L-FQ^8V%@/A6U;!]A1YONUIEGQJPE M[T:=(BX1,KI#-H&_0/1IF@\_[8E-)D2O[O5OY=U:M;G^4&[+/Y<;5CT^KO?[ M=;4]V3'HGU21+(:(P(2(E',D$Y@-FP62":T+DJYM>E:='FG408U.L+Y8UEGT M=';)_+A*W9)T,^'Z5?@VJ'6]$>]V):[N^-%6Y?>K M-'KYX*==Z:8M1M>>MW]D6=`Z7^80(4X$E5F2X[PKR$%)GE']^Q5NS'F>:RX> MR[3=0GJ@=F\'N.%:8XJ9GV8'!U_A,&SR;L/L3%N^Z."$<5MZ_/9-YH[(Q-5IASB2F*&28DBT&1YCGJC68RY]I3QF1+GF>+=A`Y M3(^G4ZLQ0\S*JMGD$""A!A/"K,3:S043"=:;!%[CX9K^.^,O!.EWYTSEXQ.; M<@A)MG?-+OS1^+NA>4XJ*"PD8AFFG!OL%(T85ILZ,SK1HT*X_>&?= MU8" M4E[0K$@$*1A&!4][FPAANOA>[KY4IKII92]XN7"6]:9?H%L)H'=<$&@/) M3*?Y,-KUV8H0[4'RVW95/9:?EC_X>K_:5/NG73UV?QQH[=P_%RFD$/$LC04# MG.`L)J@[Q<\!JG&8#)9)ACP/FA9;5(,S;A`QC3^]3:W9J#-+[XZL14=@T6<% M+6JPS;U=-<;3B/XXH3<0'7+C2^7A^S.]#5JGK*7*7-_?-[G#0[6IJ=N+?SVM M#\_#5526H1QGL!!"9#"E""*1&?U@S_F`PA(I,';W[LPXTI,H;_28*9$^,WX:/YZP,"(J5F0% MHAUVV,^;.MH38*P$W3T3D`+)4R+4OGC.01;G!>FMI+0P6BL8_NCYU,#N$IDI M4V:*X($D:TVXS;VQETQHZ((A98$I@RGZ*]I@18)FI7X=*-CF(_7:HO:'EM)IY,/.Y1$R7N[7GJ6*U_KWQ@P_%E%W M^Q.>`NNYC0JC0?:DFV!)F5-;%RQ!I+Y6^*78E/GQYB*RV4A/;!=*\OO]']F] M=T.:!V=[GFVV6[2/X+3'E2Z^%.L/WYI/U.^K]7>I47G]Z>"5VBQ#>1H*@EA& M`88($<*:U)J'.4(PQ'J;WST37H<*C+;3M\K4`?E>+%?M^9;F,:E?I;:ZE]M[ M!ISJ4K-?4CM-3S3KI)W;C;K>^+3VOK<(KN?3N=))/05G>-E?T_%G"A6=U/[PTTW ML8?P(<5M@\<"<9PD0"`0)803&"$0LSZW2&',]=]SGTU4'5(V?A-^1Y#%@SA\ MV\CW)K@\?B\^^*EN__C/4\7HT=9V'(VG-/'D.,IS[<'M2RE\W55TOA(A%%.<@9`F)8BHP M@5`6PR!-.$M@GDP464=(Z#R([F33B)I^,=_3V+H@.0N6?.E\9@,"6]1ES1P> M%`6RG+DIEW(*#D3+!`QCD6'7<^R3W=;H##LN"J:8BM M5CX6!@:FG[LV<&MU7\N#0>M76"$\LN@L18*Y7[WTN.H2FLE*A;'FFZQ:V`EZ MMVDO:>0_OBTW[1?V94Y*,<]S#CC+&_$%Q`ST@N=AI'2[N#_2.HZY?16A$V3] MXD=5I!U6%?:L_-*YT#X@EBL.VZ::?QT^#65EE(M(P.;$"8`9A6C8XY=+NNM6 MK/G:=;-DK*#ZJ_"]3E;6X,OUM=X"O%\TZ.&ZJZK!7SKI6<-AJG57/<.HG57; M/XK^KEK?OEM^+Z])79?;.K__M:SD'/OV97E52$N61=T^A[Z_T2C*XDB0-,\% MCR`".$'Y[EUTD/$4J#]9Z5`&QVE8+WGPX29H9`]:X8-.^B"_#P[E#UH%=`YJ MN33.^8:&3W;1;$[HFR3XXZ)[P5SE1K9IK:1QU,X3:YD=PW-M-;63>N80/G6* M;P*C^'#";PHUJVE]7;=.&"3:O=26W_]W\8]J0^_J;?551I;F$?MOU68KD]7/ MY6W;S#F23'`2B2C,*$\%92E+<);UD@D.,ZT&B'MQ)@RM.QT:'FBU"`8U=)<4 M)K"2XDJ!7P8RC+'5WC:7CVS3_-:@0]`K,8:V+=5JHZ$_5Y5-9U=?ZJ\)-3ZN MM*8&V_2@^.Y_F8TPW5)P=XS9CY/+ MNB>6-<'T9"*.5.+\"64C2#S8Y7'RS%;"&0ZEN&G"082RE">L/U\-X/LC+Z=O+'@I;=<7?G)4U0L\829?T9GWY*B>$7WBTHX%%E1$"06,<<$Y M1306-*6]`BGB8,*CI-9EG^1L:;Y;M*KNMO6VZ!:RBKIA5U9>M0$WB,(W07OU MH'>;Z+2]8>XM="Y=P-<-=(_N?'A]`;K3:][8K.E1?YZPK`O,]!'9R'0>!..C M0T)YFL:<4"RK,YK1F*60Q$,R$=+0CY)&4VC'QS_IIB.S^FV,GC M7]6A:]ZYBPX7=O6\YMBYSNL[L?/0EK.$54-W>O5AU127R<+J*,-Y$%9/'#2* M>,@R@K-,)"$A&<#9T+Y,HM2;R*HON?/@2E_LJ9V7>ZI1T>:OGBE'0#/GJ48M M\WG`E\?])<1A4TK%E(84YS1+4?M%_I=\+S?%;=DVJ9A,O$2Q MW/Q>K.[*PX7U2$0BA@(0AC.!4Y$S09D,&FF4"\@BX$SI8[^ZQ";FU;KQ: MD^RZ4\MAW@1:N_/NZNM`2A2T%:@_RV4V7>[E9#U6_>S5I#I_POS&\Z1&V4__ MRF0,,/,P?=$TN`HZ8)T>K;&OE1==E M]YI"LZKH:39BW9GF3DGF]"-?\Y+C)SW^=.F)IE-XL#W7GN.^^D3%&7`S;?"U M;7H/4I:'6ZV>5Q"QG,6,A2%`E`HF*`']S:$0DPS[D;+8ULJ3E*7?9^QIQF+= ME^;.6.9T(U\SEN,-RW^ZC$73*3S8^6S/<5]]QN(,N)GV3MLVO0<9R\'MYL]K MET@ED`AA1',D*(KC!*-!.RZ('^F*594\R54.MFU[FJ[8=:2Y.;#KK:\^.W&#VM0G%5P8W8.\1&-A"X@T0PG'.0\A!$P@#O8' M-%(6>GB^8;Q2$QQ]&+]9Y>B(A&KF\L+"P^O9$Z#J=*\^-+C`S,<]`7H&]R`L M?-ASS)%VG\JOQ7(M?Y]6ZW93]5VQNB@W7^L%BBB7M3@!(8\3$"&*TJ17,J:, M^+2AT85^\^QL'.0-#@0.WBUORN"G^[+8U#]K;7/TILYUXH%SE[MSNYVO5>\! M+B>JWM,NWJ+S:I(;`\^8)8][%WBA"1")<$K2#/(\PY`A MRD*<]TI&$4'^%,@NM)NC4AZ7_#PHF_^*)"\@DJCZX%^19`QX7D<2/1?0BR27 MSRMYJ:TDN;W=M#=(O96:+-?U\JKM"1SHOF"(,(%BFB2,8HSDO].A:YSBD!I6 MSKZJ,TFA/,@9#((:G/HS*8=]A5VG^O55A]=0[)[QS`,HYLA'9K+Z<^F'[\[H M4[;A/5:GD@OOA7Y!N40F@`A#$D,*0(9 MR0'.(@YSDBYD[7I9J6[,U?NV#M,=BJ',CT\ MKGHXH;J=6O6#1&*FBVZU(#XS&=V8RI/)ZDBY:@IOUYSLO-@T;=CZ8[GIF[QR ML(PD@J*0@9R&+`(Y"L4P6))PIA<)S<:8(2(.FRJ;_H^L`^;=:7D2MC-3,20!%HHY(V MWBH%@GB0BCF'*>,AC M2!"(>VE"+J#=D&.B^2LGN[-W M]`H(PCX70NM'+[M".R]I>VN##3=`( M&DB!NQ\.1-;=9FT9_/.EJ@>XZY6H`^35#O+B!.3!'Q==H2H%#EJ))W\=30O/ M@ESI#0K;8TY(I+VLP5Y8G;Z23:`5VGPS86Q.FB?@U:)+MXAK MM.YF0MZL5V?3`FK=-'5XGFJ?.0#8AWZ9"[4JMWZIF;_OMTD*J7ISRG2YOI/U MPP=9";9N6^?E3;4INS]W4?PH:_YCNRDD[LMUL;E_NRV_-C=`737G4ZN5'.GV M[5JR>EEO%TD:$0I"#GE*:42B%*2)2`1':8)"FG&=9']..=TO>#5U^64K?_!M M4WU?UDT'3?ZRK]FWC3X3IZ4.$3^3P_I@9T\27B^@J/R;AD8,)T7A/YK3&&5> MKLN;Y781411AEB>YB!@4"8,A'X8C-*)ZG3_349QW_C[ZQ2>/$'J6"\PQ]6H> MCU#CY!P<"XMZY_SFIKQJ%H6'<3\5V_+4U%\0SD"8AA$C/$,13UE*LUX"!O6> M%[(XK./X/4C:3*M`"J5:@[I`6*V%-Q.X>I7H'M==AB3%#!HYFV)(3KWE:MG* M^*9YR^9*EEE3+UDH@WAN%<.^)3RA/1>:':]UN`)/F1S)]3_NZFU3XU]4Y/IZ MV0Q6K#X6R^NW:UI\6VZ+U9ZN6VF;O.GT34+OR^V"IR%-``<"8X@$!I"#J!<3 MT@CI,.C4LDVQ+U#*U6P]*`9U@F]2GU_D;UUU&@6;ATB`%*$W"'&VUU0P50)Y:Q[`*I@\K M&'85JESYG2)_79?+8=P+^5<6(@$QB;(LX2)"&4B2#.#^^P!DJ4J^K/U1QXGN M,%,:812I1Q^8\_SM%!-#FCX/QYG\K2ZO_G9;??\WJ523NL7-#PUOQ`<9V['" M)PC"&).9>#\($C30:$UL3F^=GMCM8-&L]140LS.T'*C\QNC?4( M@ZC]L;]]L'D8:A&Q-*,QEPE<"`F+PSQA>3\00>KSW.SK4\7Q3BJ9]%ZWC]D9 MA'1-U-1CNSO`#(.\,E86X_T#$)X)_&:`><`1(Q4XD0J,@4*+,\2ROBI6_UL6 M&R%_IUY0!BB)A("Q2"*:I$A`OALJR_-4J4D^YOM3\48G5]`(%K22&3"'-G;J MW.$2-D/VT$#,(G\<`?$,@YC"YA&'&*MP@D7&P6'`(QUM=8,!3#,"$0=[QB MI,23S&(.B1*W7&R*YMCRY_NOE]5JD>$,TA#3!"=Q"C#&4/2-D0SA-%'E$[VO M.N:0G3!!)XT&:VAB\SQ3N(-%CQU4$;'`!P]4?H(#S&#Q8-X;"EZ-]0B-^=TM M;7PJ;Y?-BL9Z^[[X6BYR07.9IZ1Q'H4YCB"+".W'B7BF="^E\<==[V;LEN;V M0@6-5!JSW@RQYR>_<[#T.$`7)PM<<`J!)RAA%%@>,,,X^2M+7J/-$[1L7NE; MO5U?ES_^7MXOPBA"()3_2&)B.$P@IGTC-0NI4*XOS+X^#5/LI`I:L0(IES97 M:*.F2A8N`3-B"PVLK/'%$0AG"<,4,&\8PUB!1Y0Q#@HESJ!WF\V##DC?2\4$ MT3`6&!*!((Y02%+6C\5RK%Q&&`_@F#EV8H6:! M1Y["X@DJ&0V=!VPR7H?*HB]IYR%BN2HW5`YQ6VWN%RF*,B0H0C&`,4W2/&9# M612%L3*=F'Q[FARDE2GHA=).0#3A4DT_W"%EE'RH@F0M\WB@_]F\PPPI#WAB ME/B/Y=IF*F3-"AUC4.W5/6<`.E\$V4#6&VZRH\WC\L@> M2.IW33:']]I-J,W5.`O$!8YQ#I,H#FD3Z@$44Z#.<\X$&.EQC`8\;BYL?`#$"2X9B9@G9^I,I3^^4'$,"/K<\&M9 MW6Z*;U^6LM8B/Y;U(F="?CW!,:%92&3)E:;#@)!AK8>=\O9X.%9]+9;K M!0@1`(`0!G!$8@%#Q&`_8!X1I:[+^%$FY9U.)FWF,8=0D7DF06\,\SP+G!ON M>0J7<]PS&DM?N&>\(L?<8PF:9[FGO2ET<[_X[?,"T0@+`/(8T3#C$>0HS?LO M,Q8J+3!K?,XQF_SV_NT%9\'G"W+!/RNRB`X8Y^G"$0YZO*`(@4*79*=.0P=1 M_XN&":(#)MBK?&+*&^`Q\]PVD;@R-K[F;*7O%RG+,D!%0C+Y50PQX\G^RTAD M.K-5X7.N5W'_\^U[HCE+54!0FZ66]==+=MR M6R]P3$,A0HB3*"1)GC"R9ZN08J6(;_QQQPSRKEK?_K):?B^O@Z(52),\],%2 MHPZG..D11PO1NQ8B\@Q$3CCC&(HSC&&,FB=\82Y_9S#.[.CT5J>T!IGZ5?'.1`T"P.$Q1'+$Y$.@R6AU1KUY'9"*[;>KMC!EU._^]&/*$- MF@Y=N,3+A#7>!#UD,]/'$3#/LH@ID%Z1B;$2)SEE'"3*U'+Z:5FRI<5F<[]< MW_Y>K.[*12B+#EG/?7%\6/C@;>E]L=$RQ"$D=9QGB>KUHBB_$V8=1+0.8"D&]/&``KWF+I$\*I&1-.Z-Q MW.Z&>[):5?^4-6TY)`P3T]H9\,Z0F0W(/:$P*ZI4]CU2DZX^;LKFU:/=\W^2 M-3]LOY2;!PG,(H)1CF-,8PKS'(:Y_-P,9YC^MJ)&)2=C'6;152- MF,'5@WI&D]*L0*U&;5.CK$=Q/<`[\5I\6P&#HR)H8DY30.T,M]G$W!..LZI2 MY2#DZ6);;8N501/FV2]K\=@@A/(TNVC^ MRCC*TD3*H/-B%:11'9_]1^DC[ M#I&L'+\URT?-TVDYCRC+HC!E.4@C$0&29`,1`:IU_F+40,Y3GTZV-B27O6!O M@O6YUPX=P*F:Y4R$I&YZTXGU)F@%ZQXIVV,Y_[.S#/!B*K<3" M.%:N)&>F/M-L\=8HZ52R1Q4Z6=-IU$30+4[T\4,IA%!D3DR#]9,EIS^MEU`G2Q(ISD98> MJ1E&XT(T9J`1V9@S2U)5/N]+-HO2NUURK#O1[^O=@7?@^%>6;?Y*=[M5$"'' M-*A'3-?%!EM_V=ALQG9LQP]D1&:4`35KS@EC(SPJ>=`XS(J)T>2DRFE3A\]N M7?N'(T;0@OQQ8KD2(:Y'O4;E?2%B-JY-F<:)*BEUQ^_';"Z8V/;<"%N600+7 M@*3]?I:X$1DY$_Y2S9+5XI`4*7%.Q(1("QUR8G.="2U*(J`6TN0L1!'D<6<# M9X5267<5F!`2PNO&B$:FY5`K#-MO1W9`Y.NY5[]RDD+N@`+N=4YD*K>CTJ%2 MLIVE4GNU1"M,RT*>9UG4%XNRDD8+/\L_I_%=NDO+-"G0?E.U!MQF.\9(P8LL MYC.^906.3!0?;5#-4;Z#LRHN%AVD__,/:)G^ M/ZOB;2G:O7A\UL7T9!;"Y13GG.L:V'R[F>;JJB^+Y MWF(/F]2W0I,&KDE:1@YXJNM==5(I?@:O_!>K.W;^0"&-&*# M.)[G6T'$AL:T'8B,7V+NF%,+D1JAEIQON@;@Q1AB:&/3[OL)4F^);NX3#9O-6[E.[;A11@& MMF-&U#"1Z[>OPP*?&E)ME8:/IE]X\D.R`>OLD>^9K`\"\#7)7;)/[E/IVM`( M](J)TK3,RNE3B^U37H,#ES*EB;7J*E\]LC4>UPM1L!$-RG1-2T%=2[;E=M4\ MQ;_$^9])F>X?F@W0!1L,&L3QGVRB^&D:VC;9^L`WM57Q9@'TO<(C^0YEW9P` M!<_\"&@!XH(?JRNW";B+=_PX'2BV25*"#1,$_B^=0@,_S'BH#N:5VSP[/&S9 M[W'S21Z$F]4`N,]RD-WMTH<*7P':N%)FG8G/_T.\>4[R,BWXWXLD?T[7"?_T M.JE:?'$A!,_)?I/EQ4_@/T7]#2S([))U62%N-_8_97F5"32&="'_L#DDX*^T MW*;LG_<)>.'7/#)\S8_XQ_=9_LB(X1L9XPK:^F7-K$B9[=G^(;50!K7=27`ABXTRBF0/72$9D8SY7BF>8OR5L!AZ.:3XQ#,.U2&A1 M+X!6X%FVVQ['"0S'=U=L0M]EL@>8)0>1D8HN'F&E.![`S6M@B@>79;D32Z4G M($TN/!W9:A#-?1[Y-3$]B?)`)A>2'0^UXIT#R(-(D9@P>9*)L..]B`^L:G$)FIT:D>$ZL MG4.UM/@5+!!.3)]\;JR=1K7T6)%.J0SPDNE7DL!!;"TH#QQFQX54<`1BY(X< M7:B.6";V0HL-&(6>:UD$1@0WPR'#M&WI0T<*8V@6Z2^ONCYTEE8J9Y!4*!3+ M"J=@3TZ>:^(64$M]AYJ>Q'`HF0O)#`>;<>D\TF!:!NQU65%J8RLT(\N@D>MA M'T&C/5&)D.U8,AM[%;Y>2FJ&=FM0EQH5XL141C-G<@*S`&F14I4!Y"U$4(98 M<'6WBB09*C+2.47I1MAU;3:.;YO$-TTV7%LV0S3RL.)N.8D1-.C-1+KOXZK-=;@%YA!358\`.'^^/Q6BN&>?K3X#*, M]BT:-?EF(3*JS;RW!\LUTCC@==Z*PM`TV1(WLFP$"3(]C(\C&00[,KN.%+Y^ MDEU'HS404^%/]=W=J-1I>VBH-M@D`M0]M#II1\/K7(O)TZ0TRXG5Y0Z&"VM; M*+;%:1BU"]&L\>R1;$\H29135]"&-(2A`PT,V M;R5M3"PH=6NHXA`3;C(`685.MJ2FRIU$TJ27-H7$B7<@^,\^+4&-K+HEJVUJ M,4>Z](:@:RF3.J,+D:"A5EQ*G8:2(E'6+UBBO68KQ6K<=K3(\D(:F8[A4F@9 M-D21@=K1##>4+.4K#:&]?-^B:B3GL)=O^J7*GFC=7CMQLK7Z(V>OM6<>O;G, M3V]A?A"A"]&;H5:\*<"/0(IXT7U7\<<&V[(5/8Z+9!-V.O"UH_NN16R3AD'@ M.88/210%7CLZPH;<-<+C##E=[>C3'2DW2Q!&-&ON42 MCUZJP0DK^(.C!17@NS.=ST20VSHBQ^21[ODGSE^"8QD&/#"'NAXR!,@GJ)ATW'@:%XS]+1 M1]:LI"U>T`$,6L35`]]@!A5H\$<-N^<)G\(;_1H[OR/D)/9C^D"B9=2LOE#K M(S6^3\1:3,E2=2&8Z:5\"J$;8LL]&KD7P]\X"_W7[.B.MI0 MT%U:84TVJXB8$7)\*_!,9+F8&E'@MVAP$$KMF=,$07-LJZ'QC5E/+3B0'-&I MU!LU>$&B'CFO`Q3JE^=Z>0-.OCGB!E3`-_JJF=+L7JMVZG/70M83NJV\ M5"W53:IF5?Z:Y&G&?UWS7AXP(B'U,3\R8IHX"*S0\X[0'"+_JD#6GS^4NGF.MSU93*?@-J.\#7:UY.`8HFCQ(0 MAM`M?N-7H`&Y'G(\[*7.HI@23T.?9#6H/8QW9&W.TOJ[#/7(X'!6%R)N M(QAR?E772-2([VE<;Y/-89=\N7^EENPO2?Z-0PON8TM(7,4YC7R4Z#&MR]`(Z;?R"4[VZ@ MQ25B>C>W-^244-H13"BK0ROSR:4"P7V;-#6Z:R$2J]7$\^V=VND<*LNOD]CB M!`,Y(;2@9[N8>M0A$#J>5[TDA8;E1%BN!^?(8\\FQV_>PHPCQ.I.&"3"D_`_ MYE*_6*SEO-0.=LJR97:X>6(2.Q*-XLOOUXU(802]`$6!:]G4=9!)7+\9 MQ3<@),+7/\M]J\8E8GU0=[8NNL*=)F!Y!&4;D0G1EH!'G?>A&H$1=9?Z;EMLJ MM/,B^S9]NLWHOF1R1[+'.-VO#,\U+(38/T9^#8FI6I MBXRWT:BQ@3]J=(/E:2CQBL(U(>>R:Q5%NJ?1M7[>9!1O)`\L50O',N^:2HY* MH[!^_A+OXX>$;T=M]@P&'C:13UPG,E%@!X[E8O\XC@FE=NE)?[GNRDVR3[,< MG&#)[EQ69TU,W;02)B=?4B1ID:QS,GHT29FWA8B..OYLI`DD6R[F[PKOSD\C MHCQG4Z@:'K^6%( MH&\9U*757=M`Q\`8<9\-M[VS04_+6YJN^ZOC\ M$V0AH6,)3)S7W!<`22&\:3^1U+X;_%9;(*(V09)&!INQ7@ M@'HV@6T"CWSL2%WNLP2\4P6XYR,LE3`WMU,EXMT'\N?R`M_)6,"MG2,&ZO7? MM6"XD-FSI*BX%$HNA<>E8%M`G"2\`);L-Q5PPR>V;1#LV113PS9"W\,M<`_Y M4N6G^=%.%2,W#2CPDB8[V8.D\],T9Y34YL_EQ*W%X0&\:PC M5*%QT,3Y.X;&883H#(TCN$I_:*P;GQ?_8A\LB\_[^IST?Y/T8X1@CNN7(^ M]U\#_#&?J M"+N:I]E'#\*ZZ1DK)$_B1H6SG^?=`!CP=(WV;`6]._!WL/QTW>FLE`TQC4SV MJVT2RXL,$]JPZA"`J!,&4"[0:L*@>T=A>Q;TRWVEHH>ZJR?_:X4;,."@00XZ M#4CJ>UJ5^Y!H\YA@E%R`LR2C7>?,[MM^)C>-L^*.LQ9TE%2*Y+ZHH]EM2XD> MNLU\]XBI3EH5U!SMRW3#ATZ?D]^2]2&O;K"CW]>[PR;91(RXCF2]17]":A`? M0],T`R^$+J6^[1'<(O4C*'5H9@9X$\8`;M.GUJA:7`K0F@2X3>=A0D=0F,[Q MLO%BD3Y7#R5=<\#)GI/'[\\]?C'^+"G8C.4AH3@T^7187(B:GH%WH]=,SA"_ MC"@NMOS^#O8;/\'^'.^J&SW*,,[S%X:DKG&VI]H#"!TS]'W7L9%GNQ22T"`( M1AZB%B:NZ,Z\<0?5ITH<8'T=#O]#!^H-B$O0HFU>@LS6IT&*S1X%T>.5A8B# M)N/.+\712*'4([UR(\/^)^KLIBJ0._`A]H>9\D&.0O?)+ MB`=QQ1J5`GDAFD%5KHB%,"$+T@!QS!<>;4F#I9[8]_5B17W?@=1`D47#T.+% M29NTH[I([I##P*$T/^6_9/OD!3S&^9]L`7=_V&^DK_D;R*2X&DQ$HD+"TI^G MS"`C[U-U16!&X'A!TC.&-1=$:322QETSK+!G8"]R'<PQ&-4LG^)2D3?BB_)OE] MEC_&C(>Z0MKT*O`#PX5FX)+0=8GAN"A$7`@L2",/VXY43UG5,31G#1U8;758 ML06),HEB><,4_,DE#$K4:=&K=[CI4:BA;"Y$DP:;D8T[R:9J6M)LU_@]*19YE>Z'L0$F($%O2@'=7[,K!G.K;\CL,Y0&I6OCKE>*BV@6WX M-K#3UD+^4J0HL_6?(*MM`,^5$5.U-1GL7L&W8!_!LY+OPD;<1%B;U]U$..]& M00V>NK8C<,[)L9`0,S\/8S4S&=F7@QYY(9VD7=TJ53!F>;52IU+1NNI!8+72>S)QF+965;-$/MVR=@8?R M;\D3>Z"W'".IKIRI4=1UCA5"400CRS0]SPDCB@+3.HYL85.NSM;#8_']U+6M2-:=+Y"'9LLB;5F\=LASY,](R_9W&:_,:4N[E]NX^^\F?TV MVVVJVPS_[Y#FE7`7*X_R12^,?&+:B-(@P);?`L'8)G++QK%'U[T"S).X..0O MH)8[L$UV&WXS1%$#!V7\'?QU@E[(ZJ)&MX@NZN;TB,+ZK``=O.`V`PUBP""# M#F;0!3V_-V172G-Z9<"BIP!%QSMW+R!Y?-IE+PG[A_>?&I9FG"SA!9;#KN0_ MKDYB\,)*_9FBS-?I6=WEIU'6.Y)D]RY==#EN,:L0;0:^65#HI5+\OJHF!E1! M^]<#?]WYY;X&^&\6#E:1%]EA&+HN1;X760;Q27@:+!Q6C^"^ M`EB]"^R$1\6EP6":Q=8%4S(L%]Z.Y%;0;L"O1W8;:?UW;Z-0/7=0];/5LQX8 MB^>%+`9&,^?\3JE1:=+?X*GZY?&UL550) M``.^$L55OA+%575X"P`!!"4.```$.0$``.1=6V_;2+)^/\#Y#S[99X_[RNX> M3,ZBKPL#GCB(/6?WC6`DVN9$(KTD%=O[ZT^3EN2K)(HB*=L#S,2)S"[6Y6-U M576Q]-O?;Z>3@Y]Q7B19^OD3_`5\.HC3439.TLO/G_XX.Y1G^OCXT]__][__ MZ[?_.3S\E_IV7'58?'4)TB.$OM\7XTX&7+RT:T)]?^>MM]<&3 MZV]P?3440AS5OUU>6B2O7>C)PJ-__7YR5HMXF*1%&:6C^)/7P<'!;WDVB;_% M%P?5SS^^'3\A$%_%T:2\\BMF>;7DEU$V/:HN/%+1I/K@["J.2SD:9;.T+#P; M%3>_7N7QQ>=/\55YY86'%`085*+_;=V:\NXZ_ORI2*;7$R_Y4=>L5:*/9Y/X M]&+QR;=X%'M,?)_$)BZC9-**^RW(#B:@CHHKF8ZK'_;?,\_+Q#\:12="-B+= MLZ#GE6Y;R?%T98=LZFPZ37D'UNX`=M-*?3-]EGI_ZSU=_\XN4EVTX[]M90&%2.;7N=^ M?5HD/^-COU=/XY.LZ$"H]70[%'$10'A(6X_H\NXXOE:47E?Y1@NTH;4G41JZIQU([DFPA\WU M)$LO3SS2Q[(HO$-2=P]DHHGTD6T?2MCA]GM7V+?X9YS.8G7W>_1GEO<)E6WO MN2?5-`N-VE/L4*Q[=WX>W6[F]Y5+^V&D(7!6K^B'K6967;F@0Z:^Q.7];;[& M^=E5E,>;F%JYH$^F'N5D?C\VR616>K=6_ZJPMZ/);!R/79Y-J_!B5M;H/[UX M0:4A&(:Y^R#JRBZ>\*2B(AEYMU"+$(^7ZZH0K#,E[7[//E73[,G;L*Q#!K_% M19G/1N4L]TF7]K>ZW,S=NC4]LW:21-^3B8^(Y<@_`TG9/,ML1ZUG<;Y$>1Y5 M#_,.0JRBT3/K3S[KQ!K-*/8L5K/G<_/*#MD\*[/1CZML,O;!4U4B*^\VL;=Z M1:]L;8OFYA1Z9?MQP;4&W=T?J?_MUTF4-H7S3D0'$LY%2?Y_T63F_UI?=GI= M;9!%]=%]N%X4L^G]9QU(W?YN`ZGCGJ$GQJDO[\KLV]`?2.3::R6CNB3FK_HC M3S6`CYN(A#WDJ7Q976FL MZU6$.^3]W/OTN%NN7Y+LDM^LC"8=\_N"9#?\M@!#^9+%!I:_SN,B3N^K?2?^ MJOFU%Y;B0WWU`'8W*!6N32C6? M/WE6PNT(A`X(JH"P`GE&`/7_<8D""X$"0:"<>BK\I&I?R_*%PGN3_FQV[>U: M'7M'D\>"/)+@W!M"^;O_6*.#;S_>V-:UY-03+%UXCRD8A"]/W(6O3]_F_A7=X]D\=S) MVZ1H\'BV(1LJKR+AU:*=@!`I"*72"RU9H>C'06?O.,KV9I8AP/N429--HR1= M`\K7+@\I-I8;IHU"3/*`4ZS!0BH0@`\4-0UC_*QSG:]'TLO"4O5)^'L\3D9> M+=_B-+Z))G5;=E&],O-H)_@]GGZ/\U<`LR6%D#L-")4$2HN,H0Z28+F-.&WM MQ\'0;N;,AE!O*[B\#!-.RZLXGW2! MDBU!@CXR2/K0;"M\U+=MX40VK0N9,8XI"C23TF_J`G%.%[P'CIN6J,`?&14= M*W7P,-MON_7V^\"WS_/CXS*>-@ZIUY`(D55$.*H#IHP1&G&B@H7T0DOT<1S- M7L/G[DPP)`"?Y,%ZEE=JWK;,,E_F'S-+E!$J$-!*H1D5!BVDI)1M++UV%?;\ MC//OV9#!F7X&M#C3]!HJ,6[P(.U"A\76.9*FC/+_S/J+N[VI0>-R*3B@X M)U`S1@F6`:9^K]/`2.X"'\HJ0\5^"I$5\QM$#*DC@4>@-(5B\,+6.$6R`=LEHC'YDK;!:2^E1N(_#?3Q`R M''PZ4_=0P-JHEEW];*@"H`)'"6%^KQ6$$`OA0FYM2-ND>OOTZ47GP?N%6==: MWULX\EIOXP?K?O#9,D58$/_H*X.JPBQW=6`H`Q%@M#'7Z_N@\W4\U89IU/^P M%:'0:0PMLQ9CZ0B#%1;M0AN6?*28I6MXK#S?[$'OK0IPZ_H7-L)I2PJA@I`% M)."280N58T((O)`'`=6V*/<&@Y>><-2OP@?94!H/'AHJ?UTS6&AIL2;YZS9T M0DXIQMX<4C-*)>,:&[_3*R#\TVXDVE?^VD2&)OO+=H1"B@65P#!II4"*8\T! M7V@#$?N!&A-Z0LGS:+-/]>_;2^RUV+479\$0$QAB9B!7G'J/SJ%:V*?JC]R/ MLZAF(SQP?O?5Z[]ZSWD2)=/BRVS%X5WSQ:'#D#!FM+$>D'HQ/]*-)E^S(JG!N'D3:[(\U#Y1A5I;0`13Q*>Q M`9JW#$B,!-K8PM73J6T]:JY)._R3"T.? M`D=F;ICSZ/9>#XU@M&95""7!G%==5(0'S@H.X%)Q`=!M4;13F^V[1_Y2 MH.I>T8,'WDT#[E!#(XW0WMD:03`C$LA@J2-DV6![V:-NE0?`T/<4:&^IRV$< M3G8=Y^5=-0>N_K8#'[I=5ZFI=Y-K/?[DJ6CC<[EU>M#KH@D!&N%L&'6>V,*EVF!-K)M$TQ' MN]);=S)=Z'0(K!Q["Z67B8_DEZ'8_?1TGQ[^(\O&-\EDL@8Z39:'PDD"@0T, MI%0!O]'ZC7PN==6[W+:'E[Z+U&MG)/6@XB&`U0`\2^Z5)P$5#JA3"`$C*.!F MP;UWK6W[I(*_QN[44HW#A;<;X]I00)_SF2HVE]9!1"S2>L&YQ*(M`-A?*:#= M4HD#GV970SE?#(UM<-+0E$1HN--&&1)@JX&3P@JX.)LAR.OTXYQ,]WI4U9.^ M!T9;\Y.LU8O"0$'+D(96T,!Z[2&,V5Q"83%N6^OKZ`@"]06O[A&P&F*[J7S( MHXBOT5U5[FY^"/%T02BXMLX+1(*`(>&\F,HN)`L`W\NDM`%VN"YLO>(,8B<% M#P$=.[V>9'=Q/.^'?ZF*-2C:N#9D!(/`*2XP@ M8N8>`-6UKML.#LIG\?CW*/\15YUF\SKV:['SVNL]KQP8PHC?\0E5B`'!R()7 M)%K/(>NHTO<>'$V7^AWRE',^S:CY`>?3!:$!`%!D-+*!X$@$"--%^B$`86UK MQ%L7_)Z.X7C`CG@'V.E4Q;LXDG5?1[?"E[RV)*0^QJ/&L@>*?:W9M'0<=:'>S,8*L09<6*$$$55*,#K-.!5Y7/$HR:RR8!Q!MG)O=; MS.NMVMN#$^E&P_M)O;=*N4-KL?(*<@CX&+X:=\[!X@Q-2DR&&S7V:OUO",P, ME6IOJ>J!P=/HN/+5Z[U+591B+Q+#T#`(O62+N$Q:%[0=(M91W/LAJC6MM3T$ MBEI5E]?H2_'J97)N_<:,L+*5KP4+":E`8+_'W^\73YVI?)!>]VPZS=*:Y8UM M[<\N#:$C0D)`+`,V,"E##1?GN))9LQ>!IX-X'=Z@$TW M&AX"/>=Y'!6S_*Z1HWEY<>CU4;U_RHD1B!D(`;9+#?E_M&W5:A[[O/H]B._3 MV>RLWB$`\ZV:"9'&8QOE:9)>%G(TFDUG]V-WXHMDE*P+>C8O#A6LQJ`KRADG MR@$@);'+\`ZUGC'?4?#SGN#4N;('.O1<,+F8D>[M=A6G1?(S/DY'V32NIBM\ MB7:)Z8\<`A+;B0,E%I*!(QJVQ&T/9:&;2K;0P:WI:K?0NO9#BUG(;-6 M2\DA`MI*+[?_QZ*>*X51;:N5VU>X/QBP.E;\_D:=+#OTBOO!EVZ2W>Q]Y,F2 MD>U&G;Q8%A(H'*,T<`#ZK8((PS5SU-F`6:F@VMAYTH^DU3NDGM5Z9([7J[K[ MPQOE.#V]CJOOM4\OY:A,?MYC:[/\VQ,+E5)""^<08<(0X#BC:*$5__>VQUYO M>U3*#N#(!M;X$)N.%^(ALEH/KX?K0BP=$PS@@"@-M,)5X_="#HO>N=BM/X8FUA:\-*'SYB M!ZP(J/5)"81!=8"YD)4$K.V17D>.MK_7S/:*FQ6-<=W8:!@\>NN.DMKJ:\'W M<%GH$$*8`:J$<,99)C!8:D=#N^=A0W\5I+4V2+O&RVF6E\E_ZOME%\>IUWT: M329W)OX93[)KGQ5F%^6-U^/*-LRF!$+NQ=$,4H.`,=6WN`%B%])`Y=KV_K_! M+_M\$XCJU3H[8^WT0F79#__GK$C2N)YY7'A-Y*L_/)QFL2U'6+@P#1JV22E@O+(/`0J>7 MDFJ,VU9@MR[MKWI5X6/#LAD1B$]__/$X?WO9)RWD^ MLVKC;;0X)$1I;J#%"#!%#,*$+;.@@)BVS:T`QCMMV*_(W7O5[$T#MW5S[`>S+&<-; M0?7E\E`3K@Q67K'&0BB=QE77\+W47+0&:?.ZWX;V2-873/M`QD;P[6R`_<#N MZ?S8K2#W=&GHB+'`&]U`+*712B&UE-;_WW_Q;P/<>GN/>B]PVTGY^_5P\PDF MK=S;?&U(1=6:K!%5?L<(*.($RX6\EK'AOKAZV-G1>_5L[72_'ZRM'FZR%>Q6 MDPD%-$H$D%`+?::/$09ND7$IBOF>7Y3KK5=\+PCLS`P=);[;3JUI3B&$0BL0 M.,*`QH0[B1A#@ M$*04D'-ENNN_$>R5IBU$Y6Q$)#2%6^Q@!!(%1 MU7NJ#B^E@H2T[0G=J8SW[D#4N][W5)>K7\JY'Z?0-BI;02.4@@"?;4L7<*2% MP=:JI>>FI/67IW54E?M8GJP;&PS4G=RP)-E)9WP5D6H:2*8D=`((3%RP./]3 MF."V(T^W3TU??4VFM]1TV+[F?HRQ1S@>IS^]2^_HA8TUQ$(A3<"4\8F[?QR5 M_T_99<+D"-_+H(5^$#GD"QO=:7P(#'Z-[N:'.'+T[UF2QRN_Z6<-]IH3\O'BCF6/^O>NQK4$.?:'G^94U]F6,O@-RB9VKCVA!`Q04@ MPAD.B*K>US7+N)CPUF_7=W8R,?2>/`C\=K3"V]J*.]F"0T-54+T,'`0!<1)1 MP*U9%LX1;EMIZ2@R_`A.L#=C[!&.\R\[Z28R7$,L-!9:2Y632COH`D,TX4N- M@-:#(]Y@>_V0D6%W&A]D(\ZS41R/"^=U5D\B.+VNS%G8VS@?)5Z@=1OQIK6A MJ)(OK!W#@0+2)WV"+(L#5CO;>QRXGP)-G\AX^96=G=J@5#4 MERF&<&'V=A07Q7ET.W^WLGX47NV:?D5C:]S;3G1#!Q6U&@;,>:U`@1@SRW!# M"['G.)0*ZX(E=Q) MPRRCPD`&'EK&2/]?=+S:B;Y[+':N_B$`YSF=LWUZ<9*EE]XBT_D!TDEUZ'/Z M?9)YR:WH!(2!27"6%A.+);8^%WDX<#2P+9UP>;-+AL*,Q_!+?9GC[>5 M$W>2"X?:H,`G@(Q5QZ12>FWP1?*G@0F&:X9Y$R6:/O#8FS$&B2TO+N)1>7KA M8XVKZ/_)N[+E-G(E^T!!J,-+]&H!J6S<8!Y^KR797K$>@C&?=S1+P78A.G;K(P]C#OF M-8D01Y&E(8JH*4.1:%:/.^]X;FISJPJR9\2X'K$>CW$&K/9J]0`&NO%&D$/: M)Z8"DI0S)E20U,(/M$K,<%3:W+II1T^T/[=J`1ZL-I?"M'907P[%$)$B*LP, M]LX9(:U2U9DH1[S,]>6.3D-]I%A83"^58,\..ZK^48ODB8$(+@CO120*>:21\$9%89E`2C9F7O>UL+#-=C]DV_+MH\E% M$@DJ+9A#4BFID..51%;@_@\Q#YE+WDZG[P+_5E`.DQ[^-'#+A;'9>ETN0H"Y MB45#0OC.5DEH#>&H8T8+$;RF5AM6R0A8C5SKLK?X/5_7[Q*]N\(V:^=PFU6^ M^U#3NV>214@S;&FT(*OC.EJLJCX9:G-7$$^]XF1K?;=%`326OL"9W7_8$T^&[]B^ZQG:0P!.Z>G73?&KVU7/)`!!<&\YX ML(H[X0D*E1S>FY'3EGK+'NY0P>]N-LV'=PB:U(?"06@S_56L-K/U\Q'Q/;S9 MWS!Q00@E9;D"ITP0%C-MZSF6A=P5B5._+*`_(G6*=UZNV_UZ`V9UY0")4K(% MX#*_:RZ(V-0ND>@"E](:AA&FSGO.<.UM"Y\;R724,-2;1],]5_J`.XLJWXOK M'XOE?'G[4"ZI+1>;9I;L:9)D4$&4^U4.;*?`6`DK:UHAI8),VN"(R$R)26F2$A>RXI3U)&(Q$B41+J7?#(B'HU(48^V%V1KRN5GQMW.H!V M",+T5N[>VT`BUX)1`6-"]+>?VQZA.$1\J8G^)0$/0 M_O+11#21V%H#T:635H)8I%[+THCP3/X<7P]FV$7!?N/V%@@/NEIXT(V4'SR= M'.,$6<&\(#@*`T-"N7I"9B8WWZ[54O*9K0AFHSD(0\I=C\_+Q?)U;YM=Y_T- MDW1&:A1Y&4.6"^^>\'I0&<#@8])'+U]- MREM/$$?*$!^19.!7UL.4!)Q[HO($4SZ[)N_I:&4XYA]S.^FN&R\]58(X:2S\ MBQHOE7T>U1$FBZ$BQ/,SE]T@.M#IG8R+P3G$M41SD$/0*`7`9&LYE,&Y*]_' MEP\].UO4!L=A@KEW29?0Y:L;X/(!F_D'M$Y1!>U!X"@D98J3J`G(K#'6%@N% M<_-`6I4`/0_N=(_N8,[\CES>"+/N[';Q6*3T^N'[:K)8@Q2E9A?3[6_S1SW7 MMQI5`C<%`9U_,&E*D;5:2NT]V/%`HZMW*BF)N<'#"::Y=LJSCP*)L94SLB'- M,Z!)<8K*C+&(0E2TO$P&US(R(7)7/8Y/3>A]TNV3@-TA/,AIULEJ`>%&>31M M6RCC@#EX5Y,4L'8<41&H]#Q*2;FJDW@8SSZEJD_/@'4]\78$Z1B$L9/U[/H( MMFR?3]@Q;9@.@AL8!UO7--:+QDJ-,M<-L*G37L\-Q,E!=PS6^-G\?K.WDMR. M%LD(YG!YAW*,T6,5J>+/RQFMP6G^_O M_BY65S?;7J^O[C?KS60Q+?/_FJ>N8U^5'$@?F5&66>TL8,-#O='NG,P]HEP& MWI<^I_6,]2DQKVD./.H]*6)C6+".!TJCIYI$5P-.1/9YIJ/GQL%3'OIC3"8U M<_0Q(B^?3/@[,8YGYJXW)>\5%QQ%9!PC?EL]H,9"2Y)[#.+4L]?'9F9'^ACD MV+U?7M]O)Y`RQ7H#>OFTN%FN[K9O?-V=QJ/U.Y*H]WUACQ-P<%M`U2`1=8@V MDFB5CY8+%1@6$4DA;./NP[Y1ORZN_^-V^>L_I\6L'/"L_*&4D;T8Y_"GNJ/? MX1L?"//VD10Y8H8JQ4.D0B'.%=)5GQ',T^>_>MB#_I:=@'FXR3]4^09Z,BU[ M$^>3C\SWNV<2U8$8)#UT+B(*@8"5M.HQE:S_^RW.7/UMT.Q>_Y687ZJR,1Z\ M\@8K\.K91+U4C@6PG)@8S[#EWE82P'24RX<3*N0_C#EH@VI_O(BS]?5D_C_% M9!7A+Q]MJ^]Y.CF/G*'EG6ME%7@N(:X+3U(H:V5NHL\)9:D-PXUVN/;-CD?F M'LZ/%\\GI)TR1`2DN0<#Z#!VI)9$\ESKT>H$T/DR)!_9[CGR?34I`X=O#W=_ M+^<[>/'JF:2T(JY<9-2<2:0UQ+^5+Z0@QLC-H#^A)*U^N=`&S>[U_RC;U^)V M>PAML?D\N=OE6'ST:++16;!SDEF*K:;$4^.J_M.@+N!>YW[9T`&H?9'"@;RK MR?P3A.2__[MXV,N*-\\F3*E`&/X!>GN-.=&NYY M\72W\[.?LS\2V?5XTD8XS,H$BBB(I@(;Z2LYO-6Y4\@))0;TRXZ.@.W+<,39 MO*RJL"ENEZO]9N/5DTD*JD1T0C!$&/C+EOEZ+J28Y=+BE#;7AK`:;4#M;2YY MON7DD.V(PQJ6E!$C#::=X\:,@V$D]#`5S9>@J>([8&SG^V^B.J!U,A)!/$0H M-Q`>46RL`$?X26ZJV`45^6VO^F7?\)[O.DHJ[.W8@OMM?TNA;P#>(3U;_-[]G^ M2AW[FZ9(@I6(.!TCP`B1#O:D!B^,"+%.,","$81)HR#<$55/C?$CSU?#F9AL#2X[!WF06F77 MU\O[Q6;]M;@N9K]*\[J3/DU-$N<1!^6Y]\B##X4Z M!GHDYZ=,'CO>[ZE:)18B#P1&">(`'G/8<%G)Z+7*K7IP=F3JW.7)1'@4%I5] M/=[1>6Z5#(LJ8A&,I2X*)CT2M8Q*NMSTGO/P<8[7=&/LE8MLEF?SY^1?R]6? MQ71VO=T'G/V:3>^WE6/CY&XV?ZCOYODRGRS6^[V>C%#8C^(;:HJIK^%I]%?:FB9)&*,8T8\,R9JARG&-:A, M#EAJ8'@;U8):_:";&8&]^735IZM%8S#6U#(%+!V6Y?D5X8P)S`NN:EPHRSYU M>8+LZ$J3RSX1[I8AW_]WF5I71P)4\*I>KT]Z.QBIZ>^.=J%WINHE`]SUKQ5 M'__>DW_T=K[:UR:1\O28\QZL-&6$"JD0>^ISU(B/?"=<;_4>.J1&UQB/LPWQ MN=@\I?H>M17QW"Q%&ZRFUL9@/2D+%4H7*BF%([F1TZG?&->#D>D0YI/+IOIV M_:.8WL^+JYL_EHO;/V:_BNGCY2_VX?DUD[E9%9.+R;Q"D5(>58A"V""5]A;A M;0*<"001UFAC>Y*P*K?4E''U^L$D@,A,6\(IPXY1$5&HI1'"YT8VI[Y.VUZ[ M;U,GV\`ZQ"11=_#5P-R_Q;BS3;(^@C!<,^,4-MH(*6OYB->Y&XPG3YM,+>\B M2TM:PH1*L/"DDL]2DWU2Y_064CK0\#J MV*JOWE]2XEP'^EJVA*]?5;O/>U3M/B?IE2K7\(R"?FJB?>#/?14Q-RON!-?6 MNU?UT?`-ZD,',!JLT\8+4X.A56Y2P*D7_>O::\@%=`B* ME)=//<:VC1>VOGTT:>9PC)AH3K'AEGOS3'CL],6>^FBAU[=W]K2#](37%YY2 M@>W#-B'FXHYS"A%PWKD2T?WMR,F!*HG=28">IU!'FS"?<;,BN3G?R)J,UC][.+8/K MXCP3JS6`&D199H<+BS@)!H5*1D?9!5VM-"@CCDB\/DX#YYEX3TALE#<,,UUK%'3:I3L M@*'R2C+TW#;7^CBXS_TH-=ASJ:7SWDN(0A0J1V@E+3:29)+KY`/XTYH+V^CD M[,]=<^JG^*//71^%\9CGKI&.4LGHA4$67`1A MO7XV\](,=L/-&&S(5=HA1ZV/PW60I>?)O-CM+7WP5-+*2*UEN0#F"4SB'H,3KB;?!M7G_<,(&IF`;#/-4Q(@LQ0I5$DGE; M.TIQZ^V0])C.3&LM#+*%,;D#<%YUM=%OV=DF4:D\CU8(2P0WV#AK<"6?QS(W M)?<$IZ@VRGV[C]$1G%F^R7_=WTT6D_T.RU).$YQKT5O<:G>%( MST9T""_OG?/[2NY#$IP.?$,*SCII(:)&$HP;9F#K9#V7.93K`7;$IHM<-.U' M->=Z8#2(8+C&3'`:J0R.,5R'_T:H49*NA[CIOFL2''-Z]#C,3R[Q:CO\SC^M MBEB"$7;(4,H]IL(8YAZ+E2-E27,=O`/=BV..P6V1W5?KON4;$U7@4QM9GBFD M1"#-P;&J9`X29=]M<7H+#NW5OAP#\D&6RYL2)W=-N0?=PM#ZY2D&`W81*Q=D M=%YZKB'>>T(L!G)Y1P/:DW0T]`>9G#XMX,?B^^3W2+-._?WG.R\.F'CVM$HR M:$NCPJ!@:3FVC/(GHU#6Q6IV^P>3\Y`AOZ]9(LPR[@5!P5%OI$"&XTI2SMP% M[<)VHN]E;]`./5+'S+[O?L!&9)&W01(<@XO.$"6?"CS`?!Y((XW[E/./Y7H= M@8X0(P\UK8`;[YXH9;P&P2"031;3%8/VQBG/!<"+4%_T+_; M3PL8*<6Z&:=>OIJXI,8A'$B0SE$8+4CR"F?LU`4YJ)VP[4-S<0J:&<*/K:4( MOW\6BW5ABT5Q,SMHA+]ND:@35'O+;:3E]12>X%#+9AS-G:2.]CA_%:N_EV?+ MN[:X#K*R>W-37&\@?JN[_'6R*3X:*?L6=P]^23+!(RPQS,]!"1JDETY5"'B2 M?7/#"1:'[(-7O0$]2.6MZ;\@ZMH>[5V:Z716]G,R_S*933\MW.3G;%,FDE?C M9BMH:;2W=V7:R;J8NN5=.9BV\GTN]A;KZO9+*4CL.`HH:DU$U(@$1"LLB:.Y M1[%;;4J<#VG'U<;0;OZ(B\'=>_D`J/0H*&VB=4QKF+S\XXEHXCD5C=;ZT"7A M^[L[\+:N;KZLEK]F989M7*Y>8%K>R%M9OB>;=^#*<-L7)TF!9,(B8!G('Y0G MR%0(2(LNZVLTU2U%KA+(I"&B8\!&Y<5C(* M:0<[(SI$/-->T6^=SHY@'6=\/N\`&/"2_6Q^7]J;QQO8P^_K^3V,UL?%@;N? M]X]?OKIY]Y8Q%^^Z'.R1,A^-9S@PJ;EB!$)0Q(T.2#F.=6,%R[XWX$H=32L= M%=?W*_`6]^CI'34/KJ+1Q8>2,1QC"*=09`CB>&DQ116:@:&1=6/;AXQ,!7/TNP&D_:[FR3(D'>6LV05$'2`+^!!7B23R)Z M025^NU/UV_"D(W"'(,_7`CREV?6FF&Y[VTB<#Y]/1,M@I8D:8\PPD3R*4,EE M-,^M6G.2NW.]T:8+:,_`=?SC@+,977TB4:REUZ)T9#B!8>>MKZ&.U-\.1)B9YY M.4I&^@"59$<;!&-J;^1E^^7-*Y'L9#V[-HOI=B&_F-;MRAR_2UNL1^7=2E)H M!VRAD1'N(BC+ENG,H#'>N,;6CX2O(-\CUJOG4O1H6_A11"VT4)$#\2M9B#6# MK1>.N@-WL$+?5GAI`>40D]9?Q>SV!XQ&`^A.;HOZ1LCM)MO5_6:]F2RF_\?> ME76W<2OI?S2#?7DL`(4[.>=.DN,L][$/8S,VSU5(7TKRQ/]^`%+=6BR);+!W MZ\6Q%74WJNHK5!502^+(07E?@4RK]U2);A-D3A"P4D3%)3>TY@-AQ8U_)U@6 MU3F@^F3T((=P3P\G3P#KV=^O#,CH\TFE\S1PXA2-#5U2XF!C.V>Y)W7!TJ+0 M,>V$^\,$D-55[LBXVQY1"S=L9L02ARZ/5Q2#*$/D"EEBKK28V'XW[DT$[D\:X;YS(9_U ML.^/O@HZD+1Z8Y6[AD6:_N0T,!4)-=S4_/%V2:7'ET/DY0EA/;)\V-XXE]YM MMD)J5Q^K2-#.4$JM\D8B:JY"(T$=QYFB.CL0CR2-0:S;(5JX?7^3B-I^]&FY M'T?>U)R1IKC8=X)FKP>T/)=DU:\`1MLD M_KE9_;&YVMQ\?4#-B!>/PVX?7K&`G%LP*!U([Z*XJ_Q*?TO^R]B^\PN4^-UU MFU&[)]]2(0DA41[0"A`*?/"VX8,D8D$#*WK`QBN]^KKE^V"IOO_EU`C=$T]6S%N*:(&K:#S5.NA@:EJ96M+MM5EGG`^ODTYQ?J_+X MB8I0PQA#;05G5'BG06)-&X3B2X,)XJ8#^;Y4HG(13X?`2UR]/_BT/CGEB>Z3 M:'GV]RN/(!C%0((+D:/VS/.:+N7'20^="U:ZX.C(_LX_SZ@Y.>?Q"O,Q$9$F M6D>5,IJRZ)H=&J'T!'J".!K9\REE^>!`NUOON]W55=SM_V^U?^WB\L23E0,C MJ/6`B4KE/?7"-XQTC)<./9V@2>M6]*_AZF(VCP6IECBJM`4O4#GCM>:!<U M;;0P%MNXUN#YO-YO=A]^N5GM;X:#T"52/@,]+9E;E`WVW)'>\48CCP+(B4-_ M/&T^^%(>6,&K*J.")D9K&3%0[QQHUAAT$N4HI9+S`,Y`+!]B'_IY]?4P<2*Q MXA%!K^Q%+SU22>9TM")$9SW)[3`UN]N]/=%*EV:IGI_,;(^`VJX_9G_EU]GA MJF,.S\6.!1/11JZYE<%&$KCVMJ;*(I;:L=;9S4<[AML/LP1-!ZP="S"YO?WM M/C.O)73N'ZR<`((>!)7!<"&(%I+7E`;M2P\5S\]G7LKFTRF?QT*4+X+3W5,5 M)#]-$S!<>AF9X)QA:+99RDMSX]MG)R\*1&7<'>UR_R_S)J+>_`&3G, M262:$6^(R)$/L.-()$?3?\-WRYH/FQ?.DIWXJTPTV M+KA2;\?W07)/DQ`/U3Z/1DJ^?IG^XC,5)PA",M0&&%(0D;F&A\*1N!Q<]2+U MI\CJB,^#X.@XV/'A2D]>H+_X3&4A*:)(;I?!X)PB&`%J^I))75#/GPYD_!0U M'7'U?-1[GY<_?;+,\"X_Y^5YT8: M0DV@UM&@6(KR&IU!3TN/6J:(@,OEM;N0??/.W9(&H]4:`W4ZC\UA)+"&5A%+ M\P,G>,P[A-'IEMOSR]U2*41SDH`E/@BCO45LE$X!E#;^G.#&TYFDS\[=:L?; MHBNG.@WHU_7^K\WV((6[P8#7J\=J\F+>3=%[*J%I(""XB4YY(<`%>V^NS9)F M#G<@W]UPG)Y/1I?2/$)NLVN8LS(1%QS6=($/I:UR)FC'ND-0EQQ=2D:7<@#$ M6'T\.FYC/^.L'V6&R8CY7V<#Y;PBOVZY/UU<_GRXN$Y_ MOF]QYU7V]LK$X%$[;;FAU%G+O%(-ST18:M;0-!![B2B&M]^/*]E/VNOCKU?* M&\6=1W02A8,49;%84Y7"F=(M<8+V>3B`E?%VM*O7Q\KQ'=8V.ZXHY9Q['BAA MT@K41\.4:])5&&D@ZO`7L8;9!'H5(7K.(4'5BWC'!XI,?)<7L6=CXX*+V'9\ MG_?YN",J:B4E(>B5C#YZIFI:7<0%5:/V@H"6Y^/MN#V_\_'@$+R-7F%$KK@" MQVU-GX[%N:P31%-GDC[[?+P=;^=5VVPC9Y92!C1(!T$`-?6NGEV_!76ZZT"^ M9]8VM^-IT7U*3HQ=77]ZYI#^L)<^7P;R^M7*!:^LO":>&X@Q@E[)\+B>#$KV@Z((2WGL7@@B>U53% M<+IAY'Q\I&Z%?,[)8#O>CG8R.&+?[V%/`($1Z5BR.I02SYQFFF'=@5)K?[+7 MT:`G@'?0=%^/AC0#MEVOY;/?5M$("I+]9*@9MY8%B(DOGHC('>5L02GT/6#E MO!/!#OD_2&K]>4:W'(\OO:D"X0TSBDN'"D4P1BA5\UU$MZ#I;Z-AL2/>#V*O M#D'BI]U5$N(U_N?^CV*G[?L8__?DP6GW(QT-/]$,\6[<:.,-X7?;B*DD' M)6>.<)6"'\&,5/Y8]BG1)9B,9-'R@A\)+4&N'I-P3\59VT?+5U5),XREWH(4 M.@#GWDNH.4+4<&4\0TRO&0H\3[>5?F4RTKXRB=+DJ>XS"EF@RB83Q$C"BX\L MW(WQRZ,@W4D/L6\OY1Y]#XF#)-'MQT.IV[7[^@U"(5?CGW^S?N$W*@B4A*B= M`8\6+4=F16"[D2'`MN+[LZPHAK"(3\N+GWNQ,7\H]^K@&CJT[YK4A#A M$DMY(#[1P0PZ$JQ<4D7C\++?=[)OR;._7R$222$`%4Y;"%)$8VL;(XU9Y.W=6':Y"PF,@JQ_;6X^'3SF M7*[P:?/YUQUN;U*@>CJ1KMV;*B3,\2"988):2@7Q0M6\""0LJ8SX,BR<0E:G M?!X"<_^[VJZ.RG?28C[]U2KIG%21(B$Z"F]\%-;4U&BM2DN'YX":KN2\ZY3% MDP@B7MK#STE\N?SE56(7&*-Y\-PB:&Z=:8R$U;HTFV&"Z57C&];!Q348P+]) M2OR6J#^>$O73Y\-N\/OZ^F;]X8?ML:@PKC;[WU=7MVMZ"O8]?+**BE'EM3(F M!&*948;'YAQ-\`6E/P\)Q>>T8'SI%25:%[/MIYM/Z_VOGU;;9XGX1WK^)JQN MU@TU+Z5E#[:`2DH`(3$*HAA&S9%:K+F)VBTIXAI>%R8MRV$ZFN[>__O=^O/M M_OVG3%XXY%D<"3@>:+RV_Y]\N`*(T41&J5+"1P1+64,Q'7W2^)!]=_?OUU]7<.//*E]2&A[#^WF_W1OWMU>VWYKGS[ MENR.B3I0#HC6.J9K&EV*:PJQUGIPQ"*Q-I18!CFPVJ]7U[?[KP>]J?MK'&G[ MG_75:WU]3CR97)_(O?=2)I:JR$C0P3>T"EHZP.W\L1-+AF`_0ICTX?_TMNV7Y:GO4[DA-F_YDEK]9]!DIGV<]7WDEC5;"(J(2 MS,D46+,`)BJPR?J/7Q,UA\Q.$2PZ%B5:Q;RSGDD>:AY2C$O*&ND64[TE<+:3 MR"`Y2G>9,B?R11[^6A6<,3RHB$&8*#02Q5U-A65D09VZ1I#\TQ2D=5O-[/YO6G*L8E`VI`Y*:4@<2T[X9GE2;RNP75_,+`4!424@ M>.6I*D4%46MOO.7,,894-^BCD#0'3.G6Q%"4`>G*$7I!7!IF5(- M'=&PTIND"8)B?)?B$LY/XEQI!A4AF((+0T@@-$\MT\%2TH0:UL&"UG2" MQ@6Y5>/"Y+G>2AT)91+[ZLA)LL3QB`A6$0%Y[#`GU-<<0USFL)ZQ?(#!Q35I M@)^\/_AQM_UR2/]ZM[NZBKM]?FB4:ZGG%E(9H_)80E#!>))-+D#(D2!2IQ2C M@Y6?#M%;9$C@#G8]U8%4)ZU?C],XX,MJYVZ.V;=7-TV;K.PGK7G/$OB/_>ZZE\CHY:]5,8K( MA2,T2.#"1PLLA:Q`M,0@F2L]0S\_5'K3I\[TJ3,Q3UIU3@HC\?_/]>9!AEY[4SI]E[5;%UJG M'QTYSK M*G`(VDF8:S02VH^_J%6+BPR6$[ M/D^]R:%5CH+.+2$I6&X%DTXWU%!3FBX[!]1T)>=330[;L7C2<>E`^5O.D2A< M4F,CHK.6VM5_T3GOAO7]?[WR$1@)-EEM9IU%Q8.I[3=H)TIS&:=H1$;6F4D)I"8F:"A.6<]PP%MMXNM]N):L)]4R!2Z5%(H3UHGLFJ MRYH8(EE2B[_A9?]ZWY16G)^$QSF#OBG$HW?2&\.Y-]PK3Z'A:O!A0=/;"M$T M1-^4=D(8`MKXU^>KW=?U^D&:X,E+\Q>?J3`%B<@EH1R3QG.@$.T]LV5IS#]! MD(T+CUT_`IG$7CKR77MBDN*46V.D4$Q+3)M$S;$HQ%N_M`[M_N#BFO1=^].$ M^,[Q'<*SXR&#GZEPYZ`LX[=:,$1B\A.\(T(25"ZQM?%-"2D^U)NBI[5<5;E[U_OTFDOJ8+K5]6H:%"\4!0)V<@!6%`J:PYPIWJOP'C MT%U%)@KVOB4WAXU_VGT*&(^<,XB1!$I#^DL@S1&(]M!_ULB;IDQ1T'-0K)'# M#ZH=1DFDU8#!<,^PV:A`0:DWU3HW9,!^!,M4G4M%.P=5.4Y\/^X,Q[*`7?[1 MD!IT[A(J!8RH2)0A2)P78`VIVXTSY4-IH?Q4PY01S[NF)\TYZ-*=KYH/XGM7 MFF^^55%MN3/`)5-&AFBC1-7PDQ5762\S.7XL[;A4;+.Z-CF9<7G.)-7!%U,1 M3@F)RGF?[V@-MR'DH6,B>!8"0JF966:Z_.C7*GW)=0X&YX%1?<*&^MCDY_WF M?9]Y\V>NH.+1(]=2&Q\4)9Y*JAN8``=1J%/+OY+I`=[]14D=0F`2ZO=BLL4Y M!0:=J6!WJZ@L1I<',W'!$_\52A[JV:Q,H"M-I9UJ!+40!1P-`+-0PIK`T?6P MU4(JC(9%#S:*(`*1",299B);+)Z>.-5P[3M1Q3XQ,`EMO/2V820_]:)U54J` MSCVMK"*0^`R>J611.ZT)$+SQL/QIK01 M\3+[)$SWRJY#&<]!&Q_NH$*==D`B!>,2*89(4#>#YS@O3M)J/?OB M3;\&%^8K7.=9?JYWVT/3L?MZBIWI&2GE&K8U53@G-0!N??@E+,) M0*$NJ/-2T]*+"SWIBXMY7@GV+]XWE1M$)AYC4"IZ:HUWFJ-V=;J?-]KZ0I4S M$P[OOB.%:R7<.2A<:^_Y)>;TTL&[\T56QK$8B6=,_'][5];;2&Z$?U)X'T!> M>`8#;'86F0GR2!@:C2VLW1I(]@;.KP\I6>U;K:;[8+?U,H?E5I/UU4=6%8M5 M''&N;42M#EHS@'-W1'DV.>>`]Q08^[X]/@8U,T83)#=$B91'01FP'%#$ZR9X M5KKL&\[@3,))(3N%8,J3->=+G.RJVJX6?9=S??>=(3K80D(-I$I'-U+P9(\< M@E749G=&*SL3;9IQDZY0G`)+7B4.?%_?7EP/1IA37A^$,%9KJQ''2G#M'*:D MCD\)E]WKI=3TL6FRI@7F]U]^\$XE#VF0"V`GE&@B6,4TX@.K8T`9YO+>;_'L5+3 MLJ;)KZ'PG5C@X?EU4ELUK'<2#L\IV<4">#H M'2O^%8F_6:5%8/=;_ZY6M^?V%2=W%##26D*D%IZ+Z.0*@PY@"X&8:JR'V].: M.*WV%<0RC+2WPG(G+?20NKK6C1*#W4,LOGW%R,L=2$)\H#9PP==$P-L-9YYPPSQ#]>44:@_/PBP%F#8!G]?`&85_SX<0-.?$*2.C"6V$(98C16K]@";73R[1%OSL MQ/L0\M/FW?YX=U3>/1]"X!XI[)U!CJ:&0(H0<#@V1DIF=T4KM\/'9V;>A["? M-O,>ZM>,3+Y7HP@6.VB%DD)X"I420(I:26A^=99R^X9\9OY]%/YI4[!$KX\Y ME.P/8@PT4J?L15UW;48:L,>>(`^4 ME<)+[K7UT7]7@F/MD<5SJ]8[VZ!HCZ!_%@(7SMI`O$%&$@>0P1!)QJ2O'0\! MS&#G%S.*M?;#F@+9WU)YIDWYH[7*"^%]RS$&KKWTV!&KI5!>0<1D;14Z9G/) M/Z=]^M/0OE_=F3;WGP?KRN1^RS$&9K4EUD((F#$^JI\"M=DIE9"]1YO/W"^& M^_WJSK2Y_Z3:>IG$;S/`0"-`S$.$C6;>,$*HK/,LI?.Y+7[G=//TT["^1\69 M-N7GX]T#SP6C3FH'$0+6,_?8JI9R.\>&`V?*CZ$ZTR9\^^J"O:3C]S'.P+!Q MT493`#I"`6:&\;KS.XGJ.)2=7WR`K^2(?/_`GPE<*HX*2ZZXB)HG)++,6"CK MSH<8J]SVZ*U-]L+W\+G1MQWL11>1:93/.X5TGHBMCS(S'0PK6*:B:40,I=9( MR>*?C_<6N82YUSXS#>SY[Z[3P/G,QG%0$AYX"!5!!D6W14MF%*]1\B37UFW= M5.AS;)730'GTVE&[SU[!E(K*5=NEOO\:E27^I+KT=]4B?7*N(/6ZJ`_"4A@E M,*****@=UJFBI0924*,@:2S@^U):RZO;JYT,`,-@)X'TDY!&MJ[BFQM0>Z_L M4_LO"9AZY1@%@$L7/3;J+-*'F3E!L#]T?_A57KTW4X9V7W\_:-90^K`<" M9H@=_TL5UYMEM/%N=TOL;TD7$NK':SH=>2I`#`A2EE"A%65>*9>LFOT<&3>Y M3?@Z4C[8M?+UJ07KOJ0^HF8UEFDZ^ER01,7Y4:`Y@(`(%R=,#O.,Q)U1O:5. MT#Y-@[)D.X@_LKR^3C5QJQ__O-C\N4P6S0.3&BLJ-3T:$#48>KF=-+S04*1CO>1AE1CSC0TS!SF302<45Y5/SM4'U(> MK'CDW>+V;I/.<*+#>KG^ M'SWJ3+1Y-LZ)ON5O1XHZYGU1`%Q)9"V`"'+/H816NEI@QN6FP;W\\?:!P<,,CJQ7IWU!@$#K2#(A-'"`&2$QDH>92YS? MUJ;04&;?^O&R0G@?()1].'(^"7D=^0840N,%XEYA@K`W"%'$'`02:V!`XY6] MGH(_"<;]"5XJ[-R\I+S]0!!8N%1Y3`#M*:9.$4H.L[-(S*B*]E!J\#(2U(7< M1ZC*WJQ1;S\0/&+&>4@`=0(!+)0'JA84-;F.68$1H9$TJA.YS\D,XA19#%U* M$R*`"^N]9(>9QXVXL=M19Q&FU#UUCAK7"PXC64([U^1LX3Q5"^Z-8(!8IK4B M$D@*$`>$W>S3V/:X?H](JGCL3<44_/ME5K!5Q/`\I!3G^;NFH\=$MLY,7'OC`E!MF(E/)"8P6M-B8B MN,<.5A6IRYQB5H-5O-++=[GMS=:WB+=\41%P:C##E]9; M+`#3@F%J#?:*'N9M')]1@+L+\-=]"[A,QN_^OI\%SSG2$5.(#!46IZ-\EF)45_6UYLU]7%=5Q)]F]O5HJ3G@O("""8`M&6BR5X=:T8=HAXAP_+[\[Q,I;-95_.=B=W-@>ZI6Y7Y5(,HIE'9/Z@"P M1"/#X$$:7.`9W1GK8?GI6=I-5L;?_Y9^.85/XG_^#U!+`P04````"`!E@@=' MUWXH,M8,``#/A```$0`<`&5H=&@M,C`Q-3`V,S`N>'-D550)``.^$L55OA+% M575X"P`!!"4.```$.0$``.U=ZV_;NA7_/F#_`^;Q>T=&1SD4B7I))X?_U(2K(EB[8>=E)M-A"TLG2>_!T>'M(4_>7WU\!' MS\`%8?2XU=OIMA!0A[F$#H];CP_MDX>SJZO6[U__^I/!.7@X].5Q*Z0_0^P3CX"KK/!!*\D0I!Y+S(<@;W``8HP=.&Z-I!P?=3HO M+R\[,`+LRQ&A(N28.K#CL*"SV^T==`_WE'_*8RJ.8"1'U;E\0I\R7*\#[N\P M/E24W;V.?CS``A)RRB@-`SN#*WE'3L;0441M106<.`F?)G+EE"^MY*`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`A"B:0OG7GV>6?C77\RT3<\K.[,XV_H0^Q MTM^V,9`&YPR+T0EU]7\7/T/56+[R5KQ)'"Q751P+NW5B06M#2FMTD=*[C8@, M3'W=2]8">"QI*9Y[7?77*XMG)''C8#IC04"D7LH6NMLP*@D=JODBJ8[3,E$% M@^LGR^":$H>P[EMI@5N8IDU1,XV6D%B0+3_MYWO74M`V-QFJ9G"!*G9U(9A/ M7+UXF`KE+@,/M7?U)_NI:6GK::B$J. M2Y^]K`=#N^0"+/=*8SD3/RU+VKSF3J:.B8&IS:%D( MJHKTYLYVJ@`R6[F[9G1XK08M]T0(-KE1FX:,;2@R#IU.4-H\9.S;X,7'>I#?PS/0$$XGW_&_&7_/M%3:AN)8VU]O MK,7VZ`@S%LWHMN%5"MIZ:]XU-!2LA1]:UL*KA\:&KI)'\Z@^?JV.9)JUH+[< MM]27\0S.\&]PJ]?,P18)!1ETWU+YI3'8W*27:LMZ.2TOH"!E[5M25A:+#4U' M-R"C=K@#_C#"'*I"D1=0D)H.+*E)"4G@4&*0D;/Q2*1VI%!)SHD?2E6HFT?B MXM7Q0Q?<2\X"O4X71I[?>CDI-=/=&UM3D#H/+!,=6XS,[:-1AK43RR("@1+; MD#8.I:S3'#:9&UR,+@:=>1E<3[$@CJKM3&.#.^73B\-O%G@KV%`<;KF1NBC< MF#D$D_ M6E:-K""JA)@H03,M&YP5;3C<8,ZQ+F;6B&U.9C&BN;%Q`:)3T5L8,TV>N?A7-$DD%1)'.>1LQW@0N] MJUY.JJ)CD5!0T>Q9*IJTE+^C2,X6BU4'NA(2"W+@GF68LV&U'>7L"*9?GS*# MPN21JJ=W/J9U![IZ2HIQSHUU=IRS;VA%ZI#1A_HC-5'42K7:*A=Z&'XR!"F/NQ:N^A-/) M[1AT]4>'ER%U]),W"*BZ)A2'U:?J864HVL8:E#8'Q?;H[5Q3BU!BTC:XJB/[ MWI%4/FP^KC]LM@&2`JS>:36^\T%(2"$-G= MDO&+_BK=W3&?U'F]O;J"@I6FGFVE*5)BOIF.U>2V8\XTH435%NP"+%9>JUI9 M84'"[MF6LN)@8-6"8;O:52M$S/_5%YAKJED:#KO=WJXEW=?+#>A#I/+_.0*^ M=.;/XXOO9,_M,Z?VQ2=W(SQ04R_LR..6Y"&T3-#H<\[^/-GM=@^CT?1*84UU M1]*3K^\0#("WS%&$QZU"*N+[>B1.Q(M0Z2,RU,9\XRP<'[?,V=A'1$+00M$) M:-&!W$=@2>)?YV?:+Z7;_8[Y$^A>'1?B(N7*HN=UK(_N!(RJ08-/YLT? M1.>`'+<<#BZ1-J^BP[1E*:?L>Y8R?BT@:;!K("F>B[;,K2;$5,"X)/])=F0R M]C0;O?3)`L2%1$SL006&-X3&A8$=F>IN,^^*2N`4^_[D7'5[GXW!?6">?#&; MZ?-N%S$TV&VJPV(27U0R:,:Z26[`1GM(`8I?8B&H1/5RNXT-Y2D M_25)HJ2W^I0LH7_3)!YSLO`L?MS`D5>O$ZGVHK)@X4J5=*"UBY27E1GK8ZJ7 MV>GPU[EO5F6JNIXPE7/;E4-2GT-4G<>Z;^ M%-,U=_@N,GX.NK+4#>QVRXY8.HF9$C]+TC9ON+@(QCZ;`/2!!X0:`:=`P2-2 M8*JF.[X^TNN,"3DW9:W!UX`>^L\PP//3H;E[#;#RBCKZN!0XA^C_*UHTZZ[$ MT=SSK"0:CT;NV)_%O'6JK M^RS>ZI;QOCS/"OG6R%U37RXRV++WIYK'"P3\>O?-$3W?U>34P?X5=SZ]P[R-8*I"$R,#N:GF-DF6$U$`P;QFU#;HN;3UC,C8R>7T]3OOH1*&`)? MYL6RU>.%P)JO)4H$<`FZ!D"4_I(E8_GL7H/7[&SC?71,A?IL[Q^)D_58FUM) M+/O5';-DU8=7>>HKOY(6J,2Q0JC*1,SJT5KE),@BIVM(:%8C,,]4*"9,QWAB MZB.]SCY[/GU_@WEWP,UD7/\2P;0\LKW(L;S9WDEG0QI:Q0"C6+]9'^W6B/[- M-TXQ74,0-()4]PK^B=,>&; MXI?G6,(4^VG+O*/"!J=F,Y%X,+_YZH(:\OKL0;$);]+'KS^('.GMHFK4N8>? M(8DF.B+3@M5YWW+64^H[]^D6K#O.GHDN@"X93QTVIQ<)/0_T.Q7ZQKT"`L``00E#@``!#D!``!02P$"'@,4````"`!E@@='K41.->`6``!\X@``%0`8 M```````!````I(%EQP``96AT:"TR,#$U,#8S,%]C86PN>&UL550%``.^$L55 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`98('1T\C`Q0````(`&6"!T=WM^&N0'@``#2*!@`5 M`!@```````$```"D@30%`0!E:'1H+3(P,34P-C,P7VQA8BYX;6Q55`4``[X2 MQ55U>`L``00E#@``!#D!``!02P$"'@,4````"`!E@@='&V;=Q%-)``!WQ`,` M%0`8```````!````I('#?0$`96AT:"TR,#$U,#8S,%]P&UL550%``.^ M$L55=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`98('1]=^*#+6#```SX0` M`!$`&````````0```*2!9<'-D550%``.^$L55 E=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``(;4`0`````` ` end XML 18 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) - Common Stock Options [Member] - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Number of Stock Options

Balance outstanding at December 31, 2014 (shares) 1,724,000

Granted (shares) 34,000

Exercised (shares) (114,000)

Cancelled (shares) (224,000)

Balance outstanding at June 30, 2015 (shares) 1,420,000 1,724,000

Number of Stock Options Vested and expected to vest at June 30, 2015 (shares) 1,397,000

Number of Stock Options Exercisable at June 30, 2015 (shares) 1,108,000

Weighted Average Exercise Price

Weighted-Average Exercise Price, balance outstanding at December 31, 2014 (usd per share) $ 18.50

Weighted-Average Exercise Price, Granted (usd per share) 11.37

Weighted-Average Exercise Price, Exercised (usd per share) 9.20

Weighted-Average Exercise Price, Cancelled (usd per share) 21.79

Weighted-Average Exercise Price, Balance outstanding at June 30, 2015 (usd per share) 18.56 $ 18.50

Weighted-Average Exercise Price, Vested and expected to vest at June 30, 2015 (usd per share) 18.51

Weighted-Average Exercise Price, Exercisable at March 31, 2015 (usd per share) $ 17.86

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 3 years 23 days 3 years 3 months 22 days

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 3 years 23 days 3 years 3 months 22 days

Weighted-Average Remaining Contractual Life (years), Vested and expected to vest at June 30, 2015 3 years 12 days

Weighted-Average Remaining Contractual Life (years), Exercisable at June 30, 2015 2 years 7 months 18 days

Aggregate Intrinsic Value, Balance outstanding at December 31, 2014 ^[1] $ 12,884

Aggregate Intrinsic Value, Exercised ^[1] 382

Aggregate Intrinsic Value, Balance outstanding at June 30, 2015 ^[1] 222 $ 12,884

Aggregate Intrinsic Value, Vested and expected to vest at June 30, 2015 ^[1] 217

Aggregate Intrinsic Value, Exercisable at June 30, 2015 ^[1] $ 179

[1] The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 and the exercise price of in-the-money options as of those dates.

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Charges (Restructuring Activities) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Mar. 30, 2015

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Restructuring Cost and Reserve [Line Items]

Restructuring charges $ 58 $ 0 $ 4,541 $ 0

Employee Termination Costs [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges 57 0 3,791 0

Non-cash Employee Termination Costs - Stock-based Compensation [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges 0 0 113 0

Facility and Other Termination Costs [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges $ 600 $ 1 $ 0 $ 637 $ 0

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=ehth_NoncashEmployeeTerminationCostsStockbasedCompensationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net Income Per Share
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Net Income Per Share
Net Income Per Share

Basic net income per share is computed by dividing net income by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net income per share is computed giving effect to all potential dilutive common stock equivalent shares, including options and restricted stock units. The dilutive effect of outstanding awards is reflected in diluted net income per share by application of the treasury stock method.

The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Basic:

Numerator:

Net income allocated to common stock
$
3,023

$
5,750

$
1,470

$
3,668

Denominator:

Weighted average number of common stock shares outstanding
18,978

17,967

18,914

17,906

Net income per share—basic:
$
0.16

$
0.32

$
0.08

$
0.20

Diluted:

Numerator:

Net income allocated to common stock
$
3,023

$
5,750

$
1,470

$
3,668

Denominator:

Weighted average number of common stock shares outstanding
18,978

17,967

18,914

17,906

Weighted average number of options
623

20

702

22

Weighted average number of restricted stock units
174

48

205

70

Total common stock shares used in diluted per share calculation (1)
19,775

18,035

19,821

17,998

Net income per share—diluted:
$
0.15

$
0.32

$
0.07

$
0.20

(1)
Total common stock shares used in diluted per share calculation excludes market-based stock unit awards for which the related contingency had not been met as of June 30, 2015.

For each of the three- and six-month periods ended June 30, 2014 and 2015, we had securities outstanding that could potentially dilute net income per share, but the shares from the assumed exercise of these securities were excluded in the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented. The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income per share consisted of the following (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Common stock options
130

1,450

27

1,507

Restricted stock units
65

492

—

447

Total
195

1,942

27

1,954

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense $ 1,827 $ 1,850 $ 3,858 $ 4,295

Marketing and Advertising Expense [Member]

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense 446 579 1,037 1,236

Customer Care And Enrollment Expense [Member]

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense 139 71 256 167

Technology And Content Expense [Member]

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense 511 429 946 991

General and Administrative Expense [Member]

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense 731 771 1,506 1,901

Restructuring Charges [Member]

Component Of Stock Based Compensation Expense [Line Items]

Total Stock-Based Compensation Expense $ 0 $ 0 $ 113 $ 0

X

- Definition
Component Of Stock Based Compensation Expense [Line Items]
+ References
No definition available.
+ Details

Name: ehth_ComponentOfStockBasedCompensationExpenseLineItems

Namespace Prefix: ehth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=ehth_CustomerCareAndEnrollmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=ehth_TechnologyAndContentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common stock options $ 371 $ 564 $ 833 $ 1,206

Restricted stock units 1,456 1,286 3,025 3,089

Total stock-based compensation expense $ 1,827 $ 1,850 $ 3,858 $ 4,295

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_RestrictedStockExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 23 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income before provision for income taxes $ 5,819 $ 6,319 $ 3,793 $ 3,170

Provision for income taxes $ 69 $ 3,296 $ 125 $ 1,700

Effective tax rate 1.20% 52.20% 3.30% 53.60%

Increase in additional paid-in capital related to excess federal and state tax benefits $ 0 $ 400 $ 0 $ 3,700

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 24 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net Income Per Share (Schedule Oof Computation Of Basic And Diluted Net Income (Loss) Per Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Earnings Per Share [Abstract]

Net income (loss) allocated to common stock $ 5,750 $ 3,023 $ 3,668 $ 1,470

Net weighted average number of common stock shares outstanding (shares) 17,967 18,978 17,906 18,914

Net income (loss) per share-basic (usd per share) $ 0.32 $ 0.16 $ 0.20 $ 0.08

Incremental Common Shares Attributable To Options (shares) 20 623 22 702

Incremental Common Shares Attributable To Restricted Stock Units (shares) 48 174 70 205

Total common stock shares used in diluted per share calculation (shares) 18,035 19,775 17,998 19,821

Net income per share—diluted (usd per share) $ 0.32 $ 0.15 $ 0.20 $ 0.07

X

- Definition
Weighted-average number of incremental dilutive common shares attributable to options and included in diluted shares outstanding.
+ References
No definition available.
+ Details

Name: ehth_IncrementalCommonSharesAttributableToOptions

Namespace Prefix: ehth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted-average number of incremental dilutive common shares attributable to restricted stock units and included in diluted shares outstanding.
+ References
No definition available.
+ Details

Name: ehth_IncrementalCommonSharesAttributableToRestrictedStockUnits

Namespace Prefix: ehth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes
6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes

The following table summarizes our provision for income taxes and our effective tax rates for the three and six months ended June 30, 2014 and 2015 (in thousands, except effective tax rate):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Income before provision for income taxes
$
6,319

$
5,819

$
3,170

$
3,793

Provision for income taxes
$
3,296

$
69

$
1,700

$
125

Effective tax rate
52.2
%

1.2
%

53.6
%

3.3
%

Our effective tax rate in the three and six months ended June 30, 2014 was higher than statutory federal and state tax rates due primarily to non-deductible lobbying expenses. Our effective tax rate in the three and six months ended June 30, 2015 was lower than statutory federal and state tax rates due primarily to the change in valuation allowance, partially offset by certain discrete items.

During the three and six months ended June 30, 2014, excess federal and state tax benefits related to share-based payments resulted in increases of $0.4 million and $3.7 million, respectively, in Additional Paid-In Capital in the condensed consolidated balance sheets. These amounts are also classified in the condensed consolidated statements of cash flows as both a reduction to operating cash flows and as a financing cash inflow. During the three and six months ended June 30, 2015, no excess federal and state tax benefits related to share-based payments were recognized.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net Income Per Share (Schedule Of Anti-Dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) - shares
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount 200000

Total 1,942,000 195,000 1,954,000 27,000

Common Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total 1,450,000 130,000 1,507,000 27,000

Restricted Stock Units [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total 492,000 65,000 447,000 0

X

- Definition
UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount
+ References
No definition available.
+ Details

Name: ehth_UnearnedAntidilutiveRestrictedSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: ehth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 51,812 $ 51,415

Accounts receivable 10,169 8,200

Deferred income taxes 386 386

Prepaid expenses and other current assets 6,392 6,474

Total current assets 68,759 66,475

Property and equipment, net 8,510 9,640

Other assets 4,122 5,679

Intangible assets, net 10,140 10,774

Goodwill 14,096 14,096

Total assets 105,627 106,664

Current liabilities:

Accounts payable 2,066 5,961

Accrued compensation and benefits 8,365 8,204

Accrued marketing expenses 1,711 8,707

Deferred revenue 602 869

Accrued restructuring charges 289 0

Other current liabilities 4,647 2,996

Total current liabilities 17,680 26,737

Non-current liabilities 6,608 6,449

Stockholders’ equity:

Common stock 29 29

Additional paid-in capital 263,195 259,007

Treasury stock, at cost (199,998) (199,998)

Retained earnings 17,929 14,261

Accumulated other comprehensive income 184 179

Total stockholders’ equity 81,339 73,478

Total liabilities and stockholders’ equity $ 105,627 $ 106,664

X

- Definition
Total carrying values as of the balance sheet date of liabilities incurred through that date and payable for obligations related to marketing and advertising services received from vendors. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: ehth_AccruedMarketingExpenses

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Restructuring Charges
+ References
No definition available.
+ Details

Name: ehth_AccruedRestructuringCharges

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 28 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Balance Sheet Accounts
6 Months Ended

Jun. 30, 2015

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Accounts
Balance Sheet Accounts

Cash and Cash Equivalents—As of December 31, 2014 and June 30, 2015, our cash equivalents consisted of money market accounts that invested in U.S. government-sponsored enterprise bonds and discount notes, U.S. government treasury bills and notes and repurchase agreements collateralized by U.S. government obligations. At December 31, 2014 and June 30, 2015, our cash equivalents carried no unrealized gains or losses and we did not realize any significant gains or losses on sales of cash equivalents during the three and six months ended June 30, 2014 and 2015.

As of December 31, 2014 and June 30, 2015, our cash and cash equivalent balances were invested as follows (in thousands):

December 31, 2014

June 30, 2015
Cash
$
15,793

$
17,189

Money market funds
35,622

34,623

Total cash and cash equivalents
$
51,415

$
51,812

Our money market funds reflect unadjusted quoted prices in active markets for identical assets and are classified as Level 1 as of December 31, 2014 and June 30, 2015.

Accounts Receivable—As of December 31, 2014 and June 30, 2015, our accounts receivable consisted of the following (in thousands):

December 31, 2014

June 30, 2015
Medicare renewal commission receivable
$
355

$
8,566

Accounts receivable - from other revenues
2,462

1,304

Other commissions receivable
5,383

299

Total accounts receivable
$
8,200

$
10,169

As a result of a regulation issued by CMS, which changed the definition of a plan year from being 12-months from the effective date of a policy to January 1 through December 31 of each year, all Medicare Advantage and Medicare Part D prescription drug policies will renew on January 1 of each year, resulting in our recording of substantially all Medicare Advantage and Medicare Part D prescription drug plan renewal commission revenue in the first quarter of each year. We fully implemented this new rule in our first quarter ended March 31, 2015. We recognize a full year of renewal commission revenue at the time a policy is renewed, however, renewal commissions for Medicare Advantage products are paid monthly. As a result, the majority of renewal commissions for that product is collected in quarters subsequent to the first quarter.

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
No definition available.
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Geographic Information And Significant Customers (Schedule Of Revenue By Major Customers) (Details)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Humana [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage 26.00%

Anthem [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[1] 9.00%

UnitedHealthcare [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[2] 10.00%

Aetna [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[3] 9.00%

Sales [Member] | Humana [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage 13.00% 21.00% 24.00%

Sales [Member] | Anthem [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[1] 11.00% 11.00% 11.00%

Sales [Member] | UnitedHealthcare [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[2] 11.00% 9.00% 10.00%

Sales [Member] | Aetna [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage ^[3] 8.00% 10.00% 10.00%

Major Medical Individual And Family Insurance Plans [Member] | Commission Revenue [Member]

Revenue, Major Customer [Line Items]

Concentration risk, percentage 65.00% 68.00% 49.00% 64.00%

[1] also includes other carriers owned by Anthem.

[2] UnitedHealthcare also includes other carriers owned by UnitedHealthcare.

[3] Aetna also includes other carriers owned by Aetna.

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorCustomersAxis=ehth_HumanaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=ehth_AnthemMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=ehth_UnitedhealthcareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=ehth_AetnaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=ehth_MajorMedicalIndividualAndFamilyInsurancePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=ehth_CommissionRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Balance Sheet Accounts (Schedule Of Accounts Receivable) (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Accounts, Notes, Loans and Financing Receivable [Line Items]

Total accounts receivable $ 10,169 $ 8,200

Medicare Renewal Commissions Receivable [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Total accounts receivable 8,566 355

Accounts Receivable, Other Revenues [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Total accounts receivable 1,304 2,462

Other Commissions Receivable [Member]

Accounts, Notes, Loans and Financing Receivable [Line Items]

Total accounts receivable $ 299 $ 5,383

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ehth_MedicareRenewalCommissionsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ehth_AccountsReceivableOtherRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ehth_OtherCommissionsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Charges (Narrative) (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Mar. 30, 2015

USD ($)

position

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Restructuring Cost and Reserve [Line Items]

Restructuring charges $ 58 $ 0 $ 4,541 $ 0

Employee Termination Benefits and Related Costs [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges $ 3,900

Facility and Other Termination Costs [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring charges $ 600 $ 1 $ 0 $ 637 $ 0

UNITED STATES

Restructuring Cost and Reserve [Line Items]

Number of positions eliminated | position 160

Number of positions eliminated, period percent 15.00%

X

- Definition
The number of positions eliminated during the period as a result of restructuring activities.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=ehth_EmployeeTerminationBenefitsandRelatedCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule Of Activity Under The Plans) (Details) - Jun. 30, 2015 - shares

Total

2014 Equity Incentive Plan [Member]

Shares Available for Grant

Shares available for grant, beginning balance (shares) 4,164,000

Restricted stock units granted (shares) (692,000)

Options granted (shares) (34,000)

Restricted stock units cancelled (shares) ^[1] 85,000

Options cancelled (shares) ^[2] 13,000

Shares available for grant, ending balance (shares) 3,536,000

2006 Equity Incentive Plan [Member]

Shares Available for Grant

Options cancelled (shares) 211,000

2006 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]

Shares Available for Grant

Restricted stock units cancelled (shares) 62,000

[1] Restricted stock units cancelled does not include 62,000 restricted stock units cancelled under the 2006 Equity Incentive Plan

[2] Options cancelled does not include 211,000 stock options cancelled under the 2006 Equity Incentive Plan

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=ehth_A2014EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ehth_A2006EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stockholders' Equity
Stockholders’ Equity

Stock Plans—The following table summarizes activity under our 2014 Equity Incentive Plan, 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands):

Shares Available for Grant
Shares available for grant December 31, 2014
4,164

Restricted stock units granted
(692
)
Options granted
(34
)
Restricted stock units cancelled (1)
85

Options cancelled (2)
13

Shares available for grant June 30, 2015
3,536

(1)
Restricted stock units cancelled does not include 62,000 restricted stock units cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.

(2)
Options cancelled does not include 211,000 stock options cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.

We maintain our 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan, under which we previously granted options to purchase shares of our common stock and restricted stock units. The 2006 Equity Incentive Plan was terminated with respect to the grant of additional awards on June 12, 2014, upon adoption of our 2014 Equity Incentive Plan. The 2005 Stock Plan and 1998 Stock Plan were terminated with respect to the grant of additional awards upon the effectiveness of the 2006 Equity Incentive Plan. We will continue to issue new shares of common stock upon vesting of restricted stock units and the exercise of stock options previously granted under the 2006 Equity Incentive Plan, 2005 Stock Plan and 1998 Stock Plan.

The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):

Number of Stock Options

Weighted Average Exercise Price

Weighted-Average Remaining Contractual Life (years)

Aggregate Intrinsic Value (1)
Balance outstanding at December 31, 2014
1,724

$
18.50

3.31

$
12,884

Granted
34

$
11.37

Exercised
(114
)

$
9.20

$
382

Cancelled
(224
)

$
21.79

Balance outstanding at June 30, 2015
1,420

$
18.56

3.06

$
222

Vested and expected to vest at June 30, 2015
1,397

$
18.51

3.03

$
217

Exercisable at June 30, 2015
1,108

$
17.86

2.63

$
179

(1)
The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 and the exercise price of in-the-money options as of those dates.

The total fair value of stock options vested during the three and six months ended June 30, 2014 was $0.5 million and $1.2 million, respectively. The total fair value of stock options vested during the three and six months ended June 30, 2015 was $0.4 million and $0.9 million, respectively.

The following table summarizes restricted stock unit activity, including performance-based and market-based restricted stock unit activity, under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):

Number of Restricted Stock Units (1)

Weighted-Average Grant Date Fair Value

Weighted-Average Remaining Contractual Life (years)

Aggregate Intrinsic Value (2)
Balance outstanding as of December 31, 2014
873

$
30.86

2.52

$
21,753

Granted
692

$
10.59

Vested
(195
)

$
24.02

Cancelled
(147
)

$
26.53

Balance outstanding as of June 30, 2015
1,223

$
21.00

2.92

$
15,522

(1)
Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.

(2)
The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 multiplied by the number of restricted stock units outstanding as of December 31, 2014 and June 30, 2015, respectively.

The fair value of the restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on a straight-line basis over the vesting period. The fair value of performance-based restricted stock units is based on eHealth’s stock price on the date of grant, and compensation expense related to these awards is recognized on an accelerated basis over the vesting period. The amount of expense recorded for performance-based restricted stock units is based on expected attainment of performance criteria. The total fair value of restricted stock units vested during the three and six months ended June 30, 2014 was $1.4 million and $9.8 million, respectively. The total fair value of restricted stock units vested during the three and six months ended June 30, 2015 was $0.9 million and $2.1 million, respectively.

Stock Repurchase Programs—We had no stock repurchase activity during the three and six months ended June 30, 2015. In addition to the shares repurchased under our past repurchase programs as of June 30, 2015, we have in treasury 348,475 shares that were previously surrendered by employees to satisfy tax withholdings due in connection with the vesting of certain restricted stock units. As of December 31, 2014 and June 30, 2015, we had a total of 10,945,607 shares and 11,012,363 shares, respectively, held in treasury.
Stock-Based Compensation—The fair value of stock options granted to employees for the three and six months ended June 30, 2014 and 2015 was estimated using the following weighted average assumptions:

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Expected term
4.2 years

4.3 years

4.2 years

4.3 years

Expected volatility
45.9
%

63.6
%

45.9
%

63.6
%
Expected dividend yield
—
%

—
%

—
%

—
%
Risk-free interest rate
1.42
%

1.15
%

1.42
%

1.15
%
Weighted-average fair value
$
17.01

$
5.70

$
17.01

$
5.70


In March 2015, we granted market-based stock unit awards to certain members of senior management. Each market-based stock unit award represents a contingent right to receive certain shares of the Company’s common stock upon the attainment of certain stock prices over a four-year performance period. Once a stock price threshold is achieved, the portion of the award related to that threshold will vest on the one-year anniversary of the date of achievement, subject to the employee's continued service through each vesting date. Compensation expense related to these awards is recognized on an accelerated basis over the requisite service period. The weighted-average fair value of the market-based stock unit awards was determined using the Monte Carlo simulation model incorporating the following weighted average assumptions:

Expected term

2.59

Expected volatility

64.7
%
Expected dividend yield

—
%
Risk-free interest rate

1.13
%
Weighted-average fair value

$
6.69

There were no market-based stock unit awards granted during the three months ended June 30, 2015 and the three and six months ended June 30, 2014.

The following table summarizes stock-based compensation expense recorded during the three and six months ended June 30, 2014 and 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Stock options
$
564

$
371

$
1,206

$
833

Restricted stock units
1,286

1,456

3,089

3,025

Total stock-based compensation expense
$
1,850

$
1,827

$
4,295

$
3,858

The following table summarizes stock-based compensation expense by operating function for the three and six months ended June 30, 2014 and 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Marketing and advertising
$
579

$
446

$
1,236

$
1,037

Customer care and enrollment
71

139

167

256

Technology and content
429

511

991

946

General and administrative
771

731

1,901

1,506

Restructuring charges
—

—

—

113

Total stock-based compensation expense
$
1,850

$
1,827

$
4,295

$
3,858

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
+ References
No definition available.
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Revenue

Commission $ 37,396 $ 38,526 $ 95,215 $ 84,103

Other 2,498 4,068 5,967 9,431

Total revenue 39,894 42,594 101,182 93,534

Operating costs and expenses:

Cost of revenue 670 892 3,084 3,005

Marketing and advertising 9,285 9,609 34,736 32,718

Customer care and enrollment 7,658 8,984 19,519 18,697

Technology and content 8,591 9,550 19,364 20,017

General and administrative 7,516 6,857 15,489 15,151

Restructuring charges 58 0 4,541 0

Amortization of intangible assets 288 354 633 708

Total operating costs and expenses 34,066 36,246 97,366 90,296

Income from operations 5,828 6,348 3,816 3,238

Other expense, net (9) (29) (23) (68)

Income before provision for income taxes 5,819 6,319 3,793 3,170

Provision for income taxes 69 3,296 125 1,700

Net income 5,750 3,023 3,668 1,470

Comprehensive income:

Foreign currency translation adjustment 4 1 5 17

Comprehensive income $ 5,754 $ 3,024 $ 3,673 $ 1,487

Net income (loss) per share:

Basic (in usd per share) $ 0.32 $ 0.16 $ 0.20 $ 0.08

Diluted (in usd per share) $ 0.32 $ 0.15 $ 0.20 $ 0.07

Weighted Average Number of Shares Outstanding, Diluted [Abstract]

Basic (in shares) 17,967 18,978 17,906 18,914

Diluted (in shares) 18,035 19,775 17,998 19,821

X

- Definition
The total expense recognized in the period related to providing customer care and enrollment services. These services include pre-sales assistance to applicants who call our customer care center and enrollment services to applicants during the underwriting process.
+ References
No definition available.
+ Details

Name: ehth_CustomerCareAndEnrollmentExpense

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue recognized during the period from lead generation, technology licensing and online sponsorship and advertising activities.
+ References
No definition available.
+ Details

Name: ehth_OtherRevenue

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total expense recognized in the period for technology and content. Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website.
+ References
No definition available.
+ Details

Name: ehth_TechnologyAndContentExpense

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Income from agency and brokerage operations (includes sales of annuities and supplemental contracts); service charges, commissions, and fees from the sale of insurance and related services; and management fees from separate accounts, deferred annuities, and universal life products.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.13(c),(d))

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InsuranceCommissionsAndFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The total expense recognized in the period for promotion, public relations, and brand or product advertising.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 36 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Net Income Per Share (Tables)
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Schedule Of Computation Of Basic And Diluted Net Income (Loss) Per Share
The following table sets forth the computation of basic and diluted net income per share (in thousands, except per share amounts):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Basic:

Numerator:

Net income allocated to common stock
$
3,023

$
5,750

$
1,470

$
3,668

Denominator:

Weighted average number of common stock shares outstanding
18,978

17,967

18,914

17,906

Net income per share—basic:
$
0.16

$
0.32

$
0.08

$
0.20

Diluted:

Numerator:

Net income allocated to common stock
$
3,023

$
5,750

$
1,470

$
3,668

Denominator:

Weighted average number of common stock shares outstanding
18,978

17,967

18,914

17,906

Weighted average number of options
623

20

702

22

Weighted average number of restricted stock units
174

48

205

70

Total common stock shares used in diluted per share calculation (1)
19,775

18,035

19,821

17,998

Net income per share—diluted:
$
0.15

$
0.32

$
0.07

$
0.20

Schedule Of Anti-dilutive Shares Excluded From Computation Of Net Income (Loss) Per Share
The number of outstanding weighted average anti-dilutive shares that were excluded from the computation of diluted net income per share consisted of the following (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Common stock options
130

1,450

27

1,507

Restricted stock units
65

492

—

447

Total
195

1,942

27

1,954

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document And Entity Information - shares
6 Months Ended

Jun. 30, 2015

Jul. 31, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol EHTH

Entity Registrant Name eHealth, Inc.

Entity Central Index Key 0001333493

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 18,080,207

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document and Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: ehth_DocumentAndEntityInformationAbstract

Namespace Prefix: ehth_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Geographic Information And Significant Customers (Tables)
6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Schedule Of Long Lived Assets By Geographical Areas
Long-lived assets by geographical area were as follows (in thousands):

As of

As of

December 31, 2014

June 30, 2015
United States
$
39,752

$
36,446

China
437

422

Total
$
40,189

$
36,868

Schedule Of Revenue By Major Customers
Carriers representing 10% or more of our total revenue in the three and six months ended June 30, 2014 and 2015 are presented in the table below:

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Humana
21
%

13
%

24
%

26
%
Anthem (1)
11
%

11
%

11
%

9
%
UnitedHealthcare (2)
9
%

11
%

10
%

10
%
Aetna (3)
10
%

8
%

10
%

9
%

(1)Anthem also includes other carriers owned by Anthem.
(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
(3)Aetna also includes other carriers owned by Aetna.

X

- Definition
Schedule Of Long Lived Assets By Geographical Areas [Table Text Block]
+ References
No definition available.
+ Details

Name: ehth_ScheduleOfLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: ehth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Condensed Consolidated Statements Of Cash Flows - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Operating activities

Net income $ 3,668 $ 1,470

Adjustments to reconcile net income to net cash used in operating activities:

Deferred income taxes 0 (2,035)

Depreciation and amortization 2,108 2,061

Amortization of internally-developed software 318 209

Amortization of book-of-business consideration 1,991 1,805

Amortization of intangible assets 633 708

Stock-based compensation expense 3,858 4,295

Deferred rent 28 34

Changes in operating assets and liabilities:

Accounts receivable (1,955) (2,277)

Prepaid expenses and other assets (243) (1,282)

Accounts payable (3,895) (227)

Accrued compensation and benefits 159 (3,051)

Accrued marketing expenses (6,996) (6,086)

Deferred revenue (432) (603)

Accrued restructuring charges 569 0

Other liabilities 1,736 (123)

Net cash provided by (used in) operating activities 1,547 (5,102)

Investing activities

Purchases of property and equipment and other assets (1,432) (2,340)

Purchase of intangible assets 0 (4,500)

Net cash used in investing activities (1,432) (6,840)

Financing activities

Net proceeds from exercise of common stock options 1,049 3,244

Cash used to net-share settle equity awards (736) (3,355)

Excess tax benefits from stock-based compensation 0 3,663

Repurchase of common stock 0 (28,256)

Principal payments in connection with capital leases (40) (40)

Net cash provided by (used in) financing activities 273 (24,744)

Effect of exchange rate changes on cash and cash equivalents 9 13

Net increase (decrease) in cash and cash equivalents 397 (36,673)

Cash and cash equivalents at beginning of period 51,415 107,055

Cash and cash equivalents at end of period $ 51,812 $ 70,382

X

- Definition
Amortization Of Consideration Paid In Connection With The Purchase Of Books-Of-Business
+ References
No definition available.
+ Details

Name: ehth_AmortizationOfBookOfBusinessConsideration

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amortization of Internally Developed Software
+ References
No definition available.
+ Details

Name: ehth_AmortizationofInternallyDevelopedSoftware

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash Used to Net-Share Settle Equity Awards
+ References
No definition available.
+ Details

Name: ehth_CashUsedtoNetShareSettleEquityAwards

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in accrued marketing expenses.
+ References
No definition available.
+ Details

Name: ehth_IncreaseDecreaseInAccruedMarketingExpenses

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change during the reporting period in the amount due that is the result of the cumulative difference between actual rent due and rent expense recognized on a straight-line basis.
+ References
No definition available.
+ Details

Name: ehth_IncreaseDecreaseInDeferredRentExpense

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase (Decrease) in Accrued Restructuring Charges
+ References
No definition available.
+ Details

Name: ehth_IncreaseDecreaseinAccruedRestructuringCharges

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfLongTermCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 40 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies

Legal Proceedings—On January 26 and March 10, 2015, two purported class action lawsuits were filed against us, our chairman and chief executive officer, Gary L. Lauer (“Mr. Lauer”), and our senior vice president and chief financial officer, Stuart M. Huizinga (“Mr. Huizinga”), in the United States District Court for the Northern District of California. On May 6, 2015, the Court consolidated the two cases. On June 10, 2015, a consolidated complaint was filed. The consolidated complaint alleges that the defendants made false and misleading statements regarding the Company’s financial performance, guidance and operations during an alleged class period of May 1, 2014 to January 14, 2015. The consolidated complaint alleges that we and Messrs. Lauer and Huizinga violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The consolidated complaint seeks compensatory damages, attorneys’ fees and costs, rescission or a rescissory measure of damages, equitable/injunctive relief and such other relief as the court deems proper. On July 15, 2015, defendants moved to dismiss the consolidated complaint.

In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. At December 31, 2014 and June 30, 2015 we had no material liabilities included in our consolidated balance sheet for outstanding legal claims.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Charges
6 Months Ended

Jun. 30, 2015

Restructuring and Related Activities [Abstract]

Restructuring Charges
Restructuring Charges

In March 2015, we implemented an organizational restructuring and cost reduction plan designed to rebalance our resources and help reduce our cost structure as a result of lower than expected individual and family health insurance plan membership and revenue. As part of the plan, we eliminated approximately 160 full-time positions in the United States, representing approximately 15% of our workforce primarily in our technology and content and customer care and enrollment groups, and to a lesser extent, in our marketing and advertising and general and administrative groups. We incurred pre-tax restructuring charges of approximately $3.9 million for employee termination benefits and related costs as well as $0.6 million in other pre-tax restructuring charges, primarily consisting of facility exit costs. The majority of the restructuring charges were recorded in the first quarter of 2015, when the activities comprising the plan were approved and substantially completed. In March 2015, as part of our restructuring activities, we also eliminated certain positions in our China operation.

The following table summarizes the total cash and non-cash restructuring charges recorded during the three and six months ended June 30, 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015

Employee termination costs
$
—

$
57

$
—

$
3,791

Non-cash employee termination costs - stock-based compensation
—

—

—

113

Facility and other termination costs
—

1

—

637

Total restructuring charges
$
—

$
58

$
—

$
4,541

The following table summarizes the cash-based restructuring charges liability activity during the six months ended June 30, 2015 (in thousands):

Six Months Ended June 30, 2015

Beginning balance

Charges

Payments

Ending balance

Employee termination costs
$
—

$
3,791

$
(3,754
)

$
37

Facility and other termination costs
—

637

(105
)

532

Total restructuring liability
$
—

$
4,428

$
(3,859
)

$
569

Less: non-current restructuring charges associated with facilities

(280
)
Restructuring charges liability - current

$
289

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total grant date fair value of stock options vested $ 0.4 $ 0.5 $ 0.9 $ 1.2

Total fair value of restricted stock units vested $ 0.9 $ 1.4 $ 2.1 $ 9.8

Stock repurchased during period (shares) ^[1] 0

Treasury shares held to satisfy tax withholdings (shares) 348,475 348,475

Treasury stock number of shares held (shares) 11,012,363 11,012,363 10,945,607

Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Award vesting period 4 years

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (shares) ^[1] 0

[1] Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Grant Date Fair Value
+ References
No definition available.
+ Details

Name: ehth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodGrantDateFairValue

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares surrendered by employees to satisfy tax withholding requirements resulting from vesting restrcited stock units.
+ References
No definition available.
+ Details

Name: ehth_SharesSurrenderedToSatisfyTaxWithholdingRequirements

Namespace Prefix: ehth_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares held for each class of treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

+ Details

Name: us-gaap_TreasuryStockNumberOfSharesHeld

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ManagementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Charges (Tables)
6 Months Ended

Jun. 30, 2015

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost
The following table summarizes the total cash and non-cash restructuring charges recorded during the three and six months ended June 30, 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015

Employee termination costs
$
—

$
57

$
—

$
3,791

Non-cash employee termination costs - stock-based compensation
—

—

—

113

Facility and other termination costs
—

1

—

637

Total restructuring charges
$
—

$
58

$
—

$
4,541

Schedule of Restructuring and Related Costs
The following table summarizes the cash-based restructuring charges liability activity during the six months ended June 30, 2015 (in thousands):

Six Months Ended June 30, 2015

Beginning balance

Charges

Payments

Ending balance

Employee termination costs
$
—

$
3,791

$
(3,754
)

$
37

Facility and other termination costs
—

637

(105
)

532

Total restructuring liability
$
—

$
4,428

$
(3,859
)

$
569

Less: non-current restructuring charges associated with facilities

(280
)
Restructuring charges liability - current

$
289

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)(2)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB Topic 5.P.4(b)(2))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Tables)
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of share-based payment award (Schedule of Fair Value of Performance Stock Units, Valuation Assumptions) [Table Text Block]
The weighted-average fair value of the market-based stock unit awards was determined using the Monte Carlo simulation model incorporating the following weighted average assumptions:

Expected term

2.59

Expected volatility

64.7
%
Expected dividend yield

—
%
Risk-free interest rate

1.13
%
Weighted-average fair value

$
6.69

Schedule Of Activity Under The Plans
The following table summarizes activity under our 2014 Equity Incentive Plan, 2006 Equity Incentive Plan, 1998 Stock Plan and 2005 Stock Plan (collectively, the “Stock Plans”) (in thousands):

Shares Available for Grant
Shares available for grant December 31, 2014
4,164

Restricted stock units granted
(692
)
Options granted
(34
)
Restricted stock units cancelled (1)
85

Options cancelled (2)
13

Shares available for grant June 30, 2015
3,536

(1)
Restricted stock units cancelled does not include 62,000 restricted stock units cancelled under the 2006 Equity Incentive Plan, as our 2006 Equity Incentive Plan has been terminated with respect to our making additional awards under the Plan.

(2)
Options cancelled does not include 211,000 stock options cancelled under the 2006 Equity Incentive Plan

Schedule Of Stock Option Activity Under Stock Plans
The following table summarizes stock option activity under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):

Number of Stock Options

Weighted Average Exercise Price

Weighted-Average Remaining Contractual Life (years)

Aggregate Intrinsic Value (1)
Balance outstanding at December 31, 2014
1,724

$
18.50

3.31

$
12,884

Granted
34

$
11.37

Exercised
(114
)

$
9.20

$
382

Cancelled
(224
)

$
21.79

Balance outstanding at June 30, 2015
1,420

$
18.56

3.06

$
222

Vested and expected to vest at June 30, 2015
1,397

$
18.51

3.03

$
217

Exercisable at June 30, 2015
1,108

$
17.86

2.63

$
179

(1)
The aggregate intrinsic value is calculated as the difference between eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 and the exercise price of in-the-money options as of those dates.

Schedule Of Restricted Stock Unit Activity Under Stock Plans
The following table summarizes restricted stock unit activity, including performance-based and market-based restricted stock unit activity, under the Stock Plans (in thousands, except per share amounts and weighted average remaining contractual life data):

Number of Restricted Stock Units (1)

Weighted-Average Grant Date Fair Value

Weighted-Average Remaining Contractual Life (years)

Aggregate Intrinsic Value (2)
Balance outstanding as of December 31, 2014
873

$
30.86

2.52

$
21,753

Granted
692

$
10.59

Vested
(195
)

$
24.02

Cancelled
(147
)

$
26.53

Balance outstanding as of June 30, 2015
1,223

$
21.00

2.92

$
15,522

(1)
Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.

(2)
The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 multiplied by the number of restricted stock units outstanding as of December 31, 2014 and June 30, 2015, respectively.

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Stock-Based Compensation—The fair value of stock options granted to employees for the three and six months ended June 30, 2014 and 2015 was estimated using the following weighted average assumptions:

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Expected term
4.2 years

4.3 years

4.2 years

4.3 years

Expected volatility
45.9
%

63.6
%

45.9
%

63.6
%
Expected dividend yield
—
%

—
%

—
%

—
%
Risk-free interest rate
1.42
%

1.15
%

1.42
%

1.15
%
Weighted-average fair value
$
17.01

$
5.70

$
17.01

$
5.70

Schedule Of Stock-Based Compensation Expense
The following table summarizes stock-based compensation expense recorded during the three and six months ended June 30, 2014 and 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Stock options
$
564

$
371

$
1,206

$
833

Restricted stock units
1,286

1,456

3,089

3,025

Total stock-based compensation expense
$
1,850

$
1,827

$
4,295

$
3,858

The following table summarizes stock-based compensation expense by operating function for the three and six months ended June 30, 2014 and 2015 (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Marketing and advertising
$
579

$
446

$
1,236

$
1,037

Customer care and enrollment
71

139

167

256

Technology and content
429

511

991

946

General and administrative
771

731

1,901

1,506

Restructuring charges
—

—

—

113

Total stock-based compensation expense
$
1,850

$
1,827

$
4,295

$
3,858

X

- Definition
Schedule of share-based payment award (Schedule of Fair Value of Performance Stock Units, Valuation Assumptions) [Table Text Block]
+ References
No definition available.
+ Details

Name: ehth_ScheduleofsharebasedpaymentawardScheduleofFairValueofPerformanceStockUnitsValuationAssumptionsTableTextBlock

Namespace Prefix: ehth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of share-based compensation plans that may be presented in a single table for outstanding, vested and expected to vest, and exercisable awards. The information that may be disclosed in this table may include, but is not limited to, number of shares, weighted average exercise price, weighted average remaining contractual life, and aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary Of Business And Significant Accounting Policies (Policy)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis Of Presentation
Basis of Presentation—The accompanying condensed consolidated balance sheet as of June 30, 2015, the condensed consolidated statements of comprehensive income for the three and six months ended June 30, 2014 and 2015 and the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2015, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2014 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and include all adjustments necessary for the fair presentation of eHealth’s financial position as of June 30, 2015, its results of operations for the three and six months ended June 30, 2014 and 2015 and its cash flows for the six months ended June 30, 2014 and 2015. All adjustments are of a normal recurring nature. The results for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2015.

Seasonality
Seasonality—The majority of our individual and family plans are sold in the open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. For example, in the second quarter of 2015, the number of individual and family applications submitted on our website decreased compared to periods inside the second open enrollment period that began on November 15, 2014 and ended on February 15, 2015.

The majority of Medicare plans are sold in our fourth quarter during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. Additionally, substantially all Medicare Advantage and Medicare Part D prescription drug policies renew on January 1 of each year, resulting in our recognizing substantially all renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in our first quarter. Accordingly, Medicare plan-related commission revenue is highest in our first quarter, with Medicare plan-related commission revenue being higher in our fourth quarter compared to our second and third quarters.

Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of
payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. As a result of the second open enrollment period for individual and family health insurance that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in individual and family submitted applications, compared to periods outside the open enrollment period. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. In addition, due to the initial open enrollment period for individual and family health insurance that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications.

Recently Adopted Accounting Standards
Recent Accounting Pronouncements—In February 2015, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-05 , "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement." ASU 2015-05 provides guidance to clarify the customer’s accounting for fees paid in a cloud computing arrangement. It is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-05 on our consolidated financial statements.

X

- Definition
Seasonality Policy [Policy Text Block]
+ References
No definition available.
+ Details

Name: ehth_SeasonalityPolicyPolicyTextBlock

Namespace Prefix: ehth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Balance Sheet Accounts (Tables)
6 Months Ended

Jun. 30, 2015

Balance Sheet Related Disclosures [Abstract]

Schedule Of Cash And Cash Equivalents
As of December 31, 2014 and June 30, 2015, our cash and cash equivalent balances were invested as follows (in thousands):

December 31, 2014

June 30, 2015
Cash
$
15,793

$
17,189

Money market funds
35,622

34,623

Total cash and cash equivalents
$
51,415

$
51,812

Schedule Of Accounts Receivable
Accounts Receivable—As of December 31, 2014 and June 30, 2015, our accounts receivable consisted of the following (in thousands):

December 31, 2014

June 30, 2015
Medicare renewal commission receivable
$
355

$
8,566

Accounts receivable - from other revenues
2,462

1,304

Other commissions receivable
5,383

299

Total accounts receivable
$
8,200

$
10,169

X

- Definition
Schedule of Accounts Receivable [Table Text Block]
+ References
No definition available.
+ Details

Name: ehth_ScheduleOfAccountsReceivableTableTextBlock

Namespace Prefix: ehth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of cash and cash equivalents.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes (Tables)
6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Summary Of Provision (Benefit) For Income Taxes And Effective Tax Rate
The following table summarizes our provision for income taxes and our effective tax rates for the three and six months ended June 30, 2014 and 2015 (in thousands, except effective tax rate):

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Income before provision for income taxes
$
6,319

$
5,819

$
3,170

$
3,793

Provision for income taxes
$
3,296

$
69

$
1,700

$
125

Effective tax rate
52.2
%

1.2
%

53.6
%

3.3
%

X

- Definition
Summary Of Provision For Income Taxes And Effective Tax Rate [Table Text Block]
+ References
No definition available.
+ Details

Name: ehth_SummaryOfProvisionForIncomeTaxesAndEffectiveTaxRateTableTextBlock

Namespace Prefix: ehth_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Long-lived assets $ 36,868 $ 40,189

UNITED STATES

Long-lived assets 36,446 39,752

CHINA

Long-lived assets $ 422 $ 437

X

- Definition
Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

+ Details

Name: us-gaap_NoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Balance Sheet Accounts (Schedule Of Cash And Cash Equivalents) (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Jun. 30, 2014

Dec. 31, 2013

Cash and Cash Equivalents, at Carrying Value [Abstract]

Cash $ 17,189 $ 15,793

Money market funds 34,623 35,622

Total cash and cash equivalents $ 51,812 $ 51,415 $ 70,382 $ 107,055

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 50 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) - Restricted Stock [Member] - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Number of Restricted Stock Units

Balance outstanding as of December 31, 2014 (shares) ^[1] 873,000

Granted (shares) ^[1] 692,000

Vested (shares) ^[1] (195,000)

Cancelled (shares) ^[1] (147,000)

Balance outstanding as of June 30, 2015 (shares) ^[1] 1,223,000 873,000

Weighted-Average Grant Date Fair Value

Weighted-Average Grant Date Fair Value, Balance outstanding as of December 31, 2014 (usd per share) $ 30.86

Weighted-Average Grant Date Fair Value, Granted (usd per share) 10.59

Weighted-Average Grant Date Fair Value, Vested (usd per share) 24.02

Weighted-Average Grant Date Fair Value, Cancelled (usd per share) 26.53

Weighted-Average Grant Date Fair Value, Balance outstanding as of June 30, 2015 (usd per share) $ 21.00 $ 30.86

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms 2 years 11 months 2 years 6 months 6 days

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms 2 years 11 months 2 years 6 months 6 days

Aggregate Intrinsic Value, Balance outstanding as of December 31, 2014 ^[2] $ 21,753

Aggregate Intrinsic Value, Balance outstanding as of June 30, 2015 ^[2] $ 15,522 $ 21,753

[1] Includes certain restricted stock units with both service and performance-based or market-based vesting criteria granted to our executive officers.

[2] The aggregate intrinsic value is calculated as eHealth’s closing stock price as of December 31, 2014 and June 30, 2015 multiplied by the number of restricted stock units outstanding as of December 31, 2014 and June 30, 2015, respectively.

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary Of Business And Significant Accounting Policies
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Summary Of Business And Significant Accounting Policies
Summary of Business and Significant Accounting Policies

Description of Business—eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is the leading private online source of health insurance for individuals, families and small businesses in the United States. Through our website addresses (www.eHealth.com, www.eHealthInsurance.com, www.eHealthMedicare.com, www.Medicare.com and www.PlanPrescriber.com), consumers can get quotes from leading health insurance carriers, compare plans side-by-side, and apply for and purchase individual and family, Medicare-related, small business and ancillary health insurance plans. We actively market the availability of Medicare-related insurance plans and offer Medicare plan comparison tools and educational materials for Medicare-related insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans. Our ecommerce technology also enables us to deliver consumers’ health insurance applications electronically to health insurance carriers. As a result, we simplify and streamline the complex and traditionally paper-intensive health insurance sales and purchasing process. We are licensed to market and sell health insurance in all 50 states and the District of Columbia.

Basis of Presentation—The accompanying condensed consolidated balance sheet as of June 30, 2015, the condensed consolidated statements of comprehensive income for the three and six months ended June 30, 2014 and 2015 and the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2015, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2014 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and include all adjustments necessary for the fair presentation of eHealth’s financial position as of June 30, 2015, its results of operations for the three and six months ended June 30, 2014 and 2015 and its cash flows for the six months ended June 30, 2014 and 2015. All adjustments are of a normal recurring nature. The results for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2015.

Seasonality—The majority of our individual and family plans are sold in the open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. For example, in the second quarter of 2015, the number of individual and family applications submitted on our website decreased compared to periods inside the second open enrollment period that began on November 15, 2014 and ended on February 15, 2015.

The majority of Medicare plans are sold in our fourth quarter during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. Additionally, substantially all Medicare Advantage and Medicare Part D prescription drug policies renew on January 1 of each year, resulting in our recognizing substantially all renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in our first quarter. Accordingly, Medicare plan-related commission revenue is highest in our first quarter, with Medicare plan-related commission revenue being higher in our fourth quarter compared to our second and third quarters.

Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of
payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. As a result of the second open enrollment period for individual and family health insurance that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in individual and family submitted applications, compared to periods outside the open enrollment period. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. In addition, due to the initial open enrollment period for individual and family health insurance that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications.

In the second quarter of 2015, we recorded net income in part due to significantly lower marketing and advertising expenses associated with the decrease in the number of individual and family health insurance applications submitted outside of the open enrollment period and lower customer care and enrollment expenses associated with fewer sales and enrollment personnel required to handle the lower volume of submitted applications outside of the open enrollment period. In the second quarter of 2015, net income also benefitted from increased revenue resulting from members who submitted applications during the second open enrollment period, which ended on February 15, 2015. In addition, our customer care and enrollment and technology and content expenses decreased in the second quarter of 2015, as a result of an organizational restructuring and cost reduction plan we implemented in the first quarter of 2015, which also contributed to net income during the second quarter of 2015. Conversely, in the first quarter of 2015 and the first and fourth quarters of 2014, we incurred a net loss due in part to our higher marketing and advertising expenses associated with the individual and family health insurance applications submitted during the open enrollment periods for individual and family health insurance and Medicare-related health insurance applications submitted during the Medicare annual enrollment periods without a commensurate level of additional revenue resulting from those applicants during the enrollment periods.

Recent Accounting Pronouncements—In February 2015, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-05 , "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement." ASU 2015-05 provides guidance to clarify the customer’s accounting for fees paid in a cloud computing arrangement. It is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-05 on our consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. On July 9, 2015, the FASB agreed to delay the effective date by one year. In accordance with the agreed upon delay, the new standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period and can be adopted using either a full retrospective or modified retrospective approach. Early adoption is not permitted. We are currently in the process of evaluating the impact of the adoption of ASU 2014-09 on our consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Geographic Information And Significant Customers
6 Months Ended

Jun. 30, 2015

Segment Reporting [Abstract]

Geographic Information And Significant Customers
Geographic Information and Significant Customers

Geographic Information—As of December 31, 2014 and June 30, 2015, our long-lived assets consisted primarily of property and equipment, goodwill and other indefinite-lived intangible assets and finite-lived intangible assets. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area were as follows (in thousands):

As of

As of

December 31, 2014

June 30, 2015
United States
$
39,752

$
36,446

China
437

422

Total
$
40,189

$
36,868

Significant Customers—Substantially all revenue for the three and six months ended June 30, 2014 and 2015 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue in the three and six months ended June 30, 2014 and 2015 are presented in the table below:

Three Months Ended June 30,

Six Months Ended June 30,

2014

2015

2014

2015
Humana
21
%

13
%

24
%

26
%
Anthem (1)
11
%

11
%

11
%

9
%
UnitedHealthcare (2)
9
%

11
%

10
%

10
%
Aetna (3)
10
%

8
%

10
%

9
%

(1)Anthem also includes other carriers owned by Anthem.
(2)UnitedHealthcare also includes other carriers owned by UnitedHealthcare.
(3)Aetna also includes other carriers owned by Aetna.

Commission revenue attributable to major medical individual and family health insurance plans was approximately 68% and 64% of our commission revenue in the three and six months ended June 30, 2014, respectively. Commission revenue attributable to major medical individual and family health insurance plans was approximately 65% and 49% of our commission revenue in the three and six months ended June 30, 2015, respectively. We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include small business, Medicare-related health insurance plan offerings and other ancillary products such as short-term, stand-alone dental, life, vision, and accident insurance plan offerings.

As of December 31, 2014, three customers represented 30%, 17% and 14%, respectively, of our $8.2 million outstanding accounts receivable balance. As of June 30, 2015, one customer represented 58% of our $10.2 million outstanding accounts receivable balance. No other customers represented 10% or more of our total accounts receivable at December 31, 2014 and June 30, 2015. We believe the potential for collection issues with any of our customers is minimal as of June 30, 2015. Accordingly, our estimate for uncollectible amounts at June 30, 2015 was not material.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stockholders' Equity (Schedule of Fair Value of Stock Options, Valuation Assumptions) (Details) - $ / shares
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term 4 years 3 months 4 years 2 months 10 days 4 years 3 months 4 years 2 months 10 days

Expected volatility 63.60% 45.90% 63.60% 45.90%

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Risk-free interest rate 1.15% 1.42% 1.15% 1.42%

Weighted-average fair value $ 5.70 $ 17.01 $ 5.70 $ 17.01

Senior Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Expected term 2 years 7 months 3 days

Expected volatility 64.70%

Expected dividend yield 0.00%

Risk-free interest rate 1.13%

Weighted-average fair value $ 6.69

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ManagementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 107 175 1 true 35 0 false 8 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.ehealthinsurance.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements Of Comprehensive Income (Loss) Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements Of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.ehealthinsurance.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 4 false false R5.htm 2101100 - Disclosure - Summary Of Business And Significant Accounting Policies Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPolicies Summary Of Business And Significant Accounting Policies Notes 5 false false R6.htm 2102100 - Disclosure - Balance Sheet Accounts Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccounts Balance Sheet Accounts Notes 6 false false R7.htm 2103100 - Disclosure - Stockholders' Equity Sheet http://www.ehealthinsurance.com/role/StockholdersEquity Stockholders' Equity Notes 7 false false R8.htm 2104100 - Disclosure - Income Taxes Sheet http://www.ehealthinsurance.com/role/IncomeTaxes Income Taxes Notes 8 false false R9.htm 2105100 - Disclosure - Net Income Per Share Sheet http://www.ehealthinsurance.com/role/NetIncomePerShare Net Income Per Share Notes 9 false false R10.htm 2106100 - Disclosure - Geographic Information And Significant Customers Sheet http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomers Geographic Information And Significant Customers Notes 10 false false R11.htm 2107100 - Disclosure - Restructuring Charges Sheet http://www.ehealthinsurance.com/role/RestructuringCharges Restructuring Charges Notes 11 false false R12.htm 2108100 - Disclosure - Commitments and Contingencies Sheet http://www.ehealthinsurance.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 2201201 - Disclosure - Summary Of Business And Significant Accounting Policies (Policy) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesPolicy Summary Of Business And Significant Accounting Policies (Policy) Policies http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPolicies 13 false false R14.htm 2302301 - Disclosure - Balance Sheet Accounts (Tables) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsTables Balance Sheet Accounts (Tables) Tables http://www.ehealthinsurance.com/role/BalanceSheetAccounts 14 false false R15.htm 2303301 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.ehealthinsurance.com/role/StockholdersEquity 15 false false R16.htm 2304301 - Disclosure - Income Taxes (Tables) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.ehealthinsurance.com/role/IncomeTaxes 16 false false R17.htm 2305301 - Disclosure - Net Income Per Share (Tables) Sheet http://www.ehealthinsurance.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.ehealthinsurance.com/role/NetIncomePerShare 17 false false R18.htm 2306301 - Disclosure - Geographic Information And Significant Customers (Tables) Sheet http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersTables Geographic Information And Significant Customers (Tables) Tables http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomers 18 false false R19.htm 2307301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.ehealthinsurance.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.ehealthinsurance.com/role/RestructuringCharges 19 false false R20.htm 2401402 - Disclosure - Summary of Business And Significant Accounting Policies (Narrative) (Details) Sheet http://www.ehealthinsurance.com/role/SummaryOfBusinessAndSignificantAccountingPoliciesNarrativeDetails Summary of Business And Significant Accounting Policies (Narrative) (Details) Details 20 false false R21.htm 2402402 - Disclosure - Balance Sheet Accounts (Schedule Of Cash And Cash Equivalents) (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfCashAndCashEquivalentsDetails Balance Sheet Accounts (Schedule Of Cash And Cash Equivalents) (Details) Details http://www.ehealthinsurance.com/role/BalanceSheetAccountsTables 21 false false R22.htm 2402403 - Disclosure - Balance Sheet Accounts (Schedule Of Accounts Receivable) (Details) Sheet http://www.ehealthinsurance.com/role/BalanceSheetAccountsScheduleOfAccountsReceivableDetails Balance Sheet Accounts (Schedule Of Accounts Receivable) (Details) Details http://www.ehealthinsurance.com/role/BalanceSheetAccountsTables 22 false false R23.htm 2403402 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 23 false false R24.htm 2403403 - Disclosure - Stockholders' Equity (Schedule Of Activity Under The Plans) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfActivityUnderPlansDetails Stockholders' Equity (Schedule Of Activity Under The Plans) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 24 false false R25.htm 2403404 - Disclosure - Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfOptionActivityUnderStockPlansDetails Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 25 false false R26.htm 2403405 - Disclosure - Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfRestrictedStockUnitActivityUnderStockPlansDetails Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 26 false false R27.htm 2403406 - Disclosure - Stockholders' Equity (Schedule of Fair Value of Stock Options, Valuation Assumptions) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfFairValueOfStockOptionsValuationAssumptionsDetails Stockholders' Equity (Schedule of Fair Value of Stock Options, Valuation Assumptions) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 27 false false R28.htm 2403407 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfStockBasedCompensationExpenseDetails Stockholders' Equity (Schedule Of Stock-Based Compensation Expense) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 28 false false R29.htm 2403408 - Disclosure - Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) Sheet http://www.ehealthinsurance.com/role/StockholdersEquityScheduleOfStockBasedCompensationExpenseByOperatingFunctionDetails Stockholders' Equity (Schedule Of Stock-Based Compensation Expense By Operating Function) (Details) Details http://www.ehealthinsurance.com/role/StockholdersEquityTables 29 false false R30.htm 2404402 - Disclosure - Income Taxes (Details) Sheet http://www.ehealthinsurance.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.ehealthinsurance.com/role/IncomeTaxesTables 30 false false R31.htm 2405402 - Disclosure - Net Income Per Share (Schedule Oof Computation Of Basic And Diluted Net Income (Loss) Per Share) (Details) Sheet http://www.ehealthinsurance.com/role/NetIncomePerShareScheduleOofComputationOfBasicAndDilutedNetIncomeLossPerShareDetails Net Income Per Share (Schedule Oof Computation Of Basic And Diluted Net Income (Loss) Per Share) (Details) Details http://www.ehealthinsurance.com/role/NetIncomePerShareTables 31 false false R32.htm 2405403 - Disclosure - Net Income Per Share (Schedule Of Anti-Dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) Sheet http://www.ehealthinsurance.com/role/NetIncomePerShareScheduleOfAntiDilutiveSharesExcludedFromComputationOfNetIncomePerShareDetails Net Income Per Share (Schedule Of Anti-Dilutive Shares Excluded From Computation Of Net Income Per Share) (Details) Details http://www.ehealthinsurance.com/role/NetIncomePerShareTables 32 false false R33.htm 2406402 - Disclosure - Geographic Information And Significant Customers (Details) Sheet http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersDetails Geographic Information And Significant Customers (Details) Details http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersTables 33 false false R34.htm 2406403 - Disclosure - Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) Sheet http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersScheduleOfLongLivedAssetsByGeographicalAreasDetails Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) Details http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersTables 34 false false R35.htm 2406404 - Disclosure - Geographic Information And Significant Customers (Schedule Of Revenue By Major Customers) (Details) Sheet http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersScheduleOfRevenueByMajorCustomersDetails Geographic Information And Significant Customers (Schedule Of Revenue By Major Customers) (Details) Details http://www.ehealthinsurance.com/role/GeographicInformationAndSignificantCustomersTables 35 false false R36.htm 2407402 - Disclosure - Restructuring Charges (Narrative) (Details) Sheet http://www.ehealthinsurance.com/role/RestructuringChargesNarrativeDetails Restructuring Charges (Narrative) (Details) Details http://www.ehealthinsurance.com/role/RestructuringChargesTables 36 false false R37.htm 2407403 - Disclosure - Restructuring Charges (Restructuring Activities) (Details) Sheet http://www.ehealthinsurance.com/role/RestructuringChargesRestructuringActivitiesDetails Restructuring Charges (Restructuring Activities) (Details) Details http://www.ehealthinsurance.com/role/RestructuringChargesTables 37 false false R38.htm 2407404 - Disclosure - Restructuring Charges (Liability Activities) (Details) Sheet http://www.ehealthinsurance.com/role/RestructuringChargesLiabilityActivitiesDetails Restructuring Charges (Liability Activities) (Details) Details http://www.ehealthinsurance.com/role/RestructuringChargesTables 38 false false R39.htm 2408401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.ehealthinsurance.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.ehealthinsurance.com/role/CommitmentsAndContingencies 39 false false All Reports Book All Reports In ''Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 with value 3 years 3 months 22 days has label periodStartLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 with value 3 years 3 months 22 days has label periodEndLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 with value 3 years 23 days has label periodStartLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Option Activity Under Stock Plans) (Details)'', element us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 with value 3 years 23 days has label periodEndLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details)'', element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms with value 2 years 6 months 6 days has label periodStartLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details)'', element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms with value 2 years 6 months 6 days has label periodEndLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details)'', element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms with value 2 years 11 months has label periodStartLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Stockholders' Equity (Schedule Of Restricted Stock Unit Activity Under Stock Plans) (Details)'', element us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms with value 2 years 11 months has label periodEndLabel, but the context is a duration, not an instant. It will be treated as if it had no label. In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements Of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. ehth-20150630.xml ehth-20150630_cal.xml ehth-20150630_def.xml ehth-20150630_lab.xml ehth-20150630_pre.xml ehth-20150630.xsd true true XML 55 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

Restructuring Charges (Liability Activities) (Details) - Jun. 30, 2015 - USD ($)

Total

Restructuring Reserve [Roll Forward]

Beginning balance $ 0.00

Charges 4,428,000

Payments (3,859,000)

Ending balance 569,000

Less: non-current restructuring charges associated with facilities (280,000)

Restructuring charges liability - current 289,000

Employee Termination Costs [Member]

Restructuring Reserve [Roll Forward]

Beginning balance 0

Charges 3,791,000

Payments (3,754,000)

Ending balance 37,000

Facility and Other Termination Costs [Member]

Restructuring Reserve [Roll Forward]

Beginning balance 0

Charges 637,000

Payments (105,000)

Ending balance $ 532,000

X

- Definition
Restructuring Charges Excluding Stock-based Compensation
+ References
No definition available.
+ Details

Name: ehth_RestructuringChargesExcludingStockbasedCompensation

Namespace Prefix: ehth_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 4

+ Details

Name: us-gaap_RestructuringReserveCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Paragraph Question 4

+ Details

Name: us-gaap_RestructuringReserveNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringReserveRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Summary of Business And Significant Accounting Policies (Narrative) (Details)

Jun. 30, 2015

state

Accounting Policies [Abstract]

Number of states in which the Company is licensed to market and sell health insurance 50

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of states the entity operates in as of the balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfStatesInWhichEntityOperates

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

Geographic Information And Significant Customers (Details) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015 USD ($) customer	Jun. 30, 2014	Jun. 30, 2015 USD ($) customer	Jun. 30, 2014	Dec. 31, 2014 USD ($) customer
Concentration Risk [Line Items]
Accounts receivable	$ 10,169		$ 10,169		$ 8,200
Commission Revenue [Member] \| Major Medical Individual And Family Insurance Plans [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	65.00%	68.00%	49.00%	64.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Number of significant customers \| customer	1		1		3
Accounts Receivable [Member] \| Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			58.00%		30.00%
Accounts Receivable [Member] \| Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					17.00%
Accounts Receivable [Member] \| Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage					14.00%

Restructuring Charges (Restructuring Activities) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 58	$ 0	$ 4,541	$ 0
Employee Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		57	0	3,791	0
Non-cash Employee Termination Costs - Stock-based Compensation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		0	0	113	0
Facility and Other Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 600	$ 1	$ 0	$ 637	$ 0

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income before provision for income taxes	$ 5,819	$ 6,319	$ 3,793	$ 3,170
Provision for income taxes	$ 69	$ 3,296	$ 125	$ 1,700
Effective tax rate	1.20%	52.20%	3.30%	53.60%
Increase in additional paid-in capital related to excess federal and state tax benefits	$ 0	$ 400	$ 0	$ 3,700

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 51,812	$ 51,415
Accounts receivable	10,169	8,200
Deferred income taxes	386	386
Prepaid expenses and other current assets	6,392	6,474
Total current assets	68,759	66,475
Property and equipment, net	8,510	9,640
Other assets	4,122	5,679
Intangible assets, net	10,140	10,774
Goodwill	14,096	14,096
Total assets	105,627	106,664
Current liabilities:
Accounts payable	2,066	5,961
Accrued compensation and benefits	8,365	8,204
Accrued marketing expenses	1,711	8,707
Deferred revenue	602	869
Accrued restructuring charges	289	0
Other current liabilities	4,647	2,996
Total current liabilities	17,680	26,737
Non-current liabilities	6,608	6,449
Stockholders’ equity:
Common stock	29	29
Additional paid-in capital	263,195	259,007
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	17,929	14,261
Accumulated other comprehensive income	184	179
Total stockholders’ equity	81,339	73,478
Total liabilities and stockholders’ equity	$ 105,627	$ 106,664

Balance Sheet Accounts (Schedule Of Accounts Receivable) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 10,169	$ 8,200
Medicare Renewal Commissions Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	8,566	355
Accounts Receivable, Other Revenues [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	1,304	2,462
Other Commissions Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 299	$ 5,383

Restructuring Charges (Narrative) (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
Restructuring Charges (Narrative) (Details) $ in Thousands	Mar. 30, 2015 USD ($) position	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ 58	$ 0	$ 4,541	$ 0
Employee Termination Benefits and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 3,900
Facility and Other Termination Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 600	$ 1	$ 0	$ 637	$ 0
UNITED STATES
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated \| position	160
Number of positions eliminated, period percent	15.00%

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	EHTH
Entity Registrant Name	eHealth, Inc.
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,080,207

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net income	$ 3,668	$ 1,470
Adjustments to reconcile net income to net cash used in operating activities:
Deferred income taxes	0	(2,035)
Depreciation and amortization	2,108	2,061
Amortization of internally-developed software	318	209
Amortization of book-of-business consideration	1,991	1,805
Amortization of intangible assets	633	708
Stock-based compensation expense	3,858	4,295
Deferred rent	28	34
Changes in operating assets and liabilities:
Accounts receivable	(1,955)	(2,277)
Prepaid expenses and other assets	(243)	(1,282)
Accounts payable	(3,895)	(227)
Accrued compensation and benefits	159	(3,051)
Accrued marketing expenses	(6,996)	(6,086)
Deferred revenue	(432)	(603)
Accrued restructuring charges	569	0
Other liabilities	1,736	(123)
Net cash provided by (used in) operating activities	1,547	(5,102)
Investing activities
Purchases of property and equipment and other assets	(1,432)	(2,340)
Purchase of intangible assets	0	(4,500)
Net cash used in investing activities	(1,432)	(6,840)
Financing activities
Net proceeds from exercise of common stock options	1,049	3,244
Cash used to net-share settle equity awards	(736)	(3,355)
Excess tax benefits from stock-based compensation	0	3,663
Repurchase of common stock	0	(28,256)
Principal payments in connection with capital leases	(40)	(40)
Net cash provided by (used in) financing activities	273	(24,744)
Effect of exchange rate changes on cash and cash equivalents	9	13
Net increase (decrease) in cash and cash equivalents	397	(36,673)
Cash and cash equivalents at beginning of period	51,415	107,055
Cash and cash equivalents at end of period	$ 51,812	$ 70,382

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings—On January 26 and March 10, 2015, two purported class action lawsuits were filed against us, our chairman and chief executive officer, Gary L. Lauer (“Mr. Lauer”), and our senior vice president and chief financial officer, Stuart M. Huizinga (“Mr. Huizinga”), in the United States District Court for the Northern District of California. On May 6, 2015, the Court consolidated the two cases. On June 10, 2015, a consolidated complaint was filed. The consolidated complaint alleges that the defendants made false and misleading statements regarding the Company’s financial performance, guidance and operations during an alleged class period of May 1, 2014 to January 14, 2015. The consolidated complaint alleges that we and Messrs. Lauer and Huizinga violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The consolidated complaint seeks compensatory damages, attorneys’ fees and costs, rescission or a rescissory measure of damages, equitable/injunctive relief and such other relief as the court deems proper. On July 15, 2015, defendants moved to dismiss the consolidated complaint. In the ordinary course of our business, we have received and may continue to receive inquiries from state regulators relating to various matters. At December 31, 2014 and June 30, 2015 we had no material liabilities included in our consolidated balance sheet for outstanding legal claims.

Summary Of Business And Significant Accounting Policies (Policy)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis Of Presentation	Basis of Presentation—The accompanying condensed consolidated balance sheet as of June 30, 2015, the condensed consolidated statements of comprehensive income for the three and six months ended June 30, 2014 and 2015 and the condensed consolidated statements of cash flows for the six months ended June 30, 2014 and 2015, respectively, are unaudited. The condensed consolidated balance sheet data as of December 31, 2014 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 16, 2015. The accompanying statements should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, for interim financial information. Accordingly, they do not include all of the financial information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2014, and include all adjustments necessary for the fair presentation of eHealth’s financial position as of June 30, 2015, its results of operations for the three and six months ended June 30, 2014 and 2015 and its cash flows for the six months ended June 30, 2014 and 2015. All adjustments are of a normal recurring nature. The results for the three and six months ended June 30, 2015 are not necessarily indicative of the results to be expected for any subsequent period or for the fiscal year ending December 31, 2015.
Seasonality	Seasonality—The majority of our individual and family plans are sold in the open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. For example, in the second quarter of 2015, the number of individual and family applications submitted on our website decreased compared to periods inside the second open enrollment period that began on November 15, 2014 and ended on February 15, 2015. The majority of Medicare plans are sold in our fourth quarter during the Medicare annual enrollment period, when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. Additionally, substantially all Medicare Advantage and Medicare Part D prescription drug policies renew on January 1 of each year, resulting in our recognizing substantially all renewal Medicare Advantage and Medicare Part D prescription drug plan commission revenue in our first quarter. Accordingly, Medicare plan-related commission revenue is highest in our first quarter, with Medicare plan-related commission revenue being higher in our fourth quarter compared to our second and third quarters. Since a significant portion of our marketing and advertising expenses consists of expenses incurred as a result of payments owed to our marketing partners in connection with health insurance applications submitted on our ecommerce platform and other forms of marketing, such as direct mail, email marketing, television, radio and retargeting campaigns, those expenses are influenced by seasonal submitted application patterns. As a result of the second open enrollment period for individual and family health insurance that began on November 15, 2014 and ended on February 15, 2015, marketing and advertising expenses increased during the fourth quarter of 2014 and first quarter of 2015, consistent with the increases in individual and family submitted applications, compared to periods outside the open enrollment period. During the second quarter of 2015, marketing and advertising expenses decreased, consistent with the decrease in submitted applications, compared to periods during the open enrollment period. In addition, due to the initial open enrollment period for individual and family health insurance that began in October 2013 and ended on March 31, 2014, marketing and advertising expenses increased significantly in the fourth quarter of 2013 and first quarter of 2014, relative to historical levels, and decreased significantly during the second and third quarters of 2014, consistent with the respective increases and decreases in submitted applications.
Recently Adopted Accounting Standards	Recent Accounting Pronouncements—In February 2015, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-05 , "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement." ASU 2015-05 provides guidance to clarify the customer’s accounting for fees paid in a cloud computing arrangement. It is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-05 on our consolidated financial statements.

Geographic Information And Significant Customers (Schedule Of Long Lived Assets By Geographical Areas) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Long-lived assets	$ 36,868	$ 40,189
UNITED STATES
Long-lived assets	36,446	39,752
CHINA
Long-lived assets	$ 422	$ 437

Balance Sheet Accounts (Schedule Of Cash And Cash Equivalents) (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Cash and Cash Equivalents, at Carrying Value [Abstract]
Cash	$ 17,189	$ 15,793
Money market funds	34,623	35,622
Total cash and cash equivalents	$ 51,812	$ 51,415	$ 70,382	$ 107,055

Restructuring Charges (Liability Activities) (Details) - Jun. 30, 2015 - USD ($)	Total
Restructuring Reserve [Roll Forward]
Beginning balance	$ 0.00
Charges	4,428,000
Payments	(3,859,000)
Ending balance	569,000
Less: non-current restructuring charges associated with facilities	(280,000)
Restructuring charges liability - current	289,000
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	0
Charges	3,791,000
Payments	(3,754,000)
Ending balance	37,000
Facility and Other Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	0
Charges	637,000
Payments	(105,000)
Ending balance	$ 532,000

Summary of Business And Significant Accounting Policies (Narrative) (Details)	Jun. 30, 2015 state
Accounting Policies [Abstract]
Number of states in which the Company is licensed to market and sell health insurance	50